<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/320c2ffb-9fb6-41f5-a5a4-b2bf58c74a3f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f7b6912e-ad76-4301-810d-da036d13bcd2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
        <rdfs:label>GATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b72b3c52-fa54-4b84-a53c-eb71f682fde4">
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
    <rdfs:label>apolipoprotein E</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec6442b9-785e-46a6-bd3f-f0c041b37ec3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
        <rdfs:label>APOE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/facf62c5-97dd-4349-bb88-6d340293263c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24f90084-a5d4-48f4-97e5-ca320c8cf0af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a314421-06ea-4457-b1d4-fb252c4708a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0c0ab3a-433a-49e8-a50f-b8be5eebc81c">
        <dc:identifier>HP:0002664</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neoplastic growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a362d44-00f9-450a-8983-014667b5826a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a94cfbd8-75ac-4d0b-95fe-cabb8d0a1480"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b346b866-a0c3-480b-a946-7d71dd275818"/>
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98e0efbd-113e-4a60-8b0f-89069524f2f3">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bdfca37-8424-40f8-993c-7dfbee75df96">
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bdba5824-3fb5-49b4-be88-43e3334cfbe7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7ca911d-382d-4a31-a593-ba97fa52c631"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fcdcba6-13b1-4e0b-8dbe-ec4fc2578638"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89493d8a-f22a-43b7-aa4f-a5c4121d91b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <dc:identifier>ECO:0000352</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a0dfc985-055e-4eb0-bf1d-1ee0923d421e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4cf6cba-2d76-4c43-a021-2e01b9503aae">
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3435dc9-88af-438d-9fae-6c4a5333c66f">
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c7b1b6c-429f-4b2d-a25a-57c98012bca7">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b365219c-36c3-47fd-82b3-e8ba9e671a3b">
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a101c03d-1dc2-4618-9f71-548a56123200">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
        <rdfs:label>SLC25A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4ba5d0b-e16c-4a04-ad51-f33d4e011ce7">
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7518cff0-5fbd-4f6f-ad13-0d68ba0e0557">
        <rdfs:label>GLUD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aaa1e1bc-e7e8-4104-b155-1f80ec21a1bc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8a251ef-c622-45c8-b727-a883cd907a3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59ef575d-ed78-4b38-9d48-2ce47c1634eb">
        <rdfs:label>Growth abnormality</rdfs:label>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/76a0b0e3-f06e-4f51-a0f8-b76a87d1f387"/>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c971e211-1bd5-43bd-a6a1-ad6342e1b9d3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b49db01b-44a6-4be3-bae3-65a848ff5afc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48bd562f-d74d-4abe-9173-b724b9af5acf"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ed4fd73-d918-4be3-bff1-93d84e5a6c8f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>seizure</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/322264bc-5c26-4131-8c51-0546996934c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb5c673b-97e2-47c8-abaf-97853d074885">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7787e63-5ae2-4ee0-9632-33a86d0118b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc1df2dc-dccc-469d-a269-9983d47a9ad2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c05f5bf-0e04-4af7-92ef-47133427161c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/563d1d27-6e9a-4451-9710-da314979f74a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/708992ae-35da-49bf-84f4-5e7351ed0d53">
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec6442b9-785e-46a6-bd3f-f0c041b37ec3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/996d35dd-00e8-46ea-8149-04f9c550b347">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/68b7a334-f10e-451f-9df8-5fb3ffddce61">
        <rdfs:label>TTPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/baa7e87b-35e8-48b4-9050-5f4459c973bf">
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/294378e2-6fd1-43c9-bd18-36bc70b69887">
        <rdfs:label>AKR1D1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b3fb347-7a56-4795-b2cf-ce794f9165d5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f668771c-e417-4f37-801e-1fe3b92e89f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3124bf42-d028-43c7-94c9-6fc7117ca0d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46998c96-d2d7-4f6d-9288-715356954098">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1add26b9-141a-4104-8adc-abac0a29c9b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fff39175-bc08-4a5d-974d-486226477be3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a03b998b-d947-4149-a33b-6d5b5b8965a3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/18abb85a-c171-45e3-9feb-ff11616787c9"/>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <dc:identifier>ECO:0007764</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70567a1a-af65-4db8-84f3-09e2f166584a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b29fefb-4092-4a9b-bb8e-8dc53951ac96"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbd4e35c-7132-4fd7-bebd-c1dedb48b079">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80a4f9d1-8e7d-48ff-a187-08872cbc0fa8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f678f827-7115-473f-8716-b2a44b0ba30b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nephropathy</rdfs:label>
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3eaafef1-d57e-4339-8076-54fc3561b732">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e231cfc-4528-4e60-8cf5-a521fa9c3c98">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a000bb9c-fc8f-4f65-8e5f-63ca5fdaaeae">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Polyuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43802a6d-8de3-464d-b3fa-af7b363e6bc4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a49f1736-cb93-40ed-a2d1-822bf2b558bb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33a5138b-1afc-4fd5-ab8d-3056d9b065be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/469b68cf-6426-48ac-92f8-2a07eac7b6e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/447b2470-ece2-4403-9d17-f0ba9ee57d2a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb119e66-0caa-4d18-8c2d-74183b31c203">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7425ff17-4649-4be1-9e6a-5471d0392bbd">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef6ab83a-e5bf-45b8-b489-d71200422976">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b113e6b-547b-461a-8f9b-e3c4c1e43655"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/92326ef7-6115-4bf9-8044-6ff72434e335"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f6d4535-6317-4b1f-b5d8-1bd77b907eb5">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/667771bd-6616-4a84-885c-2578847ba00d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6e7a392e-3479-4372-a7cc-dd9010785f94">
    <rdfs:label>codanin 1</rdfs:label>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a96b7b21-8759-4079-8c07-0c2ce705a081">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
        <rdfs:label>CDAN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6bdd5b6d-0d9d-4dc7-9aa7-0ab8c5732d64">
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ec4f12d-eb81-40c5-bbf0-8a58a0f68856">
        <rdfs:label>PHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1ed633e2-db84-4193-9726-22911e8ca42c">
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bdfe2ca2-e8c7-4271-a759-619b1670ddeb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/726e2315-e86f-4b7c-8a0b-09633f6f3fc4">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7518cff0-5fbd-4f6f-ad13-0d68ba0e0557"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ec40be7-a351-43e3-8c40-65e67a6d6e5d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8f60b46-175c-44f6-a7ac-cc008b50476e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a009369b-5294-4233-ba21-a4a328782e51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c70a3abd-5312-427d-8e62-8bd81fdadb11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/846a451c-8a01-4e73-8bc2-693be71073c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/580d605e-f579-4fbe-ae5c-7330dd178b4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b700392-c8a2-40f3-98a7-1f5454d58e6f">
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/be3bdff3-004c-4f43-89c0-44b5661a86d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
        <rdfs:label>HSD3B7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/99be821e-9b64-4108-bed7-f73a1f063606">
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2e41ea6-b423-48e1-aaea-80d4a421ac1d">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/54cbba83-a1af-4d8d-aacb-cd16c2e2af1e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
        <rdfs:label>SLC1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e2c882f-2e0b-4984-99f6-5d2f46b5d192">
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a48ee4d-e681-43e7-8774-3e1bd49c7638">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
        <rdfs:label>SLC25A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d420592-89a3-494e-b9f8-a31fd35df4c1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e795a172-c8b0-4f59-8a11-b76cac4d48a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60317fa9-0764-428c-93b8-a7104e8db388"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>Muscle weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02af5563-d960-477d-84f8-6dbd5153b724"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32066a23-915b-4d8c-9ba5-395ecfaf04bd"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c980ecb-72a2-45d1-8c3e-66ba78699802"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/937c01fe-077b-452f-8d85-f4157b2985f6">
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fc9030e5-d501-46e1-b0aa-4eb2ce540ffe">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
        <rdfs:label>DGUOK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba164fef-e1db-43a8-ae63-cc1b37e56bf8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/75976640-f032-4f57-adcc-9fe155175f3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c212d191-1f7e-45a7-85ed-de01c8a4aba8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e710d622-9a3a-4031-9377-01fe219e8b58">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <dc:identifier>HP:0000505</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/358298c9-9a3b-4d4a-81b4-1828e60f3fc8">
        <dc:identifier>HP:0012638</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <rdfs:label>Muscular abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/114d627c-ef61-43c4-b139-dd79f73cd9ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a5848d84-ee93-482f-a5c5-58dea81271a7"/>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/559f2b32-2b05-4ada-8b59-f8379d863c96">
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/be3bdff3-004c-4f43-89c0-44b5661a86d4"/>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/482177f3-79b9-4db2-bc1c-3dc3597a74b9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/728a0ecf-3011-4cc6-9002-f0cf793b5a3a">
        <rdfs:label>RXYLT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3400e159-d859-4d3e-a5d3-3e6d122e03db">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03c4692a-abb4-497a-8af5-843326d1ac42">
        <rdfs:label>Stroke-like attacks</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002401</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e24a470d-8289-42c7-89ad-672a4eee59ae">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <dc:identifier>HP:0030890</dc:identifier>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b038449-9ca0-47e4-9c46-4dc68de081d5"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b909b09-54e5-4275-b08a-e66142516e07"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5209f139-8dd7-453d-8a1a-b1f42ac343cb"/>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3abce43-7799-4c00-ad60-5725a8b80d76"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ecec12b-a1ae-4504-b19f-87c259193ec0"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/081feaa7-1705-4752-a94c-995a8900f0af"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27a46e0e-2167-45fc-ac3f-36617204c10d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/672833ee-36d6-44c1-a789-2dc725f2b26f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6f34354-48c5-47eb-84fd-f2a66d15a18f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23cabfcd-75a3-4eca-a85a-67d0155803b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9033f835-8226-432c-bce3-0c1cc224c6d0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fa3867e1-f8bb-4ad4-ab9b-bba13fd51aa6">
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bc231be2-d08f-43d2-bf4b-e688de510947">
        <rdfs:label>ACADSB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e97778f-6883-44ff-a6ec-ce70a23a61e0">
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f0b39b39-f6c9-42da-a8f2-ceefe509451b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
        <rdfs:label>CYP27A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9f234fc1-6fe5-403b-8c84-35fea94055dc">
        <rdfs:label>DPM3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9e708df-fd74-4c84-aac8-35203e8714f8">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73239429-d58e-4e89-84ba-15c3528fd15e"/>
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c90c0c59-1289-42d2-9934-9d4f2c87d3ec">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23a5be26-5e81-419d-8d73-28be60c0bb2a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3761a5ad-983e-42df-8176-13892c48aace">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8dac0e7f-5f30-44b2-a5b2-50171f3ccc8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c77ee390-018c-4325-9d9d-e249d33df843"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/368e6405-dfd5-4256-9050-a8d5fa7c9f32">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a3acdf93-da7e-4833-8438-32d68462e606"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a48ee4d-e681-43e7-8774-3e1bd49c7638"/>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecae6bbd-e549-4935-a273-2e54cdad04e0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5a87d67-eed8-48d3-a90f-5a43b7c4c081">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c726b96f-82c4-45b9-8e4a-348cd8a4ef7a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e99078f-4bd2-4789-8db0-a0510ecfc3c0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3761a5ad-983e-42df-8176-13892c48aace"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce800188-e99d-47ed-8942-847a248d86b3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <dc:identifier>HP:0025065</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal MCV level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eece9bdc-ee0d-4ca2-aeba-65e4bc48890a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <dc:identifier>HP:0025546</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e87e034a-dd72-41bf-95c5-17b88a3255f5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24166807-4286-44e0-8a27-12811e46608e">
        <dc:identifier>HP:0006785</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:label>Muscle dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a293808-e537-4339-b8a7-e6b0a8cc07ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4d8293f-a0b1-4470-8873-ddf7361929fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <dc:identifier>ECO:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5fcbda58-a6ec-457f-b238-7bfd1d9553ab"/>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0cd164ed-6a2f-4e08-a10e-a50e66ae1d51">
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cd76e06e-5d4a-4842-85bb-1ff97b8794e7">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/07790a62-f838-4481-807e-da4576d03ec2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
        <rdfs:label>CUBN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2747a777-5cff-4128-819b-ad301495ea61">
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1aaf29d-7944-40f3-85e1-c0b5bd7066ce">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22c1dc46-c434-4dfb-9711-3cb7edfc633a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1065f7da-075b-49d3-a62f-3754ce03d3d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8bbf3741-0255-4e70-9fdf-1ea75e67fec4"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef49658d-cb66-4e33-a1c0-93eb26a3018d">
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bf0262fb-06fd-4f3b-a478-e7801796a6f9">
        <rdfs:label>GGT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9356c4e0-54f6-44ad-be8e-c7122f5b4368">
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48bd562f-d74d-4abe-9173-b724b9af5acf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
        <rdfs:label>DHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a54a52ae-6592-4cde-b9d6-959b8051e15a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9de9018e-4140-4c32-88eb-83337958fb92">
        <rdfs:label>Hyperglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13cbb198-fdf3-4ab0-a795-03ee758e96c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/526ce503-e8f8-4467-9b31-b59c7fe9de5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3404f059-da34-4943-82a5-05c003461d6d"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b38ca848-e39f-4e42-9223-4a58059b6941">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/804ca8c8-8158-4715-b0c0-06027b1ffb44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cabb080d-a35a-4ce5-848e-85f9f95349d9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/adfa4d60-4ffe-4f9a-a290-ce35ec163f64"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ae433d0d-5dc7-4461-a807-ce651ad0981d">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/875390e6-46bb-4dad-8b3e-d8f187d429d9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/368291aa-b3b4-49d6-b1cc-87ea33505c00"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/192a46a3-df77-4acd-afc8-3108d7d79eba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>low Hb level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18bb0fce-38a5-4fed-b438-086bfa12223f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
        <rdfs:label>Reticulocytopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001896</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21eff2a4-15e4-4f0e-b120-60c240d12db8"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/712d20da-9f4f-47be-b198-d089259eaf35"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb671fdd-234f-4fa6-bd13-daee22b724a3"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77329ebe-1770-4680-8db3-a8ada0f553a1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3ef53f9-3af9-45e4-af08-ac0bc879b4a3"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f2bdfd5-5116-4a6a-9f90-ccc92a9e4a3c"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2cc50493-e10a-457e-b598-25dd1dd6ac1e"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43300246-9cab-4525-a499-f136c3ad78ca"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f026d966-6e28-46da-8a96-c39a9c581fb3"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c80396dd-0520-416f-8d08-40ccf5e90d1d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d907b73f-a819-4b71-8aaa-4815db0bec6e"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a4acaf2-86e8-4277-bc04-1a368677306c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5f5553b-4695-4640-af0a-7c2b5f1d2f37"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b6c5376-4996-46b7-a836-7b37e425c12a">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/368fabe1-021b-4885-89c9-6dfb2acb75ac"/>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c9ac8e5-6f0b-4a42-bc70-ab58d41a4da4">
        <dc:identifier>HP:0011443</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal coordination of movements</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cce9092b-4beb-4491-bfc5-53438d2f5dde">
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2daddb6-237b-4349-ba6c-8856559c5d7d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low brain creatine phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/581636ce-cfde-44d4-815b-a94136bb3219">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81de4237-2664-43b2-bb19-4e1f8d53e3a8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d76be4b7-b5a8-47fc-b91d-33df59283d15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <rdfs:label>low cerebral creatine</rdfs:label>
        <dc:identifier>HP:0025051</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c7433c6-3914-4ef5-833a-73f3e83df80f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a76d6342-9eff-488f-ad66-4ff7610770c5">
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Epilepsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6d59260-9dd4-495e-b963-057f9862352d">
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f58b122-13b4-4e61-b778-c28b46ab033d">
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff03ac78-3b25-47a3-80ac-b6239fc9ee5d">
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9f681832-17b8-4cd8-aa91-bf63e5471666"/>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bfe61af-24d9-4a78-b6ff-1e89476f2296">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234*</dc:identifier>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/781c4ca5-07ec-4019-9fab-28620cd26806">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a358c532-4289-46f6-9c2d-1d63e27fd87c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:label>Metabolic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2cb823cd-977c-4a5c-8d7d-a01edc446d6e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f466b9d-87e8-44d1-bc3c-4d3d6972f093"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19">
        <rdfs:label>Disease progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59f8393c-68e1-471b-9074-0ca4b148abd3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cced741-40ed-4c9e-a8bb-bd6bc2801c9a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Psychiatric disturbances</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cc8d795-9ab9-4b61-a862-8f718a56921c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>Mental impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40eaff8e-b6e9-4c55-b7a0-a6607f50adb5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:label>Emotional lability</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4248d042-bdd3-4f91-b583-a2e50359aad4">
        <dc:identifier>HP:0002355</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
        <rdfs:label>Difficulty walking</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4cf6cba-2d76-4c43-a021-2e01b9503aae"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6083579e-d786-4bbd-838e-a68e8abd5a1c">
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <dc:identifier>HP:0000649</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3451fe17-efdc-4e25-b09b-0e94c1523e8c">
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <dc:identifier>HP:0006958</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bdfca37-8424-40f8-993c-7dfbee75df96"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4a026a2-bd84-4a06-a21b-f543aa4ff6f6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:label>Dementia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/95bd29bc-8a32-436a-9d3d-d0128be5bd91">
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2484a9a9-cdf9-4923-bc88-745ae873c431">
        <rdfs:label>PIGN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b6818ea-2296-4217-9f5d-e01d2a1758e9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/531c42e4-4f87-4b7b-b1bf-06c33406b0e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c014bcb-8f71-4c40-9786-7998a2cc54dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/841a465e-4a72-4fff-b69e-904c2ca94b71"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4fb643ed-a5b2-4d08-9132-de0c95708932"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c2dcc67-7c81-4b85-8b24-8a3fa1393cd6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
        <rdfs:label>B4GAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57521ce8-02dc-47b0-b13b-58f9c78bdb1b">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3363cfb0-300e-4a11-ad79-26d536f9201e">
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <rdfs:label>calpain 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b1c981d0-fef7-4742-9e96-0da635ffa871">
        <rdfs:label>CAPN3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/beaa66a3-f57c-4005-aa70-f29178462458">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4e6d58c2-8cef-43bb-861b-8a2dfafd525f">
        <rdfs:label>GCH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0b514b1-483a-4449-a919-4a6722dad7a6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bda6a7e-d369-4343-82b7-d335ce7f3327">
        <rdfs:label>Lactic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52f4851a-e488-4ac0-b212-9b54e22ca378">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Encephalopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b52c60f-2502-4167-a8ef-0b75477e0323">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/744dbc08-13d4-4503-a7b0-11688f9f2596"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1331ea3f-90b3-4f8f-975b-ce392c4a2fcc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <dc:identifier>HP:0002572</dc:identifier>
        <rdfs:label>Repeated vomiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/535993d5-a376-4bfb-b81e-47154a09b155"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ddf1078c-22a6-49a9-abd1-1795dbb9daac"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fda8f8f8-e8fd-4775-b104-ec2be493977d">
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9075cbd6-6878-4f2e-ae6a-1bef6aaa4f3a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
        <rdfs:label>SLC17A5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef2d64e8-f7e8-4b39-9198-3f449a5664f4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54a5a395-3cea-4867-a605-0c08bc6e5e74">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69292fa1-fb22-4dfc-8e07-aa6c0c775f43"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cbeb4e4-48b9-40e9-afea-462dd785f26d">
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <dc:identifier>HP:0008315</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd">
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/728a0ecf-3011-4cc6-9002-f0cf793b5a3a"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/676eb595-1458-4f91-aeb2-61a369f1314a">
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f9a87c2d-d5c1-4d29-bf0b-e6ef94df6d79">
        <rdfs:label>UROD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb2365de-4875-406e-8f66-206f64a29f33">
        <rdfs:label>HEF</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d240531c-97c0-4226-8de5-03a3ed080231">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77d0cc12-e792-4a7e-b2f9-dfd73d3319d1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2bb3d09c-8c7e-4e12-81da-23226e664cc6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b1b6ba3-021c-4252-b442-351eee6d6221">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b06d3786-44c2-4be9-a38f-a09c26935c9f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0edf44b3-01ee-430a-b318-a462ba946214"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/056e0a47-ee81-4cfe-8b1c-a46be21759d4"/>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6e77669-7cc8-480e-8698-de8aec6298ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82a8cf74-43a1-4ebf-9fa6-1dd371638fd7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccb6fb1e-abcb-4ff1-8195-571e0a716bf7">
        <rdfs:label>Developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4c31b87-7033-4b1e-b67a-b93eefb8b4be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:label>Delayed receptive language</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/106bda33-9119-4c3c-8e64-f942f53c0648">
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3fe772e9-a464-4b5b-80f2-9cc4b0f8b401">
        <rdfs:label>GYS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2e4cab4-ea5e-4bb3-bf07-0bbe6c518ef5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7aba5bb-2e14-4534-8929-0cd108edce14">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
        <dc:identifier>HP:0003162</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dea32229-75ba-4f9e-ba9b-29b9a0f52267">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>Sleep disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c67de9b0-9c9d-4a13-aab4-fa665ea30aa0"/>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d528a775-2290-4889-9aed-c50f55b42496">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed7378ae-ce6a-4e36-bfc4-0331ae3791ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00d40d8b-acc7-4ffa-95be-974c77c9cd43">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f483da5f-38d2-4872-a1a0-0a38227ffe81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fc5660d-a3bb-43fa-b9fb-5c0f55719f6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53ab4a36-50ff-4dbb-a14c-4788a4947fed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0221559a-780c-4ae5-84f8-0e374dfd0a74">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7c2a30b3-783e-487c-b021-2035706b48a7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a5a83a19-0f22-49ec-9e31-222d434e3fe3">
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/479a63d8-ec67-41ae-8374-e9ca784311c5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
        <rdfs:label>ASL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ceb4039-e967-469a-a92d-5af79fd9ed98">
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b73d66c2-1e00-4253-9c05-f1121953766d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
        <rdfs:label>PAH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/33887017-8441-49d7-8392-e95ab369f028">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/441b7ab2-1069-450a-b567-81122ed45657">
        <rdfs:label>HMBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68296df5-3d2d-434c-bd8a-1e25cbc7a867">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71c8756b-5624-4a8b-a436-1376633d2734"/>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f483da5f-38d2-4872-a1a0-0a38227ffe81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/70b3da9f-51f7-4f2a-a314-1aa24bbdd925">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3dea4db2-9486-4b0e-9a9d-750b0d2eff89">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
        <rdfs:label>MT-CO1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6cb030d6-16a8-48a8-b010-8e7632ebfba5">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67d2dbd2-c93f-4a47-85e6-feca5d347a44">
        <rdfs:label>MT-CO3</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f5e42442-c292-4ab5-ad8f-e89d6d1109bb">
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/742805c2-81bc-454d-baab-661ad52d0632">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c990764f-937c-4909-ae4d-476805848d74">
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0244183a-8458-46ca-898e-63ef1ab0cb0c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c3a1c08-00a3-4198-af2f-db94b1bce3dc">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a57b278-42d1-4b66-a5dd-3fbd56f8a0ad">
        <rdfs:label>Abnormal EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b750235-1993-4d80-9e74-fba8ef5fbd2a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27619838-f353-436e-bf12-09a689ec6ea8">
        <rdfs:label>Study is still recruiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/009c86c8-73b6-4733-9200-e4a7d72482e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/314d89a4-d39b-4be0-98b5-a258dca150dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
    <dc:date>4.10.19</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3564dbea-ff9f-4bf7-aed5-ec6e76245ec6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fafa36a2-bb7e-4f02-9cac-dd1aad88d259">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc43d827-5b8d-4db4-b8f3-e37e2210f9a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b9d3218-11d1-494c-8cf5-699a11b2c5ff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f560cf5-4771-4ab9-be74-2b3250f8ab25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ccdeeb7-51f0-4c55-b588-e76c867f48bf">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/294378e2-6fd1-43c9-bd18-36bc70b69887"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90b194be-fa5b-4b27-a9b2-60f0d9ba916c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69c82272-6b0d-4e3b-b8b7-829e66c94f55">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbed3563-1acb-4926-b323-86e481547f83">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10267dd4-a9da-47e2-b793-33d4806fe16d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b08efb7-0db6-4fa5-8c58-b9ca1f35f20c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75d23047-719f-4c0e-b9d7-7de7873dd6be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdfe2ca2-e8c7-4271-a759-619b1670ddeb"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed0a0048-5b66-42ce-b78e-765af895749d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31dcf2f1-3fa6-4ea8-9dac-2955e17bfe8d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14bc6b19-179a-41f7-a1c3-a64e0a5ebf45">
        <dc:identifier>HP:0004322</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bf7d729-3e16-4ebd-b117-1d5de0b0bc4a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c33c89d-5f4c-48ef-a719-eb609c5335fb"/>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b46fb72-810f-45a9-bfe6-c4d8989d4bb4">
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da366cf9-d27b-4273-a356-08e176a37c52">
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf57b688-8e02-47cc-915a-67dbbaa0d362">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Motor function impairment</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/054fa7d1-ebf0-4362-9e1b-7571b6c58f51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d62832f7-ff10-42bc-bacd-bf9055437f64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7b3a659-d74a-44f5-9ea5-6c2fbf8d2e67">
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/61ed8845-7107-4439-9ca4-1e2bd3e4febc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be64c2e0-4daa-422e-a2bb-aad63e41066a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ca4e1c4-25e5-40ba-b75c-3702a52943ff">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:label>Splenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/583ff101-70ba-432f-bb9b-046f7176ff75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69cdf794-7923-43fe-a1bd-fa7ae480a1f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14e0c9be-5b2f-48e7-9405-d4387c2bafb7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bf799c6-9bcb-4dc4-a0ac-15ae7cb28c67">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <dc:identifier>HP:0003288</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df03e659-2be1-4ae7-a043-9bdce567da1e">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/35c21fc3-32af-4e18-81a7-8246924d54f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67919c2e-59c1-4cf3-bbb0-bb2718753cfb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7d433aa5-22fd-4127-b0ce-4f814589a98e">
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c0e242f-188e-4a7a-893a-f38b6091b25f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
        <rdfs:label>FKRP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc65ab74-502d-4c36-bc30-7a21de1a848a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9aa74d78-f0db-4ae8-98a0-7ac8e400b623"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a76d6342-9eff-488f-ad66-4ff7610770c5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd2edc39-8ef8-43b7-a1e6-1bca90d933d9">
        <dc:identifier>HP:0001285</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/504d8445-0d67-41a1-97ca-f72ae4e5a7a2">
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f3b93bc5-0750-4fd4-b032-a5af251b4ff3">
        <rdfs:label>DNA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/279037ab-f3fe-42b9-9650-2b6e94e9c236">
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b9ec57c-e0c4-4fd4-84c4-16f1806bb6b9">
        <rdfs:label>HADHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/71fdafd7-bb5a-407b-81dd-7ba8db7d8825">
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f748b0c4-a020-49c2-a3aa-582300dcfb15">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
        <rdfs:label>KCNJ1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2498b853-c58a-4c43-835e-d0632063d9c0">
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/383a228e-de6c-4dab-8d06-56f32f72c970"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df089f70-ddfc-4eee-a21a-8c4e580afd2f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a40c456-213d-4b22-917a-fe17890e3f3c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939 *</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6090bc02-abf2-4ccb-9107-e080ac22ce51">
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e795a172-c8b0-4f59-8a11-b76cac4d48a1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ce50d414-d472-4c21-bbb7-5c8adf552e3a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71c8756b-5624-4a8b-a436-1376633d2734">
        <rdfs:label>PHKA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c28c6be0-edff-4875-89cb-2aaa0f0048c5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f026d966-6e28-46da-8a96-c39a9c581fb3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c80396dd-0520-416f-8d08-40ccf5e90d1d">
        <rdfs:label>and</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/712d20da-9f4f-47be-b198-d089259eaf35">
        <rdfs:label>RPL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77329ebe-1770-4680-8db3-a8ada0f553a1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3ef53f9-3af9-45e4-af08-ac0bc879b4a3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
        <rdfs:label>RPL11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21eff2a4-15e4-4f0e-b120-60c240d12db8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
        <rdfs:label>RPS7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f2bdfd5-5116-4a6a-9f90-ccc92a9e4a3c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d907b73f-a819-4b71-8aaa-4815db0bec6e">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43300246-9cab-4525-a499-f136c3ad78ca">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb671fdd-234f-4fa6-bd13-daee22b724a3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
        <rdfs:label>RPS26</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2cc50493-e10a-457e-b598-25dd1dd6ac1e">
        <rdfs:label>RPS17</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47000bd9-62be-4f29-93bc-8094d749df54">
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67536ce6-8fcd-4b4a-be36-7d1d7246ec57"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e9e185e-da16-4054-a714-080ea865495c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c3ba0bc-8708-4dc8-822d-4627f30fdb0b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69d849b0-b4fd-455f-8e42-8456b4219a9b">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1547c35c-fe27-4da9-b1d5-65cf4a53a119"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a293808-e537-4339-b8a7-e6b0a8cc07ed"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24166807-4286-44e0-8a27-12811e46608e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8f303b9f-3f2a-4326-83bd-b32c72162c7e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f26f86de-9ab0-476a-8996-d91696fbc22c">
        <dc:identifier>HP:0001300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9141529-4af5-4720-a491-3314d8c0241b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad15c432-5d07-41f0-a3ac-44920de8f80e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16c4a423-5c42-4445-b0ed-a2dfd01ead54">
        <rdfs:label>Bradykinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002067</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ba39383-ea44-436a-8653-d8c3049c344d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d6bab5b-d643-481b-bf17-c188fdaffa9a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a81d05c-334c-4b18-b79a-86e82103c599">
        <rdfs:label>Kinetic tremor</rdfs:label>
        <dc:identifier>HP:0030186</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/312787fc-e0ba-4299-a309-cda407dce966">
        <dc:identifier>HP:0002174</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Postural tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>Dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5d7b3e0-cfcf-4cc7-b94b-5ff037479ff6">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a215c61-bfe8-46b1-a5ed-1415e30e3e27">
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24f25095-d32f-4faf-83a7-d7ff9e70b319">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b2128ad-12d9-48cd-933c-70fee9372efc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43a944e6-ea8d-426c-a7b5-822feca2d94a">
        <dc:identifier>HP:0001681</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>angina pectoris</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/733e9112-b19b-4381-b2c0-0664b4b099d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87585278-a23b-41d2-9d5e-2b6fc1c404f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b66fb1e8-2f43-4ba7-a8f4-b8b421fe955f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <dc:identifier>HP:0001677</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54306bc5-b536-491d-9ddc-04e1780ba27a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc39bb9d-63cf-4a20-9f7f-fee466e4d506"/>
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43802a6d-8de3-464d-b3fa-af7b363e6bc4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4d5e7a45-ecfb-4470-a225-44b97a2b7d51">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c49216e-cde2-43cd-a0d1-62489e623536">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/43da5f45-4db3-4b23-b9e9-432b118ab9a1">
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8dacec9-54bc-466b-bee9-4037cc9cacbf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
        <rdfs:label>LRPPRC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eedc390a-6bb2-4e83-b2c6-82b7a37a494f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ee30146-fdf6-47fa-97cb-6bd543c7fd96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f15b9492-9a52-4009-bc01-279845757d2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f8e3a18-3daf-4dfd-bbd4-09681335cb55">
        <rdfs:label>Behavioural abnormalites</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69eea523-d265-4c6a-aeea-9664b778cc14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bea2333-748f-48b9-93cc-0d263eeca819">
        <rdfs:label>Memory impairment</rdfs:label>
        <dc:identifier>HP:0002354</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4481bc98-62e8-47b1-9283-2aefc788fd16">
        <dc:identifier>HP:0001328</dc:identifier>
        <rdfs:label>Learning impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba1261d1-37a2-4351-96ef-74e01f12f5fb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive imapirment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2d4ac0fe-dc58-4bf9-8318-62260eb59cf8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32066a23-915b-4d8c-9ba5-395ecfaf04bd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02af5563-d960-477d-84f8-6dbd5153b724">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c980ecb-72a2-45d1-8c3e-66ba78699802">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
        <rdfs:label>ETFDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/756f1bbc-af49-4d14-9331-e6c862d06b5a">
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b346b866-a0c3-480b-a946-7d71dd275818">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
        <rdfs:label>RET</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/696827b1-adcd-4cdd-ba02-ab00854a6ac4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
        <rdfs:label>DPM2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2dca07da-7ea0-4a58-a69b-7132014f5674">
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd4b9d29-aff2-4338-a74a-bb27e0f48156">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39f26b8e-057e-48a6-abd1-461991706c24"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/346ebbda-2226-40f6-8590-7d00cd54327f">
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:label>Osteoporosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86aa09d2-e9ee-42b8-a49a-92289115fc5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7804a685-9e3f-4e64-858d-aa1cf6216793">
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0244183a-8458-46ca-898e-63ef1ab0cb0c"/>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4addb4e9-c61d-4678-9340-6d844ab389bc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f264224d-473e-460a-b187-d43f663320bc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
        <rdfs:label>PRODH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/94cb2236-2dfb-4176-911b-cc3960530629">
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/183e8c03-709d-4086-b103-eb81eedcb778">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20d3dffb-b97e-49cd-a66c-642f0240b240">
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/04f7a35d-aa83-4e8b-8c9d-3a720c36c9c4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
        <rdfs:label>MAN1B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bbb8b7d2-89c6-4ce6-a439-1e5aaf9230c1">
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a20dd48-f6e3-4cb5-99f3-a3dfb5cbaf92">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
        <rdfs:label>SLC7A7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/752ed9d8-a98a-49c9-99c5-a60490df4637">
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9f681832-17b8-4cd8-aa91-bf63e5471666">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
        <rdfs:label>GCDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44c5ca8e-ae35-48d1-a56c-f67167187f2f">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bac16ef-2aac-473b-bc32-04ebfe45f5af">
        <rdfs:label>Dysphagia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4248d042-bdd3-4f91-b583-a2e50359aad4"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bfe61af-24d9-4a78-b6ff-1e89476f2296"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b0bd0bd7-070e-48c4-80d6-6350365756f2">
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/68c18d6a-f04d-4f12-8ef5-a1fe4a085eee">
        <rdfs:label>PCBD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3defdef3-f15a-4563-9ea7-b8ddafe04260">
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fc0e118d-10d8-4079-826e-7e0885aa53bb">
        <rdfs:label>CTSA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc442088-feff-4089-8774-d4a1137f62a2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c78bdd2-bc23-4953-af8e-aa55019cb762">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Spasticity</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd616bf4-322a-49d6-aa07-14d693993ffc">
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:label>Anorexia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adde1149-6b2b-4fc6-8506-d6f925148930">
        <rdfs:label>Delirium</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031258</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4cf6cba-2d76-4c43-a021-2e01b9503aae"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae2511fc-a0f5-41a3-a8d3-51f0389e45d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002395</dc:identifier>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e2dfd05-440a-4ad6-b11e-1a44e35836bf">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001878</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Haemolysis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eac13a6c-f8f8-40fd-8ed1-6b2ce0598f34">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fatigue</rdfs:label>
        <dc:identifier>HP:0011025</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bdfca37-8424-40f8-993c-7dfbee75df96"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/805b498f-adea-4560-905a-d4a432f7223c">
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0eab01a2-5f5d-4d42-bc39-abc7579dd334">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26c56c81-72bd-4fb7-bfb7-2eeae7c91064">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd9c34d4-82df-4979-8277-7a03e6f922ea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2f2f440b-50a4-4157-a9eb-0174f9e52016"/>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cb08f18-453f-4aaf-b755-dcff7d70f305">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250*</dc:identifier>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b14f9338-0163-42d4-968b-082a546f49d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/daed9eb2-5f38-4820-9caf-5c36ec8ef0b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f111a0af-25f4-4795-9700-adb9f96c90fc">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3858047c-2160-422e-ab86-cdd1865fa8bd"/>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7966c17e-d8fb-4ab3-b9f7-84bad4ebd0f1">
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <dc:identifier>HP:0040088</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35c21fc3-32af-4e18-81a7-8246924d54f1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef6ab83a-e5bf-45b8-b489-d71200422976"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3975a7a7-6fe3-4f10-85a6-5ae00d62af84">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/59bccd8d-63d6-4b6e-b19b-1d3c2f5a76c8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5a6e84a-976d-46a5-b77c-76729da408fa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
    <rdfs:label>glucokinase-4</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eebb8e58-6a63-45e8-b9bf-cbe004be9e5b">
        <rdfs:label>LDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0d20f01a-a8bd-4b86-a527-ff0e4354b1b5">
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa5d5527-cc61-4408-8946-36835b446581">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
        <rdfs:label>PYGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f4d623d-e8a0-48ac-a98e-6073b5128bfc">
    <rdfs:label>GABA-transaminase</rdfs:label>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2e5da2c8-2838-40b1-b87b-229e0694fd47">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
        <rdfs:label>ABAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f1b1646-01ea-4d01-b576-e781b42a6799">
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ccd730f1-1fa1-4de6-877f-8c85871b73c7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
        <rdfs:label>PGM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe822fda-a08a-4413-bc24-c94290f7394f">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36e00010-11c6-4dec-9b42-c975e84a18a8">
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/943c6e27-3338-4f15-827e-ad0cd7a201a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65ccc832-8e12-44ef-a17b-ef82e0127c2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75976640-f032-4f57-adcc-9fe155175f3a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2d4e4e7-f690-4c24-ab27-db802b493936">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2887f918-82ff-4477-b604-8781a83b6130"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/947b6b12-b04d-4a72-a173-ae61850f2469">
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16b63096-e37a-47ea-8c24-a50b53038f90">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9606db95-4c4f-457f-81da-0190af25cbf5">
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9d6cc5f3-67fb-451b-b153-111304c651ab">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b8e4850-b679-4a8d-9f23-66af4ace626a">
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5200e2d3-ad83-4ac1-b005-e3379609b0bb">
        <rdfs:label>HSD17B4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b1ef371-78db-497e-b934-987f59222c63">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a546271-07ce-41f9-bde3-37d458b9664c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8d68b0e-2458-46a2-a5b1-39027da256c1"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42c46ef7-1324-4348-866f-e66bdc60bbbb">
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79f66fc8-b286-4d37-bfe9-149544c573aa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e795a172-c8b0-4f59-8a11-b76cac4d48a1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccb6fb1e-abcb-4ff1-8195-571e0a716bf7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36ae960a-bcf4-4517-96f7-49ac58012040">
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:label>Metabolic stress</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef59838e-9792-46e3-8d9e-94248557a2ab">
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/66711ddc-8006-4f30-a269-f59b3d246705">
        <rdfs:label>ALPL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/97c703d9-8928-4a0d-b0ff-6cbba58a7b49">
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
    <rdfs:label>dolichol kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a456cca5-cb69-4d22-b57b-937c8bdcb59b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
        <rdfs:label>DOLK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/43bf5aac-6a4a-46f5-9123-acfcd94ec6df">
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/529c1800-caa2-4dbb-90fd-f741fb5e987a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
        <rdfs:label>GLB1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cbd43ff3-2587-4a7f-bb6f-03a9afe48b16">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2e0132fb-b9b7-4162-b51d-e6de6f57db81">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
        <rdfs:label>NPC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19deb933-a51e-492c-ab05-f0ca2d88c72f">
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/27baeacc-df1b-42b2-8386-3ca1d4c994e3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b37e83e-726c-4158-9057-84ce6bc85c5d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
        <rdfs:label>SLC36A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e1ca1c67-10e7-42a2-aa10-fc8a2c2bd979">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1345b5d7-9f77-4787-af03-2e4e4762066d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f508a599-c14f-4abd-8fee-88d9c7190076">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c67c7ca-f819-4b89-a630-f28daeaf9f28">
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4656ff5-4f4a-4204-8c3f-21495dd14e00">
        <dc:identifier>HP:0025356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Psychomotor retardation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e40adcf6-1223-4fc6-93c6-2b94a0b182b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee73c3aa-e61d-41a1-8877-c413039a38ad">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2faf5daa-023b-43ff-90a9-b5a1987f612d">
        <dc:identifier>HP:0000967</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <rdfs:label>Petechiae</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7fa1c17d-0245-4b2d-976a-2a0be74f70d2">
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <rdfs:label>Dystroglycan</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d56a47c0-1076-411f-94bf-47c0ce0d03d7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
        <rdfs:label>DAG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45bcad7d-f740-40af-b526-a655775a7d46">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d56b2d97-c25b-447d-877f-c7e23873b138">
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9141529-4af5-4720-a491-3314d8c0241b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c884cbee-ac7f-405f-89cb-bb3c46bf4d52">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00acbc92-86bc-425d-801f-1a9bfdc41bb8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fccc51a-f7d2-4ed9-bc7c-378de2fe9dc9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02a937b0-e272-4509-949b-46ea0758a2f8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ca25656-4b22-4de3-bc12-e7e67389ca45">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
        <rdfs:label>Chorea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002072</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52ec2280-26bb-4ce2-8e11-1e09ce7a19ea"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9141529-4af5-4720-a491-3314d8c0241b"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13c73ecb-2204-444a-8e7d-a94809ef171e">
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/54cbba83-a1af-4d8d-aacb-cd16c2e2af1e"/>
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c384b4fe-a072-4b83-926d-fac40006d21b">
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82c57f0e-8af6-457f-8149-6e3e44df0ef6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
        <rdfs:label>AASS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bec82527-9178-4c10-a7de-e35262042b6d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cbeb4e4-48b9-40e9-afea-462dd785f26d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54a5a395-3cea-4867-a605-0c08bc6e5e74"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20442c8b-b272-46e4-baf4-a2a4daedbcbe">
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/231616ef-1900-4332-8c98-abfe626763a1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
        <rdfs:label>DNAJC19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62ea78ca-ec4d-4aee-9630-6c70ee9a6c4d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af36d7ad-5f5a-4b69-b1bf-069711e5a451">
        <rdfs:label>PIGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ba9df27-cc55-41c9-82b8-73b54985baef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eeb8aa85-fcaa-4019-bd07-99880a473534">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e973034-2bbf-4789-a118-ef934aec7d70"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16b63096-e37a-47ea-8c24-a50b53038f90"/>
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8cca407a-33bf-45d7-a3dc-614eefca6920">
        <rdfs:label>MANBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/528d62d9-619a-4f92-bac2-40951c7f1000">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67167946-5d91-40a4-98c8-2312a7c41725">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
        <rdfs:label>OCRL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6aea494c-1b95-4705-8847-afeb46a47fea">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6aececd2-3729-4f9a-a408-f4d9a5f94961"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a00c0787-5819-4a18-ad1d-2172d3e8bfc7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow recovery</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <dc:identifier>HP:0012823*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1c7b1b6c-429f-4b2d-a25a-57c98012bca7"/>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1bb44ad8-e207-4d90-88db-634eecc0ec5c">
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0fb13dee-494b-45dd-b8d3-a564992cdff0">
        <rdfs:label>TH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/305fe8e9-e9eb-4305-bbcf-52860a5f52cf">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eef74bd0-3ff9-45e7-a3a1-c10a3b641a0e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
        <rdfs:label>OAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6ba69e45-d88c-444a-8c31-094330ae6261">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3363a276-8fb6-4f92-84aa-044e1a1ab5fe">
        <rdfs:label>PIGT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3d155a0f-8adb-45bf-9676-b45c39c01e4a">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-TK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f64f3559-6b09-4293-85b1-54d22448fbba">
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a88baf13-794f-4c67-865f-a81bfc7e4ca3">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b0174deb-6098-4cad-8675-5b24c90a5f04">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b6fd6ea-1fb3-47a5-b6f4-4426f9dedd3c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
        <rdfs:label>APOB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/54c45bff-90da-4fdc-8ce9-52d96bb5a519">
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <rdfs:label>ferrochelatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/017e23f3-2ba8-4420-a268-560651cc04a5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2ffb0baa-2246-44aa-bb33-5682d17b1c77">
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3d114c90-ee7f-4076-a98d-7e3bed570c34">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4825f4e-4425-43f6-8282-0282d1d0f156">
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22c1dc46-c434-4dfb-9711-3cb7edfc633a">
        <rdfs:label>UGT1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e97768a3-c04c-4615-9246-2af005b619fe">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
        <rdfs:label>GNPTAB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c2dbb49-b981-4986-9e15-01d5531f5019">
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/adf66535-ff0a-4dcd-80a4-88deb476b7d9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
        <rdfs:label>MAT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3620fbb9-808c-4c49-81b7-bbfc9827ea9f">
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa878ff2-14e2-4584-b6b2-a90f9b4cd715">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
        <rdfs:label>CBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0332167f-31df-4591-9607-455104115118">
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/368fabe1-021b-4885-89c9-6dfb2acb75ac">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4898d721-523b-4e6b-8d23-f7d6439ecc2c">
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67536ce6-8fcd-4b4a-be36-7d1d7246ec57">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
        <rdfs:label>ETHE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba4ef572-817f-4703-9bdb-57d110679b65">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/187a2569-61f0-4a99-992c-f6e9177ef90d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6d59260-9dd4-495e-b963-057f9862352d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26169d8c-7cf6-4723-b5ff-0aa08605db4d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cfd8ab10-f104-4764-b156-85c299faae1d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581636ce-cfde-44d4-815b-a94136bb3219"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1313d35-f7e4-459b-9bd0-a4a161cbf87b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b700e2bf-7ed4-4068-aae2-8994506fd7b7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77d0cc12-e792-4a7e-b2f9-dfd73d3319d1"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf728e2b-ebfa-40dd-bebf-034e48e97b00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee1a8bad-3848-46e2-8f06-629f47955b06"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a56f6d6d-5e5d-43f6-9ed9-79f3a58e231b"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f240fa1a-a760-4377-8472-924cd4c38cb5">
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5ef0ed12-b40e-4d8f-bd23-901f01f313bb">
        <rdfs:label>KRT5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/171b9411-2872-4ae8-8fa7-dd3a9aeec573">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
        <rdfs:label>POGLUT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0fda4efe-ca8b-4867-ac4b-0301ff7865c5">
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/368219e4-6dd6-44e7-81cd-532e93e2ed32">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78ec2517-8a43-408d-a588-107c2a376b7c">
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25735fe3-b554-483c-8b16-812bc2cd7975">
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:label>Erythema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a024a44-51f3-4b86-9540-81a865f56067"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b228dc5a-afeb-48f5-9209-e05a594e74f7">
        <rdfs:label>VX‐like lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34cba031-1467-4f71-9f04-a1ae3147c058">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>Scaling Skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2bf6a119-08ef-4072-8c00-f4f0dc355ae8"/>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54b67eb8-0b65-4c2d-8c3b-c8ad75603219">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Itchy skin</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e87d7b42-8221-4d06-a4ff-adc1c7f8b750">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007431</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e6774a6-a681-4273-85e7-b806c155b1bf">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031517*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65a74880-161f-485c-8937-10a8db217bf5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2503781d-4302-4445-9810-f6757df4f95e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6935c89b-ad84-4fce-af35-1f8d511c3431">
        <rdfs:label>MYH2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f5994fa-0136-48cd-a1c8-01fa76dc0e13">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d528a775-2290-4889-9aed-c50f55b42496"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/536c1214-a8df-4333-bb23-724c9c3538aa">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cddb0c0-b75e-4057-ba12-f83167215f34">
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7aba5bb-2e14-4534-8929-0cd108edce14"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff4586da-0503-4b24-8105-12dc2bab614e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a34d445e-7eb0-48cd-99d1-40b755494241">
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f5ad7f0a-3217-4348-88ca-629bc6c30a8a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/668b9cf4-5d04-436d-bb08-1d5b34ddea81">
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a555c19c-22b1-45e9-9214-1250a6644922">
        <rdfs:label>PLA2G6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c32e902-d49f-4083-9dcb-833982d5635c">
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/66afd427-5615-4f8f-8b57-fe0e56d5b6d9">
        <rdfs:label>MLYCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49e31f79-81fb-4aa5-bb1c-630f02b4c3bd">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6c9d376-ca7b-4160-b079-e1117665c941">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cef66e9e-7615-4e21-b164-1b65d4df6179"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c53f9133-4b8c-47a2-91b7-447a1f3e338a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd120bcf-be2e-4d32-a9da-cfa641a905e1">
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9cd0e4eb-b0db-463f-9705-1d3e0348d9bc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c95e1990-cf9e-4afd-991f-ea0e12d81ceb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e59feb3d-9853-4d90-9c7f-0de3d7b5ef70"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d0c7abe-f41f-4c39-ada2-faf6248de369">
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>Hyperurecemia</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b8b0da64-ddd3-446c-8dd0-ef0c325543e1"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14ecc967-b86f-406e-9359-9c95661ce961">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e32ea1f-6cc4-4bcc-bec7-3521f24bd9c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f18bb0c4-8884-40ea-84c8-0d885c0d859d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14bc6b19-179a-41f7-a1c3-a64e0a5ebf45"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2bb98a5b-aedd-4690-9638-08a29aed9d87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cd3a0bc-24c2-404b-88c3-f6f4f5fc5c4a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7735bb70-aff1-4f58-b450-073df39067c6"/>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42e2397a-0954-40ca-825f-d4a7ee58450d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b10bf1f8-fbbb-4b4e-bf13-e6d3ead78f71">
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52c8972a-174a-4912-9224-dcb6a660b44c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
        <rdfs:label>CASR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f59c2ff9-4a4f-4366-90be-aa84a26ba6f7">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2cb823cd-977c-4a5c-8d7d-a01edc446d6e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0eb13372-4332-443a-bf1c-0621730efba1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3f9ff3d-1be8-4f67-ba5e-842fea6086e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40b48940-bfb9-45c6-9219-501066b8aa0c">
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0003530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c05f5bf-0e04-4af7-92ef-47133427161c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a43f8803-a7c7-4923-b1fb-6cb1b379a2a9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
        <rdfs:label>COG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/028a169a-a432-4d48-ab68-8ac1866d0472">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/27baeacc-df1b-42b2-8386-3ca1d4c994e3"/>
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5b026f03-ac70-42f2-af73-d023cd8b4455">
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02c60cc9-2d1b-4d2d-8b2c-bcfad3da5ab3">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e1ca1c67-10e7-42a2-aa10-fc8a2c2bd979"/>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27baeacc-df1b-42b2-8386-3ca1d4c994e3"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8fc85e08-7c14-42c7-8723-06a8b6b31ae9">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/973433cf-9ef0-4cd2-b1ad-68fc070ab436">
        <rdfs:label>CTSC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7ae08624-cd24-438f-b6e0-d32fb26f2692">
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3bac050-f181-4a4c-87fa-f5d58cf94a4a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
        <rdfs:label>RRM2B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/be50c6b7-7734-425a-9358-68346d6f3ad3">
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/383a228e-de6c-4dab-8d06-56f32f72c970">
        <rdfs:label>MCCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df089f70-ddfc-4eee-a21a-8c4e580afd2f">
        <rdfs:label>MCCC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/334416e0-0f3e-435f-a953-d774ed59f626">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bfe61af-24d9-4a78-b6ff-1e89476f2296"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8325ad2-57f2-48a1-8748-7e96bfda650b">
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6457146e-25ba-4749-b5a8-ea766dd97e0e">
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f483da5f-38d2-4872-a1a0-0a38227ffe81"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb760c36-6a09-4769-85dc-d385332ac851">
        <dc:identifier>HP:0011505</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <rdfs:label>cystoid macular edema</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/430fcfd7-6c00-454a-aeab-f731e7f82cac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eef74bd0-3ff9-45e7-a3a1-c10a3b641a0e"/>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1154c281-af13-41b6-8af6-0020c7fedd45">
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0543df6f-38af-440a-bfac-32da5deda4aa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
        <rdfs:label>BCKDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/58a8904d-4169-4c0f-abbf-c17fd7e558ce">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1e3e087-35eb-4241-a6b2-b34ce2a7e45a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
        <rdfs:label>POMGNT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6902dfeb-48d2-4d72-b214-01573199d7a9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
  </ddiem:Disease>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="https://raw.githubusercontent.com/OGMS/ogms/v2019-04-30/src/ontology/ogms.owl"/>
  </owl:Ontology>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8afa46b8-54f7-4d68-b670-1ad9d91ca9ee">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e5d6eb9-5687-4153-82bb-d54d706064f2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
        <rdfs:label>GALK1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d027602a-4114-4242-b708-fff91930778c">
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0fb13dee-494b-45dd-b8d3-a564992cdff0"/>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4e6d58c2-8cef-43bb-861b-8a2dfafd525f"/>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/faa5e14c-8f53-48d1-84b3-6400e2763c26">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
        <rdfs:label>SPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8bf3c624-a413-4847-b90e-627e94ca62dc">
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/18abb85a-c171-45e3-9feb-ff11616787c9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/493ea51b-33da-463b-b6c4-68abf7117e3c">
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2ae5cf17-5ade-4909-8af8-c353a26f44fd">
        <rdfs:label>PFKM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3f795de4-124c-48c7-8450-fae55149ae33">
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/446d94ff-46a5-4b3e-a487-479546246ce8">
        <rdfs:label>FA2H</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e3f724e-05cf-42e9-bd8a-fe7c7cf29e35">
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8d68b0e-2458-46a2-a5b1-39027da256c1">
        <rdfs:label>IVD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b8d870ed-ffa9-45c5-89d4-0322fb0ea053">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8695efa-862a-421c-bf8d-a031e8ff6144">
        <rdfs:label>GNE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6629c378-3f4b-4bc8-958b-e5923193ab9e">
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/45bcad7d-f740-40af-b526-a655775a7d46"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b985d2f4-963d-4d0d-852f-6ae7afd5e8b6">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/66711ddc-8006-4f30-a269-f59b3d246705"/>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da6627cf-3933-4b8c-9f3d-1fe66acf1ef3">
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c32be723-f0e7-4637-bd26-87b823977318">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
        <rdfs:label>TAZ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1799c5b7-e493-42b1-8953-f315e2ec3050">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46b78ea1-e3fc-4c7f-bbbb-0b632527752b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>irritability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e31e4dc0-8036-495a-a71b-5ace7da21b5b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <dc:identifier>HP:0003657</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2dce26e-fb87-4dc5-b62b-0fafde2929a0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004372</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <rdfs:label>Defected alertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9d4d0e2d-7ff7-40a5-844b-f6cbbcd7d3e9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4617d08b-3960-40d8-aaaf-dbd265359248">
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b73f601c-962a-4637-af23-4bfc80fc0acf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8ec9c33-b982-414e-9347-0acdec89f945"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa04072d-ec83-4cba-a6ec-6017185d409e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22859e0b-b62c-4972-9849-2ef366427fd7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/70cabae8-e96d-4d95-90ed-8922c9fe9d1d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/607753a2-ee06-42f8-ae43-a55f92520b74">
        <rdfs:label>DNAJC5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b56c11d-4fbe-4e2b-a1d1-50486969d37c">
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/745776ff-92b4-45dd-93cd-f1a5f94fbc34">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
        <rdfs:label>ANKH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73136f0f-4ab3-4240-b19a-ef25c992d628">
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4489fa61-f763-4c1f-b13b-1954c8e7d870">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
        <rdfs:label>ABHD5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a554940-65aa-434b-9d58-eee665996fc5">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e3087f5-e454-434f-aaec-39df86186e58">
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e45b771-dbd3-4c9b-924d-6577aa7a755a">
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65a74880-161f-485c-8937-10a8db217bf5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52657082-92f2-4f6a-a9a3-57ce39e55c9b"/>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03dbed98-f53a-4696-994a-03c2258819cc">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/adacdcc7-eb31-4ffd-b17d-099df95e21f3">
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/92326ef7-6115-4bf9-8044-6ff72434e335">
        <rdfs:label>DHCR24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e5d6eb9-5687-4153-82bb-d54d706064f2"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3bb419a8-bd92-4f9b-84d5-eed5386831b5">
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2841af11-3e4b-4407-bb0a-7fc92fe0f73d">
        <rdfs:label>SGCG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f604c08-2487-41da-a585-1930a0fb7d0d">
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea87b4b6-fdac-48da-a545-40faa8ac2387">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef34926e-0533-40d4-ab74-66b7ebd46e49"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a456cca5-cb69-4d22-b57b-937c8bdcb59b"/>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a63878c5-9d35-4be8-9563-65278ac31fb1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1f2325a-e230-47d1-bc3d-7b1c53edaff8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14999705-cae9-47f0-98b0-7544e1212491">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36e00010-11c6-4dec-9b42-c975e84a18a8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f687c50c-6d2f-4b64-a445-5a3ffad94290">
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <dc:identifier>HP:0010893</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fccc51a-f7d2-4ed9-bc7c-378de2fe9dc9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c44530b-b8b6-47fe-97e5-17e4b9569a3e">
        <dc:identifier>HP:0040086</dc:identifier>
        <rdfs:label>High serum  prolactin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/646db336-bae1-4aac-b115-84e1a69f191c">
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9f234fc1-6fe5-403b-8c84-35fea94055dc"/>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29310802-f3ed-4eff-8e76-20159cf28e80">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a4acaf2-86e8-4277-bc04-1a368677306c"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5fbeae58-3379-41ef-b065-fed98d0eabc0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20f215bf-08f6-4281-bfa1-1e96c63cb0d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/192a46a3-df77-4acd-afc8-3108d7d79eba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/63492ec5-d64f-4d5b-b219-33cd7ffb6e04">
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/04f367a9-1687-43bb-97eb-54dec86353dc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
        <rdfs:label>FH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a5848d84-ee93-482f-a5c5-58dea81271a7">
        <rdfs:label>SAR1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea84af8e-80a3-4390-bfe6-56f874864938">
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7735bb70-aff1-4f58-b450-073df39067c6">
        <rdfs:label>IGF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e31e2bf4-e027-4dae-ae26-0a365a8a9772">
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/57521ce8-02dc-47b0-b13b-58f9c78bdb1b"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16a2f065-ab34-4f1e-86cd-fbd3dc0ad692">
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b79f0887-44a0-4462-b939-5eea4137e8ac">
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f483da5f-38d2-4872-a1a0-0a38227ffe81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d45df184-8ad3-4a00-ae33-d38ee966c044">
        <dc:identifier>HP:0001944</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
        <rdfs:label>Dehydration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e09e612d-c174-4497-b15e-0b0fa90b145b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae91baa0-d336-4435-a5bc-68efac372716"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7ed82978-201f-491e-a13d-f48c7e471588"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/003d91f7-454d-4a4d-b34e-4e7b9b21cc07">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a580be1e-d4e3-492e-921c-516fabba6b2a">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d9387c9f-f33f-4b9b-9426-05e5565d158b">
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ecbf67fc-b1ec-41fa-99b9-731dee0acab4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
        <rdfs:label>LCAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8774cc3a-d50a-458b-868a-b10daaaffc99">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
        <rdfs:label>OPA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/70bf7859-725f-44bd-b3ab-477c5247f906">
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e97768a3-c04c-4615-9246-2af005b619fe"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2faa7ca-2e1f-4c0d-a067-399964cc4c26">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ed82978-201f-491e-a13d-f48c7e471588">
        <rdfs:label>SLC5A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94da06f4-b737-4378-b563-28ded9dc267a">
        <rdfs:label>ENO3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a108903d-79d2-4070-8734-563e94c968dd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3404f059-da34-4943-82a5-05c003461d6d">
        <rdfs:label>LMF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/acff831e-0732-4d5e-929d-c8574237af1e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/229c89f7-651d-400d-b775-9d6085fa3d9f">
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67f956f1-9292-4c01-9bae-fbd900f00df1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ca4e10a-6a8c-4abb-b483-792a709d09ed">
        <dc:identifier>HP:0000735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>social interaction defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a20dd48-f6e3-4cb5-99f3-a3dfb5cbaf92"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26169d8c-7cf6-4723-b5ff-0aa08605db4d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/832449ed-4b05-4d19-baeb-747f7c467827">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/daf65a3e-96fe-4656-8052-a957c584924d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15a8a76f-ec92-446a-ab18-f8a900e59dab">
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec8f5f27-56ac-4fcd-9b13-f01277338886">
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a00fb75a-d670-468a-b908-d46e3acf86ac">
        <rdfs:label>CYP17A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3779cf62-f2e3-451e-aac1-c18804f7c596">
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f2e7517-db0f-4038-a7fe-8a8b1212309f">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9bf8a1f4-aa2b-4e4f-9ba7-175f83b6aab0">
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f2f440b-50a4-4157-a9eb-0174f9e52016">
        <rdfs:label>POLG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83bec797-68eb-49ea-b89b-d51fe3b0b94c">
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b08b1ae-eb58-4734-8bf9-1d696aefa1b4">
        <rdfs:label>MPI</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/69777afc-0543-427a-9898-491caf30c845">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7162f327-6f74-4ca3-9c66-e499efb32c20">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
        <rdfs:label>SLC35C1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc367ff6-68d7-43b6-9e8d-5e6fa8a42ad7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba8a9147-e79f-4869-8d96-a56a7820fe32"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af15ca77-2fba-41a9-adde-8109763be8b8">
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5a6e84a-976d-46a5-b77c-76729da408fa"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a97c323-ee9e-4e5c-8240-de3783ad5830">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2eaabfb3-c9d2-48c7-a763-81b579e6a03e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/846a451c-8a01-4e73-8bc2-693be71073c5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efcff9d5-6612-4730-8867-656b72c3413f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3761a5ad-983e-42df-8176-13892c48aace"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af180d8a-2704-4078-afaa-5d4bf9c95747"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ad52170-f5c2-4fb7-ab22-f0f55418d4d7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
        <dc:identifier>HP:0001889</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6dd35d53-0116-4b56-ae79-20e1aa19d471">
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0e30b737-e2c4-43c4-a3b4-de81e450339b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
        <rdfs:label>PIGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2613c1d-e403-4763-8b17-189db3627e30">
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2e3071d-a5b9-44ba-829b-f7db0d6f21f3">
        <rdfs:label>LPIN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8585d393-433d-4cf3-adda-8724f48805de">
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f3b93bc5-0750-4fd4-b032-a5af251b4ff3"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d017202-c31c-41d7-a04d-67cb575925ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b94459d-a2e4-4c0d-ad72-91f7c4d95dde"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4248d042-bdd3-4f91-b583-a2e50359aad4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af36d7ad-5f5a-4b69-b1bf-069711e5a451"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5ed561bb-97b4-48e2-ae67-dbf7e5c09991">
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c0d87ea-b2ff-444d-9e08-a5da8a1753a8">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b7f46dff-2c89-4662-8b46-c21135b1edea">
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4fb643ed-a5b2-4d08-9132-de0c95708932">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
        <rdfs:label>GLUL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c3c23016-ba92-4c40-85cf-5f153e4e899b">
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/22c1dc46-c434-4dfb-9711-3cb7edfc633a"/>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bdace873-7a52-4645-8b14-85c55c25e3ce">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/29630709-da81-4f54-ac5a-865220158142">
        <rdfs:label>ECM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d24615ad-7eee-476c-b9a9-0905a95efbaa">
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d7fcbe20-b1b8-4f73-b62a-67673bd4fb51">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
        <rdfs:label>ATN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <rdfs:label>atrophin 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4cf2021-afa7-4aa7-a34d-300dde3862e6">
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e75703b-479f-4fe7-96ec-2e6b86266079">
        <rdfs:label>AMPD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62b4941a-47fe-4a72-9b30-ace6a6ab08fd">
        <rdfs:label>RNASEH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a8fe91c9-f95a-45ec-9b1d-c72385d58dc3">
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8774cc3a-d50a-458b-868a-b10daaaffc99"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1bf77413-8afa-468c-9c09-c1d9cb4fed89">
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3bbd6739-8e49-4f70-8148-00c8cb61a699">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8bd44cdb-9b10-4661-9704-782aeb298bb3">
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3738b7a1-45a6-4a44-950b-bc8a358b6943">
        <rdfs:label>BCS1L</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d7610623-0495-461b-9adb-02e51945abe5">
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c386ea5-9690-4f5c-99b7-6b46b85ea77c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
        <rdfs:label>APTX</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <rdfs:label>Aprataxin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb2a1704-b862-4849-a6a8-7b218834c0fc">
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12c0507f-1785-4286-ab2b-416ac738428f">
        <rdfs:label>AUH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04751cea-4acf-41e5-a079-cfab917c723d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <dc:identifier>ECO:0001565</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ee6969ef-fc3d-466f-b5fd-c524ecb66071"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34bf61ce-bf4c-4446-96f9-ec4f6d9eddf0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain atrophy</rdfs:label>
        <dc:identifier>HP:0012444</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a6398fc1-2563-4c16-ac50-e989228b5594">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/412c9f16-dbaf-41ce-bc21-289e018eda27"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc488717-8e24-4896-ab69-c6796a3af91f">
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d188f708-27c7-4159-866d-8a0895e7b61b">
        <rdfs:label>KYNU</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <rdfs:label>kynureninase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d962b0d9-89b1-439a-89ba-2409474cdb61">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe0f6af8-67c3-4531-a043-a8d46ae83863">
        <rdfs:label>ADA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Adenosine deaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56276152-912b-48e6-874b-ffb366f83f36">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2401622-2c19-401c-b5b5-b14f8e6e41c6">
        <rdfs:label>GALT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba5b0188-72e9-47c7-8a3c-72edf3470739">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e4f6e4b7-7123-485a-97fe-d65a582bd2d7"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86595754-1d17-4ccb-ab1a-2f728ec79ce3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb672bfe-486d-4d47-a0db-1f7e8833d506"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0eb13372-4332-443a-bf1c-0621730efba1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26337e6e-3bb5-4e52-b4b7-365c21cae9da">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:label>anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcc8c8ec-0f2a-4d36-8f8b-271bccdff460">
        <dc:identifier>HP:0001254</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lethargy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/117b4ee3-a8a1-4e33-90c9-64320c38781b">
        <dc:identifier>HP:0004337*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a60e10db-766d-4bdf-a6f3-ea54edc870d1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>Poor growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59d81451-9ca0-4544-b50b-e60207b8ca24">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf47e818-9037-41da-9f65-d401f64b44c0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf620ba2-0086-453d-b0c9-9e349bc3e412">
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2">
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2573725b-0ad5-47d7-a6b1-108c153e1ad7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0583e3ca-e230-4669-be8d-add0c9638559">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The study was terminated</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc43d827-5b8d-4db4-b8f3-e37e2210f9a6"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5200e2d3-ad83-4ac1-b005-e3379609b0bb"/>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1dd495b5-9941-4383-a2a6-ffb6d43e2953">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
        <rdfs:label>LBR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb530d8b-2d23-4ddc-8799-4897bbf672a8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af180d8a-2704-4078-afaa-5d4bf9c95747">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
        <rdfs:label>FTCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb529ef6-68a6-40d6-9b1d-e58b246df18c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43802a6d-8de3-464d-b3fa-af7b363e6bc4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/82c57f0e-8af6-457f-8149-6e3e44df0ef6"/>
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73925f56-ccde-446f-ae04-3ea024d46919">
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <dc:identifier>HP:0010818</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c51a44c4-bcc1-4c58-91a4-27021c3866c8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2894488-630f-4cb8-8979-de212bedae22">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3eb6dbe5-ff60-4c96-b316-25788f87b620">
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c50d46fc-e151-4287-afd0-7237cfaaacc4">
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/535993d5-a376-4bfb-b81e-47154a09b155">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4f2419ef-d640-4061-a61b-6eafac045757">
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48e895c3-1a43-424c-b224-23ab8b230bcf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
        <rdfs:label>HJV</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d15c119-9c43-4e36-a53a-c083c312fbc9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
        <rdfs:label>HAMP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c0d87ea-b2ff-444d-9e08-a5da8a1753a8"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5fcbda58-a6ec-457f-b238-7bfd1d9553ab">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
        <rdfs:label>POMT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3dbdd1d1-5e06-4084-ba97-b4811f3fad4d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8b0da64-ddd3-446c-8dd0-ef0c325543e1">
        <rdfs:label>UMOD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
    <rdfs:label>uromodulin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/04e9b7cf-6f0d-4d71-b586-ffb97c710bd8">
    <rdfs:label>thiamine transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fdf8fc69-4076-4b02-92e0-8a3b304698ec">
        <rdfs:label>SLC19A3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/183e8c03-709d-4086-b103-eb81eedcb778"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d06e4a14-7273-46f6-91ca-43f7f202ccd8">
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eeb83370-16f6-40fa-ac21-16b7c11615b0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
        <rdfs:label>HADH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/27af67c2-91e2-43f3-9387-008663f1f77f">
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cae5fe62-40eb-455e-afc6-026bd8c6fdc9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
        <rdfs:label>HGD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c96d9673-04cc-46a8-a9d0-f1f7ceddd7d5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7aba5bb-2e14-4534-8929-0cd108edce14"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dfb85b1b-8326-4ab0-b68d-7db3823a1259"/>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d528a775-2290-4889-9aed-c50f55b42496"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cbe210b-7cb9-4171-ab3e-215c1c63b47e">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cddb0c0-b75e-4057-ba12-f83167215f34"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/abb2f0c2-b030-4c19-9e40-5c20b5c1a5b3">
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b47089d-e185-466e-88bb-2ff220e9e1dd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/982ed616-5b24-4008-aad0-89a12add4fda">
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/03c8d8e7-c1d5-4dd5-a9be-99da4326b750">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
        <rdfs:label>HPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c84bb457-a061-4d49-bc6b-2b8a3250b6c2">
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32f5e210-cc53-43f2-acd6-3f8313f9236a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
        <rdfs:label>CHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ad0356a6-6989-438f-8771-5debc9f7f670">
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8cca407a-33bf-45d7-a3dc-614eefca6920"/>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <rdfs:label>Beta-mannosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e9ed737a-23fb-43b1-9907-6a3d965485f2">
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52657082-92f2-4f6a-a9a3-57ce39e55c9b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cd26d3cd-99e3-4044-85fa-703a13f07a37">
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ff4586da-0503-4b24-8105-12dc2bab614e"/>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dbde49a9-f929-4052-b70f-cae68a7758c3">
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/991435a1-f421-47b1-b24d-a0a0e717b57a">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <rdfs:label>Glycerol kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7ed15ba-4a52-428e-9814-0e6d416139dc">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e52d1c31-7ad4-4728-a5fc-128977f8d3bd">
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dd03c7a-3d59-40ea-84e5-289ab36df512">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/00e00902-e033-4661-adb6-be7884901fcc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1b909b09-54e5-4275-b08a-e66142516e07">
        <rdfs:label>MT-TS2</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b038449-9ca0-47e4-9c46-4dc68de081d5">
        <rdfs:label>MT-TH</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ecec12b-a1ae-4504-b19f-87c259193ec0">
        <rdfs:label>MT-TQ</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/27a46e0e-2167-45fc-ac3f-36617204c10d">
        <rdfs:label>MT-ND1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/081feaa7-1705-4752-a94c-995a8900f0af">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
        <rdfs:label>MT-ND6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5209f139-8dd7-453d-8a1a-b1f42ac343cb">
        <rdfs:label>MTTC</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3abce43-7799-4c00-ad60-5725a8b80d76">
        <rdfs:label>MT-TS1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6f34354-48c5-47eb-84fd-f2a66d15a18f">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
        <rdfs:label>MT-TL1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/29c4224b-73c6-4662-9bb2-7e4033e11fea">
        <rdfs:label>MT-TE</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/672833ee-36d6-44c1-a789-2dc725f2b26f">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
        <rdfs:label>MT-ND5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c13f31a-e305-40bb-961f-898a76b6810e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3cdd8f6d-a4e4-46e5-86a5-86a447316e4f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
        <rdfs:label>SGCA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/350b7cf8-53db-407e-8e60-d27a54093f6d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/83688082-05ec-4556-9029-9d73d767b183">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
        <rdfs:label>PRPS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f703ccd-def1-4f91-926e-5ff789e49a82">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02265d04-5020-44e5-afd0-2020bb6f9fdf">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000793</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c44af6fd-b446-4590-aa88-53aab75e011d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91af7cca-793b-42a4-88ce-9565c5c6d080"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/355ef659-8a6e-4fa6-94d2-33a923224b8d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a877ed51-e2d8-4ddb-89ef-36451aec812d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <dc:date>3.10.19</dc:date>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2c850fd-7cda-4db8-aa16-2e98f91ab8e6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73e1f3d7-ad0a-425e-80b8-69712e73a462">
        <rdfs:label>LIPC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa513171-5848-4bf6-8964-da8928bcd379">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24166807-4286-44e0-8a27-12811e46608e"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c0e242f-188e-4a7a-893a-f38b6091b25f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a293808-e537-4339-b8a7-e6b0a8cc07ed"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24256318-ab0f-48f8-8286-68a5bf6a619e">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1dd495b5-9941-4383-a2a6-ffb6d43e2953"/>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86054d1c-2e13-40f6-b2fb-b93556c14877">
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c67de9b0-9c9d-4a13-aab4-fa665ea30aa0">
        <rdfs:label>AGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e42073a-d8d5-4478-8ee0-c0f9179c2b80">
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b7bfc299-30ee-4b21-871e-83b73070d935">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
        <rdfs:label>ABCC8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7b809996-c947-4e72-a89d-86efe44e65d9">
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/696827b1-adcd-4cdd-ba02-ab00854a6ac4"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e45f3f6b-7e58-4fd6-9e2f-b541c085fcee">
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d0c14319-f1dd-4c9e-bf97-8866d4696ccb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fc79c3f1-ff25-4ced-a6bc-495fa60f13e9">
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d267f62e-5627-49eb-accb-bec949f2141a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
        <rdfs:label>B3GALNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec9d8ab6-baf4-42d4-b16b-afc4838b617e">
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc39bb9d-63cf-4a20-9f7f-fee466e4d506">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
        <rdfs:label>DPYD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a106ea53-b463-4549-b3a0-4e178b7354d9">
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/16b63096-e37a-47ea-8c24-a50b53038f90"/>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5eb90b0d-ea48-4f8b-9b0b-89bbeaf4ed97">
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4955bda-a178-4bd8-a816-900d07fff87e">
        <rdfs:label>D2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1645e1f-436d-4350-a84a-8ba0c8ee6062">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bf1492e-2bed-4e66-92ce-2ac9f7dfbf2e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <dc:identifier>HP:0010919</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2756b8f4-d831-47c3-b763-9451854b8916">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>low muscle tone</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c526c952-c47f-41ef-a7ac-aef5c7670d7c">
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1614ca0f-fe79-47a1-b7a1-79ab899e18da">
        <rdfs:label>SLC2A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5596b22e-c1f1-4032-b168-6d711344d5e2">
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f9f18d3-751a-4d44-9e4e-328a47743eb6">
        <rdfs:label>FXN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/22f30c23-20ec-4942-81d3-d52805780d19">
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d55d0aea-c762-43af-a414-ab741cfea4c3">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/901d8dbc-1b71-47a2-bf07-8b6438dbce9d">
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/55025b88-8519-4d17-bd4b-107c352901d7">
        <rdfs:label>LIAS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/638cf7cd-b79d-49e4-af06-afb9afe79db2">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f9fe889c-fdf1-491f-91ca-84ddec2827d5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
        <rdfs:label>POLG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f8dff286-15ea-4dc2-a573-26416676f867">
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6935c89b-ad84-4fce-af35-1f8d511c3431"/>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e47f67f-0d2e-46ac-a75e-2f36d4e13db0">
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba8a9147-e79f-4869-8d96-a56a7820fe32">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e29ad84f-7702-482c-9157-813326275419">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/24f7b8b6-8d4e-4a0e-9ef7-018ba8f6c82e">
        <rdfs:label>ANO5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>anoctamin 5</rdfs:label>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79c3b8b5-d8e2-4d63-a56c-5d06589e21cd">
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5baffbf0-a82b-4fa3-aee6-286f6969ec48">
        <rdfs:label>DPM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/09937db8-55c6-4f7d-869b-ccd4e12385fe">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/09edf1ae-3d8b-4cf6-901f-76aafb5b1759">
        <rdfs:label>GNA11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3a46fcf9-cde9-4c72-9a69-612614e517bf">
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/76a0b0e3-f06e-4f51-a0f8-b76a87d1f387">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/22e65bd2-9e45-43ff-bca8-2ff6ac96476f">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f9fe889c-fdf1-491f-91ca-84ddec2827d5"/>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b22ff736-7136-4fab-835f-3028d28edaee">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1a910727-0ebf-4d48-9f7f-ef5a7a515ef0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
        <rdfs:label>MMADHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/97db780b-3b5e-499b-9b2d-2026cc84ef53">
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6cb9a641-41df-420a-b228-b8c5b8be5b9e">
        <rdfs:label>ABCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/14ddc4ed-1001-4f44-be4d-b357d49435c9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75a99c75-579d-4fde-b0ed-d862dd4a6606">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
        <rdfs:label>AGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f53789f-efc7-488c-ba98-181e1afd1593">
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9071cb00-4a84-448f-8097-5ef85fdbd8bd">
        <rdfs:label>GLYCTK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3822243a-bf4f-401a-9eb1-648ef441f976">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/28355243-4de3-4fc4-b12a-7a19e7797e21">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
        <rdfs:label>CPT1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d80533fc-038a-459d-a17f-f8a925154eb3">
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d78962d-d1bc-4bc7-8dd9-0e0e16478282">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
        <rdfs:label>NAGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28ac07bf-2abe-4ffa-9b0f-98def30f8d54">
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d742ac12-e967-49db-a7a5-9bd600760026">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
        <rdfs:label>SLC12A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9808db19-e96b-47b3-8fb6-55b3ccb57fbc">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e0ce4df3-0114-470c-85d8-21545a696942">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>PTPS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/879ef61a-8b19-4432-86ff-8dcbe87068fd">
    <rdfs:label>dysferlin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f9f8136-8d80-4dd3-8549-021e548c6657">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4894d220-4791-4f5a-b8a4-321cbbb1fea5">
        <rdfs:label>LDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed8f29b7-a946-4feb-84db-d8aa8b2d854e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b9cc1c6c-eb1c-4c53-af6c-74161e547cf0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
        <rdfs:label>HMGCL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f83cacb-9df5-4517-8d91-483b0ce7e90e">
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df60dc4f-4944-40aa-8553-b7b31f29c10a">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6204b0c1-7094-4cc5-afe9-04fe01799ef2">
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4c2dcc67-7c81-4b85-8b24-8a3fa1393cd6"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3"/>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f2c95ca-dd65-438a-bb6a-f132f3613c6c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bdfe2ca2-e8c7-4271-a759-619b1670ddeb"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57351290-9205-427a-967b-2382db620848">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dcea82a8-a767-400e-9163-32372d0ef7cf">
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a56f6d6d-5e5d-43f6-9ed9-79f3a58e231b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
        <rdfs:label>L2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2f0de8b-c8a1-4abe-95ec-9cf6679a2a85">
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb0ea71c-45f6-4704-8082-2bd4bb954134">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6d14ed87-bf91-4b86-a1c0-10bc0ad5b81a">
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3bb903fc-32fa-4c9e-8e05-1a16f816163d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
        <rdfs:label>APRT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/017aa626-359f-47ae-a832-6383bef5a820">
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <rdfs:label>enolase 3</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/94da06f4-b737-4378-b563-28ded9dc267a"/>
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c785e69d-3077-4cfc-b0df-b9511b6e08a8">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0eb13372-4332-443a-bf1c-0621730efba1"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cdb47e23-a8f8-48f8-8b5c-335f7183aabd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da66dc50-111a-48b5-b1d5-bcc5a425ec11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/479a63d8-ec67-41ae-8374-e9ca784311c5"/>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2e726698-bbed-45da-b718-43d5f3c20ddd">
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5a8baa99-7a42-4b17-8261-eaa50314ede2">
        <rdfs:label>CLN6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/35c75046-679a-4bd7-8e7c-41db625c5cb9">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7162f327-6f74-4ca3-9c66-e499efb32c20"/>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0c14319-f1dd-4c9e-bf97-8866d4696ccb"/>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8b276f5-6b0e-40c9-8384-9c807aa3de00">
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/294378e2-6fd1-43c9-bd18-36bc70b69887"/>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/addfd079-b747-4ad6-99d4-53c8cda0ed3a">
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/01dde886-bb32-4acf-bc5f-5c1a04007806">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
        <rdfs:label>ATP7A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c554b351-c32a-4212-85af-c4adca2ffd2f">
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31e8b951-4244-47ab-8691-4895240ea202">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
        <rdfs:label>SERPINA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5baffbf0-a82b-4fa3-aee6-286f6969ec48"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dfe96085-cea7-4cfb-82a1-022b3839132a">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f5ad7f0a-3217-4348-88ca-629bc6c30a8a"/>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/80cf054f-36e6-412b-bc3f-74bcc9e6467a">
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <rdfs:label>Sar1b protein</rdfs:label>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a5848d84-ee93-482f-a5c5-58dea81271a7"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d590d4e5-1184-4370-960b-5c1181fc0280">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/357b8476-ee33-44c8-8ea6-17dfd0021aeb">
        <rdfs:label>GIF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/24f7b8b6-8d4e-4a0e-9ef7-018ba8f6c82e"/>
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5967ff2e-9532-4d2f-8318-7c521e9afd54">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2887f918-82ff-4477-b604-8781a83b6130">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
        <rdfs:label>MTTP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24202cf8-34c1-4465-a191-8155966b7c7f">
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c28042f5-8b11-4d3d-bc01-cb6d27ecfc60">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
        <rdfs:label>LIPA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc5fefae-0e6f-4a88-bc6c-707e038b3eb1">
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea46e5b1-2984-422b-9a5f-5cf80708f4f8">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Fukutin</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73ed243c-71d6-47d0-a89c-3a67493b846f">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/be9784c4-fa57-4395-b22d-d8a409ff35c0">
        <rdfs:label>ADCK3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e428559-6687-4175-9241-f18e26500f61">
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30951780-9ec3-4d78-a1a3-b7d6ef340a09">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cd8257c3-03ed-4328-86a3-d6bb8a8cb0cc">
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/447b2470-ece2-4403-9d17-f0ba9ee57d2a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
        <rdfs:label>AVP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7da7bb0-ea14-4276-afe1-6280e62f4828">
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e28c2f4e-7d79-407a-a8cf-bfe4845df0ea">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/267356c2-1d6a-4e0e-bdfc-fd292725b213">
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1547c35c-fe27-4da9-b1d5-65cf4a53a119">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>LARGE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4f3534b4-e74a-4963-b07a-c451decc0479">
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5df7476-b10e-48e3-aace-1ba659ecc63d">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6be20a3c-e8d9-44d5-8138-dcef2d518fa3">
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0221e804-ccce-453d-85e9-e557192647ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
        <rdfs:label>APOA5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79cf5934-6b6e-4e1f-853c-bdbc77a2540f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34cee4a6-2a8d-4b4f-8b4f-9550a22b06a8">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1987d112-a029-4c0d-b65f-9d08938f03cd">
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c002b63c-3475-4d7e-95e8-693f1a6c4d66">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39bd8297-42d1-4599-824f-bc3e08947d3a">
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4894d220-4791-4f5a-b8a4-321cbbb1fea5"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/eebb8e58-6a63-45e8-b9bf-cbe004be9e5b"/>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/596dafbe-2e3d-48a8-af1b-b8567527ba4c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4c0e242f-188e-4a7a-893a-f38b6091b25f"/>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c6e352b4-29ad-4d55-83c9-27d44dc4f93f">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6aececd2-3729-4f9a-a408-f4d9a5f94961">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50e68955-e458-450c-a018-e6309ae17c23">
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ea46e5b1-2984-422b-9a5f-5cf80708f4f8"/>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e31b9ce7-3e5a-4a19-ad99-a7e58884ca89">
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c33c89d-5f4c-48ef-a719-eb609c5335fb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d56a47c0-1076-411f-94bf-47c0ce0d03d7"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3d114c90-ee7f-4076-a98d-7e3bed570c34"/>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/074353cc-8a38-4212-824b-6c33e6aab5a2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e355fd7d-5910-43e4-94e7-67668697986c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
        <rdfs:label>AP2S1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0517846e-8f7d-4f07-ad2e-0fa6bfcfcc67">
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4cdd5ffb-394c-46c0-8058-5395e18d4616">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
        <rdfs:label>CP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <rdfs:label>Ferroxidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d3ef688c-c379-4115-b0d1-0adf42853294">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b1ec447b-fd95-4cc4-b398-ae66c0ee6e00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
        <rdfs:label>MAN2B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c2018ae6-7f0d-4c9a-8769-e45661cee20b">
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0e30b737-e2c4-43c4-a3b4-de81e450339b"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c4218efa-df96-4e86-b02a-62a9607dd8a5">
    <rdfs:label>battenin</rdfs:label>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/805319bb-ba32-4697-9c47-09fe43b6dd52">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/45aa3c40-0bb2-41a3-aee2-cf3b9b4112f1">
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2bf6a119-08ef-4072-8c00-f4f0dc355ae8">
        <rdfs:label>NSDHL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0f6fac2f-ebea-4fa5-a22a-3be970c1dafc">
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
    <rdfs:label>barttin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/396a7aff-a42f-4979-99fd-931fac77ba7c">
        <rdfs:label>BSND</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/081c2c8c-f42a-4f88-8c8e-a54aa8ef65ab">
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ee6969ef-fc3d-466f-b5fd-c524ecb66071">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79bb2d1f-ad72-4f87-8380-fbeb84e9a738">
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f97ea1a-ea1a-4965-8c18-db10c0e88bc1">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
    <rdfs:label>biotinidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84709460-9e9c-43bb-9967-d693c82c326e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cabb080d-a35a-4ce5-848e-85f9f95349d9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b38ca848-e39f-4e42-9223-4a58059b6941"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd64d9a4-2553-4527-a548-c158407c4b1d">
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0ab25cfe-6236-485f-b86a-7ff863d68f2f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
        <rdfs:label>BCKDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b22ae59d-5a69-4a06-b99f-b100eaa760ad">
    <rdfs:label>Methionine synthase</rdfs:label>
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4812cde8-fa8e-413d-85ad-5f47c647bfc4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/adbf10c7-31cc-4d61-8088-861316790167">
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a555c19c-22b1-45e9-9214-1250a6644922"/>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8945effd-40af-4791-be1a-cca22ca81c08">
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb3fdbec-78be-4c8b-81e7-a12855673469">
        <rdfs:label>CTNS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc752387-8296-4902-9d77-1a6c5e0e4d95">
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe4fa974-dd8a-4134-a3e3-23b366d751b5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
        <rdfs:label>DBH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3d2d9929-7d7e-4624-ae0d-3b7a1cc127b2">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5fcbda58-a6ec-457f-b238-7bfd1d9553ab"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f5405de1-33d7-4492-aae0-050b54249c39">
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a0dfc985-055e-4eb0-bf1d-1ee0923d421e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c0b883cd-b8ab-4fd2-aed9-96603646fe4d">
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9aac574-fc60-4677-a03c-45b95f559932">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
        <rdfs:label>ASAH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/32cbdf4e-1996-4332-b4cb-a327ccdf6edd">
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9d4d0e2d-7ff7-40a5-844b-f6cbbcd7d3e9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75dae832-1cfd-419e-aa83-fd525196cf41">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9fc1969-d6d3-4d1a-a5d8-85ee9fed7a9f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
        <rdfs:label>FUCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/04f7a35d-aa83-4e8b-8c9d-3a720c36c9c4"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e7bd99f-326c-4290-9413-413c7c187a2d">
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0221e804-ccce-453d-85e9-e557192647ae"/>
    <rdfs:label>apolipoprotein A5</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/04f367a9-1687-43bb-97eb-54dec86353dc"/>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e5b64ca5-e899-4387-ae53-381782056481">
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5cf2bf7-5452-4d17-8873-749266c295f4">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0efd7395-2bef-4249-9abf-2197b7e7212f">
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d4955bda-a178-4bd8-a816-900d07fff87e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee6a75a9-81c3-4f71-8399-b398382df1aa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b1f712d-8967-4c5d-a357-51daf773da09"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f483da5f-38d2-4872-a1a0-0a38227ffe81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cee6aea9-20a2-4d6b-9035-944ac7c5a01d">
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5810835e-eda7-40e3-b498-7ebaa1779dfb">
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <rdfs:label>mevalonate kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/caa5f9f4-8899-4207-9b33-c5b28c921363">
        <rdfs:label>MVK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fac99708-bed1-4437-8d34-a381e723c749">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6d59260-9dd4-495e-b963-057f9862352d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581636ce-cfde-44d4-815b-a94136bb3219"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cdb47e23-a8f8-48f8-8b5c-335f7183aabd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5be2c0e6-1997-452f-b75b-ce49b42c2f48">
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/056e0a47-ee81-4cfe-8b1c-a46be21759d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
        <rdfs:label>QDPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2197eea1-e269-4003-b459-1b7e34aac00e">
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b7d2819-1725-4bd3-9646-e7a6a8f0d98d">
        <rdfs:label>GLA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c2bf660-2fa5-4163-9210-9a782f6aeadb">
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7c91b202-ac00-45f3-b73b-4e1663af1de5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
        <rdfs:label>SLC25A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b6bcb61-5939-4b58-8bbd-7598e94f2ca8">
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3858047c-2160-422e-ab86-cdd1865fa8bd">
        <rdfs:label>ATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1fc37c0-9826-419d-94c4-1fbb470d6003">
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f90f2c8b-fcab-455b-94e2-adcd1b3caf5f">
        <rdfs:label>SLC39A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6a222745-3c42-416f-ad78-bbc70e47bf91">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ba4ef572-817f-4703-9bdb-57d110679b65"/>
    <rdfs:label>Prosaposin</rdfs:label>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6f462fd-6792-4fd6-989a-d7fa202057f9">
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/535993d5-a376-4bfb-b81e-47154a09b155"/>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ab16ebd-acee-42f1-adfb-f4ef490906f8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/934927f7-37ef-4f09-b383-ab32a3b895fb">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f742f001-e689-4994-95c8-879645e4d28d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2d7353e-4a46-4741-9414-963118190fdf">
        <rdfs:label>PNPO</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca53bed7-e21e-4011-a9bd-0e46198c6e88">
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89ca3b1d-8684-4aac-9aa3-dfde4476c8b9">
        <rdfs:label>FBP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b48496cb-74d9-439c-9a24-e912030a8082">
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <rdfs:label>Arginase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b2cb2c5-f7d7-4f78-a1a6-59bfcc413cfb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
        <rdfs:label>ARG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bbe2b4e0-b7a9-4dc2-89c9-3488a3881848">
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d801f64-67f1-4c96-9f18-6f84027601ca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
        <rdfs:label>DARS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef1aefae-5e94-4082-a1f5-badca180be69">
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c53f9133-4b8c-47a2-91b7-447a1f3e338a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
        <rdfs:label>TFR2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>transferrin receptor 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6da42190-4240-4cc7-bcb2-5a15a412506d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6eb46921-171a-4d68-aeda-9adfd8017c3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/971cae57-7589-47fc-b3aa-51f7f2b3f55b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2841af11-3e4b-4407-bb0a-7fc92fe0f73d"/>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7062767a-6343-40bd-a6a8-966fb069268f">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/62b4941a-47fe-4a72-9b30-ace6a6ab08fd"/>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa7addb0-1732-4ae3-a734-1c7d4d389912">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/217cfc1c-b052-4450-b4b0-81191f86e72f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
        <rdfs:label>TF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <rdfs:label>transferrin</rdfs:label>
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa963c23-4995-4a09-9cd4-7b24722fb027">
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
    <rdfs:label>glutathione synthetase</rdfs:label>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e566e229-f7f3-4bca-8b3a-662743b8e3bb">
        <rdfs:label>GSS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9058bf28-f1af-4355-a25d-a63bea6576df">
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/664e9f7f-f05a-4541-aef2-bfc19487fe36">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0272e0f2-f34e-4492-ab14-4f29699d0f6f">
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73239429-d58e-4e89-84ba-15c3528fd15e">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8815425c-3573-4c8a-839e-0df35e224ead">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a43f8803-a7c7-4923-b1fb-6cb1b379a2a9"/>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4110df6-d507-44e3-b894-e4f243f1dc41">
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/056e0a47-ee81-4cfe-8b1c-a46be21759d4"/>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/834faff2-c7f7-415d-8dff-b2f3e42250dd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2a5210d-655e-496d-b034-0a4ddd1b345c">
        <rdfs:label>PHKA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2ecfc29-bd8d-4b89-aaf1-1096963f86c4">
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d35457c-936f-4e11-ad15-81faf2b27a60">
        <rdfs:label>LMNA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/64346c9c-b115-41a0-8daa-a81ff888346d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b1f712d-8967-4c5d-a357-51daf773da09">
        <rdfs:label>PYGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/92736f12-9b5e-45ec-9cbe-c7d78515ad58">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16fb19de-5d04-4e1b-8861-bf8fb18426c5">
        <rdfs:label>MT-ND4L</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/27a46e0e-2167-45fc-ac3f-36617204c10d"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/081feaa7-1705-4752-a94c-995a8900f0af"/>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e0c9266-5c75-49c0-af17-f4ffdb535316">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e4f6e4b7-7123-485a-97fe-d65a582bd2d7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
        <rdfs:label>SLC25A13</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>citrin ( protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9fbdb7ef-5100-441e-b3df-6e0f29bbeeea">
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/73239429-d58e-4e89-84ba-15c3528fd15e"/>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9cfa6e61-8311-49d4-ba38-670629da00d3">
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/afe118a9-574a-4d89-95e7-49c749003366">
        <rdfs:label>MTRR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9937afe3-e1ea-45fa-80e4-0ec611119f45">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9fac3033-82c1-41e9-b9ea-c9bb756b33e3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67d2dbd2-c93f-4a47-85e6-feca5d347a44"/>
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa0d8430-52db-495c-9bb5-cdef514efe44">
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <rdfs:label>Folate receptor alpha</rdfs:label>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c0e12a5-9534-4da4-975a-4a014e6c97ff">
        <rdfs:label>FOLR1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c701facb-37c5-4895-bec9-f3f2959f28f7">
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dfb85b1b-8326-4ab0-b68d-7db3823a1259">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/607753a2-ee06-42f8-ae43-a55f92520b74"/>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/171b9411-2872-4ae8-8fa7-dd3a9aeec573"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e5ce47a5-c8eb-484b-a580-810c90f19226">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6902dfeb-48d2-4d72-b214-01573199d7a9"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c32966f-4889-4f3f-aebe-eaa2d751bbfa">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ba4ef572-817f-4703-9bdb-57d110679b65"/>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <rdfs:label>prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1dda94d8-0fe1-468a-870b-967b45cdf321">
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52ec2280-26bb-4ce2-8e11-1e09ce7a19ea">
        <rdfs:label>HPRT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d3c3d7b-42b6-4d54-893b-a59f1b6d26e8">
    <dc:identifier>HP:0012433</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal interactivity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0f22cd2-5370-4a7f-98fe-dd7c396e52ae">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51497458-7f6f-44ce-a33f-ecd0385e280d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cbcc2ca6-a2ff-4b80-8acb-7529bd4b02f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ea71f30-17ea-4c81-aa04-ce4e347b9bf5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>splenomegaly</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5b8e7f4-5580-40a9-87fb-9afbc60dbce0">
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acd738e5-88be-45df-ba71-8cccd72187b6">
        <rdfs:label>primary low heamoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/113aa859-78ca-4e9c-b6b8-dc1e2f93512c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/664e9f7f-f05a-4541-aef2-bfc19487fe36"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfb0099a-1d72-4b2f-99a4-a7c61a2ac8ec">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
        <dc:identifier>HP:0000841</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45f8b09e-e4ce-473c-be56-e0fd498de0e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>thrombocytopenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/01dde886-bb32-4acf-bc5f-5c1a04007806"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
    <rdfs:label>MENKES DISEASE</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b76484dc-aff6-4411-a745-6b6613a6f89a">
    <dc:identifier>HP:0001263</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Developmetal delay</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3124bf42-d028-43c7-94c9-6fc7117ca0d1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d65a8bdd-0f49-4f32-9d2a-9c531bcc4151">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ddc93e9-9375-4f61-8e01-4355633e8857"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f668771c-e417-4f37-801e-1fe3b92e89f1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4591b412-92db-4efb-8329-0dd8a89ad38f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <rdfs:label>Pravastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c930f22-f230-4ff9-a596-386d266a3bc7">
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f668771c-e417-4f37-801e-1fe3b92e89f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb9bbdbb-3046-4cee-bdea-2c82aac32c63"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4db2aac2-71c1-4cb2-9c95-adcef5977b94">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
        <obo:RO_0003304>R219K</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee81409c-03a9-45ee-99b3-0676a5d49ed9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39229228-699f-484a-9db8-6ca9dc4b3941"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f668771c-e417-4f37-801e-1fe3b92e89f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d972ffb0-c71f-4e33-b3cb-3950030d8c90"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00175</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5624438-f71a-41fb-8371-fd0510c10f7f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/488c8fdb-0a22-4152-bec3-1106f8e6233b">
        <dc:identifier>HP:0100036</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39ddf49a-bb7b-495d-b2df-f1e71c6e11f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <dc:identifier>HP:0002756*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f905dc24-f6a9-44a4-a18d-29ba8b834f6b">
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:label>mobility problems</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/66711ddc-8006-4f30-a269-f59b3d246705"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e92d657-af6f-4192-ad3e-63ee21fc7935">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1072beea-4537-41c7-9fe2-b7fc68cd9939"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a98717b-783b-437a-94d2-c9ca0f6ccc30">
        <rdfs:label>Pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07bda21b-cf58-4233-8410-f3046bdae37f">
        <dc:identifier>HP:0001832</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de45a1b8-5c4d-4df7-a9e1-e8fd7e6bd1e3">
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006462</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ab949f8-5648-435b-8d9e-09c0375dc0a9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1930c719-0974-413e-a7e1-d81051440f2c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
        <dc:identifier>HP:0003260*</dc:identifier>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a2beedc-0c11-4fe2-a19f-70424846d806">
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <dc:identifier>HP:0003239</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fc9030e5-d501-46e1-b0aa-4eb2ce540ffe"/>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df254630-6bb0-4644-b8ad-2f3c8a128827">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cerebellar dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54b86b79-137d-4e74-b366-14c99b9154f4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002353*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc3aae74-0aea-4e82-af83-95fc3b3978b2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6cffa85-a279-4d60-b96b-23dbfaaddfd5">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c6e2a97-60d2-4a57-8409-287dfabf097d"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
        <dc:identifier>DB01247</dc:identifier>
        <rdfs:label>Isocarboxazid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/717dcfa3-3aec-4652-b00c-b8c64fcfdd05">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0e30b737-e2c4-43c4-a3b4-de81e450339b"/>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cdb47e23-a8f8-48f8-8b5c-335f7183aabd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
    <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
    <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3fe772e9-a464-4b5b-80f2-9cc4b0f8b401"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7539c8f-64e7-41b8-a059-3de380c1f773">
    <dc:identifier>DB00230</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
    <rdfs:label>Pregabalin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05e5e5f9-5d5c-4fdb-9a34-6bb7fddd9f9e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/417c943f-e56a-46b4-8c05-0552fe2c6589"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98ce0237-9fdf-4da1-b409-49097816a51e"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e6ae98a-aa7c-4f38-af58-d573865c4183">
    <rdfs:label>Givosiran</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d26689be-c20f-4154-b917-c0922e2c8338">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e750d45-6c01-4f13-8cb3-a9a86992702c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81a606ee-99b5-4577-a330-c5e70d7c0dd8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB15066</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb8f02d6-112e-41d7-a616-2aab2b922ef9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9baae767-331f-4f69-9c1b-ac151678bb6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b98d9f8a-6ca3-445d-a102-9d7e007ed405"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32e3b2ef-ce9d-4dd4-b4f4-a95cda040346">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Trial is no longer available</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b1749704-e514-40a5-8405-c327fa585043">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
    <dc:identifier>DB00620</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f865736c-ff77-4846-8477-2e3eafe0e0ee">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0938fc4-e89e-4d12-b360-f85199fbe522"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/106b49f3-faac-4807-aa6a-9cf140062a95"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4046e707-cd23-4917-9264-e1e1baa66dd8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a8d1018-7fe8-48fc-aaa4-562dc01a71d8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Triamcinolone</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93f95be3-220c-4871-90ef-0a44705221a7">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae3c4622-b41c-494e-ad51-0fcfedea8c02">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3873c731-d400-4489-9a2e-6339ecfcffcb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3eba52b-e211-4466-b802-91e35d8f6103">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>polyuria</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb0877f3-4251-4be4-808a-f8002bdb4e5f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>affected functional activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8b57378-51dd-44c2-a149-1738af98d3b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91915cdb-30ad-4146-ad6d-3f5805902266">
        <dc:identifier>HP:0012026</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <rdfs:label>high ornithine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a092306-f6e7-44bc-912f-30a89b810fb5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cfb6e8f-8a10-4af2-a413-3a1bd15a0fd3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e8d2a99-44d5-4ab9-a92d-c92903524738">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d74095cf-bf6a-4ccd-b795-1536128ad372">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
        <dc:identifier>HP:0003713</dc:identifier>
        <rdfs:label>fiber necrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2e3071d-a5b9-44ba-829b-f7db0d6f21f3"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ccca0c3-eff5-4b68-8b6d-3cff4a80ad2f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased muscle lipid droplets</rdfs:label>
        <dc:identifier>HP:0012240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1a73c4e-da2d-474a-b2f7-35cbc9899ee5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/408bc3f8-dd8b-4e65-8ffc-1d562ee37e8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0af8d235-a81c-47c5-a62a-633864bc2bd5">
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/092aeb74-9192-4805-bb6c-3ddd150928aa">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a186c0cd-8e26-4d3a-8fdb-b110a6d4ecce">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f82fd44-0098-4f13-bb65-a18860b9312b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33176421-8783-414c-8134-704744668d95"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ebfd6c0-7021-4f1e-9551-5d829deab670"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/352f3d99-9654-43fc-81ba-0d2362beeae4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ce2434e-c9ce-44cf-8421-0fce83d85926">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb055aee-00a4-45ac-81e9-d96ad38135a9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b7d2819-1725-4bd3-9646-e7a6a8f0d98d"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83e8d8a9-c6ab-4b4b-a714-cff8065d335a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d0a418e7-a10f-4bc3-9aba-ba36a9903c24"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7a76be3e-6e9f-49bf-9e2e-307f1fd2e244">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7869fad6-d171-4967-8600-608cb644cfc9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1152db02-f2b5-48e1-81bc-d0e411c37b17"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/880defd6-d6eb-49a4-9fb0-75386e5f9cb4"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>VITAMINS</rdfs:label>
    <dc:identifier>A11</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001290</dc:identifier>
    <rdfs:label>Hypotonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5a8baa99-7a42-4b17-8261-eaa50314ede2"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19ac1883-1b39-4035-9add-c3f7fff0a47c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98488272-2123-4ac6-9f0f-d49adfd14ec0">
        <rdfs:label>high serum ferritin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c7a1423-d029-445f-a9f5-cd0605562670">
        <rdfs:label>high brain and liver iron stores</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4cdd5ffb-394c-46c0-8058-5395e18d4616"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0355ce9-e5b1-41f4-ad43-cba14e043b65">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4d77e1a-b5ff-4f7a-b02b-df263e81e680"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4264ab45-71fb-4eb6-81a0-4fbcc6595039">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a353e85-bb03-47ee-8028-c1eff4cbd339">
        <rdfs:label>abnormal gait</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e40adcf6-1223-4fc6-93c6-2b94a0b182b1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/723182ae-b659-419c-89b7-21b06258208f">
        <rdfs:label>Incoordination</rdfs:label>
        <dc:identifier>HP:0002311</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa002e01-466e-4508-abd1-c8311c91d4ff">
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001665</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05d80dd1-7eda-445a-a644-5da55192b8eb">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>EEG abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/435a6cf2-faaf-448a-8e9d-968014c0cbd3">
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35227879-1352-4907-aaba-4fba71e26b1d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Movement disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ed4fd73-d918-4be3-bff1-93d84e5a6c8f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bb33bfb-99e4-44bb-85da-b5c1a6cbf7a8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f0b39b39-f6c9-42da-a8f2-ceefe509451b"/>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4591b412-92db-4efb-8329-0dd8a89ad38f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <dc:identifier>HP:0001114</dc:identifier>
        <rdfs:label>Xanthoma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ddc93e9-9375-4f61-8e01-4355633e8857">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd7117c1-dc12-4eaf-befd-745166b318e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <dc:identifier>HP:0000518</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cataracts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0df7acb2-fdc2-4960-a5e0-90a87f59e027">
    <dc:identifier>HP:0011729</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
    <rdfs:label>Abnormality of joint mobility</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfe3e2b6-d40b-45b0-84ff-898261dcaaeb">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cabb080d-a35a-4ce5-848e-85f9f95349d9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0649404-4a74-4e84-b5ed-78ac4868e529">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34bb4c77-99a3-4de0-b1ad-412be80f7688"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/863bb9be-004b-4fd0-9588-69a497dad4de">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/888f606b-3259-44da-9b09-63c444cc650d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd9bcade-186a-4f1e-8511-449d27ed28c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4daee65-d089-4c40-9d86-98f6edb7d78b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a42b0bc-9a23-45c8-bbf1-68c45cd174df">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5a3df4c-ad80-469e-83b4-7838a503bc9b">
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdaf651b-ffd5-40ff-a9c9-046f385135f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf7bef0b-5adb-4dee-9fd4-7742e69f4fbd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a0c02d2-4afd-4855-91e5-73d24585be5a">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71cfb60d-6694-4343-b287-da29dfaa3d2e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0221e804-ccce-453d-85e9-e557192647ae"/>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbc4cd1c-0efd-4c2c-9e6d-9955bd6ed77a">
        <rdfs:label>High total cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46998c96-d2d7-4f6d-9288-715356954098"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/820a46ea-2426-4319-a026-5dfc91e51b8e">
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:label>High LDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9348695a-4333-4499-8a07-c20d1317a386">
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47711a0e-d090-490a-b871-7fd000038c45">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e7d64db-8e5b-49ea-8549-e1d0e353c822">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e355fd7d-5910-43e4-94e7-67668697986c"/>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/041ace3f-9bac-4a52-84d4-bb5506ed407c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
        <dc:identifier>HP:0003127</dc:identifier>
        <rdfs:label>low calcium urine excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5aeff573-e8f6-4878-942a-2e5c7fb77210">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd558b0e-3313-4694-b581-6e225df5a3f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd6f98c4-b9a7-48f5-8bec-4cf0b233f29b">
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
        <dc:identifier>HP:0003072*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fc56461-a19c-41ac-80f7-c5a690c43234">
    <dc:identifier>HP:0001376</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
    <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a58d0822-2c57-4430-98d5-6ba76ec452bc">
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e77121e-951c-4f0d-a3b2-d774f55188be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63185821-a268-40bc-b2cb-da6f9e138c47"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9309ddd-48cd-4b0b-b931-ec8ff0173afe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Anemia</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b631c17-6808-49f3-88dd-d7b44ae2dec4">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
        <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34cee4a6-2a8d-4b4f-8b4f-9550a22b06a8"/>
        <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f7e3538-61b5-44d4-9fbe-5145fc772304">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2de11e04-db33-4257-9705-fa2e200303bc">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:label>cardiac dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6992f538-9625-45b2-be67-45438c8315e3">
        <rdfs:label>fasting ketogenesis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
        <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c8c8871-9628-4e75-898a-f5c0befca2fa">
        <rdfs:label>cognitive impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84fdc90a-f31c-4f97-bb2c-ae6b1f29f85c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3f329ef-b815-429d-b6f9-3245bf05ff5c">
        <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0d158f6-cbac-4b86-875b-3bb4f0717769"/>
        <dc:identifier>C09A</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22adf1d4-aa86-4526-aa4b-e474af91bd48"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02d91a85-f1a8-4aed-a592-4db958ae023b"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf3c4afd-ea2e-4e55-a8aa-ba80ec51811f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
    <dc:identifier>HP:0010876*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9bb8934d-56a8-4238-a448-cadf169d76ca">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfccf03d-ef40-4194-be6b-dbbaa76e3f1a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>somnolence</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
        <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0e30b737-e2c4-43c4-a3b4-de81e450339b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71e12ac3-a3e1-40ba-9c17-b57d729ae0cd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79aab970-0537-45bf-90a1-143a9520ba53">
    <dc:identifier>HP:0002155*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>high fasting triglycerides</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed4d99a5-84be-44cb-bb19-45fed773d2b4">
    <dc:identifier>M01AX</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5573663-7a00-4672-9eae-211f0b36c9d4">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19a6b821-b9a9-4f8a-8e06-1509ccc82a1a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04cbe884-9144-4f40-8265-f7b7035f8c57"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b682f74a-e4a7-4084-8341-6c444be483af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c779088c-75c5-42c2-bc14-460b6ca57cf1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a00c6d4a-29a9-4f46-b96c-349c541ece40">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/865404ac-8874-4ea6-ac4f-d5b3b92bfd03">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46d71376-da81-4991-a741-f1fca9ea476f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c30b613-2dda-4b53-a7ea-be331563791e">
        <rdfs:label>Hypertension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000822</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ecbf67fc-b1ec-41fa-99b9-731dee0acab4"/>
        <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
        <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b29fefb-4092-4a9b-bb8e-8dc53951ac96">
    <dc:identifier>DB12449</dc:identifier>
    <rdfs:label>Tempol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bcc63816-24bf-4f76-9bba-51e179ff9c09">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bbe7a54-8527-4575-8a2c-a3af6549ecf2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbe9e143-64d8-437f-a772-fbd52f8eef3c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005242"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f678f827-7115-473f-8716-b2a44b0ba30b"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70567a1a-af65-4db8-84f3-09e2f166584a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9507830c-5795-4b4b-93eb-5b9f8fc7fa77">
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Abnormal muscle physiology</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54971c2c-a20c-454a-87ad-231d0bbf7efd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f916675e-053b-4250-82d4-3021b18b6c2d">
        <dc:identifier>HP:0012664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:label>Low ejection fraction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da9376a4-8354-4475-8089-4ce7d09ee098">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <dc:identifier>HP:0005180</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c32be723-f0e7-4637-bd26-87b823977318"/>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bad8d3ea-1382-4eeb-aa6e-42525422fb54">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d9e84c9-e709-4c2e-9306-9d2ec108232e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17493a17-53c4-4ecf-8767-94f0a04f2d23">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001653</dc:identifier>
        <rdfs:label>Mitral incomptence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39cd7fd5-1fd4-4a5b-a7fb-054fdf58703c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011923</dc:identifier>
    <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9a69199-6bb6-42e6-8068-cac02246e7aa">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a337689-2907-4061-b0e2-0df0bb856446">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a13c98ce-9f49-4172-84db-5a83cd0b731d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeb8aa85-fcaa-4019-bd07-99880a473534"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/55025b88-8519-4d17-bd4b-107c352901d7"/>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fd962f1-20a6-4ddd-a897-b9ab43695bc3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2088ad03-dc77-462e-b1eb-8e5b1168771a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16954635-51fc-4fb5-9b98-778fe59b2684">
        <rdfs:label>epilepsy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/35aa216c-7462-4b33-8d39-9697f14955c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2e93818-38e4-434a-983d-3424d9cd4852"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/66711ddc-8006-4f30-a269-f59b3d246705"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d0a418e7-a10f-4bc3-9aba-ba36a9903c24">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <rdfs:label>Lucerastat</rdfs:label>
    <dc:identifier>DB14872</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ce2434e-c9ce-44cf-8421-0fce83d85926"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccd730f1-1fa1-4de6-877f-8c85871b73c7"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fc3669b-85bf-4f13-9b16-203c14121816">
    <dc:identifier>HP:0009020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <rdfs:label>Abnormal exercise physiology</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac4db1c5-c423-4ad4-ab40-c099c1b432a8">
    <dc:identifier>HP:0002570</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>increased fecal fat excretion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab8cd42a-bb4e-43a8-a37d-ff0eb497c943">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d42427be-1c5a-4283-a363-0553dd0f6028">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
        <dc:identifier>EC0:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4d34455-b794-4826-a139-81786d8888f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0a2e711-65e6-45e3-9f4c-0db76c7e2fe1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d78962d-d1bc-4bc7-8dd9-0e0e16478282"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/daed9eb2-5f38-4820-9caf-5c36ec8ef0b5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <rdfs:label>Phenytoin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f3e9550-d6ac-4a28-a34b-f2708709f92b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b14f9338-0163-42d4-968b-082a546f49d6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00252</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb1e2c27-6cec-487a-b4fe-7848a66be00d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b14f9338-0163-42d4-968b-082a546f49d6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5abcefc1-1f43-47f9-9af6-c5f394726541">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>sensitivity to sunlight</rdfs:label>
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ec1194c-82f6-46f3-9a23-54b91fd453ab">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a96b7b21-8759-4079-8c07-0c2ce705a081"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d77f0e2c-7e23-472b-95f8-464b9de9c95e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
        <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/337dee61-16d7-4fc4-a713-72d9417c12df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca1dffca-34e9-4000-9f15-74525f77b278"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb5bccd9-def1-4e66-916b-92db72e0d208">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:label>low hemoglobin concentration</rdfs:label>
        <dc:identifier>HP:0001931</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c779088c-75c5-42c2-bc14-460b6ca57cf1">
    <dc:identifier>HP:0003566</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
    <rdfs:label>Elevated prostaglandin E2</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c483f3e9-f80e-4f2d-b13a-155813f480a4">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6749d5d-af52-4964-87fe-97f26c2f718f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4163862-1867-4150-b387-a28325dd9c98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6ccb5a9-ccb7-405d-9f56-86e7049ee1f1">
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/961639ed-7a25-4521-b56f-f425a0f6670b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6377736d-572a-4d15-b59d-0cb88358ca1b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22bc794b-9706-4d72-87ae-d61c9a4946d4">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26c56c81-72bd-4fb7-bfb7-2eeae7c91064"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1614d4a1-c985-425f-bec5-3b853b6047a9">
        <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
        <dc:identifier>HP:0031951</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/745776ff-92b4-45dd-93cd-f1a5f94fbc34"/>
    <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
    <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ac6cf53-3b20-4d1a-afdd-89d81aaafa38">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a6ecab7-3b98-492a-8092-a9fa33774ddf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <dc:identifier>HP:0006670*</dc:identifier>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb33cb32-d840-4a50-b907-5226e2f3dd4f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030872</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dca6bf4e-5d79-426c-9912-7d29905626e9">
        <dc:identifier>HP:0001714</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5ad7f0a-3217-4348-88ca-629bc6c30a8a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d92a83c4-0e7c-491f-bcac-7be9c6afe12f">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b89bd58f-f43e-4491-9873-75a1060bc0ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55bebe48-cbbf-4792-b242-18e29fbc6d0b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/940320e0-606d-48a7-9b7c-4147794db03b">
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94e6139d-86b8-4e55-89f5-92590ae4b832">
    <dc:identifier>HP:0011943</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
    <rdfs:label>abnormal thiosulfates level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0256de13-be85-41f0-bdaa-33806b03c402">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10b72d8e-e0a9-47eb-8781-e326d3a2a794">
        <dc:identifier>DB00533</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83afba56-be16-47c2-896c-548beece0241"/>
        <rdfs:label>Rofecoxib</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5016a8c-be4a-4b8d-8fde-95369641c09c">
    <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f614950e-5296-44f1-8e53-ec0fbf38fc53">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/967ef55a-5321-4a78-9f6a-8b7f0424a10f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b2c5d7b-3708-412c-bdf1-19a60f7ed59b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a117ee42-c23e-48f2-a05e-0ae13b9f3fbc">
        <dc:identifier>HP:0001941*</dc:identifier>
        <rdfs:label>acidotic crises</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8dacec9-54bc-466b-bee9-4037cc9cacbf"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44c8b8cb-f0e2-4d7f-9c17-b774a518d1cb">
        <rdfs:label>Low COX content and activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/587b44f1-9e85-42d4-b924-e95610c9b146">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/077dd925-8647-49ec-8b02-c1ed72d8e2cc">
        <rdfs:label>Azathioprine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abff2dbd-db35-4318-8927-374c37c0a36a"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
        <dc:identifier>DB00993</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6eb6d4ae-26b7-4219-a02f-4404fa4875e8"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c999cca-f783-4231-a3eb-47a8b2f53717">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
    <dc:identifier>HP:0000114</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6e392f6-d5a5-477d-9611-389282452e94">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ac58125-2303-4790-a4ff-683df6ea8672">
        <rdfs:label>Amitriptyline</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/983527f0-f62b-4598-95fe-494b1a62954f"/>
        <dc:identifier>DB00321</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6174f37a-6e08-4803-a066-b2a7bb19eaf0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26c45fcf-f774-4363-bcaf-1eb2e69a61bc">
        <rdfs:label>mitochonic acid 5</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0edefae-8c4c-4491-a5b4-a47230b94d91"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c23dcc8f-73bb-40f2-8853-4dbb799ca8c9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3a4d5c2-ae9e-41b9-af3a-56a10a3842ac">
        <rdfs:label>low RBC count</rdfs:label>
        <dc:identifier>HP:0001877</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6f03430-2f77-4876-8d1a-6d150c3addfd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9534626b-f7d1-42e4-b9ab-80176bb06f3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55e84ed1-3526-4fb7-bd79-f93ad0e32b3d">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32594584-649c-44e4-8f77-bc2d20b0d762">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/adb0e266-ae9b-4a83-8bb6-0f39b90a6e63"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b9e7b92-53a3-4e1e-8f75-664a1afeadd7">
        <rdfs:label>Hypophosphatemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002148</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/03c8d8e7-c1d5-4dd5-a9be-99da4326b750"/>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa965d78-bb06-4cb8-b215-b2022042d4e9">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:label>High serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0763e628-6ec2-40b9-a666-d9640bd3ce70">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24045f8b-a89f-4e77-9416-04a08a05c0a1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
        <dc:identifier>HP:0010438*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c3c2a9f-712e-47ce-a029-d498dd660ec8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <rdfs:label>Ataxia</rdfs:label>
        <dc:identifier>HP:0001251</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2e6961d-2a99-443d-a21a-0c524e1a292b">
        <dc:identifier>HP:0001712*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5f9f18d3-751a-4d44-9e4e-328a47743eb6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df254630-6bb0-4644-b8ad-2f3c8a128827"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdfa619e-5480-43b3-b9a9-3a0c97dce490">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000570</dc:identifier>
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60f58cab-b145-43f6-9a7a-6291748de398">
        <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9957f246-c68f-44f1-bd08-781edec15e27">
        <dc:identifier>HP:0000639</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
        <rdfs:label>Nystagmus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a601478-470a-4a27-9de3-fbfaa91e99ec">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/724f2308-749a-4a71-8e61-0ef57b1182dd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Generalized muscular hypotonia</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>HP:0000750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf8304a4-bd16-43e6-903c-319f9f4c5a9f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Developmental impairment</rdfs:label>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae8497f6-9fa2-423b-bf20-26b8c785e57e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
        <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
        <dc:identifier>HP:0012011</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/864e38e1-508c-49db-b579-0da0727d9572">
        <rdfs:label>Speech and languague delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81730b0a-97d2-4613-a8f5-9e141533f9b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba089162-874e-405f-aa63-a234272ed847">
        <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a63878c5-9d35-4be8-9563-65278ac31fb1"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a8af3df-c396-4e48-8a8e-67ccba092fdf">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9f0e87a-879e-41c2-a8c2-8bd4d87c70be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
        <dc:identifier>HP:0001997</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>gouty arthritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c95e1990-cf9e-4afd-991f-ea0e12d81ceb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5bb04d1-bd25-432d-9813-523c86600662">
        <rdfs:label>hyperuricemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/541ba10c-1973-41b8-aaf2-c6a0fc53f59d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fccc51a-f7d2-4ed9-bc7c-378de2fe9dc9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9115339-9caf-48dc-859b-25e06f62c884">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c9c9f4c-ae97-41d0-983d-e12b53dec8cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f998908b-e73e-47ca-bb81-d149e15a7b5e">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e0ce4df3-0114-470c-85d8-21545a696942"/>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e52d1c31-7ad4-4728-a5fc-128977f8d3bd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca44eeb8-225c-4f4e-908a-6d31868578f3">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
        <dc:identifier>HP:0002188</dc:identifier>
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dbe073c-b6da-4000-a110-5fe4f7a3b4c5">
        <rdfs:label>Intellectual disability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b1b6ba3-021c-4252-b442-351eee6d6221"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/295e1599-e03f-41b5-9910-9ddb1788dce4">
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8f60b46-175c-44f6-a7ac-cc008b50476e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <dc:identifier>DB01914</dc:identifier>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2370dd3-c05f-42cc-bf8e-265875334e90">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ec40be7-a351-43e3-8c40-65e67a6d6e5d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ca98b34-0e0c-4e0b-9e25-4a9fd64b5cd0">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ec40be7-a351-43e3-8c40-65e67a6d6e5d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/511bb399-2b2d-4d74-ba63-905c4f657d4a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73d5d828-d8fb-441c-bce3-52f21623b29c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27342a5b-0788-4ef7-a85d-a17d549a12ed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a74456da-fe9f-4e1f-94fb-f15dee407a78"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ec40be7-a351-43e3-8c40-65e67a6d6e5d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e706967-c643-4bb9-a939-475c5c09b03e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ec40be7-a351-43e3-8c40-65e67a6d6e5d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b50248a8-d5c7-4827-bd87-0b0b951fc885">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72bf2674-b1fe-4dc5-94d3-fabaac212bf5">
        <rdfs:label>Aggressive behavior</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76093f11-8fff-44d6-a268-73be189611a1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <dc:identifier>HP:0100716</dc:identifier>
        <rdfs:label>Self-injurious behaviour</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b588af37-0958-4d5a-ae91-87e54c320588">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f3bec90-31fa-4dc3-b408-beda869053ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb5a3c3a-cd84-4013-9c2d-549931a17b09">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1614ca0f-fe79-47a1-b7a1-79ab899e18da"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
        <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
        <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b90813f-d7a6-422c-ab66-fe9c656be926">
        <rdfs:label>EEG with focal spike waves</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
        <dc:identifier>HP:0011197</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/714c871b-4508-4082-baa7-78f5db158f98">
        <dc:identifier>HP:0100660</dc:identifier>
        <rdfs:label>Dyskinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b19d8bd-fbfb-48cb-8f1b-c6f657cb3512">
        <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7aa3c1a4-1440-440b-b61f-4d9c925624d0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>movement disorders</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d47a7f4-d355-4fcb-9f63-5a261618932b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/574bfe97-1e3b-47b2-8341-17ef66715cdf">
    <rdfs:label>GNE gene lipoplex</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72664d11-7c51-4664-9491-2d3623d12450">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56a76daa-0b84-4e2a-9d3e-62383299cc9b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f081ba46-25ed-40e1-bfd3-1928106d6894"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9de31126-a9f6-4e64-889c-db580ed688d2">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8695efa-862a-421c-bf8d-a031e8ff6144"/>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01bb7747-d4c7-4f0c-8a93-a953fff650df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f4162db-c069-4f54-b835-8a6fe8e3655f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32ca1a3a-69c8-4ecb-9701-c4690b870f77">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e12dbae-190f-4708-8415-0047282887b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21c3a254-b94c-4702-ae1d-2f179ee65aad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72c5debc-32c5-447b-8663-c1cc8f1b2ad3">
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:label>Ichthyosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38e9bbc1-cbc7-40bf-9c24-36609e3c2cd8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <dc:identifier>HP:0010783</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61f8e2be-caed-42ca-ae14-68f862c406a5">
        <rdfs:label>scaling</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4489fa61-f763-4c1f-b13b-1954c8e7d870"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/458af38b-0f03-4655-88da-9a6f2c1738d2">
        <rdfs:label>Pruritis</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25cfc924-594b-4fe4-be17-4415d956b617">
    <dc:identifier>HP:0040087</dc:identifier>
    <rdfs:label>Abnormal Folate level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4cad84f6-5727-4e0c-a632-d1d70bf0520a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04896202-9261-4ffb-95c0-4ecb3e39ae69">
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d64b43b-5f9e-4430-9954-dbc532ad2f1c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
        <rdfs:label>Elevated serum lactate level</rdfs:label>
        <dc:identifier>HP:0002151</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd80e74c-7ffe-4223-a2ca-0d9fe0d4a5a8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum GDF15 level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec570a6f-da83-48ba-b4fb-5d6545abdecf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86595754-1d17-4ccb-ab1a-2f728ec79ce3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d57900eb-9a03-41ae-a728-8684476ea8a2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22c1dc46-c434-4dfb-9711-3cb7edfc633a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c186e20-61b9-4cec-84df-853e60e9dcc5">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1065f7da-075b-49d3-a62f-3754ce03d3d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1217d62-45aa-4b30-9972-5b442deec3ed">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7270693d-3d1a-496f-82e3-53b5810c0b3b">
        <rdfs:label>Fatty liver</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1afac6d-1866-48f2-9b48-c66261bb5330">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver steatosis</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45b90de7-3840-45c1-a1b0-7111b560cebe">
        <rdfs:label>Liver fibrosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef6ab83a-e5bf-45b8-b489-d71200422976"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02c60cc9-2d1b-4d2d-8b2c-bcfad3da5ab3"/>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a50b6039-94ad-4ad7-a8a4-1b719b2b8ba1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DNA hypermethylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6a2cbb2-e220-4ab6-9a98-ecf2b53905ef">
    <dc:identifier>HP:0004322</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>short stature</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b69850ad-67df-4c05-b771-9a1cdcf4a17e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Misfolded AGA</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b2d1d9f-3e33-4a5c-8ece-a8e6d4928c73">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a88baf13-794f-4c67-865f-a81bfc7e4ca3"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e96b6542-beb0-40df-a0b1-93a8cb07db53">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15a22976-fdcf-4672-995a-f96304e9fc45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d733d5d7-90f4-4e2a-85db-45f933939634">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
        <rdfs:label>tachypnea</rdfs:label>
        <dc:identifier>HP:0002789</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f0323dd-02ba-40b1-a43e-17439567051e">
        <rdfs:label>congestive cardiac failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7a4368b-0b5c-4161-b2be-9e856381383b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000790</dc:identifier>
    <rdfs:label>Hematuria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07518080-9e30-4279-9d15-60ea2652eeea">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8edb081-6572-4d2e-ad33-ff8050c6797f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47511082-42a5-43ce-9646-8159761a7962">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8743bde-2fd2-46cd-a358-5a048c4ab80f">
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1ec447b-fd95-4cc4-b398-ae66c0ee6e00"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47fa32aa-f2fa-462a-b9a2-fcb981874ef1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14fc6b81-2337-4ab4-b49c-8a61ac6c5cdb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d6ab44b-be79-4b97-8f16-731cfc53c9e1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dadab97-2c81-4890-89d5-556187a7b681">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive deficits</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b146e03-786d-4501-910e-68d3971aae49">
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8810b7f0-81e1-47b0-9ec6-53c4fd10f450">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low FVC%</rdfs:label>
        <dc:identifier>HP:0030878*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05242de0-8919-4f98-8237-a04dc4f0a856">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e74e6c98-3e57-494b-9b96-f2c053a3af26">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003738</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f7eb77d-f2e0-483b-92dc-d9853aac9417">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
        <rdfs:label>Muscle cramps</rdfs:label>
        <dc:identifier>HP:0003394</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/efee7f21-b3c8-433e-b524-26c46e96c59d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a8884f1-b0a2-4f39-9760-eb42e990a806"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e75703b-479f-4fe7-96ec-2e6b86266079"/>
        <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2ac6013-1166-4c52-abc1-921a772dab52">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Limb muscle weakness</rdfs:label>
        <dc:identifier>HP:0003690</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd32f031-42a4-49da-b13a-ceadae8aff53">
        <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0009020</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/940589a1-2620-42e2-b615-1984ec17aed9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33a5138b-1afc-4fd5-ab8d-3056d9b065be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4ae71e9-0cbf-47e0-bb33-80cad344eb7d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Ployuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc9c7348-09f8-4f57-b5fc-fb26909604a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3301f59-cb4e-49af-9d1f-152fce512386"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ff2c52f-a200-436c-abec-5a077a11045d">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/357b8476-ee33-44c8-8ea6-17dfd0021aeb"/>
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c44af6fd-b446-4590-aa88-53aab75e011d"/>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c0df78d-307d-489d-bacc-10779722d034">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
        <dc:identifier>HP:0004295</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d472d553-25b6-47f8-952a-3ba08b4aae6b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb3fdbec-78be-4c8b-81e7-a12855673469"/>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20520db9-c4da-4003-8604-21d36b8d61b4">
        <rdfs:label>hypothyroidism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000821</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c40a53b5-d4f0-4f44-aea3-c7e9f94e9e67">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c39453f4-faa4-47b5-b67a-6cbe413a545a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e5a3982-aeb5-4fe9-aa3b-5617dd286b24">
    <rdfs:label>Chronic kidney disease</rdfs:label>
    <dc:identifier>HP:0012622</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8304e831-e98d-4fa8-920c-0babc89679d0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Personality disorder</rdfs:label>
    <dc:identifier>HP:0012075</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d957489f-49ed-4cd1-95ca-83aa0036fcbe">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
    <dc:identifier>DB00178</dc:identifier>
    <rdfs:label>Ramipril</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9291236a-97a3-4850-a799-703ddb717204">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d8184f04-7a03-44f9-b48e-d6f2e660aba7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e75a6e9c-0574-4c57-ae57-801b7f2276d7"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fc3669b-85bf-4f13-9b16-203c14121816"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
    <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
    <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/742805c2-81bc-454d-baab-661ad52d0632"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95ea52fd-6704-4bf7-8bec-3f98f3949a04">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3b9db05-2929-4aaf-a4dc-6ad2f2fe2c8a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66b79f3b-24a6-4d69-86cf-9cbffe404fdf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ca1f5e6-ddaf-446c-80c4-6c5bc0d16462">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>abnormal muscle function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbc9902e-c8ae-4531-af7f-67591b298e9a">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b2cb2c5-f7d7-4f78-a1a6-59bfcc413cfb"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <rdfs:label>ARGININEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cdb47e23-a8f8-48f8-8b5c-335f7183aabd"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17fe3292-5533-411b-9434-c750d9c94f3b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df60dc4f-4944-40aa-8553-b7b31f29c10a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/806e38f1-2547-4ddc-8653-0ff794b2438f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a1eb0df-f35f-4870-8f1f-e792ce8bf12b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b253d08d-40c5-44b1-ba22-9b79787b571f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Abnormality of the nervous system</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8503d98-176e-4f6e-8feb-fffc21dcfb42">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46b78ea1-e3fc-4c7f-bbbb-0b632527752b"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f90f2c8b-fcab-455b-94e2-adcd1b3caf5f"/>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea0c649f-0077-443b-a34c-d71399d6cc6a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <dc:identifier>HP:0001596</dc:identifier>
        <rdfs:label>Alopecia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f599e33c-6f8a-4404-a706-40e266881555">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:label>emotional disturbances</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfd4698e-6195-4083-815e-b078f72d6fb6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:label>Agitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce5eb480-8b3f-4df6-91fb-b88879116421">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>diarrhea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99511b85-063e-464a-88a5-bd4fa767147e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>skin inflammation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ae1c1a6-9c67-45fd-9bd5-22f1a4e75e64">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f35faf30-d441-488d-a293-5d0b4c9e6572"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/be9784c4-fa57-4395-b22d-d8a409ff35c0"/>
    <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e840584c-ad31-4350-9d6e-9b7289bc4837">
    <dc:identifier>HP:0004319</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
    <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a73e053e-09df-49a2-a481-ec9c953791a2">
    <rdfs:label>Rapid progression</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f7d4757-2f9a-41e9-a6e5-766976740947">
    <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
    <dc:identifier>HP:0008064</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a888d64-687f-4efb-b220-c97db42c19aa">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfd742dc-1845-4dd4-8649-03c7c2003026">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tremor</rdfs:label>
        <dc:identifier>HP:0001337</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9141529-4af5-4720-a491-3314d8c0241b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2c0640a-07e5-4acf-b246-600b7a4ac076">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe03af42-eb4b-45d8-aea5-f7b17cbf1525">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56ace922-8b59-4d0e-b653-ca982295c40f"/>
        <dc:identifier>DB00755</dc:identifier>
        <rdfs:label>Tretinoin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24464bfa-cc74-4626-9e2d-67cc1f6eefa3">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1acb2eb-9e43-4f33-bca8-bf6d23e7ab57">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2f795e0-cf77-4fed-a05e-fa19f1b1f18d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fb13dee-494b-45dd-b8d3-a564992cdff0"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b3e954c-2c73-405b-9166-42f1a61b44bf">
        <rdfs:label>Poor head control</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c884cbee-ac7f-405f-89cb-bb3c46bf4d52"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29e8e06b-9c5e-4789-b6cb-03f50643d2c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:label>lack of gross motor function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0a6bae2-7ea0-47d5-86ae-2a59f96c74fc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <dc:identifier>HP:0001336</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d81689-2bf6-464c-af50-02dbb229b353">
        <rdfs:label>lack of eye contact</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ebe7131-f022-4534-8333-a847cb5ee168">
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
        <dc:identifier>HP:0003785</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50e2e55c-f7db-412a-9d07-518c464b9957">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/427d95c3-7765-4039-87c6-e542500e6e23">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Delayed mental development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3f8c971-1fef-45cd-8cef-fa92e4bc31a7">
        <dc:identifier>HP:0002375</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:label>Hypokinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cf87a9f-c85e-49f2-bcf2-4ed97fb30c8d">
    <dc:identifier>HP:0003107*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53c021c5-b228-4064-a92a-f6e9b14beb91">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal AGA processing</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99935169-a7d0-48a8-bda4-11142ebd2ee2">
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:label>Delayed motor milestone</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8b7554c-c1fb-4752-beb0-8104930e5be7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f3a3aa5-e112-4ad8-8822-1fd0b2d3268e">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cdb47e23-a8f8-48f8-8b5c-335f7183aabd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e95b877c-c8be-4fe5-b358-4535e984168a">
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc9fcdce-d89f-4e2c-90ab-c1200f227446">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <dc:identifier>HP:0008344</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2f2e7517-db0f-4038-a7fe-8a8b1212309f"/>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbd222f0-ccce-4eae-8c82-460fd7d6ea66">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e561e661-dabf-4a27-a0d1-feea27eb4680">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce1b238f-ed31-48b4-909a-c3af7364ca17"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80196547-8f25-4103-834c-3417bd65b80b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fd7d306-3299-4abe-b30d-29a1e1e366cc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthritis</rdfs:label>
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/745776ff-92b4-45dd-93cd-f1a5f94fbc34"/>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1694343-a069-40c1-a27f-c28aac6b8f1c">
        <dc:identifier>HP:0031375</dc:identifier>
        <rdfs:label>Refractory Arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81d2c616-9cc1-47b7-86ea-f6f6ab703f16">
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
        <dc:identifier>HP:0025303</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca1c1556-40a5-4fbe-9178-f2ddec0855b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Synovitis</rdfs:label>
        <dc:identifier>HP:0100769</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3dc2cd3-9e6f-4366-a20f-c98ff6ba9872">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fee8f07c-525d-4b73-b16c-7a9b02bfb01d">
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd5df4c0-5a9b-4486-a5d0-816a199b1442">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82966be7-2bfa-4e42-9ff4-716414b310bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da66dc50-111a-48b5-b1d5-bcc5a425ec11">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d1b2c7a2-e485-4ad9-af64-899b90dea824">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cdb47e23-a8f8-48f8-8b5c-335f7183aabd"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbc9902e-c8ae-4531-af7f-67591b298e9a"/>
    <dc:identifier>DB06819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/717dcfa3-3aec-4652-b00c-b8c64fcfdd05"/>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f3a3aa5-e112-4ad8-8822-1fd0b2d3268e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5af25f86-a5fd-47e9-b9ec-3b96c7d41bfd">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd9465fb-80db-4868-a16e-bea596cceff6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21f713ca-379b-44d8-a0e2-fb63172ee7d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9bc6312-224f-4a64-ac64-e3ae3a9dd08b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cardiomegaly</rdfs:label>
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d04248ef-7d04-416f-a862-4cd848d767c0">
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:label>pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9066c92e-81c1-41df-bc50-d73632cdf2b6">
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2a856e2-7483-4ede-b4cc-ac6f6f28f3e6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc423090-c6c9-4565-bfd9-04d2d5f8b3ff">
        <dc:identifier>C09</dc:identifier>
        <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fffa6dc1-9471-464e-bb65-ef04580507d3"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2a5210d-655e-496d-b034-0a4ddd1b345c"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fa504e8-6ecf-4d1b-a7a5-9fc1aeb9ceeb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
    <dc:identifier>HP:0001337</dc:identifier>
    <rdfs:label>Tremor</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9cd9719d-234c-4379-a999-8f6bc6c0628f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6f38e52-4600-41fe-85a7-4c04550c2ee6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d29cae5-5d01-48ad-8f15-6b9a8f6dddc8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4a71b93-cfe4-4f1c-86dc-b53659073dd4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fdf73bc8-1fbe-4fe2-a56a-f41e7e8d2373">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af1966da-2b40-485e-81d6-60499ad36804">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000572</dc:identifier>
        <rdfs:label>Visual loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17bf2181-a7b6-4228-b14c-81ef4ee6d98a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <dc:identifier>HP:0000479</dc:identifier>
        <rdfs:label>Retinal ganglion loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebe4632b-bfba-4ceb-9be8-4a6a7b152677">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebefa275-fdb8-434b-8b1b-502cf1d696c6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4046e707-cd23-4917-9264-e1e1baa66dd8">
        <dc:identifier>HP:0030532</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe">
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3984eb27-88fc-4baf-bac5-fee713d64430">
    <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b508497d-7c68-4518-ae3e-6ae9c047eedd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
    <dc:identifier>HP:0008993</dc:identifier>
    <rdfs:label>Increased intraabdominal fat</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c4bc9ac-87f2-4e8d-bca4-3346ffaea554">
    <dc:identifier>B02BA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
    <rdfs:label>Vitamin K</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4985d387-d468-4d02-a51e-a2369b183a20">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7def8e75-fa30-4cb1-ad9c-a03813395032"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f72f596-4f3d-4bb2-9302-8db8adc6f8ed"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/372910bb-164e-4e3a-8f5e-b6ffd26c256f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/552ab966-fa7a-4806-a158-dc92a0b68c57">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67f8bc1e-2bda-43f9-96b9-b8cf3d21d8c7">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/490feae3-0b38-4f79-8654-689e60b9269f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df6cfa3e-7bf9-4659-b68a-625b56ef6e5f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef052dda-2d2e-442f-95a0-bd7ee9ed6c03"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7671cc0-c0f5-4c49-9930-854f1593a6fb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9eae8588-af20-438c-a717-7a4db8507019"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB14778</dc:identifier>
    <rdfs:label>Setrusumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
    <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb3fdbec-78be-4c8b-81e7-a12855673469"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/746fcd20-3815-4f7e-829e-2a3ab3721535">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e52d1c31-7ad4-4728-a5fc-128977f8d3bd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9141529-4af5-4720-a491-3314d8c0241b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86467b77-eb53-4926-a6a4-6221833d7787">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2596ab0c-9860-4627-9962-02b813715d51">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/732853b1-e2e9-4d89-960b-dd1d031336d9"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
        <dc:identifier>DB05134</dc:identifier>
        <rdfs:label>Tanespimycin</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08649d8f-e8f6-4976-a5f0-9336e863196e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc640a2e-097a-4c2c-8175-ae63b878767b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a9f61f0-abea-4aec-bbb0-ca89c575ad01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb760c36-6a09-4769-85dc-d385332ac851"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b99b9bfd-b9bc-40dc-855f-9fa42557e60e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac46ddd4-fe2f-4675-bc1a-dbfbfaf00b5f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8cb6da1e-0d60-4cad-9208-782009a846d6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52c3cb53-dcf0-4f04-bb71-eb51d24d80de">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
        <dc:identifier>HP:0002071</dc:identifier>
        <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8da5c17a-d8d1-436e-ad25-5cc106dc5edc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed0a0048-5b66-42ce-b78e-765af895749d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb0ea71c-45f6-4704-8082-2bd4bb954134"/>
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4be59f76-4c2a-4eef-b66a-3ead657fa86e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c742c63e-7935-4b14-91b2-7db757721f23">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ed32a57-c530-4cd7-be77-11dad8e55244"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3942670-8616-4fdd-963a-687d08e58de7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b16c1472-a0fc-417b-9225-bedce0698eeb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24147933-b439-421b-a2e2-e0b9613ba864"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e18b79b8-020a-4d78-b7c3-b6456e5d8186"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00413</dc:identifier>
    <rdfs:label>Pramipexole</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9c05c87-0111-4856-bfe0-d86f94dc6b68">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06b789fe-33c1-4e5a-ac85-007017c3ae22"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29bb72bd-49a7-4435-a0ef-39fdc4fff088"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c1d71b7-f130-4a7f-94b9-f76b53041963"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/500d465d-2243-4db0-bba8-a2dfef071299"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3942670-8616-4fdd-963a-687d08e58de7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79d10fcf-7b34-4223-ae82-9c4ab9aca1c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cbed3563-1acb-4926-b323-86e481547f83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04cbe884-9144-4f40-8265-f7b7035f8c57">
        <rdfs:label>Hypokalemia</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45806735-3dd0-43f7-a90d-0d67432867f2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abd27c74-88de-4868-8e89-f03749fb4691">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/529c1800-caa2-4dbb-90fd-f741fb5e987a"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14d2b9e3-70cd-4a03-9524-fbcba41dbef5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c04333d-ae39-4c50-ae57-40031f358602"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc818bd5-5120-46cd-813e-7829bec6c992">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6bcd3838-c0b3-4f2d-9497-0b8c5015a40e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4121d27-5eaf-413f-86a9-85b93cdce3ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118610"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5e62586-f07d-4637-b1cc-959300d8a80b">
        <rdfs:label>acute arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5907cbcd-9a8d-4932-97e0-9406c8885c11">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <dc:identifier>HP:0100851</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcc53a53-ec28-4988-821b-0eed3469e33e">
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03dbed98-f53a-4696-994a-03c2258819cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3887c1b-e30d-4120-9bfd-4f6c4ebee4d8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccb6fb1e-abcb-4ff1-8195-571e0a716bf7"/>
    <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12654155-063c-4ccf-b150-3c90220a4243">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9988cdca-97f2-442f-822a-154144244fbd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3be96baf-3d4e-4055-a31e-4e49bf665790"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cdbf370-17ac-497c-b4f9-347f0a32d75a">
        <rdfs:label>dementia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000726</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8806a01-6efe-479d-91db-36da0946f05c">
        <rdfs:label>diarrhoea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b1bab22-b839-40fa-8a9e-c6f2eef78b54">
        <rdfs:label>dermatitis</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d188f708-27c7-4159-866d-8a0895e7b61b"/>
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5abcefc1-1f43-47f9-9af6-c5f394726541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bccab5ee-be31-4aae-a1ea-5c294fd2dd1c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
    <rdfs:label>Oculomotor apraxia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000657</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30333ecf-19dc-4f7e-9e6f-c30ad83ed703">
    <dc:identifier>DB00594</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <rdfs:label>Amiloride</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bfa2a1c6-b1d6-4ed0-b96a-d68a63f42287">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8863db44-f1c1-418f-a022-d0fc128246ef"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e16e09e1-822b-4448-9a49-b3dcfb615a8a"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/155a244c-5ff4-4ad5-a0a0-0cd29dcbc671"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/416b5fbd-a62e-47d9-bbdf-e69f8678452b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
    <rdfs:label>low insulin senstivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008189</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5dfa105d-8fa4-4aa9-b7cd-248a75351662">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4e6d58c2-8cef-43bb-861b-8a2dfafd525f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/faa5e14c-8f53-48d1-84b3-6400e2763c26"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fb13dee-494b-45dd-b8d3-a564992cdff0"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f93a0169-1918-4a6e-82d7-92baa7c75e5a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <dc:identifier>HP:0000722</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fafeb52-37e7-426d-9757-c0c97d5a9c45">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Depression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
        <dc:identifier>HP:0000716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a52461f5-a5d9-4bed-a319-27bc0644bcf9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1380804-882c-4dd5-8910-ffd37904d0a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a337cf09-e90a-447a-aac8-05af35ec220f">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67167946-5d91-40a4-98c8-2312a7c41725"/>
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71ab480c-83e9-4720-bf7f-80bb44bae244">
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cae06b65-bf7b-4080-b64f-c574d1422711">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e563117-f217-4b1d-a00d-f8a097422e14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68e5a94a-6092-4bf7-88fc-d800b53ee4c9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:label>Renal rickets</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32594584-649c-44e4-8f77-bc2d20b0d762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b9e7b92-53a3-4e1e-8f75-664a1afeadd7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef4b6ee3-58b4-47c4-b984-bf9702e38004">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neurological abnormalities.</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/820faf79-f231-4af9-ab36-10c74d4d7c9e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab4a5568-e80e-407f-81c2-50ecc6a8f878">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e694286-d0c4-4c96-ae33-c66f84521676"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22c1dc46-c434-4dfb-9711-3cb7edfc633a"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
        <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4c56390-9a47-4da0-bc01-e3ad1ed635bf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>hypocupraemia</rdfs:label>
        <dc:identifier>HP:0010836</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c9a14ff-dd57-4962-bdd7-b84c67a134bf">
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>Behavioral abnormality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf2254d2-7322-42ea-871b-9dfb69337c7f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Gait abnormality</rdfs:label>
    <dc:identifier>HP:0001288</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9dac2919-ffdd-4fee-96ea-743fa9f17797">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15140a51-73df-4538-b8a0-cbe8809b0d52">
        <rdfs:label>Diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1152db02-f2b5-48e1-81bc-d0e411c37b17">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <rdfs:label>Malnutrition</rdfs:label>
        <dc:identifier>HP:0004395</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88edf143-81b0-4d2d-ad57-c69768e0a3b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low weight,growth</rdfs:label>
        <dc:identifier>HP:0004325</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef34926e-0533-40d4-ab74-66b7ebd46e49">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2bced80f-e8d5-49bd-adb2-b8c06b54cd0d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea87b4b6-fdac-48da-a545-40faa8ac2387"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33717664-5f2d-4c31-87dd-abcad665f218">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ed23827-0789-40cc-a4ed-016d7bf81c0d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b61e24aa-b008-4d25-89a2-f89a8b75534f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
        <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea87b4b6-fdac-48da-a545-40faa8ac2387"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01080</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d3e49565-2dcd-4c0e-8945-9e919cd762dc">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130d34d3-06f8-4aa8-922a-47c95a1836d2"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c0c29a5-d6ff-4ef7-b722-bf0bd46dd68f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea87b4b6-fdac-48da-a545-40faa8ac2387"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75630b3e-d051-4958-8a71-3c04792e4e95"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2e8d9ad-c7cd-41f1-97fe-a587578edf64"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6819030-f5f2-4d8a-8c52-2d92fe6a15cf">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea87b4b6-fdac-48da-a545-40faa8ac2387"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e103df7-aea4-445b-9c4c-0474fd3e2a2e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eeb83370-16f6-40fa-ac21-16b7c11615b0"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a4acaf2-86e8-4277-bc04-1a368677306c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/326449e3-1272-4b72-a7c3-ef476caf94c0">
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eed095ff-2346-4269-a723-1d6efd83de1b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <dc:identifier>HP:0040129</dc:identifier>
        <rdfs:label>Impaired nerve conduction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3938b34-fbde-4b01-b7f5-b451bebee436">
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74865371-e741-4202-896a-47e9ac7b15e8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97894f03-b52d-4cf0-9960-23e5ea5527b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30be2429-5d3a-4d52-a7e4-749744734b33"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ffec843-1723-4f57-a457-29f54f3ab7ef">
        <dc:identifier>HP:0003158</dc:identifier>
        <rdfs:label>Reduced urinary osmolality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33e8e206-a084-4527-a550-0d8692c7abdc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum osmolality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4ae71e9-0cbf-47e0-bb33-80cad344eb7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8642364-0fd2-4cef-aff7-a8e329a3f399">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a209a0c-90a3-46f8-8b7f-b7c55423a1c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe0c8894-a4b3-4103-ab1e-9665333c7509"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1586366c-17d2-4d17-a824-3c01bcece01d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000742</dc:identifier>
        <rdfs:label>Self-mutilation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db8cc964-9ede-4186-af2a-5f27b4a783c3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/974a03f1-4d8b-4add-b3ec-17fb0ef542c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc9adb8b-53c6-401e-93b2-65d1b3d0fb82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0df1938-b4d9-4764-acf2-78bb935605e1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:label>Low enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/667771bd-6616-4a84-885c-2578847ba00d">
    <rdfs:label>Thiamine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4d7a735e-df8f-42d6-bf96-4d40bb28984a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b52c60f-2502-4167-a8ef-0b75477e0323"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1fd33c4-e64f-46a0-95d7-315615f75f69"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f25e6d71-662f-4ef2-97aa-b978bb1b5204"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb5cc76d-9352-431a-987d-81284558d654"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04d353a8-6a56-4b81-9645-3f55392d5bd4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/042eb257-b5ee-4ec4-b105-0a38be2e4430">
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc9fcdce-d89f-4e2c-90ab-c1200f227446"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/42916c12-6b46-48f8-a620-2a7b70ca3d6e">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa66503e-1406-4186-8942-7543ad5bb64e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00dd0b5f-6242-4e6b-a4b4-5989eedae94c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75c275d1-3a96-44aa-bb9d-d626b08bf414"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
        <obo:RO_0003304>p.I480M</obo:RO_0003304>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d070b7d-873d-4444-9345-73a5011c5cfa"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03669103-4b9a-4687-888f-b42cce9944bf"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5f5553b-4695-4640-af0a-7c2b5f1d2f37">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e103df7-aea4-445b-9c4c-0474fd3e2a2e"/>
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d30b6e26-64a5-4a0b-a937-abae1616efb1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a1e09b9-9f3d-4f3e-9304-6fab9f01369d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d73dc357-63cd-4469-841c-fbd1c69776b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ede613b6-93d0-4c02-b076-c73b8a14acb8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a4acaf2-86e8-4277-bc04-1a368677306c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7802d54-4387-454b-8d96-31b4d742bde8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a7cef2d-d12a-4bdb-81ed-70d7cd4e43f5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd413f02-0560-405c-ba91-937102567eef"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/017e27e4-161a-46f5-abd1-56878c6b165e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34f612ed-0cc4-48af-a1ef-3cd290812663"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/241d27c9-31a7-4ec8-89fc-0a0d6bf2bb0b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a4acaf2-86e8-4277-bc04-1a368677306c"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7096a802-ee4f-4c3d-be89-c8643f39253c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1e365f4-1d32-4c1b-8c5c-f9697c301594">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fd7d306-3299-4abe-b30d-29a1e1e366cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a4acaf2-86e8-4277-bc04-1a368677306c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00635</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bbef015d-cadf-49e5-95ee-0c537c741dbb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33d49587-4f7d-4e10-ac5c-92f9edfb94c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a52d3ad-315e-432c-a82d-bc9ff58803f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eb19d12-108d-49dc-87b4-0589877f5743">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:label>Renal salt wasting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09cf4420-09e3-45e6-a66b-6f631d971a92">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dea70f3-e1f0-4f90-9d2e-060cfcaba33a">
        <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0500014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44120b20-1db9-4499-b5df-b74af2843a8f">
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea273cd6-5158-42ab-84cd-e1327fa4ef23">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Bile flow defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad4fcd06-ce4c-4a1b-a585-b45d6d72ceb8">
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99fb9682-2c65-426c-9dcb-e6520c9097a7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d9b1ab0-5bee-49e5-9f75-40d9d0a35255">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>biochemical abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5862dff7-8374-4449-bf02-989d449817de">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/823ffdf5-c954-44f7-af09-1a0e39860fce">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4011bf6a-b9ac-4221-9a4c-f4c1bc850098">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atypical bile acid synthesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4870c88c-c798-4e82-be96-aa6df4998242">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a95ef0a5-1644-4209-b4a1-e5e2f3375579">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
        <dc:identifier>HP:0001396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af2e624a-45ff-4696-95ea-5c9b9c76bef6">
        <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc43d827-5b8d-4db4-b8f3-e37e2210f9a6"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e68be91-439b-46e2-83cc-570ee8c8d44c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea5d4f57-1d06-4351-908a-3739e4ff2a9e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a1aa8e4-da90-49d9-a722-963e150b34e6"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb2cf10a-ba95-4832-9b2d-39d2b88995c3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c78ae9d8-e383-443a-8a6e-99990b009351"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0be33f4b-4770-4d4c-86fc-2de2dc547382"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfeefbcd-e92d-4fe2-bbcd-9cf64634c9e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00435</dc:identifier>
    <rdfs:label>Nitric Oxide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5be863eb-f52a-4ef7-ac01-cedaa49d70b2">
    <rdfs:label>Low CSF glutamine level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030980*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1e32ac5-ba67-4da8-95a0-9302841b5d71">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
    <dc:identifier>HP:0000934</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>chondrocalcinosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10d3aaa7-f5da-47db-a66e-86d8716e5a70">
    <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d622c379-90c9-4d4a-b995-8ee004a3e530">
    <dc:identifier>HP:0008281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acute hyperammonemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ae134e0-20ae-441a-9005-72b1c4dcf7e9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b1fee8d-ec5a-4b77-9f35-46d6da6d79d6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <dc:identifier>HP:0007346</dc:identifier>
        <rdfs:label>Subcortical calcification</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b06d3786-44c2-4be9-a38f-a09c26935c9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d907f7eb-5941-4645-a8e6-5c6c02ecafdf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002135</dc:identifier>
        <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/069dd966-5c35-4335-bdf5-6b9709a20030">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Seizure</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9f69f8d-1a59-406c-9b5b-bf9c29cc9576">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/346ebbda-2226-40f6-8590-7d00cd54327f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd4b9d29-aff2-4338-a74a-bb27e0f48156"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24b7d0c5-2972-4894-ab41-55d5fefb6f9b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5cc9035a-e403-459e-b23f-d544ff440c0a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a2c1910d-942d-48b9-a3c9-f12c38d244bf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/416589ef-b48a-4edc-ae62-910bb2b5c200">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:label>Growth impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58596a5a-ea70-478c-ba85-d957ec3a3955">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4606af79-0288-4ccd-b00f-05f862b9b009">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77a39deb-1e88-456c-b97b-df93c6069114"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8993785-602d-4f73-9cf6-d175939ac07a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d55d0aea-c762-43af-a414-ab741cfea4c3"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/329d9001-092b-4230-bef8-02ee35240e18">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6967e339-3a64-4af2-8c24-17cc89221e07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/412c9f16-dbaf-41ce-bc21-289e018eda27">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f5580b2-054d-4f93-8960-1d739769096f">
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a6398fc1-2563-4c16-ac50-e989228b5594"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34bf61ce-bf4c-4446-96f9-ec4f6d9eddf0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a989a07-9b5c-45a0-aa3f-fc17bc51de6e">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa5d5527-cc61-4408-8946-36835b446581"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/beeef7a2-d7fb-475c-ae66-bff2686ebbb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d335b5d2-328d-493d-bb07-708f609ae9b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/652f8740-c86a-480b-9204-4428185f15f1">
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>exercise intolerance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9fe889c-fdf1-491f-91ca-84ddec2827d5"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
    <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b94eec31-0c90-4d73-9aae-f72a9123f692">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8181ac68-0df9-4ec0-a331-c6ab46d06025">
        <dc:identifier>HP:0003326</dc:identifier>
        <rdfs:label>muscle pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/644306a3-0351-4eed-996c-22af4e0e8037">
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Lack of energy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8d119c6-b06e-452f-aea4-88b2d0bf8e0c">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defective heart function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e28c2f4e-7d79-407a-a8cf-bfe4845df0ea"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80ede094-f9ce-4ca0-88a3-03ee16b395c5">
    <rdfs:label>Piracetam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ff86968-b0db-42d0-8eb4-c13b180c0cbb">
        <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e352df34-8cc2-42c0-bed2-7ab151c80097"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04c62eab-e203-4576-8abe-9b8e4b3c0c93"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <dc:identifier>DB09210</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31aaf23a-f20e-4d45-adb5-7795a8084ef5">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
    <rdfs:label>Muscle inflammation</rdfs:label>
    <dc:identifier>HP:0100614</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1e83365-c6a7-46d0-87c1-20b83cf76f35">
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9f974ee-3cc5-43b7-8fd2-01192ea58ddc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e779ce96-f611-454c-837d-d9ef04678868"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33d5fd29-13d7-4a3e-bd19-7067df5ab37e">
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004387</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63033298-4941-495d-bd1e-6d79059f1454">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39c5f999-a117-4c32-abb2-b6f92f062f52">
        <rdfs:label>spasticity</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e9ef9f1-e895-4c0b-878d-26a3342b4b36">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c54d4c63-8c0f-452b-a709-577a3ded5099"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f83f3e0-2ccb-4f1a-acd4-a91af04c5459"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c6ac36b-4bcb-455d-9a70-60ccb62490b6"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a55c2ec-d492-4e68-8a00-282d5c7455ef"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74693e17-2e86-4fbd-926e-40c317324fc5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/446d94ff-46a5-4b3e-a487-479546246ce8"/>
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6511aa6-1524-40ae-a5a3-576d47d4c3bc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/999e3f45-7bb5-4c45-83ff-d473e361005e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0175baa-a17a-4e50-92b5-78842688e533"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3a4d5c2-ae9e-41b9-af3a-56a10a3842ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b82cd115-6ae7-4ae4-8b23-98166a334ca1">
    <dc:identifier>DB02691</dc:identifier>
    <rdfs:label>Glycocholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9aea19de-249e-4c6d-9dbd-3d7b9880564a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/275f104b-d049-43e2-9474-5a45ac2afee4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10b8640b-2385-4f0d-8a85-bcfff6724674"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95a63ba6-b1a2-4c2f-a473-74dbaf3ed615">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/838fadaa-4a5d-459f-9350-6c2736aec36d">
        <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cae5fe62-40eb-455e-afc6-026bd8c6fdc9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d3080e1-2987-49c7-b7ab-76318f18d133">
        <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004355</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24a9bbd4-b4de-4ef8-b54c-05a6cdd67d52">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec45da7a-9af2-4124-a5ae-42da9117d387">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Abnormal motor function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c731e7f8-00f8-47e6-91d3-7c278d2efc47">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a5398a5-1678-4bb5-a784-8bc9b30c9685"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a1b24f0-868c-49ec-9be0-01fcfd1c4a76">
        <dc:identifier>HP:0007166</dc:identifier>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf91e58d-6565-464d-92e8-89b5fa92de36">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031884</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbb61d4a-1216-42ed-b5b0-597565808a00">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
    <dc:identifier>HP:0001129</dc:identifier>
    <rdfs:label>Large central visual field defect</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d7310a2-d388-4ce5-8db5-a45a6d3003ea">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1119fcdc-6ee3-4d66-b5d3-374b3d6729e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50d072f1-a848-4852-bf30-0b7ea50ce0d7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01d41002-c065-4c11-9ee3-c1b61ca7bf28">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/017e23f3-2ba8-4420-a268-560651cc04a5"/>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da65354e-867b-428e-a1d7-c7e273f6d838">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/172902b5-30f0-4b03-8e33-1b70f10a3d1b">
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
        <dc:identifier>HP:0003541</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d18e01a4-c1ea-4e43-9d0c-4cff5cc3f7cf">
        <rdfs:label>pulmonary regurgitation</rdfs:label>
        <dc:identifier>HP:0010444</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc7f5d77-bbbb-4f4c-b333-49e11338eb1a">
        <dc:identifier>HP:0012763</dc:identifier>
        <rdfs:label>dyspnea at rest</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/336803fa-55c8-4a5a-a78d-e4cae4a18430">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad7ac9f9-a07c-4297-9210-702dd00aa549">
        <rdfs:label>conjunctival irritation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
        <dc:identifier>HP:0030953</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11c87486-34d5-440b-866f-78c3d937423d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Daytime somnolence</rdfs:label>
        <dc:identifier>HP:0002189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3df147d2-1a7d-4679-be33-25e985d7ec96">
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:label>white matter abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a4e94ad-2a5a-4383-90a4-f8821263b64b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b01b4ed6-394f-4804-b402-6583cd1906ea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a9dfc97-6b8e-403c-995c-9feb334ee177">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/157981c1-581d-491d-a748-810a2f2d4ccd">
        <dc:identifier>HP:0000969</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:label>pitting edema</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8519854-2226-49e5-871e-f08d755f907b">
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3906df6d-8256-4369-bbb8-681d566abb6f">
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f7bd4b8-2921-429e-825c-835916129974">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>low quality of sleep</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71ce7da8-8571-4137-bfc6-2d7ae1c25521">
        <rdfs:label>low exercise endurance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0df7acb2-fdc2-4960-a5e0-90a87f59e027"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/512c4e6f-9a1c-49c2-be19-020ef9bd2363">
        <rdfs:label>Sleep apnea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010535</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/229c89f7-651d-400d-b775-9d6085fa3d9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f5012e8-c55b-4c92-be18-b63072e79230">
        <dc:identifier>HP:0002119</dc:identifier>
        <rdfs:label>brain ventricular dilatation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc842b5f-f05f-4694-a32e-f0b3f4a263ae">
        <rdfs:label>photophobia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000613</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89524b4f-b599-4825-9d40-7200b816d553">
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
        <dc:identifier>HP:0002877</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efc78ccb-bb2c-409b-8537-766434396b4c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccf6850a-bece-4558-957c-a204580fa2f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum bilirubin level</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a9aa0c1-ad18-4981-88fb-1ca3f1930511">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c78ca3b-f775-4039-bd56-ed0c0e067be6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01e8e043-6dd7-4041-a174-fcd700d250d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d7fcbe20-b1b8-4f73-b62a-67673bd4fb51"/>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/617c44b1-8ca1-49cd-8d8b-4ae7fce4870b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/052b6975-e813-478f-bdda-aff73af84dde"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27c5c36f-3cbd-493a-bc2b-daa5a90ed97d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000709</dc:identifier>
        <rdfs:label>Psychosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66067311-e5de-48b2-86ac-7576db596496">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
    <rdfs:label>lymphopenia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001888</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bae94f1a-b0dc-4ca8-b56e-c9bd0a0126dc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33a5138b-1afc-4fd5-ab8d-3056d9b065be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bb3ef8f-8acd-41d4-b54d-2abdf866f6f3">
        <rdfs:label>Polyurea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16d48b36-3e37-4069-84dd-bab082169292">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9e45094-0930-487b-b648-d748dd91bc87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b2c52f6c-b2a0-4125-ba78-f95ccf447d3e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0221e804-ccce-453d-85e9-e557192647ae"/>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52fa3732-71d3-453d-bcf6-faf20278fb1e">
    <rdfs:label>Nitisinone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b47622e7-73a9-40ec-8d55-2b028589f289">
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46233dc8-3254-4bef-8b56-19b6a21ab3a0"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3420464-ad9b-4e28-a4dd-8df97ddfa7ee"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d9524d5b-2b5c-4f09-82b4-2af658c5d481">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46233dc8-3254-4bef-8b56-19b6a21ab3a0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69c149c7-db39-4e31-9d9f-209702c739ea"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42a32b14-37d1-413f-a1f7-fc4738b104bf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b29adae0-975a-4518-b83c-26366a94ff3a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00348</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dafefb28-321e-4301-99ff-66100d27c848">
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/28355243-4de3-4fc4-b12a-7a19e7797e21"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11ece83e-e6c9-4f1c-8f82-e3366119d2de">
        <rdfs:label>neurological damage</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/490feae3-0b38-4f79-8654-689e60b9269f">
    <rdfs:label>bone weakness</rdfs:label>
    <dc:identifier>HP:0002749</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92aa0c5b-14aa-4ba5-bd7c-989f7a08838c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No result was accessible</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dade0e3b-6e5e-48c3-b094-96927627d31f">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/716de7fc-3106-432f-8563-f184730fe980">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e48708ed-fffb-43ca-bb10-66a90752e36a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/15c89e7e-bdd0-4c05-8b02-9eefc473f715"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Tolbutamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
    <dc:identifier>DB01124</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fba80b89-8f4a-4399-bca5-aec8b8e679f2">
    <rdfs:label>High blood ammonia levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
    <dc:identifier>HP:0001987</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83f06d42-22ef-4130-9508-50eadb9ec5e3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c3c2a9f-712e-47ce-a029-d498dd660ec8"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/68b7a334-f10e-451f-9df8-5fb3ffddce61"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9551ba7-e598-4b32-acf7-8a186590ebb3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <dc:identifier>HP:0100513*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10395a82-9470-48cd-8449-f80eda871de7">
        <rdfs:label>Neurological abnormalitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a63b314-608b-4a9a-81ca-6e9a2d708469">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscle necrosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <dc:identifier>HP:0003713</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7b02a1f-41e8-4b96-b3aa-137b375c00d4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
    <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
    <dc:identifier>HP:0007479*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2df13e4d-7f28-40a1-86a2-1fb36533919d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebc77532-7da3-44f7-9019-6cfc8265375a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd4b9d29-aff2-4338-a74a-bb27e0f48156"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/632f0b83-e3d6-4a14-ad5d-d2090e92564c">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9d7f9c6-4203-48e8-bec7-d17517e1525e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
        <dc:identifier>HP:0010975</dc:identifier>
        <rdfs:label>Abnormal number of b cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/398e858f-daa9-4b8b-a643-6f2015ddc16d">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>Recurrent infection</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23009fbf-7ee0-4df3-9d56-a53320a6a13f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:label>Abnormal immune function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5dc80ac-28b2-4a7e-a589-9ce9c42d83c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94e6654f-e073-4892-86f2-49209e6ed11e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20c44b8d-5609-4ee3-845a-2aeb97b7b0d7">
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe0f6af8-67c3-4531-a043-a8d46ae83863"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7966c17e-d8fb-4ab3-b9f7-84bad4ebd0f1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3f9ff3d-1be8-4f67-ba5e-842fea6086e2">
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/985cac99-0c1e-4a9b-818b-cc6fa2f4491f">
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1fbecd4-0917-439f-8d5d-2e6f659a2fcf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84472cdf-7c2a-41dc-bd17-2a3521a41629"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d51f5541-c24e-4d09-8af0-65683337d268"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab017742-a065-4a74-8d93-f699ba798654"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f7da07d-5722-45b0-b77d-78ce3c9912a6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d621512-0120-4e28-a497-023ccb67a131">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0eb13372-4332-443a-bf1c-0621730efba1"/>
        <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe"/>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52f4851a-e488-4ac0-b212-9b54e22ca378"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>L-Arginine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a705bba0-5312-43ee-973d-5e98873de158">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0eb13372-4332-443a-bf1c-0621730efba1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e4bf97c-6cd2-489e-85ed-0b147e140d94"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59741b49-9b15-44e6-aa11-0d82be562599"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80582869-b76d-4df1-a776-867537320c74"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68234d1f-7a90-48ea-90f4-3583726b6c8f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/895ce81d-18fd-4dcb-8dd4-dfdf5754d009">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c99ea13e-4dc5-4538-be9f-7fbb693e151d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0aabcf89-2744-46db-872e-45a766e42c92"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21b77679-726e-4bea-a5a9-182ec825941a"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0eb13372-4332-443a-bf1c-0621730efba1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52e80729-7f27-41e4-be94-030cfd63996b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d6e017a-9b2a-4e54-9ad8-6e792bbf4625">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0500014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea273cd6-5158-42ab-84cd-e1327fa4ef23"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3f9c5b2-7df9-4c86-8397-8c2dcf63d807">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44120b20-1db9-4499-b5df-b74af2843a8f"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e218a7bd-2f51-4974-bf4d-7da1b726cef9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15e02c19-7648-4fda-9ea1-670458c6aee7">
        <rdfs:label>Atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc43d827-5b8d-4db4-b8f3-e37e2210f9a6"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2a40498-60ea-4b34-9b40-eea7e66b8925">
        <dc:identifier>HP:0001394</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cirrhosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/275f104b-d049-43e2-9474-5a45ac2afee4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f88f49fd-62fb-4eff-8bb2-56ceb9e0d856">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19778a67-92bf-4160-bb70-30b59ab1b86b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected bile flow</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/be3bdff3-004c-4f43-89c0-44b5661a86d4"/>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b856cfb-b7ad-41b9-8e2a-2f23b285ffc9">
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed7378ae-ce6a-4e36-bfc4-0331ae3791ed">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82dbb548-b502-4cf7-b136-4ae5ddab41c9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71c9a73d-4af7-43ff-a3dc-6711c7180453"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d528a775-2290-4889-9aed-c50f55b42496"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81cf865c-490e-42d4-a540-590710a1362e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acab9460-0fde-408b-8a99-fb879fca2aa6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal muscle function</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a555c19c-22b1-45e9-9214-1250a6644922"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
    <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
    <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3a54c00d-3085-47e2-bcdf-461bae7da7a3">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d516c4bd-eeb1-4ac2-917e-739f782ce4c5">
        <dc:identifier>HP:0002459</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a"/>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f826f302-961f-45a1-8216-931a11c638f4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <dc:identifier>HP:0010553</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4270e1c-80de-44c0-9036-a103e44566d9">
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b3e954c-2c73-405b-9166-42f1a61b44bf"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f581ab3-8a40-4cb8-b6c9-902be38c6323">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06eeebd3-9001-40f2-8602-80838be02074"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c346cdbd-ded6-4a78-ac65-e6ff0b8c7d28">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b510fea3-cbe4-4e8d-8af1-74b8c79b7c5b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1712752-1ecf-4679-8d10-1ef9c9ff1116"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50c33221-193c-4b0a-b4da-00db87c52f2f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00624</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d01d473e-7370-4403-9741-0d692b3b8eaf">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792fb394-03b3-48d1-a48c-95786023df70"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50c33221-193c-4b0a-b4da-00db87c52f2f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <rdfs:label>Testosterone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fccaf5ea-1646-4c2a-8201-721c4488cc11">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a517e4cf-1d2c-402d-91b9-516bf37fe194"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66dcdf86-c8e0-405b-a7a2-62a46393911d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be07b39c-5bf4-4305-b1df-c33c04d9b1a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50c33221-193c-4b0a-b4da-00db87c52f2f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac24dd1e-a761-48f1-a5ac-2a4328748acc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>Abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fdf8fc69-4076-4b02-92e0-8a3b304698ec"/>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d8475e4-3f83-4149-a06c-b9c4cbc2cd99">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7e184c5-5538-490f-95ca-56d5d5fe7c19">
        <rdfs:label>Etanercept</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3fc97b8-d5c0-41e4-9631-f56c65435c67"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
        <dc:identifier>DB00005</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b70ee3b0-c4bf-4a0c-9954-b53da7fee5da">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88f39a42-5319-45bd-853f-bf07bdc0c780">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
        <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
        <rdfs:label>SALLA DISEASE; SD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9075cbd6-6878-4f2e-ae6a-1bef6aaa4f3a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7ca911d-382d-4a31-a593-ba97fa52c631">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6329472a-6642-47bb-ac7c-249425293fa1">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d1eb49c-1091-48b7-99d0-dfa5a89b30ed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7a244c9-85d3-4775-a122-0cc3d958833b"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00650</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3069b46-b304-4eb6-8364-028812e70c21">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebd5e161-ffcf-4e7e-9881-42e8b637f66c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/881a2012-73ef-4207-b6d4-60ad01bb6c52"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83964963-bd6a-4d0f-8f92-252e6370601c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/562a830d-2b30-4874-818b-d2b4db5678d1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2739179d-0f5a-423e-9227-d26e904ad81d"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7609e6-d4dd-4c7a-8d2d-88e256ea7d9d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c360d1a3-3aee-4de6-be54-82b2539bea4b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6397fcfc-b3bc-4752-a2d9-38bf6431c786"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ad52170-f5c2-4fb7-ab22-f0f55418d4d7"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9b02ee2-4adc-4a3b-a1ef-082422d16b49"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7da5e0a8-3bcd-4ac2-aaf5-071e1bf6f93e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613068"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e352df34-8cc2-42c0-bed2-7ab151c80097"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35227879-1352-4907-aaba-4fba71e26b1d"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfcca95b-cf48-4c3a-b6a3-dfefa46fb10f"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/447c18c4-8e70-4041-9d19-3b7df3df189b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ed4fd73-d918-4be3-bff1-93d84e5a6c8f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/012a566e-c8e0-41df-a028-9b8020385bb9">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cfcec46-c8a4-4ab9-a61c-143725815653"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Leucovorin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59929b26-9698-4576-8cf4-0204e3d0a62e">
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b6b592b-f592-437e-835b-546df7618a67">
    <dc:identifier>DB06262</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d80b4197-3fa3-4fea-acee-8596637054b2">
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/223360"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b78512b2-5386-4780-8ef7-98a84ccd690c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b03bbcb-312f-41c5-b866-df2b6bcfc69f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Droxidopa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcdff5f7-3d09-43b2-bcf5-c0fda8e28954">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
    <dc:identifier>HP:0004312</dc:identifier>
    <rdfs:label>Abnormal reticulocyte count</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec4c9975-62f3-4e05-9345-4357e607e277">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e5fe1cc-aed3-4a41-8dfb-292c58650540">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5bdb5842-da73-4703-abb8-76142c6dc116"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
        <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9a87c2d-d5c1-4d29-bf0b-e6ef94df6d79"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb2365de-4875-406e-8f66-206f64a29f33"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4847973e-2c96-4c9e-9150-0476bbcba8c8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased liver iron level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <dc:identifier>HP:0012465</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f0764ea-7075-4bdb-b848-54ff2aa576c7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased serum iron</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca066ed1-84c4-4223-bb9b-3a6117e3e831">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c67c345-7738-490b-a0f9-5f38739e35dc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d920bc2-7325-4fc6-93ee-2b89d08752a6">
        <dc:identifier>HP:0012463</dc:identifier>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50">
        <rdfs:label>Abnormal liver function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1e098e85-25de-43c3-ab5b-6d5bb6dcd9cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8886629b-3b4f-4fc4-9333-8a2742c9c902">
        <rdfs:label>Hypsarrhythmia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002521</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/130d34d3-06f8-4aa8-922a-47c95a1836d2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>EEG abnormality</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9f05d34-bddc-4464-b1e0-bb80fdacf000">
        <dc:identifier>HP:0001992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Organic aciduria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b52c60f-2502-4167-a8ef-0b75477e0323"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd387055-df08-4c3b-8e7e-d17bcafbd9a9">
    <rdfs:label>Skin papules</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0200034</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18dfd05d-aa02-42a4-a254-a5677682c753">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f264224d-473e-460a-b187-d43f663320bc"/>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1303f50-46f3-4033-94ee-4beb573b02ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/478501a6-c93e-48a1-96aa-83021109e67e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6db65638-087b-4678-83e2-f4ff710a49e8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>tissue damage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0288547c-70c1-4796-bd44-26e31c59cd0b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e795a172-c8b0-4f59-8a11-b76cac4d48a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a40c456-213d-4b22-917a-fe17890e3f3c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1985368c-c5e0-4570-89e7-6c957bcde6ff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected excertion of 3- MCG</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8f4768d-250b-4b26-8c09-b616aa002769">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/20073fed-71e5-4f03-8e14-c255590f446c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ccc5b64-b760-4248-bfbc-3776a057812f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e62e238-2b99-4f2d-a58c-762a889bbfdd">
        <rdfs:label>Hyponatremia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
        <dc:identifier>HP:0002902</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ae10844-6032-4214-b1e3-3b8a509e3695">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012450</dc:identifier>
    <rdfs:label>Chronic constipation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
    <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3bb903fc-32fa-4c9e-8e05-1a16f816163d"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04e6393c-51c2-4240-9b4f-bde636baef9c">
    <rdfs:label>No Studies were done on this drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2e8a314-9fee-4a3b-ab19-306d5852cb48">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08643ee8-0221-4226-8f96-766a7ac5d717">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b588af37-0958-4d5a-ae91-87e54c320588"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42eaa325-30f4-40ac-ab3e-15ea0ce54256">
        <dc:identifier>HP:0002098</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:label>Noctornal difficulty breathing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7730a875-69c2-45e2-9273-2eceff4ca78c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ff31fbc-2e37-49ce-a3e9-5edac4b417a0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>frequent hospital admission</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdd19c41-fe54-4a29-ad03-143f1a63a0f4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
        <rdfs:label>low levels of purines</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b848540e-5e6b-4414-bc1b-966c2a428105">
        <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/398e858f-daa9-4b8b-a643-6f2015ddc16d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
        <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/83688082-05ec-4556-9029-9d73d767b183"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ada9b0b5-c20c-4d7c-9cff-36f5a08e823c">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78342ac8-0ff2-4b14-8c60-3ec3954f8522">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eb59051-4edd-49e1-9489-134a4417da72">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
        <dc:identifier>HP:0002173</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoglycemic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a36348fe-6aac-49fa-bd8d-feb6319a3651">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/143e662d-e5f1-40e9-b1f1-0627aec00aad">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c7433c6-3914-4ef5-833a-73f3e83df80f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8cb6da1e-0d60-4cad-9208-782009a846d6"/>
    <dc:identifier>DB00148</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/692ea2f3-eb8a-4971-ade6-a3e16ebc94dc">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/652f8740-c86a-480b-9204-4428185f15f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14739dd5-6bd5-48c0-9373-68413d6e0e36">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3149512-e11d-4925-9ffc-fbfdd68a9a29"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79da40d1-0326-4d01-81a2-d3c9df608ee4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8edb283d-cb61-4cc7-a980-ce95fe25ffaa"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a5688f0-e1d5-474f-998b-f1e68ed2ae4f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e8d2a99-44d5-4ab9-a92d-c92903524738"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3d11d14-06d0-4295-bbff-6cb26700e247"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5232d7dc-c5a9-4c0c-bd68-c69ef40bd1a6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e950836-613f-4389-9b58-cd8a8def2c2e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f55346f4-47df-44ce-8e86-0b70de4388f8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90dbb52d-ab49-4056-b217-b7dcb90963f7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f254ba62-3390-47a5-bcf5-9c880861332b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9620f95-9da8-4aa8-8828-72bafc3eb8e0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0388cf8f-5692-4cc6-aa5f-334d793abb09">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4d1fb51-5a91-44b7-9c66-b3086e0ff041"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/753373f4-6f0e-4751-bc72-8df9da12ec0b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
    <rdfs:label>Creatine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f7f1e34-0d2a-4075-9ad8-2fda856d531d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>edematous</rdfs:label>
    <dc:identifier>HP:0000969</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83616fef-9147-4e33-9b66-d10c6556045a">
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Oxidative Stress</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b49db01b-44a6-4be3-bae3-65a848ff5afc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4130dcb0-5318-4232-870d-d0a897f2677c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8b7554c-c1fb-4752-beb0-8104930e5be7"/>
    <rdfs:label>Levetiracetam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd9358a7-b04d-4f63-a19f-9db5d84251a7">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b70ee3b0-c4bf-4a0c-9954-b53da7fee5da"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63874f6e-4956-42a5-b9cc-bed2eec84f24">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75e099df-0d38-4815-b814-e38a71fe5170"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca5e5b44-4674-4bda-bbb4-97d8524e7828"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba6ddd20-ede6-44cd-9085-63a388e848b9">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2894488-630f-4cb8-8979-de212bedae22"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/914a92ba-f699-4217-97ff-69b94d96a411"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cad1756-2add-480e-a5d1-76b544cfc904"/>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6548ab9e-4580-4f11-b2f9-e6f02e6ff5e1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7147dac9-11b0-422c-ac98-0bae9aab327c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130d34d3-06f8-4aa8-922a-47c95a1836d2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76d233a1-495d-4cb3-aa4c-43de40ab2df8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfeefbcd-e92d-4fe2-bbcd-9cf64634c9e0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>endothelial dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7caac1cb-9525-4e22-9b5c-9d181fa30ba6">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
    <dc:identifier>HP:0001878</dc:identifier>
    <rdfs:label>hemolytic anemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
    <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1a910727-0ebf-4d48-9f7f-ef5a7a515ef0"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f5740f8-a3e5-47e1-8fc1-15a186c6ccde">
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>Poor fine motor skills</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c89da8b5-146c-4e6a-b845-8ad12d669ab1">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14bd8e1f-27b9-4097-8d71-0b57644b6de0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc4f41b5-b7a9-4a62-b5db-94cb79ceed8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d35457c-936f-4e11-ad15-81faf2b27a60"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cb8e13c-41f5-483a-91f3-2a6a90a5ce96">
        <dc:identifier>HP:0002155*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fa0a813-d261-4d4e-aa1d-696f354d8d5b">
    <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
    <dc:identifier>HP:0012654</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8be1e54e-5ca0-41f4-9738-4fe98bd965f3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75a99c75-579d-4fde-b0ed-d862dd4a6606"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afbcb7e4-1c64-47f1-8ff8-343f1ae9cccc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ab33ff5-4bbf-499e-9938-2010dabde1a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/558cd837-9993-45cb-aa8b-398918286d07">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74fa56aa-53ef-431b-b57b-e32d68316b20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40593c70-edc0-41e0-8218-d057de3bf631">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pathology in many somatic tissues</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
        <dc:identifier>HP:0000924*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9facdff1-266c-4e7a-8673-348446ef53a7">
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfa4096c-8afa-4652-a6bd-d500b6351f6a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c5b7dcf-4598-4e4a-8b20-eda3e217e715">
        <rdfs:label>Duloxetine</rdfs:label>
        <dc:identifier>DB00476</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b801f1a5-2f90-4180-b328-c9d893483647"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/248fe1f0-7114-4e59-b746-5b84b963700b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c355af06-d5b4-4ff7-a85a-b1e6f81eaa2b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ece562a-6c74-4116-be0d-778144dfa6dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9ce8e94-172e-45e9-8232-d64777ba12c7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rimmed vacuoles</rdfs:label>
        <dc:identifier>HP:0003805</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffb34c7c-fc63-445b-9900-0f9105216713">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
        <rdfs:label>Amyloid deposition</rdfs:label>
        <dc:identifier>HP:0003216*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af8179a9-f62f-4c86-a5e1-7f3ca49bf650">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <dc:identifier>HP:0012350</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5fd7b57-8059-4bfd-8a35-8055cb13336e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
        <dc:identifier>HP:0012363</dc:identifier>
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f1664f-387b-4a08-98fb-0784b8bd51ad">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low muscle mass</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a298c8c7-3eaf-4e47-9f08-3b988034ba1b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75abc58a-1329-404a-a830-9734646de3b7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/212127cc-64c0-4894-b037-4db09f0db16f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2e8a314-9fee-4a3b-ab19-306d5852cb48"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01e3bf7a-1ac5-4d1b-b50e-222fc8b1a452">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/879115bb-b085-4041-9813-26414511a8d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e17a954e-a7bd-45db-8665-6d121880504d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7def8e75-fa30-4cb1-ad9c-a03813395032">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c4bc9ac-87f2-4e8d-bca4-3346ffaea554"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7568c4f2-502d-41b9-bc60-ffa1b2930da5">
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3294089-a5f7-4829-83fb-61a570e8b847">
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab4a5568-e80e-407f-81c2-50ecc6a8f878"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e885d4d3-7218-4056-b724-1abc4e85617a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c053f7c-469e-4da1-bc7b-b0575a9ab4d5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>CHEBI_25548</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d972ffb0-c71f-4e33-b3cb-3950030d8c90">
    <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edcba2df-3bc2-4b7c-8762-e811613a356f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
    <rdfs:label>Acid regurgitation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09e55f1c-b95f-49a8-ab9c-5d18bef9a6b0">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
        <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b7bfc299-30ee-4b21-871e-83b73070d935"/>
        <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>E1506K</obo:RO_0003304>
    <obo:RO_0003304>delSer1387</obo:RO_0003304>
    <obo:RO_0003304>R1353H</obo:RO_0003304>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/846a451c-8a01-4e73-8bc2-693be71073c5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0227f94a-91b7-4c4a-a06d-6576450d1d82">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60af4e1b-676a-47c6-8f3e-29f26c623579">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8361ed3b-85ca-4df3-bc7b-06c998864924">
        <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c041c64c-d72e-4d5c-8ec5-7d0425d63bf6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9d64e21-570c-4f6a-a8db-1d52ffb20ee6">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
        <dc:identifier>DB01186</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e1ac6c1-4e4b-49f6-9d5e-1c96523d29a4"/>
        <rdfs:label>Pergolide</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d6336a1-dfe9-4703-bc7a-0cb660774827"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a5a138f-e485-4aeb-95da-485426b1f914">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e41558f-ed05-42b4-8314-3ba0d04bc15a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36f359a7-baf7-4318-82b5-5a358b5d8112"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54c71098-722d-443c-9eeb-a821f00610d6">
        <rdfs:label>acute congestive heart failure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c030f2a-4d15-477f-bfdd-694fd2e6f68b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7666698-507f-4c8f-a50e-aa4dc0edc6f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba4ef572-817f-4703-9bdb-57d110679b65"/>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a36eb23-c90d-403b-937b-692859a45b72">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69b214e7-258f-431e-a431-797401890e0b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30e357a9-e356-429b-997c-a8e54c8c8446">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/639ffb7b-4623-4abb-ad56-9abd7b6f14ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a847fd8-af6f-49bd-b1dd-22eee15a8860">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lower extremity weakness</rdfs:label>
    <dc:identifier>HP:0007340</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb6f416c-da54-4c91-9e92-526eb30870cc">
    <dc:identifier>HP:0002415</dc:identifier>
    <rdfs:label>Leukodystrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a8884f1-b0a2-4f39-9760-eb42e990a806">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05242de0-8919-4f98-8237-a04dc4f0a856"/>
    <dc:identifier>DB02053</dc:identifier>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46d71376-da81-4991-a741-f1fca9ea476f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a00c6d4a-29a9-4f46-b96c-349c541ece40"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa2e031f-08e4-425f-93c5-392e9e30a806">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/865404ac-8874-4ea6-ac4f-d5b3b92bfd03"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bad8d3ea-1382-4eeb-aa6e-42525422fb54"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ebbc211-7403-4711-87f4-f8a35ba78086"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d887c3d-7e4a-4d41-8e61-f972eb663aed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/084b2a35-3fd9-4b13-8d21-1eefca74efc0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cc81f5c-e26d-47ff-9b0b-d185c6095e20"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b76484dc-aff6-4411-a745-6b6613a6f89a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Captopril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <dc:identifier>DB01197</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
    <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
    <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27baeacc-df1b-42b2-8386-3ca1d4c994e3"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cfcec46-c8a4-4ab9-a61c-143725815653">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012446</dc:identifier>
    <rdfs:label>cerebral folate depletion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac078216-4579-4de7-aa4e-e000ffe5a095">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012379*</dc:identifier>
    <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7465158f-4a9f-43d5-abb2-b60ffd5967a5">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c78bdd2-bc23-4953-af8e-aa55019cb762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f97ea1a-ea1a-4965-8c18-db10c0e88bc1"/>
        <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/781c4ca5-07ec-4019-9fab-28620cd26806"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09b55116-ec33-4d04-893d-7f1c23732e45">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22c1dc46-c434-4dfb-9711-3cb7edfc633a"/>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbe9e143-64d8-437f-a772-fbd52f8eef3c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <dc:identifier>HP:0003676*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/510c05df-f4ae-42f7-9262-eb808efa48e0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0003304>R266K</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1881098b-f70e-4cb7-98d0-36bbf2724bb5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <dc:identifier>HP:0002156</dc:identifier>
        <rdfs:label>Homocystinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f066127-89d8-44d4-9a0a-02e61580fcd2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4a88fcb-1cfc-4dfb-8803-ae050482ecda"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa878ff2-14e2-4584-b6b2-a90f9b4cd715"/>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0003304>R125Q</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac078216-4579-4de7-aa4e-e000ffe5a095"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dc9222c7-f2bc-4539-bcf6-fe886f4d2735">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4869f79-04ef-4d6c-b556-28be1a9fe4cc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
        <dc:identifier>HP:0002625</dc:identifier>
        <rdfs:label>Deep venous thrombosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f377d32f-e9da-4ad8-bf9b-167661ce975d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3542b8d4-fcc3-4a68-95ac-d8318bb886f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
    <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cd76e06e-5d4a-4842-85bb-1ff97b8794e7"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07790a62-f838-4481-807e-da4576d03ec2"/>
    <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
    <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/afe118a9-574a-4d89-95e7-49c749003366"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7cbb890f-5b9c-4d2e-a695-b0aa843f57b0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0583e3ca-e230-4669-be8d-add0c9638559"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/978dfce7-c580-4f13-a5f6-002f57685ed5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/189b1414-7512-4e1e-98b8-431f269bbaa0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc43d827-5b8d-4db4-b8f3-e37e2210f9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55ac47d4-73a8-4133-9f02-958fc4db6760">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9071cb00-4a84-448f-8097-5ef85fdbd8bd"/>
        <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
        <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/107ee0cb-2dea-4a05-bf04-7bdf40f332c8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04f5ac8b-ce8a-4e13-9402-c3379a5f7847">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04acc8ab-a56b-4e54-8b25-9f06d42f4484">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c22b2787-e320-4af5-aafd-03f5b0d74d89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5ad7f0a-3217-4348-88ca-629bc6c30a8a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28384333-ff3b-4aaa-a13e-dda66b00bbb7">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79aab970-0537-45bf-90a1-143a9520ba53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ccb86494-7216-4f01-bafe-0c1e2ec6ae11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f38d2639-0ceb-458d-b83c-264ab11070c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a7e915e-6125-4fb1-b28b-935db0ee37f8">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fa40c90-7227-4a58-befd-16f84b337951">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired myocardial contractility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <dc:identifier>HP:0006670</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8deac836-9cb9-436c-aa83-94d42e857401">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/daaffc22-1237-4fb3-9912-b2ec1672af8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff73247c-10ce-4bdf-bbc4-8cdea315df39">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
        <dc:identifier>HP:0003470</dc:identifier>
        <rdfs:label>paralysis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/786e445e-80c5-46bd-8565-c7da10c179c0">
        <rdfs:label>progressive leukodystrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <dc:identifier>HP:0002415</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abcf5447-fdb9-4c11-9dcd-fcf27098b029">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>cardiomyopathy</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/114d627c-ef61-43c4-b139-dd79f73cd9ec">
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf653b29-3c4a-40d3-8440-f18fb54cb841">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d1becee-4360-436b-bdf4-8c2075762591"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93dc9b2c-8f7b-4ee0-855b-8c36240118e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cea846f-7cc8-47c4-9c84-f91f94ebed07"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1c458c-6136-4db6-bb89-386a2f7e165f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7030ab2-bd5e-4086-9bf1-68b2e17acba2">
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e764719-be9f-4ed7-907d-e629b4a4327f"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ed2c575-c465-40ee-8c8b-837ea062305e">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc152143-24d7-43c6-b1f1-1a3c319ecd7f"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34c71ec5-ea13-4a7c-a538-9efab3c76a56"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83f06d42-22ef-4130-9508-50eadb9ec5e3"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d9838b9f-37c0-4f8d-848d-7053567ab0e9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4352fb42-1424-416d-921d-4f2cfcad126d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e27df70a-ed41-41df-aa9f-5ed03d5e6eae"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e05fc1b-a2ea-47ea-89ca-8bfb8e4ad85d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80f44e37-a174-49b5-a926-b54ac8bf0b14"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc864910-7d07-4b28-aff5-55fdd9e068c6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61a9f4ae-2510-41c0-8ea0-5bb10f59e6e4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af2cb7e-1ca6-4e92-b6aa-cf2bf387f1ac"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65b07fc7-794f-4601-bf3d-e118ec972145">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20c44b8d-5609-4ee3-845a-2aeb97b7b0d7"/>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d75d6234-be92-44be-baa9-6d6abb5d8245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/500d2c2b-a1f5-4bfc-ad66-3ddee042a7b1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85d425bc-b325-4e79-ae63-8377d9642407"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dba1005c-974f-4951-8e2a-633b4cab5783"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef0394ad-f9b0-4f43-90e2-39dd569fdced"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/99c24e66-97b1-4fcc-af19-dad0dccf1047">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6048bb24-42dc-45e9-b746-a7d09772c4ec"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c286c14-0358-45b8-a29d-9b1de0065748">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/414f01dd-ec91-4661-887d-dca8eafcbaf2">
        <dc:identifier>HP:0012647</dc:identifier>
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b295f3c4-f1fc-43c7-9041-e0aa536e8e9f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9645bead-9a97-48bf-b7b2-8567e88c7352"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48bef712-5d88-424f-ba22-d119e89f3ca4">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c49216e-cde2-43cd-a0d1-62489e623536"/>
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12fc773c-e73e-44cc-8eca-f4959a40c9a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35f61bf6-7cfa-4b40-8ddb-aef9dc58bd85"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb932a71-0e2c-4c0c-81c0-0a841bbe1438">
        <rdfs:label>Diabetes mellitus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000819</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a74e264-2f87-4099-8ada-e63e92a7410b">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c09d6251-9766-45c1-8260-39a6d6033900">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5d3f7f17-c9b4-46a9-940a-8e9cbd2ea8e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd31a38e-9277-4435-8433-ecbc419c655d">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
        <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae64bf98-9bb4-405a-a1a4-e27501e31c04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/664bdd9f-f917-4d10-aab7-b145cc3ca9b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/984ce5b9-0372-4b15-a6bb-c67458ca0e4e">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a00cd32-7516-42b3-b02e-c6ab04f6c6a7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1125ed8-5d20-46bb-8b79-8299044051bf">
        <dc:identifier>HP:0003201</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>rhabdomyolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
        <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22859e0b-b62c-4972-9849-2ef366427fd7"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8181ac68-0df9-4ec0-a331-c6ab46d06025"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89fee7bd-5373-44ba-af7e-7b1f9ae4a6b7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc195ec9-5e19-45d6-8819-5c162f58edc3">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6339c89-f68e-469b-9746-4708fc4b88aa"/>
        <rdfs:label>Ad-mG6Pase</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8bb8fe9-fd37-4e16-aa31-3d212628ddb1">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Clonic contractions</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/374cd58b-b119-4c6c-9fc7-f3bf316e3be9">
    <dc:identifier>HP:0000982</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:label>Keratoderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e13ec00-0f7a-4252-b63b-6096c31b5830">
    <rdfs:label>myoclonuic Jerk</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001336</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a16bf620-0e49-4a29-8145-4807c5bf25f0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <rdfs:label>hypoglycaemia</rdfs:label>
    <dc:identifier>HP:0001943</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bdd4bbc-78c9-4a96-aba3-711acc866796">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:label>Fine motor impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5af2cb7e-1ca6-4e92-b6aa-cf2bf387f1ac">
    <dc:identifier>HP:0001875</dc:identifier>
    <rdfs:label>Neutropenia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f4a619b9-23ca-4ae3-bbb0-b6ac3b40dfe5">
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14bc6b19-179a-41f7-a1c3-a64e0a5ebf45"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10136859-98ba-4191-bf3a-cfbc9e136b13">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>growth impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b6eff20-4285-4cf9-8a26-3348bdc137af">
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4046e707-cd23-4917-9264-e1e1baa66dd8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6acd5b57-4c44-49b2-a815-fff15b8f2bad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be2de346-bce3-4f12-b90c-32336203e5c7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f58afc4-48f4-4750-a615-21d9a08b1391">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000648</dc:identifier>
        <rdfs:label>Optic atrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98df5d42-1e1e-4e80-8f5e-143016fa0ca0">
        <rdfs:label>Low ATP synthesis</rdfs:label>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d785bbc6-da9c-40c3-893a-6ea1e79f2bb9">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74634091-e657-411d-a9f6-a2584c4f6c57">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d51f5541-c24e-4d09-8af0-65683337d268">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypolysinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd3ded96-9a37-4e75-9e23-4d4f8f280dfd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/303d5dcc-dccf-400e-ba91-b9d18da8bd92"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8befc30-584d-43b7-b466-dfe02ccd1cf8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b64d042-f24e-40d0-acb3-c7dae35d9d76">
        <rdfs:label>abnormal fat metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/559b62b0-6e71-4a72-8ec4-41aca07e2656">
        <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
        <dc:identifier>HP:0011013</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ed23827-0789-40cc-a4ed-016d7bf81c0d">
    <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
    <dc:identifier>HP:0002069</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7147dac9-11b0-422c-ac98-0bae9aab327c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:label>Tonic-clonic seizures</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/26234d44-5127-4d36-846b-30e4762f7b02">
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85efeb9a-7392-4d9f-903e-4d0ded5befb7">
        <dc:identifier>HP:0000613</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:label>Photophobia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b73f601c-962a-4637-af23-4bfc80fc0acf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a50eaf6-35e3-4dfb-91ed-6c16ff61002e">
        <rdfs:label>renal function declines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f7e3538-61b5-44d4-9fbe-5145fc772304"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20520db9-c4da-4003-8604-21d36b8d61b4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8242f846-45fb-4adf-b931-ef344672631c">
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71036728-0ffa-4b21-ae75-141aa5d884d1">
        <rdfs:label>corneal crystals</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0a02f6f-6e4e-4799-95ee-9d3aef6a4b10">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <dc:identifier>HP:0010918*</dc:identifier>
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f9cd963-dab1-4532-bb45-e90134a9c7e7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <dc:identifier>HP:0000095*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>glomerular damage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5cc4963-3620-4f51-97c1-b4cfc45d42f1">
        <rdfs:label>shorter life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00a4c874-b0a3-495e-b944-a16d81c41db4">
        <dc:identifier>HP:0003358</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf996219-88e7-47ee-9b85-69753fd2c551">
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a8d1dc5-5f77-41e3-a023-0b7389a2851b">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d47a7f4-d355-4fcb-9f63-5a261618932b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2dd59389-c91d-4682-94cc-1c0e7270537d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05b208a0-d210-443b-8f4e-7eb2c4746eab"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b707f73-55f9-4d24-be0d-7f914911b7c4">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1595ea90-87f2-43a1-baf6-2abd120f870d"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2607e65a-d8bd-4185-bdad-86f84da24069"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB11677</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b94eec31-0c90-4d73-9aae-f72a9123f692"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3a5be94-8c63-4ba8-b4ab-703360265116">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bd2ea45-801b-4dbf-8c6c-0362e143cbce"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cad1756-2add-480e-a5d1-76b544cfc904"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08f2fc91-953b-42ae-bf5f-80a758220de3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9c1f5e1-5369-4832-a2ab-27bfd3f439f0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/984ce5b9-0372-4b15-a6bb-c67458ca0e4e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8befc30-584d-43b7-b466-dfe02ccd1cf8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb5a3c3a-cd84-4013-9c2d-549931a17b09"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c848d5e-e6f3-4790-97a7-e5282ab6925f">
    <dc:identifier>MP:0013277</dc:identifier>
    <rdfs:label>abnormal fasting glucose</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fab7ae9-b35e-4aae-9648-597101e0f21c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e77121e-951c-4f0d-a3b2-d774f55188be"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cf872f6-e88a-4c85-bbc5-722837ec7114">
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b10fa57b-42fb-418d-b75a-8de4d1a69fe7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc8a7462-f4b8-4586-a0a6-4fd96c01ce8c">
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <dc:identifier>HP:0010903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0080126-5944-4d37-840d-90115d5f626f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>High blood ammonia level</rdfs:label>
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8197fc5-c4a0-4b32-8706-decc791470d8">
        <dc:identifier>HP:0011966</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <rdfs:label>High plasma citrulline levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666887c7-75af-48ed-b449-608deff8ffe3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68862529-9990-4976-ae4d-221c74ee31b5">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1aba7e1a-2eae-4566-8739-4c071dfd6770">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941*</dc:identifier>
        <rdfs:label>high-anion gap acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a024a44-51f3-4b86-9540-81a865f56067">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7a8140f-a6ca-4931-9d0f-cefce7c99cea">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07fbebbf-36bc-4762-9b28-18e697db7c02"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcc53a53-ec28-4988-821b-0eed3469e33e"/>
    <dc:identifier>DB00641</dc:identifier>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4177a1f-76f0-4c94-9187-9649c516ec64">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/319c3092-2761-4215-a373-f7bf3254e0cb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3442f9c1-8acb-4c02-a711-77d13215941a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f7d4757-2f9a-41e9-a6e5-766976740947"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fdffce3-029b-48ea-a6ca-e2c3b0b319d2"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e17d2857-1041-4121-ae99-297fed615fc4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c002ef9-8b82-486c-a136-d8a157a4782d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf355c7f-b9d2-4d59-8d9c-212a1814f27c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c327b2e4-64ba-4d19-a3fa-43ac99e941b2">
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ea6f20e-d453-4da5-be14-73ce43509c95"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1607c18-ccc7-42c7-8007-08a1fa0bd03d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33e537cd-4efd-4e52-8c28-768b06df58de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d42a4fd-9a90-438d-8576-307dc6e5f71d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
        <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
        <dc:identifier>HP:0040081</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c44af6fd-b446-4590-aa88-53aab75e011d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a73e053e-09df-49a2-a481-ec9c953791a2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2762992a-71f3-4523-88a5-ae81d7f142f3">
        <dc:identifier>HP:0100614</dc:identifier>
        <rdfs:label>Myositis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c0e242f-188e-4a7a-893a-f38b6091b25f"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acab9460-0fde-408b-8a99-fb879fca2aa6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24166807-4286-44e0-8a27-12811e46608e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4248d042-bdd3-4f91-b583-a2e50359aad4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36952fb1-378b-487b-b273-ba0aa348f937">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eece4296-487e-4702-96a3-90db79862000">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7255c96c-f940-4541-81be-887b7ac848c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e764719-be9f-4ed7-907d-e629b4a4327f">
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>steatohepatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34bb4c77-99a3-4de0-b1ad-412be80f7688">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a58fcd66-8a67-40e1-bd30-7aeea7c6eedd">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0649404-4a74-4e84-b5ed-78ac4868e529"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44aaaf8e-d9a0-4cf4-990b-2d1bfa727864">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0649404-4a74-4e84-b5ed-78ac4868e529"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ef31913-10fa-4a67-965d-063be7362d34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78e509e7-a088-42e8-ab51-56fcff45688e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b39058ac-240a-4232-b101-6235b762cc6f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0649404-4a74-4e84-b5ed-78ac4868e529"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <rdfs:label>Fenofibrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0edefae-8c4c-4491-a5b4-a47230b94d91">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6174f37a-6e08-4803-a066-b2a7bb19eaf0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f72f596-4f3d-4bb2-9302-8db8adc6f8ed">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4530725f-f682-420b-a41f-83bde115cc95">
        <rdfs:label>Decreased cellular ATP level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011925*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9861ebc4-847a-4976-b0e0-e5b14ba82984">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed2bfe29-5508-43e4-952b-98a78d7a2baf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <dc:identifier>HP:0001260</dc:identifier>
        <rdfs:label>dysarthric speech</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/178d02ab-9126-4d78-ac2f-14f9d2daee65">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <dc:identifier>HP:0001251*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52947ca6-3f18-4db9-be45-9dda416b445e">
        <dc:identifier>MP:0004144</dc:identifier>
        <rdfs:label>Drawing inabiliity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf2254d2-7322-42ea-871b-9dfb69337c7f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20633563-ffbe-4438-9775-7ff130cc3281">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001336*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5587f91e-2149-4644-b944-d2e9819e07ae">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
    <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2894488-630f-4cb8-8979-de212bedae22"/>
    <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/652f8740-c86a-480b-9204-4428185f15f1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfd742dc-1845-4dd4-8649-03c7c2003026"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31f04c99-d8af-4055-993c-6e24039f5011">
        <rdfs:label>Speech problem</rdfs:label>
        <dc:identifier>HP:0002167</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c89c1da-631f-4622-9ab8-ccf6073ff360">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>hyperlactatemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
    <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3452a816-b8a1-4aaf-9c0e-56215349bc72">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ataxic gait</rdfs:label>
        <dc:identifier>HP:0002066</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84472cdf-7c2a-41dc-bd17-2a3521a41629">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <rdfs:label>orotic aciduria</rdfs:label>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0003218</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0a0c901-effe-43d4-8c00-4d0c846d40d8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Delayed development</rdfs:label>
    <dc:identifier>HP:0001263</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/771143d1-c8fd-44c3-acdb-5c86d748e58d">
    <rdfs:label>Splenomegly</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <dc:identifier>HP:0001744</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc85e83d-62eb-4cce-a741-3413a424e97b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defect of bone mineralisation</rdfs:label>
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f186200d-ebcf-4d9a-90d9-03d2ada3b9d7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3cc05bbb-2bdb-46a4-938d-a4885de7a6c9">
        <rdfs:label>Oprozomib</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb293a1b-8c72-40ec-89c8-2257b8eb63ec"/>
        <dc:identifier>DB11991</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b39b6d5-ff53-43cc-82f4-47995c8d4f5c">
    <dc:identifier>HP:0000083</dc:identifier>
    <rdfs:label>Kidney failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cafc5e66-6def-48b3-84a9-780ac1d4ea77">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6a2cbb2-e220-4ab6-9a98-ecf2b53905ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01be87dc-ef53-4c19-9251-ede48f221fdb">
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
        <dc:identifier>HP:0011015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c333baa2-a40d-4477-9d1f-9f411d44643c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cee6aea9-20a2-4d6b-9035-944ac7c5a01d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020">
        <rdfs:label>Failure to thrive</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01b1aa18-6ab9-42ed-bc01-482e72972995">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be607dbf-968d-4e69-9982-fb806d67d3cc">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdfe2ca2-e8c7-4271-a759-619b1670ddeb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57351290-9205-427a-967b-2382db620848"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ac07aa7-b8ce-4607-af69-5fb4413c44bf">
        <dc:identifier>HP:0002900</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/155a244c-5ff4-4ad5-a0a0-0cd29dcbc671">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d02d7ca-fb06-4e0c-9b08-3bc3b16c1af3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be12a21b-cd3d-407b-9db3-2e181f813f3f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c355af06-d5b4-4ff7-a85a-b1e6f81eaa2b"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af8179a9-f62f-4c86-a5e1-7f3ca49bf650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01bb7747-d4c7-4f0c-8a93-a953fff650df"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d335b5d2-328d-493d-bb07-708f609ae9b7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
    <rdfs:label>Sucrose</rdfs:label>
    <dc:identifier>DB02772</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a989a07-9b5c-45a0-aa3f-fc17bc51de6e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0701b11-4762-4bc4-b620-8725b5f03a59">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c422164-aaa6-4c54-b2cd-7b2d58aa2730">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75976640-f032-4f57-adcc-9fe155175f3a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d2fb2b7-bb7e-44d7-b7e4-09a08a0fe37b">
        <dc:identifier>HP:0000488</dc:identifier>
        <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b6fd6ea-1fb3-47a5-b6f4-4426f9dedd3c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c49c61a-9455-4f8d-8ad8-5d4c76881d22">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7de2a42-ed02-43cf-a7c4-c892651298b5">
    <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
    <dc:identifier>HP:0011021</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adfda94f-4061-4802-9398-3e903d11c1f9">
    <rdfs:label>Elevation of creatine kinase</rdfs:label>
    <dc:identifier>HP:0003236</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2168ae15-d342-4d41-99ee-68a3df6fb132">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
    <rdfs:label>unalertness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002329</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7ecadb8-f721-4f28-913d-e06a3effb08d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/832449ed-4b05-4d19-baeb-747f7c467827"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6f41a3e-1a5d-4b47-8e7a-cee169457383">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ccc1aaa5-62ba-406d-bbc4-1a344a8df075">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76e4d810-1838-48ea-a1ba-5f3c8b68241a"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d39cffad-b5f8-4d75-81d2-dc9131571284"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/889f8492-8f67-4070-bce2-9b6e6e1be536"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03669103-4b9a-4687-888f-b42cce9944bf">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002572</dc:identifier>
    <rdfs:label>Recurrent vomiting</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/449654ea-303a-4579-86d3-f4a15fd785e6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fb10102-ed2f-46be-a7a7-12b8300c49b8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
        <rdfs:label>Low energy level</rdfs:label>
        <dc:identifier>HP:0003473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e3cf9b5-1da9-412d-8fbf-a4cfd5f4e6b1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003737</dc:identifier>
        <rdfs:label>Mitochondrial myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4374e942-ecb6-4579-9a6c-743f6b654c98">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf4fc711-41eb-4039-a5b2-93ac7e4dda54">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5be863eb-f52a-4ef7-ac01-cedaa49d70b2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/906a5496-77b0-4bc9-90eb-3359a896aac5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f7c72e5-86f9-480f-bb7f-6bf5b7814569">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <dc:identifier>HP:0030980</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2168ae15-d342-4d41-99ee-68a3df6fb132"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f82b273-c84d-4f2f-b7a0-ffafedbae07d">
        <dc:identifier>HP:0030213</dc:identifier>
        <rdfs:label>Lack of emotional expressions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/553dfff6-3d44-4fe1-b2e1-4ca85b84b9b7">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG results</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2cb823cd-977c-4a5c-8d7d-a01edc446d6e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5b5ee4a-212b-4371-a162-d1e4772bf29f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51adc0f7-a192-4332-b0e9-384c84a889b8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f71410f-a452-4230-a1f6-efea264a730a">
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
        <dc:identifier>HP:0025547</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a0b2d38-14bb-41b7-8790-a9c9e515aec4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45f8b09e-e4ce-473c-be56-e0fd498de0e0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b95f44ef-84f5-4c6b-8ef3-4886327a94d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67266c63-40f5-4a26-8623-2f750b81b365"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca4e1c4-25e5-40ba-b75c-3702a52943ff"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2503781d-4302-4445-9810-f6757df4f95e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6dc970b-6266-4176-a464-b3556cc479d4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7425ff17-4649-4be1-9e6a-5471d0392bbd"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65a74880-161f-485c-8937-10a8db217bf5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB04540</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb597f6d-6c5a-4442-9818-c20c303edba2">
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9d1483-d8ed-4f5e-a562-cf9e4c209b7a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7787e63-5ae2-4ee0-9632-33a86d0118b7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e87d7b42-8221-4d06-a4ff-adc1c7f8b750"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65a74880-161f-485c-8937-10a8db217bf5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cholesterol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
    <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4e6d58c2-8cef-43bb-861b-8a2dfafd525f"/>
    <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/500e2245-77db-4575-a2b5-3461d9a8f856">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54b86b79-137d-4e74-b366-14c99b9154f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e47c329-58eb-4928-850f-028568942cb8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
        <dc:identifier>HP:0002453*</dc:identifier>
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581636ce-cfde-44d4-815b-a94136bb3219"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6548ab9e-4580-4f11-b2f9-e6f02e6ff5e1">
        <rdfs:label>Epileptic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bdba5824-3fb5-49b4-be88-43e3334cfbe7">
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ae34b59-c1a3-4566-9b99-babf70aac2fa">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7e4d492-d639-4368-95ad-12c34576ee31"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b2eb42d-33f4-43a2-9fa4-ea7ec643760e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c1a7953-4211-4664-bf81-db243ddb6f6e">
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5b5d06b-dc08-40ec-bf82-4c1947ae586a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e63c954-0c21-4e98-98e3-7700d4f46046"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250950"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cff52bb-109d-4202-ad41-4639a7f0a666"/>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a35dadd8-c5dd-44e9-b562-f3bcec7218b2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01076743-72aa-4fb1-93d6-27f5a506deb6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/059d5b91-9b42-40d4-97bf-63fa67df4f87"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600721"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c32eda36-58c6-4afd-937f-939d33650e89"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d63f5ac3-edb1-4b27-ba29-474ad40af789"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49a013a0-b2b2-47a4-a8cf-5ffbfe8fac8f">
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaa32e72-3a07-4ab1-b1bf-748377e6c894"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4002ef2-5463-420e-8f85-2af7f6383384">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9612a008-5079-4800-9d46-29ad81a08d72"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ccf4ea2-aa11-4d93-9155-dac0754482dc">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa66503e-1406-4186-8942-7543ad5bb64e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd93adad-0255-49a5-b50e-5bce2606d902">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9f05d34-bddc-4464-b1e0-bb80fdacf000"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <dc:provenance>Abstract</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/985cac99-0c1e-4a9b-818b-cc6fa2f4491f"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/998d6995-713d-48fb-90ff-2560da2e3546">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12ddbe99-6afc-471b-83f2-cdc35559011c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/470c05e9-4ff3-4fe2-bda5-cad00f9a3871">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236795"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/155c502a-a0e2-4929-8087-768da900f7c8"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3c0f164-79d8-4db3-a94b-1443fedb7ef1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/215399cf-5e8a-4238-a6d4-b862ea27bb64"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01b1aa18-6ab9-42ed-bc01-482e72972995"/>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b631c17-6808-49f3-88dd-d7b44ae2dec4"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da904f1f-b243-40ae-90c5-174015e8f8fe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9507830c-5795-4b4b-93eb-5b9f8fc7fa77"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08d84b2c-edf4-4782-95be-bcff28efecd4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c726b96f-82c4-45b9-8e4a-348cd8a4ef7a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8d8be0c2-2010-4060-851b-1dfb6a5b3719">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cfe38ed-a891-41d7-834a-734a98aa40d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0649d754-dc46-4c54-9310-d79b79cb3eb9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b720a29-2e63-478d-b3eb-36551c86adde"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb6f416c-da54-4c91-9e92-526eb30870cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b222a6ca-91b5-4ede-9796-362df96ea8d0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf728e2b-ebfa-40dd-bebf-034e48e97b00"/>
        <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77d0cc12-e792-4a7e-b2f9-dfd73d3319d1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32949da6-1087-4b4f-8eff-5be758bfb998">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0af8d235-a81c-47c5-a62a-633864bc2bd5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88227ac9-d7db-4d10-a016-716278adecdd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51824288-3886-4f58-b6f7-a4f92dfddfb4">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55c8d768-83f6-4e0d-b52f-d2191cf03fa4"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b329582a-5b4e-4250-9e43-8998f1cea136">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff857c39-be7f-4bd4-8d23-26d494f026a5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca2a0961-88f1-4a5f-a942-7858d8380ff2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/616596c4-a738-4e30-a000-d0b78a7c4434">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
        <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9872c26-cafe-49f5-aa9d-df813573be9d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/826d506e-e9fb-47bc-b701-c4d776a0bfae">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/215399cf-5e8a-4238-a6d4-b862ea27bb64"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8a6e0ee-a3e7-4cfa-a424-550562648550"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b2eb42d-33f4-43a2-9fa4-ea7ec643760e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cbe905a-cc20-4747-a444-a14ba62c42b9">
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Heart failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6e77669-7cc8-480e-8698-de8aec6298ef">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1b6d236-52a4-4f6a-9ef6-5696c1a3829f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b60cb1f8-5302-4311-b718-ab860b3bd779">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4db9845d-b472-4f0a-9581-cb67d1580911">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed0459aa-0cf5-4b29-87b0-5097b9345eec">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9515acc-343f-4947-9384-e52cd1a2ab0d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee73c3aa-e61d-41a1-8877-c413039a38ad"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0cc8185-e007-43ba-b4e1-5ae50cc01f96"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/230d7243-bdd4-42cc-af06-c3b2cedf788b">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0936f615-6cc1-4183-a1a3-d5c9a6dd1e70">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6df2948d-ca54-41af-a254-0d7bbc1ab0a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8f6bd3f1-4777-4284-b93e-2b4fd948cbdd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf2254d2-7322-42ea-871b-9dfb69337c7f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fa504e8-6ecf-4d1b-a7a5-9fc1aeb9ceeb"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfbb0cec-20eb-4e2a-9385-22c8d805d89c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fab512fd-a2f6-46ff-825c-6ef4cfed4dec"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e5e9361-80b5-4365-9882-a366a1096059"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16c4a423-5c42-4445-b0ed-a2dfd01ead54"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/955645a3-fb33-448a-8503-5a6790690bc5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/26b208ae-5493-47c4-b127-4fd80a7f7258">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfbb0cec-20eb-4e2a-9385-22c8d805d89c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b89bc4e5-e8e1-4f2b-b644-b8852b055404">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8617caf3-17b0-4e6c-a2c7-5c65ee8b58bc">
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3eb8708-b70b-47dd-ab6b-970d40e0d432"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e52d1c31-7ad4-4728-a5fc-128977f8d3bd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35227879-1352-4907-aaba-4fba71e26b1d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac24dd1e-a761-48f1-a5ac-2a4328748acc"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87219aed-169e-477d-99f2-c11eee5c3bd0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df254630-6bb0-4644-b8ad-2f3c8a128827"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa4056a7-b466-4750-8ab3-027608a21b64"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfbb0cec-20eb-4e2a-9385-22c8d805d89c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b4987a1-0a1c-461d-bd0a-baa3c5e0f575">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54256ce1-aa2e-44b4-acf7-aa768828b943">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfbb0cec-20eb-4e2a-9385-22c8d805d89c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1e8d1f2-355f-40ae-8958-479821c2bbb0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/429b45f7-2373-4489-b098-85a4f5d93920">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6cc822c0-829b-4a2c-9424-96f3a2828174"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7f32594-6f10-407d-a125-956e1b038c54"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
    <dc:identifier>DB04075</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9badca47-581f-4812-93c5-43b12a78d11f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d82773da-ecdc-4640-911d-75eb4f483318">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fdb2f0a-ff13-4606-980c-debf4cbb4513"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/155c502a-a0e2-4929-8087-768da900f7c8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acidemia</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c38d84f-cc92-47a1-a389-415b7b85cf58">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e9e185e-da16-4054-a714-080ea865495c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce5eb480-8b3f-4df6-91fb-b88879116421"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b540bef-0169-4aff-9f35-1eea4595d7c7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
        <dc:identifier>HP:0003219</dc:identifier>
        <rdfs:label>high EMA levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b393836a-1c5b-47ce-947c-81731ad33012">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94e6139d-86b8-4e55-89f5-92590ae4b832"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39d06032-401a-4a07-bfa6-3caf755ca7b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b4b5e5f-86b1-4059-83fa-42803da074c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68e906e6-5273-43c6-bd5c-c7ec92b894e4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5ab43d9-394c-4700-a162-5a796412392d">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a7f5997-0548-4ca7-86f8-842373a2a7c8"/>
        <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3cdd8f6d-a4e4-46e5-86a5-86a447316e4f"/>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0a8e426-576b-4c36-a026-0277e11645a5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1558eed8-563b-47ef-ba94-5162cf6a7c35">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abcf5447-fdb9-4c11-9dcd-fcf27098b029"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3707fef4-a7be-4ae4-a1ca-947e08906b41">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a7e0e8e-8a48-47b3-a167-fc485a689800">
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>high creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9144ae56-2835-432d-952b-b50ffc9d582b">
        <dc:identifier>HP:0004359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0a8fba8-bbba-4536-8ab2-f520e9cee606">
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <dc:identifier>HP:0011025*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42d6b54b-223f-4f34-8b62-56390a560e13">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3dab6d11-e3b2-4a18-9f03-f5a65289d40a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a269c45f-0ca9-4453-9682-6f264d8740de">
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeaab8fc-3b02-4755-a22b-3054adf8a8bd">
    <rdfs:label>Abnormal neuromotor function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
    <dc:identifier>HP:0002333</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5a53024-4960-456d-b6b3-d2b1dbfa9833">
    <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f636d678-b760-425d-b48c-c9cb44472451">
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0d158f6-cbac-4b86-875b-3bb4f0717769">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97447b63-c7f4-4b6f-9de4-cafc71e99268"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50f62047-630f-460d-9707-c2451acef4f4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0437f0d-a1c0-4667-a9fd-13991c3a9dfa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>C04</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2dd3077-07e9-46da-b33d-13754228cb32">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4955bda-a178-4bd8-a816-900d07fff87e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c26c367f-6ac9-46c6-9c07-fc2fdedc6097">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/994c0ea1-028a-4612-8b03-5760bee283a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9fe889c-fdf1-491f-91ca-84ddec2827d5"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
    <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/396a7aff-a42f-4979-99fd-931fac77ba7c"/>
    <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a9d32c1-188a-4a9e-8a23-38a9d52ce4eb">
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f039aa01-f89f-49d3-baac-d11b13a59ee5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91c5c9f2-3277-4b10-aba7-afdcb9210b8f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/322264bc-5c26-4131-8c51-0546996934c2"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1f2325a-e230-47d1-bc3d-7b1c53edaff8"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9aa74d78-f0db-4ae8-98a0-7ac8e400b623"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2e5da2c8-2838-40b1-b87b-229e0694fd47"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75517e81-8bac-473e-a345-7a8a7c29e2de">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83f48e92-241a-4a91-9391-11231e1afe28">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dysuria</rdfs:label>
        <dc:identifier>HP:0100518</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3b21aef-676f-48ef-a5e4-b2fa7a4b8d1e">
        <dc:identifier>HP:0000010</dc:identifier>
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0b78829-830b-4e99-af0a-42913cc19a1a">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e30eddb6-309e-42d0-acdb-c493e4f5c659">
        <dc:identifier>HP:0000787</dc:identifier>
        <rdfs:label>urolithiasis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8879ed05-1c5d-4a5e-9ef4-57472403359b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c10a5c47-f9a0-44f3-bae1-da39ee2eb7dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b295f0a-4d3b-4d9d-9527-cc8e4020925b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7a4368b-0b5c-4161-b2be-9e856381383b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5a3982-aeb5-4fe9-aa3b-5617dd286b24"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd332f50-fdcd-4d36-87b5-1c61d238c13c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ac07aa7-b8ce-4607-af69-5fb4413c44bf"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/155a244c-5ff4-4ad5-a0a0-0cd29dcbc671"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93f53cd3-4f92-4020-835b-90d43b91495a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d9a716b-3871-4a06-8881-8adb54c1f6f6">
        <dc:identifier>HP:0010918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:label>High total cysteine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4155295c-d556-4566-b875-eb260d002503">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6541a68c-3c8d-4712-8a57-fe7ed9fa0149">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c77ee390-018c-4325-9d9d-e249d33df843"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89493d8a-f22a-43b7-aa4f-a5c4121d91b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23cdb8ea-5337-4d86-bc86-d129a4f89b62">
        <rdfs:label>High total homocysteine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97d17212-f8ef-4f0f-86b4-afe734fb04da">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
        <rdfs:label>Low plasma serine levels</rdfs:label>
        <dc:identifier>HP:0012279</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06b789fe-33c1-4e5a-ac85-007017c3ae22">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>Movement Disability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33654628-ce75-496e-808c-70afd7e22902">
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b3284ef-8f51-4202-b466-864793868e78">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36e00010-11c6-4dec-9b42-c975e84a18a8"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c853963-4544-453b-8727-608930aee968"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f807f2e3-c815-42a6-a226-c6dd9de66d3a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49fe8e79-b26e-48d7-babf-19a9d9736406">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e6de0ad-a31d-4629-a581-5c4fef738289"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ce7ecdc-1860-4039-813e-d9049d78266f">
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2e0132fb-b9b7-4162-b51d-e6de6f57db81"/>
        <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0c991f8-347e-4a90-af0f-a44dfe5341bb">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b74981c-3593-484d-adaf-b0907d83940e">
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bbe7a54-8527-4575-8a2c-a3af6549ecf2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal renal function</rdfs:label>
    <dc:identifier>HP:0012211</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e17d2857-1041-4121-ae99-297fed615fc4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c58f845-2b9b-41cf-9650-b246227e1345">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008282</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e9f8e23-71da-4d77-99f0-dee80f00f86c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
    <dc:identifier>HP:0025521</dc:identifier>
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a404b486-ca51-45c1-97db-df6a5b6f9035">
    <rdfs:label>Niflumic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/118c9491-3e80-40ea-8e28-8ee3c4f781fa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43e2b74f-109b-4bab-bfe2-6559307b6751"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aae9e1c-eb01-4b3c-ae0a-e1b2722a1f07"/>
        <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
        <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <dc:identifier>DB04552</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a57ca62-d9f5-473b-89cb-a38f14dae220">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3b5928c-485e-41ec-96cb-af6354fd80bc">
        <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46d001c5-069a-40b1-a4f4-bf95ff72b66d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
        <rdfs:label>hypokinesia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b3e954c-2c73-405b-9166-42f1a61b44bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6126727-bea0-492b-ab8f-bed67a9dcce8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/230061ed-6a4a-436f-986e-818f1397bcc5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2782964f-028f-40ce-adaa-62aca16b12ae">
        <dc:identifier>HP:0008936</dc:identifier>
        <rdfs:label>axial hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d516c4bd-eeb1-4ac2-917e-739f782ce4c5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45521df5-fe2f-40c6-be9a-2dd1246c00e7">
        <dc:identifier>HP:0010553</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crises</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b846f6fd-9978-4f97-8dc4-b8814c3591e9">
        <dc:identifier>HP:0002509</dc:identifier>
        <rdfs:label>limb hypertonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de4595e4-cec7-450a-8edf-edf5b5437159">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
        <rdfs:label>choreoathetosis</rdfs:label>
        <dc:identifier>HP:0001266</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/586d65ec-d6e4-492c-8198-b68f7fbec862">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bd3c2ed-d4df-49ae-8e0a-b4fff22a1923">
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:label>swollen joint</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46575db7-53aa-42f8-aac1-0458689c6f00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31674645-e85d-4263-b6c7-9213121adb8d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f6788ae-7674-4fa9-9dff-109fcf316539">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
        <dc:identifier>HP:0003040</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd135e98-0d38-4372-a5f4-7977e1f829dd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002829</dc:identifier>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e73e9a8-a1f4-4c77-a1c8-3a847cb452cb">
    <rdfs:label>fine motor dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3997a458-ab76-46b7-a691-24d25d762a9b">
    <dc:identifier>DB01325</dc:identifier>
    <rdfs:label>Quinethazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bd8b9ad-43f7-4e32-8951-2f480654a538">
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1d7c965-9325-4f91-b315-97513188f98c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/552e6b7a-ad88-4b4a-9fed-d6bf770b90b4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
    <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/664e9f7f-f05a-4541-aef2-bfc19487fe36"/>
    <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
    <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0907f41c-ea8f-4ea1-a2df-a34ec8b92c08">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18730c3d-ab21-4c91-8138-78b0997121b1">
        <rdfs:label>Self-injurious Behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <dc:identifier>HP:0100716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebd76b3d-d378-4383-9dc3-ad8bfe1d77d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/090d79eb-30c3-4772-ab9e-7135a36ade71"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1164811-a5af-4e90-bf6f-2e18380dcb53">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef6ab83a-e5bf-45b8-b489-d71200422976"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf4fc711-41eb-4039-a5b2-93ac7e4dda54"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef0394ad-f9b0-4f43-90e2-39dd569fdced">
    <rdfs:label>nervous system abnormalities</rdfs:label>
    <dc:identifier>HP:0002011</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82966be7-2bfa-4e42-9ff4-716414b310bc">
    <dc:identifier>DB14751</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3dc2cd3-9e6f-4366-a20f-c98ff6ba9872"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e4dee7f-6a5f-4f9e-8f50-98410cd1e689">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26cf30f1-7c89-4b70-acba-0ff09f2e258a">
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>High serum iron</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/624592bb-ba6c-4c68-b26f-5d14748a086e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42948e3e-e4ae-4a24-804d-c153e79f4073"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d02d7ca-fb06-4e0c-9b08-3bc3b16c1af3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <dc:identifier>DB00761</dc:identifier>
    <rdfs:label>Potassium chloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd332f50-fdcd-4d36-87b5-1c61d238c13c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be607dbf-968d-4e69-9982-fb806d67d3cc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2bfa4fc-71e4-4b0d-92da-f35a1c152d83">
    <dc:identifier>HP:0004918</dc:identifier>
    <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cf05fbf-d39b-4b28-a814-73477b20cfbd">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:label>sleep cycle disturbance</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3229e786-6eef-4e8d-aef7-9640a244a362">
    <dc:identifier>HP:0003153</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cystathioninuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c19c1d05-d5dd-400b-a0b1-4a45e05bb423">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb760c36-6a09-4769-85dc-d385332ac851"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b49d962-4fa7-4563-a4b9-c70f9530fadf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/919c9e46-c21a-4a89-aa77-ca0789633d8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cb8b1bf-6493-46e6-90ae-a2cd1000ed9c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aef592d9-99f3-4675-a5a6-0d92cace2357"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb293a1b-8c72-40ec-89c8-2257b8eb63ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f186200d-ebcf-4d9a-90d9-03d2ada3b9d7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1881098b-f70e-4cb7-98d0-36bbf2724bb5"/>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/542dc51d-07b7-4898-a3b3-542e13f07f84">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919*</dc:identifier>
        <rdfs:label>Abnormal Hcy level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82944638-774e-4c95-8945-7ea02caf8cc0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>gait abnormality</rdfs:label>
    <dc:identifier>HP:0001288</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b049b9f3-3846-43ca-b8e7-821c1ea01232">
    <dc:identifier>HP:0009124*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
    <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d23c1c1-1c0a-494e-a8fa-d31fd071d08b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b1b6ba3-021c-4252-b442-351eee6d6221"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ac20bcc-3b59-4d9f-9b18-d92c1facf538">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f07cf0b0-657f-4ee6-abfd-5d08eb795f16">
        <rdfs:label>Growth failure</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
        <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/68c18d6a-f04d-4f12-8ef5-a1fe4a085eee"/>
        <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b18676ce-f7e7-481d-bf18-86060704b03e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscular hypotonia</rdfs:label>
        <dc:identifier>HP:0001252</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43aa0aa5-daf8-4149-aced-4385674da80c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000855*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
    <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf9e1e66-de3d-4a43-99b3-ac9ab91e2f81">
    <rdfs:label>Left ventricular hypertrophy</rdfs:label>
    <dc:identifier>HP:0001712</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21c3a254-b94c-4702-ae1d-2f179ee65aad">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01939bf5-3e60-4a7a-a7dc-09afc9291440">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72c5debc-32c5-447b-8663-c1cc8f1b2ad3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e12dbae-190f-4708-8415-0047282887b1"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da78b2fe-1715-420b-bbea-404974d4782f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b93592b3-6401-4449-989e-a96e370111f5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25735fe3-b554-483c-8b16-812bc2cd7975"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/131dc5a4-95b1-45a7-a9a4-cc2ce92cba7e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1af35628-5f9a-4acb-a0a9-df768cf80679"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7b02a1f-41e8-4b96-b3aa-137b375c00d4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <rdfs:label> Softeners, emollients</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32ca1a3a-69c8-4ecb-9701-c4690b870f77"/>
    <dc:identifier>A06AA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fda852e-893a-430f-ae67-596443cd3c8e">
    <dc:identifier>DB01025</dc:identifier>
    <rdfs:label>Amlexanox</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f87c2922-123b-4e44-8d9f-bfb4c25e1639">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c15ff7a-95d3-47c9-9adb-3b732241d47d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68339f5f-fadf-4b61-a5e3-ae20ffda4ae1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
        <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f15b9492-9a52-4009-bc01-279845757d2e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c486f7b-3f50-4412-bfee-a0d54df2a44c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ee30146-fdf6-47fa-97cb-6bd543c7fd96"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85888ba4-7cfb-4f6a-8953-ce89e1a18573"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00746</dc:identifier>
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa75c208-79c9-4c8c-b978-adbaa52ecc67">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e96424cd-2691-46ab-b359-7a51c2c5b60c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ee30146-fdf6-47fa-97cb-6bd543c7fd96"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2575940-19c4-4eca-b414-53c490229cbb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e96424cd-2691-46ab-b359-7a51c2c5b60c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ee30146-fdf6-47fa-97cb-6bd543c7fd96"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/927c0d39-237a-47ec-9b44-0552635df0e4">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ee30146-fdf6-47fa-97cb-6bd543c7fd96"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84cbbab0-38aa-47c1-ba0b-75017bfc3481"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5e525a7-a37d-48b6-991e-ad49185082ab">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d0c7abe-f41f-4c39-ada2-faf6248de369"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98e54c28-4d94-4df7-8b0a-db5eb4284d47">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f067665a-a644-4fb5-acf8-e21c36d56913"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c95e1990-cf9e-4afd-991f-ea0e12d81ceb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5741305e-fca6-404c-b2cf-ac7cd60f4f4b">
    <rdfs:label>abnormal glucocerebroside level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003656</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea63a6e8-0536-46ba-9b4e-bf1cecd64d09">
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f41dfc8-cc6f-420e-9d39-bb64247ad6ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31511e7d-915c-41c0-83ee-726d7766b53a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601780"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45ffa80d-e72b-4cff-9819-261c5c8f539a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13cfeb53-68ff-4a83-bd13-a16ea727959f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma MCP-1</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f98de81a-699a-4243-ae6a-e6ea53625e6b">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d9aac574-fc60-4677-a03c-45b95f559932"/>
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54f4e976-34c1-4536-a682-a348c14772ff">
        <rdfs:label>Abnormal spleen size</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22a38e88-9117-44db-8ddb-358556644f67">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:label>Joint inflammation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/959dced1-6825-4c65-8af1-eaca10547552">
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fa83894-20f5-48b7-8c1b-242729fd9cd8">
        <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
        <dc:identifier>HP:0012647*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71bcbd1c-a18f-4437-87be-aadec0eda92c">
        <rdfs:label>High cermaide level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f7e3538-61b5-44d4-9fbe-5145fc772304"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05f664ff-1e0f-486d-9645-adcbd463ef43">
        <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>MP:0009587</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbe1b0d1-fc61-4a7e-b57d-5b2416cae76a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ab76d29-5daf-4c9d-8158-ace75a6665cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/087af317-5bab-49b6-a65a-4e469a72c134">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f72f596-4f3d-4bb2-9302-8db8adc6f8ed"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc97a6b9-f10b-41c2-9b67-0dd4c264fe68">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94ac7d1b-edd3-4285-848d-32e260cac7c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7f5d166-76a5-46ee-867e-e1687ee6207a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4904660-6bc5-436d-a8ee-17a9e167fe0d">
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20d8e76e-1dde-4064-b48d-6359f4ca9819">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>abnormal motor development</rdfs:label>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dea32229-75ba-4f9e-ba9b-29b9a0f52267"/>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39c5f999-a117-4c32-abb2-b6f92f062f52"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/61594208-a4af-491d-9d1d-c075d6f8e1b4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/704e18cf-4d40-44c2-8510-a5ab6c804130"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dba1005c-974f-4951-8e2a-633b4cab5783">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Retinopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <dc:identifier>HP:0000488</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69eea523-d265-4c6a-aeea-9664b778cc14">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ddeb53b4-049c-4032-a17d-14500bedc816">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e28f9d7-95c1-4ae3-90f2-9ba535568097"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f8be94d-7341-4cd9-af72-abf8e3654070"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f7e3538-61b5-44d4-9fbe-5145fc772304"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba1cd846-ea7e-49da-8e9e-8fc6fa4025ff">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12043873-f5de-41e3-8158-cbae595205b6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/233c7054-f3f6-46f0-9059-217a05388fd6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79aadd4f-c123-4dc4-87aa-8bf4aeae8edc"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ac74b5b-d475-4abb-a4aa-52ad91939d4c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1886b9ce-d457-4f01-98f9-2e53308eaa59">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86f669f7-a772-454c-8aae-628976d513b0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB06151</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f171be81-68bb-4e34-86ab-e7cd7e85a973">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d1960b9-56ea-4f15-b05e-12485d99e70f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6dcf5382-2d3b-4f21-8d6e-83bca3f41caa"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25ca3332-a2ca-49c8-bbaa-ba28014f4072"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ce23170-6bb5-48ea-b230-618f9e8e0436"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2da628ba-ec89-4ff4-8693-a0bc97b6a6be">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fcd2db-5eb8-4b11-8f70-5a6eb65414f8"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f531ee1-aa02-434f-bea4-4534870d6666"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b41f9643-2396-4c15-bc82-05c35b36721c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eeabfa1-3bd3-4f81-a0b1-a8773db5a3a2">
        <dc:identifier>HP:0000842</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperinsulinism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/846a451c-8a01-4e73-8bc2-693be71073c5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd705ec0-4513-48bd-a2d8-a15a5cd8e332">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>epileptic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56a59fd8-c98e-4080-80d7-51012a3f4fd1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d62dde4-778a-4aca-8c73-b93a94b1618e">
        <rdfs:label>hyperlipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee305c21-1476-42d5-a1f2-4163d7080a98">
        <rdfs:label>lactic acidemia</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff43c870-c75e-4341-a761-cfc7a516c07e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5cdc9ed-101e-4f1f-bdc8-c6881bf567ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43aa0aa5-daf8-4149-aced-4385674da80c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f67957a0-540e-43b8-9b71-3f2b00a28714">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001513</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <rdfs:label>obesity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5bb04d1-bd25-432d-9813-523c86600662"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70eba8c7-beb2-4158-87a5-1d246d35d2ca">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a30629f9-c65a-4971-acd9-08152ac6bc0a">
        <dc:identifier>DB05386</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59865a3d-5335-48e3-b598-572954f43ff2"/>
        <rdfs:label>Regramostim</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69b214e7-258f-431e-a431-797401890e0b">
    <rdfs:label>Methyclothiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a5a138f-e485-4aeb-95da-485426b1f914"/>
    <dc:identifier>DB00232</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ddf1078c-22a6-49a9-abd1-1795dbb9daac">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6e61bb0-d166-40c2-a1cd-9d4770877f67">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e8d2a99-44d5-4ab9-a92d-c92903524738"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68862529-9990-4976-ae4d-221c74ee31b5"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b75cdd6-9395-44d3-b613-012a51fb6556">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/823f18e4-2620-427e-8cc8-22d3776e2639"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28b2bed5-e7e4-4f1b-9e82-e627dada064c">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ef85155-c4c3-4b3f-bd0e-0b1a3abf2b86"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d3c3d7b-42b6-4d54-893b-a59f1b6d26e8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19b403d7-2efd-4dd4-a855-503b25d259f6">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9861ebc4-847a-4976-b0e0-e5b14ba82984"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <dc:identifier>DB09270</dc:identifier>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/449654ea-303a-4579-86d3-f4a15fd785e6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09b55116-ec33-4d04-893d-7f1c23732e45"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/633fd5f6-22d5-4377-a618-85d4c6f92ced">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba4ed023-3be6-48f7-ba57-870873f3c8b8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0af8d235-a81c-47c5-a62a-633864bc2bd5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68031c69-8db3-4b98-abbb-5aba0ae57b02">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594ab8ca-e7d7-4282-9ca1-98d510ff83ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0c9dd11-58cb-4eeb-b570-652b8892260a"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1624430b-5c96-4693-a0e8-9d5303c2aec7">
    <rdfs:label>Abdominal pain</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
    <dc:identifier>HP:0002027</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d33271b3-12b9-4428-a3ca-6bcd6b660d67">
    <rdfs:label>Developmental abnormality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6179482c-be19-47c6-aa2f-1a9abf1aabe9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>strabismus</rdfs:label>
    <dc:identifier>HP:0000486</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c6b7daf-947f-41ff-96a7-e210d31b369e">
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/792fb394-03b3-48d1-a48c-95786023df70">
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
        <dc:identifier>HP:0008373</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a00fb75a-d670-468a-b908-d46e3acf86ac"/>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cec1a89-adcc-4be5-bd38-00cb7653b579">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84a95174-ae3c-4e59-8027-e42858917452"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a4c65d7-3ad3-4a0c-b7f2-c5b4b4ae0f67">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Amenorrhea</rdfs:label>
        <dc:identifier>HP:0000141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07f2fb21-125d-49b8-a949-daa6d2103bec">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0aba08e2-9891-42c7-9e66-d18a96a21f07">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <dc:identifier>HP:0008166</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/529c1800-caa2-4dbb-90fd-f741fb5e987a"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ede499e7-b5a9-45ab-b1b5-113eb3daf45a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1e9917b-f90f-4ab8-9a45-bf9ad4bb5ff3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e70a9f5-921b-4874-937b-0cd72d98798d">
    <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
    <dc:identifier>HP:0001013*</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/272324ef-3f9d-407b-9e57-f01ec19da783">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/501e51e0-3ad7-401a-8221-340442333119">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ccc4ae5-4489-44df-843b-d942ee1a1030"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2264a4f2-8459-407c-b826-0fd858b66db9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>Elevated long chain fatty acids</rdfs:label>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17726352-8761-4327-94c1-ce24e65046b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ae1c1a6-9c67-45fd-9bd5-22f1a4e75e64"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a024ebfd-1f64-4f90-ad64-2f9c982b7959">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased ROS formation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/23592d79-8156-4cc6-bd21-8d04b2e0d029">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/951ab410-1c39-4902-86e8-ecc12b467625">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/531e48e3-afb3-4961-970b-1c66e0ed148e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9be0681-4063-406f-8fb6-22299a483f46">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cba3e0e-94d8-44c1-ad9e-5e87f17a61c0">
        <dc:identifier>HP:0001976</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fae1b1f-f8ff-4cf9-afa9-fb7c93e42b82">
        <dc:identifier>HP:0001976</dc:identifier>
        <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c4039d2-cc80-4037-acef-5f82b4fd500e">
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:label>Abnormal aPTT level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14eba78a-e6cc-4a33-adf0-e4e2d16f8372">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6d38459-a6b9-473e-8ba5-13205b4865db">
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd02ddb5-d9fe-4731-9ad4-710cbaa852d9">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24464bfa-cc74-4626-9e2d-67cc1f6eefa3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/195a4c67-ad5b-4352-a327-edb77f826d78">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b28a9bfc-ac71-4431-a48d-4f41a961153e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8bb8fe9-fd37-4e16-aa31-3d212628ddb1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfeaa9bf-f3ac-49e1-b409-7a7a71bdbfc3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2d7353e-4a46-4741-9414-963118190fdf"/>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
    <obo:RO_0003304>R229W</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c7202ab-fb63-43b3-a7d8-e0d61e917f97">
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ccdeeb7-51f0-4c55-b588-e76c867f48bf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eece4296-487e-4702-96a3-90db79862000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31129da8-d54e-4f35-bb14-85564f5030b5">
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b0c1d00-d31d-4887-913d-24dd26aa6c9e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/504166bd-1808-4e09-811e-8fd9192a476e"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0437f0d-a1c0-4667-a9fd-13991c3a9dfa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbb61d4a-1216-42ed-b5b0-597565808a00"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>H02</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6c28310-dbdf-4e25-96f3-b64f33d05b27">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3541cbba-2f3e-4a37-a68f-960deb314170">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6ffc6139-af38-4605-84c3-9ec77a8c93c8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0003304>Spa</obo:RO_0003304>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71c7024f-b4e2-4a79-a027-4775ba0b8f58"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15d32543-c054-45a6-b4b8-6243a94c7985"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00829</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
    <rdfs:label>Diazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e473bf18-1503-442c-bac3-c9bce77e48c0">
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f48e92-241a-4a91-9391-11231e1afe28"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0b78829-830b-4e99-af0a-42913cc19a1a"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e30eddb6-309e-42d0-acdb-c493e4f5c659"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3b21aef-676f-48ef-a5e4-b2fa7a4b8d1e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c95e1990-cf9e-4afd-991f-ea0e12d81ceb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fab0b352-a068-4b0c-9dd5-e7b5cfd284c9">
        <rdfs:label>Kidney stones</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7a4368b-0b5c-4161-b2be-9e856381383b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5a3982-aeb5-4fe9-aa3b-5617dd286b24"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b295f0a-4d3b-4d9d-9527-cc8e4020925b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb1e630e-c82a-446c-98d0-9742f12ebf8e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/581581b1-99d8-44ae-942b-ec40161494cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0052fce8-325d-4d18-9533-cc43d31391bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dadab97-2c81-4890-89d5-556187a7b681"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3bac050-f181-4a4c-87fa-f5d58cf94a4a"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88227ac9-d7db-4d10-a016-716278adecdd">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
    <dc:identifier>HP:0200125</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/755e72c5-1640-45f4-a14c-902ada56edc6">
    <rdfs:label>Irritability</rdfs:label>
    <dc:identifier>HP:0000737</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01b85f1e-e464-4442-b88a-55e2b44a652a">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/003498c4-a12d-4ae2-8a2c-6865d5637bf6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c191b8e4-70bd-4315-bbaa-d2b29d945502"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48505edf-4d02-458a-93f7-eb172be26b60">
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012120</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c650589-1dae-4a18-8c1f-cb67a300914b">
    <dc:identifier>HP:0006462</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
    <rdfs:label>poor skeletal mineralization</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3eb8708-b70b-47dd-ab6b-970d40e0d432">
    <rdfs:label>Paroxysmal movements</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007166</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25e7c569-08be-4419-8b1d-50242cc044de">
    <dc:identifier>DB12351</dc:identifier>
    <rdfs:label>Siagoside</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd1afff4-a458-4ea4-a77e-8fc7a6634bfd">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0007121"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6e07e0b-458f-4db5-b092-9eeee0c04c72"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56c98cfe-15b4-47fe-a8a9-bf0174aa0cef"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c77ee390-018c-4325-9d9d-e249d33df843">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc799264-ffbb-4c85-89a5-21b4f75cd884">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdb4131b-1dd5-4595-ba36-40050f9f83a7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/652f8740-c86a-480b-9204-4428185f15f1"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c42a41e3-20a0-4f12-a74b-7640708c319c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8b57378-51dd-44c2-a149-1738af98d3b9"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f92e4b21-df86-445c-92a0-389f95586fa6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac078216-4579-4de7-aa4e-e000ffe5a095"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e3d60e4-4e84-463b-a692-8f66a3e4a3dd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5359bf7d-a570-4685-b26b-67f6bf316ca6">
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/069dd966-5c35-4335-bdf5-6b9709a20030"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93f53cd3-4f92-4020-835b-90d43b91495a"/>
    <dc:identifier>DB00165</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6501adc-fe82-4e71-86ab-a7646026fd01">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99fe085b-8d45-4d84-8f94-d3b7dbcc4617"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84e51c3f-60b7-440d-827a-05c0534f8329">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c798239-a637-438f-bf34-853c76310a40"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Pyridoxine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b28a9bfc-ac71-4431-a48d-4f41a961153e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9bb8934d-56a8-4238-a448-cadf169d76ca"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88a5215a-0ecd-4105-ab25-c7db2f63e61d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c1ecc5a-60e7-4b1d-bd1e-7ccffec27c70"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3229e786-6eef-4e8d-aef7-9640a244a362"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130d34d3-06f8-4aa8-922a-47c95a1836d2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdb22dfc-c107-41c8-ba10-b47356ee5e76"/>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fa504e8-6ecf-4d1b-a7a5-9fc1aeb9ceeb"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be783e1f-b84a-4e4e-89e2-410f36e3fca3">
    <dc:identifier>DB05481</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5d7a1f6-83e3-49a4-8f66-0b5057dc70fe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83e19865-0c93-4606-addf-eb7584a90e52"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abbc1ecc-505b-4989-a291-00ffa20eaf83"/>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e42ec896-87c5-433f-b7b6-fc48876846b4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/398e858f-daa9-4b8b-a643-6f2015ddc16d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc059ede-8270-49d2-a22f-756ba65fe401">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000982</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18826038-41d2-47f3-af91-65c42632c41d">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2484a9a9-cdf9-4923-bc88-745ae873c431"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeb8aa85-fcaa-4019-bd07-99880a473534"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5750773b-4ba7-4e6c-992c-48345bca2fd2">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88936b56-b35b-4939-9f14-2a9224889cab">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27c5c36f-3cbd-493a-bc2b-daa5a90ed97d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/174c9653-38ac-4bce-9917-a12eb164a7da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c76fc8c2-e924-4433-90bb-4eb17f5b2737"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4b6d131-7b7b-4923-aab2-80a43bb83e93">
        <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011999*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3741f1d-4a82-4105-9703-d11142e452d6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Auditory hallucinations</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
        <dc:identifier>HP:0008765</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a5fd61d-2b31-4626-81e3-3c50f23c718e">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8619018-7832-4ef9-baf2-d39272ab4dc4">
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <rdfs:label>thirst</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38047ba8-6026-49ce-af90-b80ef1cc93ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a49dd2ff-df08-4eec-8816-a3becbfeb839"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8524dbf1-ae54-4b33-a709-7824d45ce521">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001426</dc:identifier>
        <rdfs:label>polydipsia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2cb17e77-1287-4de5-806d-6236f16f7e9b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
    <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b1b6ba3-021c-4252-b442-351eee6d6221"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b73d66c2-1e00-4253-9c05-f1121953766d"/>
        <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
        <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
        <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
        <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e487ec45-c9c9-4e0b-bd57-629b9ae73a23">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fc18f3f-9d9e-4153-afda-cdd26557c7b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c54c9432-88b0-472e-ba09-13b7927f93b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66712bbd-7a5a-458d-8f2c-88af87f56ff2">
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a56e387e-07b3-4c20-824e-79e5b46a09de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee9968b9-2734-402f-8edf-f05688cfa4a6">
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fff8444c-9e32-4bae-b5b8-4eff57ea12ce"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a493053-fd3e-4b15-a63f-356716842ae7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:label>Receptive language delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5a87d67-eed8-48d3-a90f-5a43b7c4c081"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/293777eb-22b0-40ac-aa73-0491b5c6ac45">
        <dc:identifier>HP:0002329*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>unalertencess</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9141529-4af5-4720-a491-3314d8c0241b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f422f51b-c7ab-470e-9b5d-8f6bf0b7c2ab">
    <dc:identifier>HP:0004732</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
    <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e290107-82f1-4e85-b31a-042078366cc3">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
    <rdfs:label>Albuminuria</rdfs:label>
    <dc:identifier>HP:0012592</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/64d16ac4-414f-4291-9983-8bea3fa3c9fa">
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/411a8627-a7f2-440c-b406-edea5ca3d8b4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03112008-ad31-43c8-9c1f-e41753e7f9bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b1df6df-d023-4454-bf84-3355a9e75860">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Perioral dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
        <dc:identifier>HP:0040181</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea0c649f-0077-443b-a34c-d71399d6cc6a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15140a51-73df-4538-b8a0-cbe8809b0d52"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42ca353b-99fb-4740-98a1-d19d07913b29">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3314f8c-e1d5-44d2-9cb1-f282dfefb6a1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06ecbe77-c893-42ae-b1ce-5b556e009fb7">
        <dc:identifier>HP:0004910*</dc:identifier>
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d9aaa2eb-ada7-4519-b5c7-0724ad14c0f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60df6c0a-8b1e-4cce-866d-74c0d9acd56d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69292fa1-fb22-4dfc-8e07-aa6c0c775f43">
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75596fa7-b6ea-43a3-ab2f-6b58867e6df2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80947943-13c7-441f-83e9-18563a0554f4"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a6afa18-9d3e-41f0-a437-93fb0dc7463b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eaa8a71c-36bb-4ca0-93f4-ff1750f45390"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55ac47d4-73a8-4133-9f02-958fc4db6760"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09761484-78a9-4657-aed2-4f2dd233e9a5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa8d75a7-f3cf-4b42-b04f-d2960af0cfa7">
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603358"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b982aafa-c84c-4ca2-a528-61b0ff1dc933"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81b0deda-ab44-4145-905c-74c9f92d7500">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79aadd4f-c123-4dc4-87aa-8bf4aeae8edc"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/daaffc22-1237-4fb3-9912-b2ec1672af8a">
    <dc:identifier>CHEBI_113373</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a7e915e-6125-4fb1-b28b-935db0ee37f8"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d741dccb-ef8e-4039-822f-1239c1aa2a67">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c05f5bf-0e04-4af7-92ef-47133427161c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1607c18-ccc7-42c7-8007-08a1fa0bd03d">
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a569d6a-d56b-4187-b34a-e946321b53fc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad0e6303-a2bb-4a4f-b0ae-3fd144a8dff8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/943c6e27-3338-4f15-827e-ad0cd7a201a8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78177983-6b3a-47df-a93f-8ce746584ad1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9fbd9ca-459a-4469-bde3-bde960c34d92">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a8fcb9d1-1478-45f1-af01-204d681995e2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <dc:identifier>DB00593</dc:identifier>
    <rdfs:label>Ethosuximide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e74c417-e8fa-4945-ab87-a631dd43f8ab">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236270"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b16c1472-a0fc-417b-9225-bedce0698eeb">
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>movement disability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a20fa06-94ef-4ae1-b240-f58f6f69a2af">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51497458-7f6f-44ce-a33f-ecd0385e280d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/61ed8845-7107-4439-9ca4-1e2bd3e4febc"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/664e9f7f-f05a-4541-aef2-bfc19487fe36"/>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c45520f3-f968-4ef6-a4d5-332ebd4244c4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50c36cc6-dfcc-4bb3-a618-12ff7306f198">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <rdfs:label>neuropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0009830</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46e2fd91-75f1-4056-a208-570b53596079">
        <rdfs:label>speech impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002167</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95a624bc-345e-45ab-aa73-e30db5e9b62e">
    <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff2cbb02-83a0-41ee-8c7c-e566faaedb2d">
        <dc:identifier>HP:0000002</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e9f8e23-71da-4d77-99f0-dee80f00f86c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73d2b216-c9e2-4d06-a8a2-e3ca53c60ac3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
        <dc:identifier>HP:0040215</dc:identifier>
        <rdfs:label>Abnormal circulating insulin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6aa42a0d-4b64-49ca-85c3-b889bfabaaf4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased body mass index</rdfs:label>
        <dc:identifier>HP:0045082</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9fbdc15-6da0-4a4e-ba6c-f16f9c24c170">
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>Low height velocity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edd15b18-46d2-42ee-b1b9-eed10e2bf302">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000855</dc:identifier>
        <rdfs:label>Insulin resistance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5061e918-bb90-4f28-821b-f3de3ed4e198">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
        <dc:identifier>HP:0032367</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal circulating GH level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/416b5fbd-a62e-47d9-bbdf-e69f8678452b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2bb98a5b-aedd-4690-9638-08a29aed9d87"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30455499-c9ae-4824-9840-2a70cee67bfa">
        <dc:identifier>HP:0045082</dc:identifier>
        <rdfs:label>Low lean body mass</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6cb5afd-953c-4658-8ae5-ba6026c7c816">
        <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
        <dc:identifier>HP:0031034</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0696fc40-29e6-41da-afeb-80422681a622">
    <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a235f133-7c07-4a8c-9a71-5ecb4aff13d0">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac61665f-ee90-44a4-a320-94a36792b5a8">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>Increased urine output</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae3c4622-b41c-494e-ad51-0fcfedea8c02"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3eba52b-e211-4466-b802-91e35d8f6103"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59865a3d-5335-48e3-b598-572954f43ff2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70eba8c7-beb2-4158-87a5-1d246d35d2ca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c850f412-d211-40d9-a71c-99606138691f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006517</dc:identifier>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11a90611-0182-4d8e-aaf4-838cf2b08f0d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:label>Low pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c550d03a-eaad-4d3c-82d1-0220b220a506">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12cf4ab2-3588-4975-8d12-615441fe2807">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4fe7eb71-b343-4076-9d16-7efba7106f38">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c70036fe-7c25-45fa-94c6-08d097e76905"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83616fef-9147-4e33-9b66-d10c6556045a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/784ea5eb-2c48-46f4-a6e5-f350888bc58d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14bc6b19-179a-41f7-a1c3-a64e0a5ebf45"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8961b596-7037-41d3-9206-e6c181f9e7c1">
        <rdfs:label>Decreased serum IGF‐1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e48708ed-fffb-43ca-bb10-66a90752e36a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005978*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
    <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d74de25c-0cbb-4c0c-9dec-7703166a1c70">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7c2c505-4373-497a-9ba1-bf24a28d045a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5b14531-b4bc-4c2e-bca1-413c28cb2f30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2723d6ca-4728-4427-984b-27637743f7f6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040084</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
    <rdfs:label>Abnormal serum renin level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4abb85d4-8517-4861-b5eb-c510673a09b2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f084392-460b-4cc1-b67e-b64a1cddedbb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84d65beb-7e5c-4be9-998d-0544ce0bd97d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bcc830b-5710-4694-93a7-81c2684c739c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
        <dc:identifier>HP:0012379</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/226bb2c5-9400-4a3c-895f-e84a507f117e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/364451c5-2950-4eb5-b077-6302c13c73cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a52cc20b-8b83-46cf-ac3c-3be3910161a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/432bee8f-0e7d-42e5-8561-672f6970c64c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c76bc7d-269b-4f21-9037-2efa7257d245"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fde6a11a-3686-4e23-a728-cdb5e93f603f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a836316b-3d8c-4839-960f-6414de8ce35c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef052dda-2d2e-442f-95a0-bd7ee9ed6c03">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
    <rdfs:label>bone fructure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002757</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c85881e-087f-4a8c-8c79-cb324570e655">
    <dc:identifier>HP:0008282*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79484d3c-506c-4703-b75a-c1d3c7fed59e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e26efd53-b057-4bc4-a1d2-72311d0e4d74">
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:label>Photosenstivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/458af38b-0f03-4655-88da-9a6f2c1738d2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbe18e52-959e-4b53-824b-5e1405126036">
        <rdfs:label>Hepatotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1624430b-5c96-4693-a0e8-9d5303c2aec7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50f33437-edf1-4706-8d10-ca2317a6de71">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/856a13ca-1fcd-4074-aba2-92752413f2d5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61de6ab3-b5a1-4d23-8747-ab839eb98f1a">
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>Fluid retention</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55f6373d-fe5d-4eb6-9d0c-0110d9dd680f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal liver function test</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc4e9ef9-94d5-44ec-ba55-d0f23eed4c1a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b36017c5-d38e-450b-8e1d-9a86a0d76348">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/519761aa-7000-4cf5-9645-afbd14a6fd7d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91be3887-e6a7-4325-a4eb-bdd9b9055eb6">
        <rdfs:label>oromandibular dystonia</rdfs:label>
        <dc:identifier>HP:0012048</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a5a4ac4-09b2-4a17-a8f0-d05d334d397c">
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c850f412-d211-40d9-a71c-99606138691f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/37077978-f73c-4347-9ecf-1ef10dfe5b4d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64c08b25-0018-405a-b512-dfc20eec8bd3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11a90611-0182-4d8e-aaf4-838cf2b08f0d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa44c95f-9f64-41f7-9071-dd4849eeb337">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84ac0cb1-1658-45b1-aee3-192a81a6e9af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da0a3235-96f5-4141-a351-a7070e223e41"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/259ce279-57a7-4697-9aa7-12861cd81051">
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6735ef42-0b41-419d-b1fd-eb112d5fc71f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43802a6d-8de3-464d-b3fa-af7b363e6bc4"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e13bc82-b2df-4f9b-a2f6-4b3ebd4b2225">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/560ee669-989a-418c-a7e0-882276424301">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4c207e8-5349-4931-bc4d-e78d47765c7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a98717b-783b-437a-94d2-c9ca0f6ccc30"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ec08122-ac5a-4d22-82e4-896c2254a8ba">
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:label>Pruritus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/740663fe-c5b1-4146-bd54-2e4c6c0d19c9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Unstable AGA enzyme</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e7224d1-b07a-4c2c-b246-ac9c247a0f1e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37be7d6e-6657-49e2-b5fd-a6012c2786a3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002</dc:identifier>
        <rdfs:label>delayed growth(stature)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e73e9a8-a1f4-4c77-a1c8-3a847cb452cb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59d81451-9ca0-4544-b50b-e60207b8ca24"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5e5b55b-a3ad-47dd-a1a0-62bea075eea7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007015</dc:identifier>
        <rdfs:label>gross motor dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c650589-1dae-4a18-8c1f-cb67a300914b"/>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e8d2a99-44d5-4ab9-a92d-c92903524738"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1020743-c64b-4d85-9b4a-9d6f4b739555">
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:label>rickets</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc85e83d-62eb-4cce-a741-3413a424e97b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/829aaf12-bdde-482d-acec-e639a1140f11">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>growth delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdf14921-58f6-4313-a0a7-eca4fa4f971f">
        <dc:identifier>HP:0002093</dc:identifier>
        <rdfs:label>respiratory insufficiency</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c8c8871-9628-4e75-898a-f5c0befca2fa"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e0d631f-cc40-43c1-9c69-014e15933c87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/933d065c-9a60-45fe-b5f4-3568e8a272fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/442bad41-442e-4752-90b8-117632f4194d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c78bdd2-bc23-4953-af8e-aa55019cb762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/781c4ca5-07ec-4019-9fab-28620cd26806"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
    <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3"/>
    <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9fe3633-b03d-4142-a981-4b6fe72bfb95">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ad47ad3-1c9f-402f-a3e4-9d9ffc744b96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7f319ab-2f17-4152-aec1-22abcb9c8bfa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/118d17bd-ed81-4ff2-8e76-87501e1f6b78">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/820a46ea-2426-4319-a026-5dfc91e51b8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46998c96-d2d7-4f6d-9288-715356954098"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/850da02e-01c3-4126-9123-e20503c7bbe0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f2aaa8b-28c3-48ac-9862-af1e6592861a">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
        <dc:identifier>DB00458</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af3f10f4-c8b6-4f11-ab93-78156a39bd49"/>
        <rdfs:label>Imipramine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b621a7e9-531d-42c5-a3d7-0a170640ad51">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68220dcf-473f-4d06-920b-762f9e1957c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91f5c738-56ff-4e27-bf4f-68ceeb365ded"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3683f47-e2a3-45d3-b9d4-d74e61678cf3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/775ea768-77c2-47d8-b587-727b883736ac">
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ace0012a-9719-4153-9512-61b383cfe1aa">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/440e08ff-2a50-4fed-bcdf-ba6867a8fab5">
        <rdfs:label>spastic bladder</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005340</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/560ee669-989a-418c-a7e0-882276424301"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d801f64-67f1-4c96-9f18-6f84027601ca"/>
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4631fdf-72f8-4149-b1c3-99074d207c52">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/740663fe-c5b1-4146-bd54-2e4c6c0d19c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b69850ad-67df-4c05-b771-9a1cdcf4a17e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53c021c5-b228-4064-a92a-f6e9b14beb91"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c15ff7a-95d3-47c9-9adb-3b732241d47d">
        <rdfs:label>Low AGA activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2a97b9d-fe67-4c94-ba4c-e281ceeb9ea0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eda555fe-a2a7-42ff-a5a2-24dafb462e63">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e9e9564-f122-4d1f-bac4-437c92432974"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/512e3c69-989d-44b6-bbaa-cc358eea4c8d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Eliglustat</rdfs:label>
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c0b40ba-1fd7-422c-98e5-a601b9351711">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90d9b9e5-2a42-4f37-9171-bfd78f416b05"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca4e1c4-25e5-40ba-b75c-3702a52943ff"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9100fec-5a81-4c2c-a575-c2a15b286cd8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/512e3c69-989d-44b6-bbaa-cc358eea4c8d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17b8daf2-fdc7-4603-8918-a85f8cec77c4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/229c89f7-651d-400d-b775-9d6085fa3d9f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5741305e-fca6-404c-b2cf-ac7cd60f4f4b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f71410f-a452-4230-a1f6-efea264a730a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/512e3c69-989d-44b6-bbaa-cc358eea4c8d"/>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
        <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45f8b09e-e4ce-473c-be56-e0fd498de0e0"/>
        <obo:RO_0003304>CYP2D6</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50ae3a8e-f73e-401a-95db-9b8ee75f5b16">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6df2948d-ca54-41af-a254-0d7bbc1ab0a2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>parkinsonism</rdfs:label>
    <dc:identifier>HP:0001300</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6e07e0b-458f-4db5-b092-9eeee0c04c72">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25e7c569-08be-4419-8b1d-50242cc044de"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0174757b-1f42-4e31-9ed5-c5f4950b1356">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high facial soft tissue volume</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
    <dc:identifier>HP:0000287</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a9180ef-750c-436d-bd52-289367f4f9df">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1c981d0-fef7-4742-9e96-0da635ffa871"/>
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dab890a9-8185-4497-b511-7ff02902af35">
        <dc:identifier>HP:0003797</dc:identifier>
        <rdfs:label>Muscle atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/906de99d-08d6-4ad2-bfdd-69abf51a470c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f3f75f0-00a9-4109-a5b9-797f1daa2268"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62ad1d2d-0fc6-4133-b454-d5a056b802ed">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscle strenght</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91c1e748-9af2-4125-9063-9a8be4052fe2">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ed4fd73-d918-4be3-bff1-93d84e5a6c8f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fba80b89-8f4a-4399-bca5-aec8b8e679f2"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e435437-9603-452f-ae7c-35a36c775603">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26290467-a6df-44da-aa12-11845ddbddb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9da4e1a7-5897-4556-bfb4-558d015e4a41"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ad8aa50-c8e3-481c-a5f9-890cd05964fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/846a451c-8a01-4e73-8bc2-693be71073c5"/>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdf2d7b4-d137-4616-8f55-ae94a5b0283d">
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc7ce2b-330d-4968-8b03-30dd9b30ad97"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a214faaf-a48e-477c-bfcb-57fd1090dceb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c8428d4-7353-41dd-83a7-f0e8ee2cf001">
        <rdfs:label>motor malperformance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f521a51-02d4-4874-ba5b-e197912e8e74">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20d99d82-7194-489d-b4e4-5fd6e535d195"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fa0a813-d261-4d4e-aa1d-696f354d8d5b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8200960d-25ec-4bb0-8ced-e7f931e749c6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7ec7757-b67b-44b2-ade3-cf2d29777748">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581581b1-99d8-44ae-942b-ec40161494cc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dadab97-2c81-4890-89d5-556187a7b681"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33b5a937-dcb3-443e-98fb-711f10c4b22c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a83cb2bf-4a87-4b49-b99a-666f702e941a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1121da36-d08c-4866-a795-5a2f0e72f1d4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <dc:identifier>HP:0003146</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/946e611f-fea7-45da-a601-0ce0d2909960">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5602421-c834-4dd0-97f7-da39f6fda9d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49783e45-228f-4d54-b702-4204de465164">
        <rdfs:label>hyperuricaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea147d3c-0038-4454-839f-4fd6521ece6b">
        <rdfs:label>T wave abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005135</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5b5d06b-dc08-40ec-bf82-4c1947ae586a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Delayed Growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af2cb7e-1ca6-4e92-b6aa-cf2bf387f1ac"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ef6097c-bc03-43f8-b282-7e256a0d0f93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low myocardial function</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9091c4c-5ff1-4ab9-b1b5-dff2320afb0d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa2e031f-08e4-425f-93c5-392e9e30a806"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <rdfs:label>Furosemide</rdfs:label>
    <dc:identifier>DB00695</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e55fb50-596a-44e2-b1fa-3629af243374">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d0c7abe-f41f-4c39-ada2-faf6248de369"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d510aab-e949-4aae-abf2-8b369b0bdd83">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Mortality</rdfs:label>
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c95e1990-cf9e-4afd-991f-ea0e12d81ceb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78383dc2-c2dd-405d-a0b4-9c96df2b0619">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/62c6c722-06b0-4641-914e-cd9ce5e70406">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4046e707-cd23-4917-9264-e1e1baa66dd8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d408083-07a8-419d-ad0f-65c4b0162038">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/706371de-39da-4b65-bb89-ac1d7fee73ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c393967d-800e-4163-9926-928f4fbdb5f3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46998c96-d2d7-4f6d-9288-715356954098"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79aadd4f-c123-4dc4-87aa-8bf4aeae8edc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
    <rdfs:label>metabolic acidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001942</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/233c7054-f3f6-46f0-9059-217a05388fd6">
    <dc:identifier>HP:0004396</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>decreased appetite</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d1c4a8e-0316-41a2-8a20-2aa48c09cc16">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031798</dc:identifier>
    <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee21f419-9976-4f91-a8a2-ac1e9921e1c7">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bda6a7e-d369-4343-82b7-d335ce7f3327"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/511bb399-2b2d-4d74-ba63-905c4f657d4a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003546</dc:identifier>
        <rdfs:label>Exercise intolerance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1c2e7cd-bc34-4326-8229-97b742e02005">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003200</dc:identifier>
        <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0af8d235-a81c-47c5-a62a-633864bc2bd5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5589fa4-49a5-40c1-a8f5-813910abf286">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <dc:identifier>HP:0003750</dc:identifier>
        <rdfs:label>Fatiguability</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e154a342-4670-49d9-95be-30deaf4dde98">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <dc:identifier>ECO:00055442</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fba5667-5fa5-41ed-a8c9-a1f543023606">
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f3194b2-59da-4468-8a11-27746c99b2a4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:label>Arterial pluque</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f8c0f96-0b02-4805-8535-e4de34ab5833">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031799</dc:identifier>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf41da3b-8b05-4a5a-bec6-26625cfe008e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5d85c5f4-f092-49cb-aaff-62dc35218f54"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8296a14-4326-4125-ac70-63e35849e961">
        <dc:identifier>HP:0002633</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Vasculitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b47089d-e185-466e-88bb-2ff220e9e1dd"/>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/504166bd-1808-4e09-811e-8fd9192a476e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31129da8-d54e-4f35-bb14-85564f5030b5"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dcd69c2c-9ad3-471e-9322-b6cdac1712a3"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/29c4224b-73c6-4662-9bb2-7e4033e11fea"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6f34354-48c5-47eb-84fd-f2a66d15a18f"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
    <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
    <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3a73903-edc5-450d-a7d5-cb9a2dec5e54">
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a80d1a93-a1cf-4bbe-b6d9-1b853d121f7c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06a6ecad-7999-4afe-8314-af9183ea67e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cfb6e8f-8a10-4af2-a413-3a1bd15a0fd3"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10ee2d5e-c863-4f2b-bed6-7de530fabb2a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High triglyceride levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9d6cc5f3-67fb-451b-b153-111304c651ab"/>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c99ea13e-4dc5-4538-be9f-7fbb693e151d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low plasma arginine levels</rdfs:label>
    <dc:identifier>HP:0005961</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb9bbdbb-3046-4cee-bdea-2c82aac32c63">
    <dc:identifier>MP:0002647</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12fa3b3e-1bd9-46b4-9b70-b4cd595973e5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4248d042-bdd3-4f91-b583-a2e50359aad4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ef31913-10fa-4a67-965d-063be7362d34">
    <dc:identifier>HP:0002155</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>Increased plasma triglycerides</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c51102f3-5469-487d-9741-3638c21d2db8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eece7d67-96e3-4b2a-a85f-7e25f96a5a75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d0abf48-ecf3-4382-bd98-f4376a907ead"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53ab4a36-50ff-4dbb-a14c-4788a4947fed">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78342ac8-0ff2-4b14-8c60-3ec3954f8522"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7945b6dc-2407-4f9e-9f66-3da2833628a1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
        <dc:provenance>PMC2676979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a51cd54-d4de-428f-9d34-01eb7978c3eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Starch, corn</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cafc5e66-6def-48b3-84a9-780ac1d4ea77"/>
    <dc:identifier>DB11599</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22687dab-2bc1-4ea3-8895-a3f3906d0a6c">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc25812b-fec4-4998-84ed-d04237370942">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f52c18e-dac8-48c2-9bc7-51b12f52b065"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76154b12-6a67-4372-8586-0c63cd6eee92"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/401bba3a-cc56-415d-bd79-4e3dc539d694">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b1b6ba3-021c-4252-b442-351eee6d6221"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8304e831-e98d-4fa8-920c-0babc89679d0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c9a14ff-dd57-4962-bdd7-b84c67a134bf"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36f446a0-f352-4224-b760-d4dc61b0e1bc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cac4ead-99f4-42fb-8ca8-6bcd0c6764cb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurologic deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e950836-613f-4389-9b58-cd8a8def2c2e">
        <rdfs:label>cognitive dysfunction</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/724d407d-6d25-4d04-964c-85a79c8128d4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/975c4dd3-517a-4036-90e8-f2bac136b7a4">
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <rdfs:label>loss of ambulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34bf61ce-bf4c-4446-96f9-ec4f6d9eddf0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6b4facf-cba2-4abd-943d-833fe6b75b85">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/823d662e-a1b8-4690-9524-87ba85a53702"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e05fc1b-a2ea-47ea-89ca-8bfb8e4ad85d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007367</dc:identifier>
    <rdfs:label>CNS damage progression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b6c4e79-125f-4c59-af9f-cb0f2601ac9c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
    <dc:identifier>HP:0025280*</dc:identifier>
    <rdfs:label>Pain in the skin</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f7da07d-5722-45b0-b77d-78ce3c9912a6">
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45ca0386-5fac-40d3-a6a9-e42827b533d1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/511407d8-f3e3-4112-bf6c-45920020fd5b">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97e50583-8e2d-4518-b6df-b37a607d3ccb"/>
        <dc:identifier>DB01015)</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b34edc80-92ea-4f13-a054-25b7ca05327f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c410c376-1fbf-4d0a-8e28-79aeb71aad32">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/703ec44b-3f81-4e54-997c-a228326ae009"/>
        <rdfs:label>Copper Histidine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/352f3d99-9654-43fc-81ba-0d2362beeae4">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavioral abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/131dc5a4-95b1-45a7-a9a4-cc2ce92cba7e">
    <dc:identifier>HP:0040189</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Scaling</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91c5c9f2-3277-4b10-aba7-afdcb9210b8f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a9d32c1-188a-4a9e-8a23-38a9d52ce4eb"/>
    <rdfs:label>Midazolam</rdfs:label>
    <dc:identifier>DB00683</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67d78716-1229-4a44-ab4e-bfd836af8583">
    <dc:identifier>HP:0040084</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating renin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80947943-13c7-441f-83e9-18563a0554f4">
    <rdfs:label>Renal tubular acidosis</rdfs:label>
    <dc:identifier>HP:0001947</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0e5c43f-622a-4b86-ae94-366e1fc006f0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51adc0f7-a192-4332-b0e9-384c84a889b8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa0f680a-ab30-4cd3-8608-bfe089cb0f1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8da35c72-ebb6-4c4f-aecb-1268144503b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3761a5ad-983e-42df-8176-13892c48aace"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e77121e-951c-4f0d-a3b2-d774f55188be"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85c68e43-8ab5-497c-b8b3-da3bf47c591e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c4556ab-b0ad-4522-becd-929ab8e3c4a5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a16207a-5413-4fb7-93bb-3ed76f7b8d14"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f79713ba-41ef-4fe0-882f-5460223e535b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1e32ac5-ba67-4da8-95a0-9302841b5d71"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/013535eb-fad4-4e7b-bf0c-a845f4008380">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e84b6790-1d51-4d82-b40d-07b22a078bc2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f79713ba-41ef-4fe0-882f-5460223e535b"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eefa2201-46e1-4eb5-97e2-6dde2db21d05">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fedbb36c-5c51-4098-ab19-2d988566c337"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601776"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f79713ba-41ef-4fe0-882f-5460223e535b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81fa20fd-13da-4b13-ad33-6c883bb3869f">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f79713ba-41ef-4fe0-882f-5460223e535b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c245617-8921-4787-af7f-cf2bf1df18a3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Magnesium</rdfs:label>
    <dc:identifier>DB14513</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8ec9c33-b982-414e-9347-0acdec89f945">
    <rdfs:label>Cysteamine</rdfs:label>
    <dc:identifier>DB00847</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3159378c-16c3-4062-b83f-1bd9ab1e8fbc">
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13816ab9-0bd1-438f-8b5f-bd706b9d2f8b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b73f601c-962a-4637-af23-4bfc80fc0acf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fa26930-b07c-4da1-a953-0b3642aba507">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8b36679-e0c6-4ab5-ab5c-37f448fed306"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b73f601c-962a-4637-af23-4bfc80fc0acf"/>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85cce31a-014b-496d-8162-8da63acfc942">
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b73f601c-962a-4637-af23-4bfc80fc0acf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71036728-0ffa-4b21-ae75-141aa5d884d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219750"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26234d44-5127-4d36-846b-30e4762f7b02"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a1224a3-d2f0-4029-a543-982fef3444a6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7796e94-2b74-4882-a87e-b217b403b120">
        <rdfs:label>Increased reactive oxygen species production</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98df5d42-1e1e-4e80-8f5e-143016fa0ca0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ecd68c0d-50a5-4504-80fa-c10e11c772b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e99309dc-104e-4b55-98c7-30d72bbf637b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dcaff8f-0ee5-4043-82b4-3d90c3500e20">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35f554c7-022c-44c2-8025-203f50e66eef">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
    <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025373</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4339145d-3d73-43f5-b5f2-57b1c6da2906">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45f8b09e-e4ce-473c-be56-e0fd498de0e0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df92b97d-7957-4133-80d8-eb34f97b7a58">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>High spleen volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d9b2cbc-acb5-4410-b15b-5d00cec7d5fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e57c0cf6-1002-4a5a-b829-6d76a819e5d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3808f1ed-cb72-4498-bb0f-eb7d2daeb400">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b40c6862-bae6-4ef8-9ac4-050fa016c335">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>high liver volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a3f32f6e-6bb2-497a-b68f-7f1edc816a82">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca19a113-b5a9-4116-bb70-63b9526b8b3e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38aaf2d6-7da9-463a-a372-b8e5f2e14b92"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea35de46-7b7e-4559-8637-ece906663b86"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
    <dc:identifier>DB14507</dc:identifier>
    <rdfs:label>Lithium citrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efaeca2a-58dd-452c-a1fc-9816227af1b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6766e28-4214-4594-b228-31c9e2c79ce3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40206f83-bb06-467f-9706-1ade4f91c3ad">
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c5f11e5-d6e3-41a9-8b88-05c1f9dc32f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low neutrophil count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e352a7b-8a44-46fc-a023-724a20bb0982">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>recurrent infection</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0297783-1a58-4a5a-8d1d-fc2a20d75066">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected phagocytic function</rdfs:label>
        <dc:identifier>HP:0010977</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ec91d00-2352-47eb-bc61-5ca646c5291c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7162f327-6f74-4ca3-9c66-e499efb32c20"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b9f9de0-523f-44a2-959b-f06ab0330071">
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a87d3b0c-a508-4398-8aaa-bca75c8ca474">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb48ff8b-2c8a-4688-a9b6-d283d4a88423"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af2cb7e-1ca6-4e92-b6aa-cf2bf387f1ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d5091aa-e213-428d-884e-7efa8b43d68a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed5ebe35-bdca-40d9-bcd3-1b5546f5239d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ae1c1a6-9c67-45fd-9bd5-22f1a4e75e64"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27c27f73-2347-451f-87d7-02bca0740f04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f2955f3-3fec-4ed0-9fd1-a1777bf4e342"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a673bb9e-d4f1-43f0-bfca-1b286745dbe2">
    <rdfs:label>pathogenic exon trapping</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1245d36d-7a40-4e03-91e0-0b5ca11f613a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3984eb27-88fc-4baf-bac5-fee713d64430"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a05a177d-507c-4d6a-8c4b-d9cfd2c71496">
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7787e63-5ae2-4ee0-9632-33a86d0118b7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51af8498-91e6-4837-aad9-014545d5d5f5">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c93af0da-ddca-4874-8130-2655505974c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9573f1b5-8cb7-4b77-95d9-5b23be9e746f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42d5ce64-949d-42b6-b35c-b671b5d5e63e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edfe617f-a8f4-4a9f-8f4b-3a72b68bc195"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b1ea80d-1aec-4366-a5b5-e2236d30f72a">
        <rdfs:label>NO revealed clinical benefit</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02fe4fc6-f4f8-4194-9f78-30ea4f4dcb17">
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6d5d5f6-2546-46be-9dc9-d57b406ad4ec">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000938</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:label>Osteopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/875390e6-46bb-4dad-8b3e-d8f187d429d9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bdff136b-deec-48f3-98b1-d8d31864a96e">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13fa427e-4d5e-4802-a9e1-52d8ea80f1ec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20322566-345d-447b-9445-35410c113b6c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6a2cbb2-e220-4ab6-9a98-ecf2b53905ef"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b72b2611-f5bf-4506-9aed-e198ea6373ca">
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9715614b-3a1a-4599-af4d-84d93e883fc7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82746bdf-b553-44e4-9e28-9d4ec8de3641">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/159d192a-b66c-4c9f-8fc9-f603686329c7">
        <dc:identifier>HP:0001347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperreflexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/914a92ba-f699-4217-97ff-69b94d96a411">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:label>Poor appetite</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98727c91-1bac-4de4-901e-d6c5d1cd16b0">
        <rdfs:label>Foot clouns</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011448</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e66dbbb-7831-4966-981a-1add12999f19">
        <rdfs:label>Poor weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d64ffec-f8fc-4c7d-926a-530a12b71cc6">
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Low IQ</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0a0c901-effe-43d4-8c00-4d0c846d40d8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71ebe6b2-ffe6-469c-bfc6-d94f7b050db0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/295e1599-e03f-41b5-9910-9ddb1788dce4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99935169-a7d0-48a8-bda4-11142ebd2ee2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cab88272-e2f1-4c74-a38a-c8922fa3f767">
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6adab3dd-a20c-4bd2-b5eb-d33b6a36551f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioural abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1af8f6e5-b6b5-4c1b-b8f3-dab1b2aa0045">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed mylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
        <dc:identifier>HP:0012449</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6213ecea-521c-46d9-8cb1-dd3c23dab6d2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor traction response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88f6e574-a098-4fa5-aec5-6c890bfc2814">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007266</dc:identifier>
        <rdfs:label>Brain demylination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/adf66535-ff0a-4dcd-80a4-88deb476b7d9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b588af37-0958-4d5a-ae91-87e54c320588"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba7ba54e-0fa0-4475-a7c2-f664cce27759">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/755e72c5-1640-45f4-a14c-902ada56edc6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f4d38ae-58ca-4318-a782-e06a5783241c">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/329d13eb-3110-4dec-9dc1-b479a6191fd5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal Awake EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1daf8b3b-c100-4e80-918b-0e5b2fd67324">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dcaff8f-0ee5-4043-82b4-3d90c3500e20"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0696fc40-29e6-41da-afeb-80422681a622"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46998c96-d2d7-4f6d-9288-715356954098"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73e1f3d7-ad0a-425e-80b8-69712e73a462"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ddf10a9-41ba-4116-986b-39c5dff32904">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d66d1830-071a-43b7-9d28-777d0f910509">
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b3e954c-2c73-405b-9166-42f1a61b44bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/408ab719-dacb-44b6-80a9-5cacc2b5b092">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
        <rdfs:label>Defective eye motor function</rdfs:label>
        <dc:identifier>HP:0000496</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44c87c4e-e9b3-448f-90d1-7d549186371b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7df10b9e-9e90-4f5d-885a-2b7a5db33ddb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac984289-6399-48f6-aec8-e9a81869f039">
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b111dff7-3a31-4bb3-9dfe-7111121609fd">
        <rdfs:label>Bulbar dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <dc:identifier>HP:0001283</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ae10844-6032-4214-b1e3-3b8a509e3695"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9ad5d78-174c-4673-8fcc-eabe5b0cbcb3">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dadd9c7e-2969-42e1-89d1-d5ee03719225">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c58f845-2b9b-41cf-9650-b246227e1345"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab83ec28-3662-40bd-80e3-0f5e885452c3"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Orlistat</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6085ffe0-518e-49b4-862d-abc08928f18f">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab83ec28-3662-40bd-80e3-0f5e885452c3"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c85881e-087f-4a8c-8c79-cb324570e655"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c58f845-2b9b-41cf-9650-b246227e1345"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac4db1c5-c423-4ad4-ab40-c099c1b432a8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01083</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee35785a-9d20-44de-88cd-1e506c5936d6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5fbeae58-3379-41ef-b065-fed98d0eabc0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/192a46a3-df77-4acd-afc8-3108d7d79eba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92601fe1-9cf2-4864-8f45-1daa8acb808c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:label>Reduced hematocrit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/624c6b8c-ccb7-47d9-be45-f08ccb7860d9">
    <rdfs:label>Hydrocortisone</rdfs:label>
    <dc:identifier>DB00741</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff15b717-5a04-4521-9723-7fd7ce93cb53">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7281dc3f-4131-406e-807a-e80bffd9e761"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86dfe25a-fb55-4d3f-84d9-dba08d869c51"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67d78716-1229-4a44-ab4e-bfd836af8583"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c30b613-2dda-4b53-a7ea-be331563791e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b6bdad2-25ce-498a-b8ad-82fd18045d49"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6eb6d4ae-26b7-4219-a02f-4404fa4875e8">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/caa5f9f4-8899-4207-9b33-c5b28c921363"/>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c44af6fd-b446-4590-aa88-53aab75e011d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c09d6251-9766-45c1-8260-39a6d6033900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2430d674-e64b-46cd-a343-635cf878fe8e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001954</dc:identifier>
        <rdfs:label>periodic fever</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/587b44f1-9e85-42d4-b924-e95610c9b146"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6eebe778-4538-4f53-ba95-0a5d17d872f9">
    <rdfs:label>Myelopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002196</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/daf65a3e-96fe-4656-8052-a957c584924d">
    <rdfs:label>L-Citrulline</rdfs:label>
    <dc:identifier>DB00155</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7ecadb8-f721-4f28-913d-e06a3effb08d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0c6942d-254f-4083-ae1b-3559a18ab6e6">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7f3aa1e-bf25-4f18-b2ea-91105fc9cc4a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2612d739-bc2b-4fe4-8d9e-4007a2be443e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2e42a18-dc16-4123-bf4f-40e2521f750b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/812a0bc8-8b23-45cc-ad98-7b36528b462c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/675413e6-10b4-4817-8044-46a3b3271263">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
        <dc:identifier>HP:0000972</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
        <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/973433cf-9ef0-4cd2-b1ad-68fc070ab436"/>
        <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56ace922-8b59-4d0e-b653-ca982295c40f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c862dc4-1828-4e2b-ad36-f3b641c4ba72">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
        <dc:identifier>HP:0002086</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1e67657-9deb-4a19-a77c-1b3237bbe8e4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
        <dc:identifier>HP:0006530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd4eefdd-ee91-4d97-9a83-4f1743280511">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:label>Difficulty breathing</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f2c0640a-07e5-4acf-b246-600b7a4ac076"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31e8b951-4244-47ab-8691-4895240ea202"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a21ff29-efc1-4f39-b020-cf9210daf3f9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fafeb52-37e7-426d-9757-c0c97d5a9c45"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9ae6771-de73-4403-9afa-a677b1332a2e">
        <dc:identifier>HP:0003117*</dc:identifier>
        <rdfs:label>Serotonin deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5449bf6c-ac9b-460b-ad46-6be56a54ee11">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35ad1674-b94c-44bc-9655-c572da58f542">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High serum triglyceride</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d1c4a8e-0316-41a2-8a20-2aa48c09cc16"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0433c0b2-cfed-42a1-9ee1-78a0a086f1e6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfb9bc69-a680-4c7c-a27e-0d878db142e4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b463fc4-ebf1-4945-af34-8185da6512dd">
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c741607-0a3c-41ee-ab3a-495ed905b5cd">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>High serum total cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24f25095-d32f-4faf-83a7-d7ff9e70b319"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1a9c460-1115-41a5-9619-f4eed48bb6bb">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ec4f12d-eb81-40c5-bbf0-8a58a0f68856"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88c1d2f1-dc91-49bb-9054-e53dd38dceb9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80a81f30-6647-4c2c-b1b2-2588e2f612d9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b33821e8-a863-4004-af1b-3c29df0e1f4a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/703ec44b-3f81-4e54-997c-a228326ae009">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e66dbbb-7831-4966-981a-1add12999f19"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41926dfe-ac73-431b-b19d-8802255f1645">
        <rdfs:label>Rapid disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee712843-5fa9-4f6c-bb6c-4eeeb126c3e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
        <rdfs:label>Woolly hair</rdfs:label>
        <dc:identifier>HP:0002224</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a17bbf82-68ab-461f-a183-4508ef5d1bba">
        <rdfs:label>Hypopigmented skin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <dc:identifier>HP:0001010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b34edc80-92ea-4f13-a054-25b7ca05327f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1655177-6ace-4470-b4ea-3d65ca16b8b0">
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012389</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35f554c7-022c-44c2-8025-203f50e66eef"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fcfdb8e-3ea3-4414-906d-812330361302">
        <rdfs:label>Low muscular tone</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/025109bd-343f-4155-a80e-53232cf0599c">
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/124a9c89-1817-483c-84d3-cce5f886cab3">
        <rdfs:label>Neurologic burden</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <dc:identifier>HP:0002344</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef4b6ee3-58b4-47c4-b984-bf9702e38004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2cffb29-7650-4198-85db-85d1c5bcabaa">
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ae10a49a-e401-4b12-befd-ba3efb8ab1a4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1b6c7510-a1ef-4b30-b917-1aeac0f14822">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28f27c16-ad9e-4c95-acc5-82803591bb98"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f093a514-f850-4bfc-9fb4-2e31711f9432">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
        <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a580be1e-d4e3-492e-921c-516fabba6b2a"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0240d6bb-39b7-4dcb-9d4c-c1a8f4354096">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1101fad2-de67-4287-a1a6-87e05c6a105a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48f6288a-bc13-440a-a739-dac9c629b4c3">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0366fc5-0da1-4974-999b-fa2f57b827ed">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d3273f5-09f6-4e6b-995d-869809507bef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f29b7ef2-cc96-4b6e-af96-eebed375bf70"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca5b95af-91b9-4f7e-8155-58ea3c7ac25c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Fat malabsorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24cce4b6-7547-4c7f-97c3-c152ee88f135">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004322</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
    <rdfs:label>Short Stature</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/830d1413-354f-4ed4-b369-5d47ab367db8">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6b2c52b-d4c4-47c0-94c4-07fc6d976fbe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eb77f5f-bca9-4516-8f14-9a97f47976f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
        <dc:identifier>HP:0010909*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c882fa34-a363-4ce6-b3f7-047d0d42a504">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e1fccea-7ace-4711-94e2-3b17b771c3f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/954199fb-1c81-40b7-8dbf-0eb5ed2cdff6">
        <dc:identifier>HP:0000707*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d9d5b87a-b9b0-4dde-afb5-6e5a7e48d31a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7729134-952a-4bb3-97db-a7d8dde77036">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>excessive adventitious movements</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e6e5620-a3bc-4aca-9775-2d7ff756254f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e5362ec-213e-45f5-bfab-8519b0b3feb3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bccab5ee-be31-4aae-a1ea-5c294fd2dd1c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/130d34d3-06f8-4aa8-922a-47c95a1836d2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee73c3aa-e61d-41a1-8877-c413039a38ad"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6011f871-8f2c-4fe4-bd27-0eb91cc48dd9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100786</dc:identifier>
        <rdfs:label>hypersomnolence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccb6fb1e-abcb-4ff1-8195-571e0a716bf7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2168ae15-d342-4d41-99ee-68a3df6fb132"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96d14e8f-0179-4357-a1f5-35b2862b4987">
    <dc:identifier>DB04789</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6b4273b-985f-4ec6-be76-57f4de7da30a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d35fdc13-5137-4df1-88fc-272eb870ba06"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e19c4292-fbae-420c-9b4c-fc636d83e437"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25cfc924-594b-4fe4-be17-4415d956b617"/>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d63b4ce0-6414-4570-81ad-a6955c99b875">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c715244e-4ceb-4bd9-9b5c-5cebbcf482d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/276ca744-4bdb-4b0f-87e6-df3bdecc629b">
        <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
        <dc:identifier>HP:0003117</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e52d1c31-7ad4-4728-a5fc-128977f8d3bd"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e9b6243-a513-4941-b0ce-4590448f14a2">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001959</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <rdfs:label>Polydipsia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
    <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
    <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/529c1800-caa2-4dbb-90fd-f741fb5e987a"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
    <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
    <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73239429-d58e-4e89-84ba-15c3528fd15e"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e1ac6c1-4e4b-49f6-9d5e-1c96523d29a4">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d516c4bd-eeb1-4ac2-917e-739f782ce4c5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f826f302-961f-45a1-8216-931a11c638f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2595441c-8fcf-4028-b4c2-23b5164a7d86">
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c041c64c-d72e-4d5c-8ec5-7d0425d63bf6"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b3e954c-2c73-405b-9166-42f1a61b44bf"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8828d469-f070-47a2-a705-34a46d968164">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb2cf10a-ba95-4832-9b2d-39d2b88995c3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:label>hypertension</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46ad9311-07bc-4fcd-bf4a-0e4b90a156f8">
        <rdfs:label>abnormal mental status</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc85f618-3523-4df9-aa9d-6ba0d7758263">
        <dc:identifier>HP:0011009</dc:identifier>
        <rdfs:label>Acute attack</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/441b7ab2-1069-450a-b567-81122ed45657"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d04248ef-7d04-416f-a862-4cd848d767c0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/372f1448-2f93-47e1-974d-5fde4af3e370">
        <dc:identifier>HP:0001649</dc:identifier>
        <rdfs:label>tachycardia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1119fcdc-6ee3-4d66-b5d3-374b3d6729e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d10a936b-63c3-4049-a844-01c8118148b3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b25eee9-c19e-4509-b18e-60f2bfb6f09d">
        <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
        <dc:identifier>DB14002</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f8651f1-c4d7-44bc-a1ca-cfc1ffbce608"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/936a38e9-31ba-4df7-9859-a65fc32e97dd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f28f0b0-c369-45b0-b7a5-e111d1aaf316">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f59d912-bf34-4531-b294-73250e2717af">
        <rdfs:label>Microhematuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002907</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
        <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4812cde8-fa8e-413d-85ad-5f47c647bfc4"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9309ddd-48cd-4b0b-b931-ec8ff0173afe"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe2d1da2-650b-400e-a1d5-37318a9c7895">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a3c7b81b-3771-4903-a6e1-e406613eb99d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90d9b9e5-2a42-4f37-9171-bfd78f416b05">
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b88c229f-6204-475e-b8ca-6006a341d8e7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012594</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
        <rdfs:label>Microalbuminura</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24b9801a-35ce-4ddc-8e3d-2e47c1036c27">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba4ef572-817f-4703-9bdb-57d110679b65"/>
        <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30d8fe96-ce85-4ea2-97d9-d0cef190ff5b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49bae8d4-b801-47e6-a7ff-5f611b86ea9f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0258430f-dd35-484c-832f-2b241023d0ad">
    <dc:identifier>HP:0001945*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
    <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
    <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/66afd427-5615-4f8f-8b57-fe0e56d5b6d9"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7537b02d-43f9-4b0a-af71-28cb1ced89b3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8635fbba-27ce-4227-96a8-e1f354a84f6e">
        <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58fb0a73-0e75-4fec-809a-e14b2e14696f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/408bc3f8-dd8b-4e65-8ffc-1d562ee37e8b"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b2128ad-12d9-48cd-933c-70fee9372efc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/349fd930-c2e3-4c34-b1a4-550bb5731cc2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72f93fff-0ed1-40ca-8546-250931a0b02f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69b8d8c1-a904-4da1-ba87-4c3a744b0df6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03f1664f-387b-4a08-98fb-0784b8bd51ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/717fe949-c57c-4f89-b227-59cdab7a396e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased visual acuity</rdfs:label>
    <dc:identifier>HP:0007663</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc9adb8b-53c6-401e-93b2-65d1b3d0fb82">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8bb03da-bd70-4762-b0a8-986567881b1a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccb6fb1e-abcb-4ff1-8195-571e0a716bf7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/974a03f1-4d8b-4add-b3ec-17fb0ef542c5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/145f511c-049f-4e9b-b173-b149f3226a91">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/974a03f1-4d8b-4add-b3ec-17fb0ef542c5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99fe085b-8d45-4d84-8f94-d3b7dbcc4617"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00114</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db8cc964-9ede-4186-af2a-5f27b4a783c3"/>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81074a48-4029-4184-b6dc-a0128dc3c2b7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25735fe3-b554-483c-8b16-812bc2cd7975"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01b8b11e-2f57-4958-ad58-96bf0bbef09e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/adb207de-2f0d-4c8d-8f5f-de690bb50192"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0775b009-3172-4976-8d54-3e398b144a26">
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cutaneous photosensitivity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d38b9ec-ebd4-43b5-8420-2990b4dade0b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
    <rdfs:label>Lower limb pain</rdfs:label>
    <dc:identifier>HP:0012514</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/555b1923-13e5-4975-96fb-fc8997acb521">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9fac3033-82c1-41e9-b9ea-c9bb756b33e3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecf65b9f-d143-489e-9fb3-746b559bf224">
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:label>Acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/364451c5-2950-4eb5-b077-6302c13c73cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0cc8185-e007-43ba-b4e1-5ae50cc01f96">
    <rdfs:label>Abnormal facial expression</rdfs:label>
    <dc:identifier>HP:0005346</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7f319ab-2f17-4152-aec1-22abcb9c8bfa">
    <dc:identifier>DB13961</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <rdfs:label>Fish oil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9fe3633-b03d-4142-a981-4b6fe72bfb95"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a1ca30b-560d-4162-8d7e-4538fb28adcf">
    <dc:identifier>HP:0200125</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2ae5cf17-5ade-4909-8af8-c353a26f44fd"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f067665a-a644-4fb5-acf8-e21c36d56913">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5e525a7-a37d-48b6-991e-ad49185082ab"/>
    <dc:identifier>DB12319</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <rdfs:label>Benzbromarone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2eaabfb3-c9d2-48c7-a763-81b579e6a03e">
    <dc:identifier>DB09341</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57c0ad32-dba5-4f73-b9e6-ee0a03a8ecc6">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/980090c3-ccac-4a28-82d5-39cacc0d9ee1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfb6866f-78e5-4b16-860a-0beff0e3ca0c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a97c323-ee9e-4e5c-8240-de3783ad5830"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40fe9f35-ffae-4b66-9037-bda6e28c5020"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/97005234-86d2-4e41-85be-6d5fc411939f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a97c323-ee9e-4e5c-8240-de3783ad5830"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f52c18e-dac8-48c2-9bc7-51b12f52b065"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ee5f69d-d1b6-46fb-928a-1b56ace61fda">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <dc:identifier>DB00563</dc:identifier>
    <rdfs:label>Methotrexate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70fead79-0893-4e08-a898-27b96b2602be">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e98ceca6-0760-4ad7-8b0c-53b853cf936b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bd3c2ed-d4df-49ae-8e0a-b4fff22a1923"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd135e98-0d38-4372-a5f4-7977e1f829dd"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27162c9c-a137-423d-b975-3e4ccebc48c2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c186e20-61b9-4cec-84df-853e60e9dcc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c05f5bf-0e04-4af7-92ef-47133427161c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9093d3a-5a81-4574-b974-70bd07884ec1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/603bdac3-9a43-436f-9059-106cafeca75c">
        <rdfs:label>Phosphocreatine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0d1c163-6ad1-4481-b3ab-73bf9ce9720a"/>
        <dc:identifier>DB13191</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14739dd5-6bd5-48c0-9373-68413d6e0e36"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48e895c3-1a43-424c-b224-23ab8b230bcf"/>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d15c119-9c43-4e36-a53a-c083c312fbc9"/>
    <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c10a5c47-f9a0-44f3-bae1-da39ee2eb7dd">
    <rdfs:label>Febuxostat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75517e81-8bac-473e-a345-7a8a7c29e2de"/>
    <dc:identifier>DB04854</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2706dcde-fb0e-4ab3-bc18-49d194e5c32a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df25a6c0-b0cf-4293-a1be-d0f2b6209228">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a71b36c-d255-49cc-a7e7-0c57ac693a0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3a4d5c2-ae9e-41b9-af3a-56a10a3842ac"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cec103dd-0c84-4a62-b26d-d4aa207f1c0e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1119fcdc-6ee3-4d66-b5d3-374b3d6729e1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9d22385-ff91-49c6-8911-33948b3ca643">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low pancreatic zymogens</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49ea6816-9bb2-48d5-a6fb-61bd3bf54018">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
        <dc:identifier>HP:0002574</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17fed48f-cf3c-414c-9690-7207b16cbf96">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac4861fc-4dc5-4d44-98da-69333cf3794b">
        <dc:identifier>C07</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0d158f6-cbac-4b86-875b-3bb4f0717769"/>
        <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22adf1d4-aa86-4526-aa4b-e474af91bd48"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fffa6dc1-9471-464e-bb65-ef04580507d3"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ed2fbc5-c5de-4664-baf4-29c106ae7096">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75976640-f032-4f57-adcc-9fe155175f3a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93dc9b2c-8f7b-4ee0-855b-8c36240118e9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Retinal degeneration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
        <dc:identifier>HP:0000546</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e6428e3-a020-40bf-8357-a1b5208bb24f">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5101b76b-b12c-40ed-bb9b-99fa3ebb0aad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66a283fb-3262-4131-a020-4a7922e6f797"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1644c49-b598-4c82-8ac9-d265384117d6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Brain pathology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c541570-804f-4247-83f6-65d374d75cb9">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
    <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1a73c4e-da2d-474a-b2f7-35cbc9899ee5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7baa74d-a83d-4f71-8619-3eb346f1cd20">
        <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <dc:identifier>HP:0004359*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22b1f3af-fe5a-4ada-a398-072de87247bc">
        <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
    <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b9ec57c-e0c4-4fd4-84c4-16f1806bb6b9"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/580d605e-f579-4fbe-ae5c-7330dd178b4d">
    <dc:identifier>DB01119</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b41f9643-2396-4c15-bc82-05c35b36721c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ad8aa50-c8e3-481c-a5f9-890cd05964fd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <rdfs:label>Diazoxide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09e55f1c-b95f-49a8-ab9c-5d18bef9a6b0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c66b1e8-1a35-4bd6-92f2-59da68026a41">
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:label>renal salt wasting</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/664bdd9f-f917-4d10-aab7-b145cc3ca9b1">
    <dc:identifier>DB14644</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a74e264-2f87-4099-8ada-e63e92a7410b"/>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e96424cd-2691-46ab-b359-7a51c2c5b60c">
    <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
    <dc:identifier>HP:0011031*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ec27308-357e-4901-9bd2-8a648661c944">
    <dc:identifier>DB03227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/467191bf-6d13-48bb-99d7-a715f1bcba5e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/901d7225-0288-4090-9d8f-a32dd6060542"/>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59909865-fad0-4a6d-a503-cb70bbace729"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcb1e093-8427-4d1e-bd8b-ae0db764e78d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b71f332-8448-435c-b747-993ab7ce1f17">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased red blood cell production</rdfs:label>
        <dc:identifier>HP:0012133*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/75f170ee-e8d4-4eef-a46e-33f563dc3369">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cf4bb63-a589-4e60-9384-0a66e585edb2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf3c4afd-ea2e-4e55-a8aa-ba80ec51811f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8efc44c-d2f2-4127-a61c-053c2b090959">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low heamoglobin leval</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3dda97d-f782-4821-9c9a-4dfb840a5740">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6ae65e5-efb8-4bac-bccc-88287f669232">
        <rdfs:label>Brain damage</rdfs:label>
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d064ac58-9f6f-4b3d-84df-5b372b86b9e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
        <rdfs:label>Cerebral palsy</rdfs:label>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <dc:identifier>HP:0100021</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bfe61af-24d9-4a78-b6ff-1e89476f2296"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08b13a70-d9d7-4a7d-873e-18ebe9becfb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8c733a31-6bec-4274-aced-e7cff820ce12"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2cb823cd-977c-4a5c-8d7d-a01edc446d6e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7281dc3f-4131-406e-807a-e80bffd9e761">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/624c6b8c-ccb7-47d9-be45-f08ccb7860d9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89072408-ea3f-4f19-a8d8-50734e63ee00">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High chitotriosidase level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/810479e5-f3ec-43fd-8d91-db4be799f603">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
    <dc:identifier>HP:0003678</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22af28e7-5a4b-4cb4-8146-6e1bb27510d6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1607c18-ccc7-42c7-8007-08a1fa0bd03d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7787e63-5ae2-4ee0-9632-33a86d0118b7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d94b2e23-a6e9-44ee-8e55-c59e62d8b2ef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/771143d1-c8fd-44c3-acdb-5c86d748e58d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7fa1ee18-4909-44fc-94c2-a5be16e173fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fa9770b-e0cd-4264-ba34-b46fc9d6ae0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89072408-ea3f-4f19-a8d8-50734e63ee00"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca4e1c4-25e5-40ba-b75c-3702a52943ff"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9309ddd-48cd-4b0b-b931-ec8ff0173afe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a49ae98a-ec2b-4e05-8165-842c0c2e8627">
        <rdfs:label>Thrombocytpenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5476bc29-ad06-479b-8b80-a88b31853643">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>hepatomegly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e099df-0d38-4815-b814-e38a71fe5170">
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/881a2012-73ef-4207-b6d4-60ad01bb6c52">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>deambulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a3acdf93-da7e-4833-8438-32d68462e606">
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/863cd01d-7f05-4ec8-acd1-aa50469a4b2c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f07cf0b0-657f-4ee6-abfd-5d08eb795f16"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d0c7abe-f41f-4c39-ada2-faf6248de369"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22a10056-db11-4ad5-a1cf-cef90f73b7f7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d59c870-703a-4d84-a24f-d6ab22e21966"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/829aaf12-bdde-482d-acec-e639a1140f11"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60bec5bb-5f9f-40fc-8950-7112b4cd07a2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7caac1cb-9525-4e22-9b5c-9d181fa30ba6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2c1910d-942d-48b9-a3c9-f12c38d244bf"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d7ba286-55a7-45af-95a2-f1c5abdd4715">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5a87d67-eed8-48d3-a90f-5a43b7c4c081"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dac2919-ffdd-4fee-96ea-743fa9f17797"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dafefb28-321e-4301-99ff-66100d27c848"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72f5a6bd-0015-40ba-8e6c-9e58a50b54a0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c6b272b-c8ee-467d-9d53-b32c42c6fc34"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f07cf0b0-657f-4ee6-abfd-5d08eb795f16"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b10fa57b-42fb-418d-b75a-8de4d1a69fe7"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee11e650-89b4-4ed0-8bdd-2fb45dd69fb4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08004a20-6566-4335-9333-1216cfc209d4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6be1ef24-de92-43e4-a708-5e5286c87473"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d6be053-f9a6-439a-8694-5ec575f64596"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc47b9bf-4dfe-43c8-83f8-49b8b3ee2fd7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96c96015-ffd4-494e-be70-11e9e1534755"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0244183a-8458-46ca-898e-63ef1ab0cb0c"/>
    <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/231616ef-1900-4332-8c98-abfe626763a1"/>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4281184f-087b-472a-bf30-1aae71b3e3f1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:label>Increased total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f78ab660-5a46-4434-a37b-2d56269a8ac5">
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e795a172-c8b0-4f59-8a11-b76cac4d48a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c15ff7a-95d3-47c9-9adb-3b732241d47d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7c91678-e965-48a2-9827-529829af25e0">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3363a276-8fb6-4f92-84aa-044e1a1ab5fe"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6fda5fa-65d4-45f5-b21e-7506913fbf8f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
        <dc:identifier>HP:0002872*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cb8b1bf-6493-46e6-90ae-a2cd1000ed9c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51e7a0fa-29c2-487a-9048-9bc7631c521e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c66c0008-e5c5-48b0-ae80-269e9846a7da">
        <rdfs:label>Ketoconazole</rdfs:label>
        <dc:identifier>DB01026</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5d147a9-78fb-4d49-9af2-5c06758aee6a"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66a283fb-3262-4131-a020-4a7922e6f797">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e6428e3-a020-40bf-8357-a1b5208bb24f"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0fb8417-ab21-4e91-b48a-9b3a7725c67b">
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e55487c-98ce-4d47-b383-5c582a83d613">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oedema</rdfs:label>
        <dc:identifier>HP:0000969</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9aaa2eb-ada7-4519-b5c7-0724ad14c0f6"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c015534-ed12-4eff-abf3-2c33af2d2429">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/859866f5-6f49-49d1-b96c-542db3a30686">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:label>glomerular proteinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e290107-82f1-4e85-b31a-042078366cc3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd902432-e2dc-463b-bd1d-76e4f83099d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6834f325-703c-41c7-b695-ad856a577238"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/707499fa-4573-4a74-836f-adfbb5394520">
    <rdfs:label>Hepatic steatosis</rdfs:label>
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13b0702a-9a03-4f93-9236-44c19993e46a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94ad72ca-e4f8-4960-9d25-3a28f278d34e">
        <rdfs:label>Desipramine</rdfs:label>
        <dc:identifier>DB01151</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ebe7342-0e60-4ba6-9fc1-5690fb980348"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29467f99-74c6-4b52-90fb-ee3c2970b474"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9075cbd6-6878-4f2e-ae6a-1bef6aaa4f3a"/>
    <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d63f5ac3-edb1-4b27-ba29-474ad40af789">
    <dc:identifier>HP:0025463</dc:identifier>
    <rdfs:label>oxidative injury*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4989dd2-09f8-442d-bd98-5e1774923823">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a209a0c-90a3-46f8-8b7f-b7c55423a1c6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47cefe7c-a71e-450a-8d93-4d139f2a06ff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Psychiatric disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba17a744-451a-4ebf-a810-01f6d892595d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a0f8f72-bda8-46ae-8de7-4debfa8b73b4">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>Dermatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f3b4f23-8ea8-4ede-a582-c744daace8f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f4170cf-9e1d-42c0-8e75-4ea0eea07009"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47bc38e5-2fbc-4c92-972f-bc0b22ba7ca7">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/edcba2df-3bc2-4b7c-8762-e811613a356f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e96bc720-badc-40df-a38e-526e8c3db33c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
        <dc:identifier>HP:0410019</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Epigastric pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4688b30c-fa96-44df-bc21-1acf185a4c08">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/382f05d2-061e-44f7-ab45-dde12da5b8ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35f61bf6-7cfa-4b40-8ddb-aef9dc58bd85">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abd31417-e0b3-4d0c-a050-bad369ba2d3f">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12fc773c-e73e-44cc-8eca-f4959a40c9a4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb932a71-0e2c-4c0c-81c0-0a841bbe1438"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Insulin Human</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48bef712-5d88-424f-ba22-d119e89f3ca4"/>
    <dc:identifier>DB00030</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b7e575d-d1bc-4a78-92a4-22cdbdc86ec0">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d4e6f18-d6ce-467d-a66f-9614e0bc00ea"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12fc773c-e73e-44cc-8eca-f4959a40c9a4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36bc30a3-7eb3-41de-8c92-4ed94f3a63a0">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11126f6b-feb2-41fc-9674-f134241006a6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d27d109-32e0-4e9f-bde6-b1f8ce6fe32c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain lysosomal storage disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b225bfe-2be1-49f2-9b3d-7bf1e474065c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab8fde9e-4e62-47c2-a44e-6b057698086d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b94dbcb8-ac55-412a-bf04-46d05aff4b1c">
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9715614b-3a1a-4599-af4d-84d93e883fc7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfd6eaba-bccc-45a0-bdbc-8afca2ace769">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Increased ROS production</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/97e50583-8e2d-4518-b6df-b37a607d3ccb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da78b2fe-1715-420b-bbea-404974d4782f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00fa6db0-1891-4015-bcf1-639f4660a786"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25032d64-fa4c-46c8-b512-fa610ebedc68">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a0815c4-74dd-4612-acb5-be4dc9db6b37"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc059ede-8270-49d2-a22f-756ba65fe401"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/796d0a93-fcbe-4de0-8f39-9dd0d77b9208">
        <dc:identifier>HP:0000704</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
        <rdfs:label>Periodontitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45ca0386-5fac-40d3-a6a9-e42827b533d1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17b27d39-08d8-4224-af37-88e041c2a3d6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5e2341-16d1-494b-abea-5fb1e04c8936">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43a9b925-a778-4544-8af8-41d4d2e45e09">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012238</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b38ca848-e39f-4e42-9223-4a58059b6941"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c30d1c7-1d29-4fae-a729-d3bf5baba82e">
        <dc:identifier>HP:0003362</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e70a9f5-921b-4874-937b-0cd72d98798d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5a8f266-c13d-4def-a75b-b0d0a3d1b5e7">
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/409d4a75-0f3c-48a2-85b5-365dbcdcad5f">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee182544-7dbc-4a07-92ad-36dda56595f7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98cf90ac-e13b-47b4-9d02-27625baa8dfd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:label>Dyslipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e5485ad8-2d5d-4354-add8-8a4bc6821973">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6dc2a651-4860-41d2-91aa-ba124d8e412b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/454d0933-048c-4a95-8bf0-73a7fdaffaf1">
        <dc:identifier>HP:0003107</dc:identifier>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c28042f5-8b11-4d3d-bc01-cb6d27ecfc60"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bfd445c-0bb1-4494-8fd0-037882310f3a">
        <rdfs:label>hypertriglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9357e507-2685-4323-abc4-2f8ea55e511a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc152143-24d7-43c6-b1f1-1a3c319ecd7f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>Neuropathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d1becee-4360-436b-bdf4-8c2075762591">
    <dc:identifier>HP:0007009</dc:identifier>
    <rdfs:label>Central nervous degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9de9121b-1cfe-47d9-bd88-db86bce6a895">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/174c9653-38ac-4bce-9917-a12eb164a7da"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5df0232-171b-4138-84ed-c2bd3bf87c49">
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavioural disturbance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eaf65c72-71a2-4a6f-a95f-d8b9cdf337e4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <rdfs:label>L-Cysteine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd19a858-812e-48b3-b0c3-79ba40d305a7">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/06f80dce-5e2a-4feb-b2b5-a6b3528093c9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1402e13d-78a2-452d-b079-146a32615abc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00151</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12ddbe99-6afc-471b-83f2-cdc35559011c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
    <dc:identifier>HP:0012100</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82af25dc-9e92-46fd-b9d5-ebc351e5082c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd6bfba3-4d80-4520-b209-2cd302935503">
        <rdfs:label>schizophrenia</rdfs:label>
        <dc:identifier>HP:0100753</dc:identifier>
        <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8031d14-2e73-43f4-b112-c9cd5fcee1c6">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4889cb63-f43d-4450-ac88-7b1d515da08b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b76affa-d308-4ba0-b0e6-c39ecdcc8ee0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f72f596-4f3d-4bb2-9302-8db8adc6f8ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6967e339-3a64-4af2-8c24-17cc89221e07">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
    <dc:identifier>DB01626</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8993785-602d-4f73-9cf6-d175939ac07a"/>
    <rdfs:label>Pargyline</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3dafc4fc-7345-449d-a601-663ec1be2fc6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ac07aa7-b8ce-4607-af69-5fb4413c44bf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6bcd3838-c0b3-4f2d-9497-0b8c5015a40e"/>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00a4b3c3-2342-4a61-afe3-301f9b823caf">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37b1495d-5c9f-459c-afbc-3c08a4b23b7f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic epilepsy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f6cc0c9-b675-40d0-85f3-ee5c2e8ead56">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c66ffd6b-5fbd-4f64-9849-3ec2702289b0">
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32a559cc-d5eb-4be6-8f53-6c92037fc4a7">
        <dc:identifier>HP:0003199</dc:identifier>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8eb0a165-e35c-4616-987a-db76ac6d38c3">
        <rdfs:label>Short Progression-free survival</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3a362d44-00f9-450a-8983-014667b5826a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/810479e5-f3ec-43fd-8d91-db4be799f603"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d40148d-b493-489f-ac07-13319f9dfe9a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <dc:identifier>HP:0003528</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5a53024-4960-456d-b6b3-d2b1dbfa9833"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35fc09ca-565e-4ba6-a6eb-c36475e327fa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
        <rdfs:label>Bone pain</rdfs:label>
        <dc:identifier>HP:0002653</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a98717b-783b-437a-94d2-c9ca0f6ccc30"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa8b40f6-21af-461c-87c4-18e2fea0b86b">
        <rdfs:label>Weight loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <dc:identifier>HP:0001824</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8906045d-efad-4ea4-b841-c89799cccf80">
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a21c9292-0b1b-4dd5-8074-c57ce583d0d8">
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/395b00df-1952-402a-b18b-937fea46fe49">
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26169d8c-7cf6-4723-b5ff-0aa08605db4d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a101c03d-1dc2-4618-9f71-548a56123200"/>
    <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/260ce4be-58c1-418a-94c5-89a31d9ac355">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <dc:identifier>HP:0001945</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fever</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ef85155-c4c3-4b3f-bd0e-0b1a3abf2b86">
    <rdfs:label>Poor eye contect</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000817</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a81cc19-c3a8-4dc9-9071-21c71bf7aa10">
    <dc:identifier>HP:0001072</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elbow skin thickening</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9f1e57d-7787-464a-b3f3-8a2615fbf412">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72535f40-2267-494e-bb5e-9df6bf9b6489">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c879aefe-d798-42c0-a4c0-42308913acc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30263682-21fe-41a9-923d-e802ee38b83e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a7f5997-0548-4ca7-86f8-842373a2a7c8">
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ad30654-0be0-4852-98e1-f53c79bd0270">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pseudoexon activation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68e906e6-5273-43c6-bd5c-c7ec92b894e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
    <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a47d96b8-0115-4c4f-9098-90b50b0c3685">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13326632-2de1-4560-924b-9432017da319">
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <rdfs:label>inability to walk</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92afe24b-715f-4741-9b01-2cd6fe1ebc81">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Diminished intellectual abilities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5587bb08-2e6b-4eb2-bef5-9d0b44e1a8b4">
        <rdfs:label>myoclonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b9f5030-a908-49db-be57-2876c01f5b54">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70e73ca8-5250-4ca8-88e0-5751ff6b97d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca2de4aa-d0b5-4e08-b0da-7b1fee71c95a">
    <dc:identifier>DB01394</dc:identifier>
    <rdfs:label>Colchicine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07922f02-8549-48e2-89f0-797a65754dcc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fd7d306-3299-4abe-b30d-29a1e1e366cc"/>
        <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c3dd4e7-cf58-4178-a0e3-8b869a154ea6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd135e98-0d38-4372-a5f4-7977e1f829dd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c2e02e2-0d01-4bd5-85e1-3f789147df7c">
    <rdfs:label>ARC-AAT</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22127342-5c8d-45dc-a858-8cb538f92381">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8a53c9e-b713-4539-bc8d-f817556927aa"/>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93cdef08-4d7a-4cb0-a286-897d1994b6b7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cb8b1bf-6493-46e6-90ae-a2cd1000ed9c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5262343a-69a6-4ff8-bd76-f4fffc90d8fa">
        <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002066*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b49c1c06-cf34-4b1f-8533-2c1b3e2db12d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1fee7ec-f1af-4cd3-bab4-85dee588a509">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80bf7385-9735-4a3b-bb50-ba6c8b9c3281"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/707499fa-4573-4a74-836f-adfbb5394520"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bbc515d-21b5-4d93-b361-2ca7e5749807">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37077978-f73c-4347-9ecf-1ef10dfe5b4d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af2cb7e-1ca6-4e92-b6aa-cf2bf387f1ac"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/398e858f-daa9-4b8b-a643-6f2015ddc16d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73b034b4-4892-410b-adb3-82b7d25d9ae0">
    <rdfs:label>protein-losing enteropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
    <dc:identifier>HP:0002243</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55bebe48-cbbf-4792-b242-18e29fbc6d0b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ac6cf53-3b20-4d1a-afdd-89d81aaafa38"/>
    <rdfs:label>Gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f35faf30-d441-488d-a293-5d0b4c9e6572">
    <dc:identifier>DB01593</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b91caf6-6105-483d-8a26-91b3d931a754">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28ed736c-c558-478c-9833-119f898ae5a3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ae1c1a6-9c67-45fd-9bd5-22f1a4e75e64"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d07a211e-c05a-4b1f-9484-bcb7c695adeb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6db65638-087b-4678-83e2-f4ff710a49e8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8503d98-176e-4f6e-8feb-fffc21dcfb42"/>
    <rdfs:label>Zinc</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17726352-8761-4327-94c1-ce24e65046b1"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d42c3f8b-434b-48e1-b439-6ada342a638b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92aa0c5b-14aa-4ba5-bd7c-989f7a08838c"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f68de0be-0cdd-4148-9643-41b6ae9ee708">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea2e7b38-dff9-4bfc-945a-24c3ef90312a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bc231be2-d08f-43d2-bf4b-e688de510947"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc900168-313a-4318-8fee-2251a3eaeb6c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d440596-f84b-42d0-a97c-89562d33ce21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1991909-2133-40ff-baf0-5694ab5089b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa965d78-bb06-4cb8-b215-b2022042d4e9"/>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/202a3757-37c4-4e55-add8-e94c9dffa203">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43802a6d-8de3-464d-b3fa-af7b363e6bc4"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0edf44b3-01ee-430a-b318-a462ba946214">
    <dc:identifier>DB03256</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/afcf85c6-80ad-4d5c-a904-96b6e6f069cc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9d33ce6-8238-4e76-9408-d1171f898933"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b06d3786-44c2-4be9-a38f-a09c26935c9f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ae134e0-20ae-441a-9005-72b1c4dcf7e9"/>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b764ccc-b1d1-4293-880d-db167bc12900">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002718</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
    <rdfs:label>Recurrent bacterial infection</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/545acae2-21b4-490f-bb7a-0ef0a52c3c04">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5478c052-4e2d-47e2-94b0-97ad7d5c90f4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cf5f290-9651-4e58-88cd-a5ed71990198"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/510db69f-7841-4f13-a3a9-463a01a58791"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01345</dc:identifier>
    <rdfs:label>Potassium cation</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66b49d87-5b3a-463c-9f65-07038eabd615">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5299495b-ede7-4667-b473-caecacfd527b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84c636f9-7dd0-4d90-bc29-e8e7a01880e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/765040e4-ae9e-445e-a994-771773ec1d50">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0db9dd51-2991-4753-aa56-b7b17db43f0a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67d78716-1229-4a44-ab4e-bfd836af8583"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04cbe884-9144-4f40-8265-f7b7035f8c57"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3d08770-f6f6-4e27-907b-d5ec35d8e173">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f9f94fe-74bd-41f6-b05c-b8f02e1970d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfabb3b7-781e-4ae9-b8e8-31e4afc2c8cb">
        <rdfs:label>Bone mass loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c30b613-2dda-4b53-a7ea-be331563791e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86dfe25a-fb55-4d3f-84d9-dba08d869c51">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
        <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
        <dc:identifier>HP:0040085</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a13c98ce-9f49-4172-84db-5a83cd0b731d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
    <dc:identifier>DB00555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9a69199-6bb6-42e6-8068-cac02246e7aa"/>
    <rdfs:label>Lamotrigine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/704e18cf-4d40-44c2-8510-a5ab6c804130">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <dc:identifier>DB04159</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7f5d166-76a5-46ee-867e-e1687ee6207a"/>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7159043c-a4aa-405e-8d8d-27604f655feb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c186e20-61b9-4cec-84df-853e60e9dcc5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/009c86c8-73b6-4733-9200-e4a7d72482e7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ebe7342-0e60-4ba6-9fc1-5690fb980348">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/269920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13b0702a-9a03-4f93-9236-44c19993e46a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cc81f5c-e26d-47ff-9b0b-d185c6095e20">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiomegaly</rdfs:label>
    <dc:identifier>HP:0001640</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2df2591f-22d6-4adf-9070-f63de964fe6e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af36d7ad-5f5a-4b69-b1bf-069711e5a451"/>
        <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
        <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
        <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe2d1da2-650b-400e-a1d5-37318a9c7895"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6502392-095a-41a4-9929-02c753b698bf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
        <dc:identifier>HP:0004818</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f748b0c4-a020-49c2-a3aa-582300dcfb15"/>
    <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2bb3d09c-8c7e-4e12-81da-23226e664cc6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a21ff29-efc1-4f39-b020-cf9210daf3f9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d63b4ce0-6414-4570-81ad-a6955c99b875"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f998908b-e73e-47ca-bb81-d149e15a7b5e"/>
    <rdfs:label>Oxitriptan</rdfs:label>
    <dc:identifier>DB02959</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2cf9d3c6-2dd4-438b-8e9e-4cf5f48ac7f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/749a97b7-2b68-4b18-a182-6305f7d4dc11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74693e17-2e86-4fbd-926e-40c317324fc5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f46d7ca-8518-4c32-8b11-6267188e1f04"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfd742dc-1845-4dd4-8649-03c7c2003026"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/237cdb08-bdfd-43bf-a99a-b24570015f86">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003141</dc:identifier>
    <rdfs:label>Increased LDL cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90cd58dd-f5a5-4aef-a380-595f451fb0a9">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32f5e210-cc53-43f2-acd6-3f8313f9236a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4664470b-0ffb-40ad-aeaf-e59d6de1c5a8">
        <dc:identifier>HP:0000964*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
        <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a911af1a-def5-4080-b222-9ccc08f55308">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/679c5186-b72f-400d-a626-42d37ed253cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e2e0528-5514-4b70-89de-e64810973ffc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e12d6d64-59c3-40c3-92ed-d4d2f1b2e994">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e07fa432-8e13-435d-8387-20bca48b43b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34445af4-b5f0-4e0d-a2a3-1312e6522f13">
        <dc:identifier>HP:0004371</dc:identifier>
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a22a840-a01a-4e2f-b629-164589f297f5">
        <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002180*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cd3a0bc-24c2-404b-88c3-f6f4f5fc5c4a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <rdfs:label>Mecasermin</rdfs:label>
    <dc:identifier>DB01277</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95a624bc-345e-45ab-aa73-e30db5e9b62e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87867f47-be92-4112-9ef5-567709890e4a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70c5f983-807a-49e0-9692-5f4a1bb318b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/698c9ed4-8026-44b2-aced-327e32728a58"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca210f46-51de-4c40-b89c-f5fe2b46d00b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce1b238f-ed31-48b4-909a-c3af7364ca17">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5153516d-ef1c-4d39-9e30-791e9e8a1f9b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
        <dc:identifier>DB00026</dc:identifier>
        <rdfs:label>Anakinra</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbd222f0-ccce-4eae-8c82-460fd7d6ea66"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/805319bb-ba32-4697-9c47-09fe43b6dd52"/>
    <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
    <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/519761aa-7000-4cf5-9645-afbd14a6fd7d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
    <dc:identifier>DB12783</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc4e9ef9-94d5-44ec-ba55-d0f23eed4c1a"/>
    <rdfs:label>Benserazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>FUCOSIDOSIS</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d9fc1969-d6d3-4d1a-a5d8-85ee9fed7a9f"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
    <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ce23170-6bb5-48ea-b230-618f9e8e0436">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
    <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
    <dc:identifier>MP:0012604*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c76fc8c2-e924-4433-90bb-4eb17f5b2737">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88936b56-b35b-4939-9f14-2a9224889cab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9de9121b-1cfe-47d9-bd88-db86bce6a895"/>
    <rdfs:label>Olanzapine</rdfs:label>
    <dc:identifier>DB00334</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79bbeaed-e415-4c4c-94d6-5b2f87f29a56">
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b38ca848-e39f-4e42-9223-4a58059b6941"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33176421-8783-414c-8134-704744668d95">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/092aeb74-9192-4805-bb6c-3ddd150928aa"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a829df3a-e02b-4016-880e-73edaab94a60">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59a9da93-2b68-40fa-853f-70d182f75541">
        <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24f90084-a5d4-48f4-97e5-ca320c8cf0af"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/904cdbe2-d3bf-4e7f-a753-8edb4059e2c8">
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/441ef81c-1ad1-426b-8028-d7a242b48b35">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>skin photosensitivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
        <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
        <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e5cf2bf7-5452-4d17-8873-749266c295f4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/328c3a38-d6ce-4245-b096-eba2758246d9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
        <dc:identifier>HP:0010473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3a4fd3f-446b-433c-ac0c-4948b5a15017">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9deec541-75c3-4cfa-8943-1dc721ff8f33">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7de2a42-ed02-43cf-a7c4-c892651298b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6ee1bf4-036f-439e-b962-321e8070e31c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00393</dc:identifier>
    <rdfs:label>Nimodipine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e09c443-969d-431c-8142-8918875747c9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a49f1736-cb93-40ed-a2d1-822bf2b558bb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6735ef42-0b41-419d-b1fd-eb112d5fc71f"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/202a3757-37c4-4e55-add8-e94c9dffa203"/>
    <dc:identifier>DB00564</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d73eb5c-5b9f-4a45-8a9e-0f95fa83bd2d">
    <rdfs:label>Amantadine</rdfs:label>
    <dc:identifier>DB00915</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a37d795-a548-4439-b81a-73cb6d6be999">
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/20961677-21c2-4689-a414-09fbb712ccb6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7bc5ef8-a482-4b40-ae9b-f980b56d96e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ef24f88-490b-440e-943b-b387a8b8e2d4">
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/20961677-21c2-4689-a414-09fbb712ccb6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6df2948d-ca54-41af-a254-0d7bbc1ab0a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b37a75a6-1d24-4853-9cf5-d2b30b9e1c47"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c3c2a9f-712e-47ce-a029-d498dd660ec8"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f90b53e7-e983-4d45-a842-792db8cadf27">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/796d0a93-fcbe-4de0-8f39-9dd0d77b9208"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da78b2fe-1715-420b-bbea-404974d4782f"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8c733a31-6bec-4274-aced-e7cff820ce12">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
    <rdfs:label>Amino acids</rdfs:label>
    <dc:identifier>DB09393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3dda97d-f782-4821-9c9a-4dfb840a5740"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/308f312e-299d-4ab8-a176-ff67e3488d4b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc320829-aba6-4a61-b5de-8698add64c1b">
        <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <dc:identifier>HP:0011925</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0cee0bca-6f4a-4bba-aecb-acc499ed79ea">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cafd351-d831-408c-a0b4-2f237938b9b6">
        <rdfs:label>abnormal muscular co-contraction</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3adc0299-e316-475e-a73b-062af1e4fdf2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ba6865f-031f-4a88-95f3-34f48667abe6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28af4e36-da69-44ff-ad70-434d070e79e5">
    <rdfs:label>low HDL level</rdfs:label>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/adb207de-2f0d-4c8d-8f5f-de690bb50192">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81074a48-4029-4184-b6dc-a0128dc3c2b7"/>
    <dc:identifier>DB04931</dc:identifier>
    <rdfs:label>Afamelanotide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2eeee490-7ffc-404f-a4f9-f094dd6b6fd5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c0d45ba-2aca-4a62-bb35-199a35eeb5c6">
        <dc:identifier>HP:0000155</dc:identifier>
        <rdfs:label>Oral ulceration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a98717b-783b-437a-94d2-c9ca0f6ccc30"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/165317cd-f2df-4c04-9ab8-2c09626753c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/766cd1c7-b047-47ee-b485-cadebeed35c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/414f01dd-ec91-4661-887d-dca8eafcbaf2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/260ce4be-58c1-418a-94c5-89a31d9ac355"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/059d5b91-9b42-40d4-97bf-63fa67df4f87">
    <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <dc:identifier>HP:0003254*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7bc5ef8-a482-4b40-ae9b-f980b56d96e7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
    <dc:identifier>HP:0100660*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1e03c11-dbee-4b18-85a6-93019614afa6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e40adcf6-1223-4fc6-93c6-2b94a0b182b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/993666a3-7241-42df-92a6-7f81f9083d31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor motor coordination</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b720a29-2e63-478d-b3eb-36551c86adde">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040144</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27d4411b-2432-415a-8335-31864d36ab64">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edf961a8-2d44-4698-a546-caf430e0eea6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2319cda4-5430-4482-8246-df01173a3e26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/781c4ca5-07ec-4019-9fab-28620cd26806"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4743e309-9333-4591-856e-23c89e149930">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80fd8f70-e883-471c-be59-5995be8c2ea5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2bfb5cdf-c8bb-44fe-95ac-5a5160feed12">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c848d5e-e6f3-4790-97a7-e5282ab6925f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5d3a598-a8af-4274-95b7-7b9a260650f0">
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040217</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab0bb002-c4d1-4130-8004-488442c45091">
        <dc:identifier>HP:0040300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/098bb553-6518-4ff7-bd07-984c7250f916">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4452984d-16b8-4eb7-9d64-42183c7158b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0174757b-1f42-4e31-9ed5-c5f4950b1356"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab017742-a065-4a74-8d93-f699ba798654">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3f9ff3d-1be8-4f67-ba5e-842fea6086e2"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bdba5824-3fb5-49b4-be88-43e3334cfbe7"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/303d5dcc-dccf-400e-ba91-b9d18da8bd92">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74634091-e657-411d-a9f6-a2584c4f6c57"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/985cac99-0c1e-4a9b-818b-cc6fa2f4491f"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6530288-8bd8-4db1-8f74-f2e17d566567"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
        <rdfs:label>L-Lysine</rdfs:label>
        <dc:identifier>DB00123</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8f92031-55a5-4d78-b7c8-4a38beedaeca">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e3f99e2-a881-459c-aeb7-7a9741e1ff34">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80196547-8f25-4103-834c-3417bd65b80b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/260ce4be-58c1-418a-94c5-89a31d9ac355"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70b75395-9321-4ddc-85c4-4a07f59199c7">
        <rdfs:label>High serum amyloid A protein</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05555050-3d13-44ff-8770-5327e0de09eb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated C-reactive protein</rdfs:label>
        <dc:identifier>HP:0011227</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3942670-8616-4fdd-963a-687d08e58de7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4be59f76-4c2a-4eef-b66a-3ead657fa86e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0175baa-a17a-4e50-92b5-78842688e533">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6511aa6-1524-40ae-a5a3-576d47d4c3bc"/>
    <rdfs:label>Lenalidomide</rdfs:label>
    <dc:identifier>DB00480</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39564387-dbde-4850-b7b8-c7490016434a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5907cbcd-9a8d-4932-97e0-9406c8885c11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df052ebb-fefe-4230-828f-ef06ba537e12">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e9d1eb2-2e5f-472d-bb44-b1df7d283982">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/642e2f85-f3a2-4463-912d-6e5d43409b2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29c98386-5f80-407a-98ac-b30189d777a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Hemolysis</rdfs:label>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c72931c6-8054-44bc-ade1-ee4227c7ad85">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c43c3e51-92f3-4ce5-ba70-b1a84dbbb24c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
        <dc:identifier>HP:0001879</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23009fbf-7ee0-4df3-9d56-a53320a6a13f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66067311-e5de-48b2-86ac-7576db596496"/>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be765751-46de-43e1-b544-4a83ab8ad4de">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b1bab22-b839-40fa-8a9e-c6f2eef78b54"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47224550-d1c6-4785-b188-c23aaff8e46d">
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d87b8a21-8589-4e4a-aa4b-c7d85abc288d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:label>Low weight</rdfs:label>
        <dc:identifier>HP:0004325</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/128df633-d824-41ac-b6d9-0d26434a6907">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35c21fc3-32af-4e18-81a7-8246924d54f1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee305c21-1476-42d5-a1f2-4163d7080a98"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b6de9fc-45a1-41f2-a74c-112eca9500cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pyruvic acidemia</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93ca0b06-8259-411e-9116-eaf520c78120">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81d2c616-9cc1-47b7-86ea-f6f6ab703f16"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/743f6ef8-bc2a-4293-8841-8e6f5c1e3ccf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c72cc30-22b0-4c43-8e22-237aec1f8571"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b524c7c-a9fd-48e5-a03b-0e5cd9750e87">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ea22750-3092-4f30-b364-7599b1253a13">
        <rdfs:label>mortality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <dc:identifier>HP:0040006</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa8b40f6-21af-461c-87c4-18e2fea0b86b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
        <dc:identifier>ECO:0000305</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f30e96d9-f33b-4680-92ef-fee725ea2225">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91e8e6bb-6127-4f86-adf8-70aff8f1e111"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e18b79b8-020a-4d78-b7c3-b6456e5d8186">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <dc:identifier>HP:0000870</dc:identifier>
    <rdfs:label>hyperprolactinemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30f4a107-63df-43e0-897d-d95d44f49952">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/867aca79-2088-4035-b3bc-d1f2a51003db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/416022be-ec89-49af-a54c-1be19343b3c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c30b613-2dda-4b53-a7ea-be331563791e"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/edd15b18-46d2-42ee-b1b9-eed10e2bf302"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5327574-bd6a-47c4-8390-b485dd551d74">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/583ff101-70ba-432f-bb9b-046f7176ff75"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c587a040-67cc-4be0-b85e-de5247a52626">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48120451-d476-4a9c-9bcf-20b90800b1a6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6dde8c3b-c8bb-4b4b-9bd3-808d19414f63">
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e0d3a33-9458-4b95-a239-2e22036eef3c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d08a57fa-d6a4-4bf9-ad14-dd91722a514e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/430fcfd7-6c00-454a-aeab-f731e7f82cac"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ac4a5e3-6621-4349-bcab-9ac3ef493e7d">
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:label>Disease progresssion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2705a380-8b8a-4dc9-b4fe-dc65524fca44">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:label>High ornithine plasma level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c3ba0bc-8708-4dc8-822d-4627f30fdb0b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c38d84f-cc92-47a1-a389-415b7b85cf58"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <dc:identifier>DB00916</dc:identifier>
    <rdfs:label>Metronidazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b81c65c4-fd0b-4419-9225-64458b27930d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>done</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
    <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3542b8d4-fcc3-4a68-95ac-d8318bb886f8">
    <dc:identifier>DB00682</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
    <rdfs:label>Warfarin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc9222c7-f2bc-4539-bcf6-fe886f4d2735"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eabd970c-5968-40b6-9ae7-9bc36993741e">
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7a98ba6-e8c7-48e4-863f-e0839e5eabdd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Frataxin expression level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e67e23b-edf4-41f3-8669-86584251376b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa0f680a-ab30-4cd3-8608-bfe089cb0f1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0715d925-a942-4a4b-a415-00885ed76fb7">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>High ferritin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a44d4fd-60b1-42ff-838a-de33ae504b3e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tiredness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa6a0257-be10-4951-9fc1-10f942912a34">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
        <dc:identifier>HP:0003254</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77d0cc12-e792-4a7e-b2f9-dfd73d3319d1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d0b9735-9f36-4d57-8aa0-249e0b097e81">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9348695a-4333-4499-8a07-c20d1317a386"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b0c4127-3e23-4033-988b-e3faa9dc64e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f3730d5-dfba-4ea8-9738-33d3a0eeff4f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b2128ad-12d9-48cd-933c-70fee9372efc"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1add26b9-141a-4104-8adc-abac0a29c9b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>TT-1131</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5721f4c2-c513-477d-9cee-28e130aacf05">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0559970-d04f-4b8d-8d8c-414a6baaf7bd">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7e991f1-f03c-4081-a48d-7c0f30185c40"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00996</dc:identifier>
    <rdfs:label>Gabapentin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76f16336-3e70-46d5-99a7-a049e99aa3ea">
    <dc:identifier>HP:0004356</dc:identifier>
    <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04a21a12-cabf-4b37-895b-26e5378dc3a6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/62e89461-367e-486f-980d-b95f67aaf728">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e96424cd-2691-46ab-b359-7a51c2c5b60c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e327836-ca42-41c4-a564-b7cc593af2e3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01115</dc:identifier>
    <rdfs:label>Nifedipine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a040b17e-741e-4853-b890-0624562bba5f">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51e372cc-08b2-44c8-87ea-f553a95bb3e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67c3e8cf-e01e-4ba6-b75d-dbf44b5d4782"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fafa59bc-0ab5-4436-8c7d-14cdd349cbb7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64c11458-3768-4faf-918c-747b8036fb2d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/106b49f3-faac-4807-aa6a-9cf140062a95">
        <rdfs:label>Macular cystoid changes</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
        <dc:identifier>HP:0008028</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52c1c685-cd16-4a71-9da4-dcb3e392dc6f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82c4ce4b-f7e1-4aa9-aac1-bad5327990d9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:label>Cardiac dysfunction</rdfs:label>
        <dc:identifier>HP:0001635</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/511bb399-2b2d-4d74-ba63-905c4f657d4a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1a73c4e-da2d-474a-b2f7-35cbc9899ee5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a517e4cf-1d2c-402d-91b9-516bf37fe194">
    <rdfs:label>decreased male libido</rdfs:label>
    <dc:identifier>HP:0040306</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/983527f0-f62b-4598-95fe-494b1a62954f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c550d03a-eaad-4d3c-82d1-0220b220a506"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6e392f6-d5a5-477d-9611-389282452e94"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59a3413e-ef0c-4516-b195-f9dd5dfc77f4">
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86595754-1d17-4ccb-ab1a-2f728ec79ce3"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/421d9d6d-4568-4d49-997e-447cb5fef2c0">
    <dc:identifier>DB00542</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7409f2a4-05ee-4552-9723-a090510f1feb">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a7f0ce7-7601-409d-9259-637d04204b50"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/043ab169-0ca0-4911-a450-305bed85c438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb2cf10a-ba95-4832-9b2d-39d2b88995c3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b39b6d5-ff53-43cc-82f4-47995c8d4f5c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Benazepril</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/919c9e46-c21a-4a89-aa77-ca0789633d8a">
    <rdfs:label>Dorzolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c19c1d05-d5dd-400b-a0b1-4a45e05bb423"/>
    <dc:identifier>DB00869</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6dba8e66-11b9-4f6a-a077-3d9c9e6ef355">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13fe06dc-81b2-40c5-be31-6e8fe4ee398a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93988ec6-fe69-4659-8d11-6f7cb60e8668"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24f25095-d32f-4faf-83a7-d7ff9e70b319"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f262ddde-b494-40e6-bf47-5f71cade6e42">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06f80dce-5e2a-4feb-b2b5-a6b3528093c9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eaf65c72-71a2-4a6f-a95f-d8b9cdf337e4"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f8ef834-32d8-4e1c-9a06-0d21005e357f">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ba39383-ea44-436a-8653-d8c3049c344d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b3e954c-2c73-405b-9166-42f1a61b44bf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f826f302-961f-45a1-8216-931a11c638f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2595441c-8fcf-4028-b4c2-23b5164a7d86"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d516c4bd-eeb1-4ac2-917e-739f782ce4c5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39a9b5c4-1401-49d8-869f-798feaa37cc4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4046e707-cd23-4917-9264-e1e1baa66dd8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f55f7337-45bd-4101-bc34-636849498639">
        <rdfs:label>Functional loss of vision</rdfs:label>
        <dc:identifier>HP:0000572</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fd542a4-26c2-4ffe-94d2-8819ce996a6f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
        <dc:identifier>HP:0001112</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a68871ad-8de5-4431-a8ab-60bb943840cc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
        <dc:identifier>HP:0002171</dc:identifier>
        <rdfs:label>Gliosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d30fc696-3a72-47ba-8ce9-1d83340b88a6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
        <dc:identifier>HP:0000630</dc:identifier>
        <rdfs:label>Retinal thickness</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/42599921-0a2d-4ddb-be08-0ba8b116b786">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d73713d7-aee8-47a0-85b0-19fec37cbe1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48d96a3a-8831-469c-9956-7d9b3671fbef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d38b9ec-ebd4-43b5-8420-2990b4dade0b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d98e601-ef2e-4837-beee-09860babce10">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal walking distance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f3b76d4-78cd-4947-b5fd-020bf47e512c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <dc:identifier>HP:0011023</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cddb0c0-b75e-4057-ba12-f83167215f34"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e832841-0e59-492f-816e-243a998fcd0a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low level of serum B12</rdfs:label>
    <dc:identifier>HP:0040126</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c191b8e4-70bd-4315-bbaa-d2b29d945502">
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01b85f1e-e464-4442-b88a-55e2b44a652a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0dabe0d1-33c0-446a-9264-fbc31b4f3a13">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1e6c1e0-a192-4f9a-9234-1d24a67f54aa">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ddb12537-e141-4725-a775-b39463959f59"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
        <rdfs:label>Carbenoxolone</rdfs:label>
        <dc:identifier>DB02329</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25bddb0e-a921-46d3-8c31-d58b68da910b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed0a0048-5b66-42ce-b78e-765af895749d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e840584c-ad31-4350-9d6e-9b7289bc4837"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee90e210-51c1-46d9-ba0b-13ed1542d430">
        <dc:identifier>HP:0000847*</dc:identifier>
        <rdfs:label>high plasma RAAS activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2723d6ca-4728-4427-984b-27637743f7f6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5a87d67-eed8-48d3-a90f-5a43b7c4c081"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36559af7-b59c-4f67-92e9-89bc98f76d31">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e96424cd-2691-46ab-b359-7a51c2c5b60c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/709fbe18-83c1-4813-9a43-f6d8872c706b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8623bcb-682c-4a58-aa93-022461b52971"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65528f4a-6815-4fb7-80ff-102d0ec11bb2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
    <dc:identifier>HP:0010535*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eae1669b-4d6d-4200-bcd9-8bbb97589fb7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2af4dc96-c81a-464d-ab92-9d6bd9484fb8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000127</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>Salt wasting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/450cde2c-98a7-4fc2-8542-28f1cdb77653">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b98cb1bd-e13d-4943-a683-07b9f8fe5e89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ad553b7-b4f0-4ae6-8f4c-4a904469c502">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deleterious prognosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f8fba4a-43bb-4590-8e5e-2122b025b59d">
        <rdfs:label>Growth retardation</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcbfb389-45bd-40c1-858a-c4fca714a554">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c6017a4-ae23-4e6c-936a-b8e0b79a30a7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
    <dc:identifier>HP:0000164</dc:identifier>
    <rdfs:label>Dental Defects</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c87e4f5-a85a-4520-ab01-62d40addbb8d">
    <rdfs:label>Involuntary movement</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <dc:identifier>HP:0004305</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GRACILE SYNDROME</rdfs:label>
    <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3738b7a1-45a6-4a44-950b-bc8a358b6943"/>
    <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/711a8d7b-bd7b-46c6-bf59-20090d9ce915">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b38ca848-e39f-4e42-9223-4a58059b6941"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39229228-699f-484a-9db8-6ca9dc4b3941">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ecde138e-c458-4556-8a7d-e8e2e1f3dcb1">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac078216-4579-4de7-aa4e-e000ffe5a095"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24f90084-a5d4-48f4-97e5-ca320c8cf0af"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23cabfcd-75a3-4eca-a85a-67d0155803b5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <dc:identifier>DB09081</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/697894c0-8b4a-4ba8-abdd-19a84a93627d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5953b2-abd3-43a9-ba41-35f668d45e73"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/308f312e-299d-4ab8-a176-ff67e3488d4b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0763e628-6ec2-40b9-a666-d9640bd3ce70"/>
    <rdfs:label>Idebenone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39a9b5c4-1401-49d8-869f-798feaa37cc4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42a32b14-37d1-413f-a1f7-fc4738b104bf">
    <rdfs:label>Joint disesae</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001367</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b2eb42d-33f4-43a2-9fa4-ea7ec643760e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234*</dc:identifier>
    <rdfs:label>secondary carnitine deficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3b83eaf-1ad8-4692-b0bc-207c4fc2c7fa">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2cff935e-a62e-46f0-9b63-1bbb41ff18b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6dda16a3-1b83-48d3-8c50-2760565b0dfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a485b982-cb0a-4faa-8655-66bd77e563ad">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low life span (Mortality)*</rdfs:label>
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52e12eae-0deb-4ec0-918e-eeb7c42bd721">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26169d8c-7cf6-4723-b5ff-0aa08605db4d"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f54f0a4-e344-4a63-bb01-c1b5dc304cc2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49b26a80-764a-43ad-b839-2de98dab7927">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72535f40-2267-494e-bb5e-9df6bf9b6489"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34ac4711-f38b-4e68-b446-fe4dfcc7ea3f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Retrovirus</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39dcc46a-af61-4039-9876-385cdbb32d6d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Proteinuria</rdfs:label>
    <dc:identifier>HP:0000093</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d05e88b-76a9-4624-ad45-7bf5a91f13cc">
    <dc:identifier>HP:0003710</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8341c50-7a1d-44d6-8a83-24f5ba5030db">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27402058-df8e-4263-9a0d-345e72198054">
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c4da8eb-60ee-4e71-a608-64bec49af682">
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f72f596-4f3d-4bb2-9302-8db8adc6f8ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3ebaebd-e9c2-4b82-91c1-4f86b450d2e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1537f38d-ce08-48e6-9f60-e120f876a4eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac63736f-ffa4-4c27-b534-20b30d4bbe70">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Six Minute Walk Test</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2d7caf8-7894-455c-a5e8-175402cbae8b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581581b1-99d8-44ae-942b-ec40161494cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a4ac985-7091-42ed-9acf-91cb7822023c">
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6048bb24-42dc-45e9-b746-a7d09772c4ec">
        <rdfs:label>neurological abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/648e01d6-f688-495e-8ba9-e786bcbbf5ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/925c5b1e-9d13-4285-ad6a-515c220e1b3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7c6ecd2-7c11-49a7-ab14-c62a2040b8b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0258430f-dd35-484c-832f-2b241023d0ad"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/574168e1-9b19-4f06-b1b3-93766e7a3f83">
    <rdfs:label>Beta carotene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <dc:identifier>DB06755</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abc451ab-472f-448d-9963-470e73c16077">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a19679d9-516e-4c7e-b339-3f2e7704058a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88ee7d78-44e7-4b55-98df-320dc5e1f85a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b6c4e79-125f-4c59-af9f-cb0f2601ac9c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d5691ad-6043-4189-8ad9-d5b805ebdb15">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10864a43-1400-452b-81ba-9fdb364a4df1">
        <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
        <dc:identifier>HP:0008347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39cd7fd5-1fd4-4a5b-a7fb-054fdf58703c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69971d89-d79b-4219-b981-33f672984b00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8bcbbfbd-b5d7-46d2-80e2-2350a69fe2d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfd6eaba-bccc-45a0-bdbc-8afca2ace769"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a56674e-7899-427f-945f-ec9806c72542">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
    <dc:identifier>HP:0010978</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/198f3976-2360-4600-b36e-3f6dcdcda81c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19a77541-f8da-41ec-860b-e800e7993c48">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of metabolism</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da019ad3-639a-47e0-88e2-61270ce47d26">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/238c7b10-4591-4afe-bbc0-6eb2070b8727">
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0342f820-dc50-4b24-ae5a-bf1d020a4532">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee9e3047-7857-44f0-a4d5-266b0a5fac53">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalties</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c9a14ff-dd57-4962-bdd7-b84c67a134bf"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e751f8c-23d3-4276-8897-6e419a885f0a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <dc:identifier>HP:0012535*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fd55fa3-d60a-402c-bc7b-253115e1aded">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:label>Abnormal growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f25d14d8-a322-40df-8502-6818ef954401">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c12a2ce3-138a-4b7c-8690-32a092264c0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b78ba9ae-978b-40fd-b3c8-4752f401b9d2">
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9988cdca-97f2-442f-822a-154144244fbd"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05f0c7c7-5da3-437f-a513-b09c8ad425de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1eb1275-9bde-496f-9681-354255c735af">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
        <dc:identifier>HP:0010979</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39dcc46a-af61-4039-9876-385cdbb32d6d"/>
    <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbd4e35c-7132-4fd7-bebd-c1dedb48b079"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90ce1d56-2388-44b3-931b-a2f1414a3f55">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ecbf67fc-b1ec-41fa-99b9-731dee0acab4"/>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bbe7a54-8527-4575-8a2c-a3af6549ecf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db435108-f8a5-4675-b4c6-0864dacf5393">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2bfa4fc-71e4-4b0d-92da-f35a1c152d83"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/432bee8f-0e7d-42e5-8561-672f6970c64c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04cbe884-9144-4f40-8265-f7b7035f8c57"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21814c36-9226-44ef-b887-bc8d8bb294e4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c66b1e8-1a35-4bd6-92f2-59da68026a41"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c999cca-f783-4231-a3eb-47a8b2f53717"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed0a0048-5b66-42ce-b78e-765af895749d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25a2409c-49e1-431b-9e00-b791a2ccef7b">
        <dc:identifier>HP:0004324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
        <rdfs:label>weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3eba52b-e211-4466-b802-91e35d8f6103"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b647fc3d-a893-402c-a07d-d245c580bb35">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b76affa-d308-4ba0-b0e6-c39ecdcc8ee0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c03f50f-5dd5-4daa-990f-634ec267fbfc">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4889cb63-f43d-4450-ac88-7b1d515da08b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792fb394-03b3-48d1-a48c-95786023df70"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Estradiol</rdfs:label>
    <dc:identifier>DB00783</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8031d14-2e73-43f4-b112-c9cd5fcee1c6"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73b5f7ce-bf56-4a3e-94db-70937ef2ead7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fd1121c-55a3-492c-a321-aedbf15f7508">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2501ba3d-58e9-4f7d-a98d-c25cfaa11ee1"/>
        <rdfs:label>DTX401</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/230061ed-6a4a-436f-986e-818f1397bcc5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <rdfs:label>Bromocriptine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a57ca62-d9f5-473b-89cb-a38f14dae220"/>
    <dc:identifier>DB01200</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58ed00ea-bb52-49f1-bb94-c2fc48dd2e5c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e6393c-51c2-4240-9b4f-bde636baef9c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edd112d5-24f7-450a-868d-143caafc6440">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50eee7e4-80ba-44ec-a088-7afdaf8f7ef1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cf4bb63-a589-4e60-9384-0a66e585edb2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <dc:identifier>DB00149</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcb1e093-8427-4d1e-bd8b-ae0db764e78d"/>
    <rdfs:label>L-Leucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02bff4ab-2bbb-47c0-9094-95f83f33e532">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbf56bf6-f6e0-46eb-884f-e7469a5bba2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2dc28944-2bf7-4c6b-83d9-4b3f23e80434"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34cba031-1467-4f71-9f04-a1ae3147c058"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42e2397a-0954-40ca-825f-d4a7ee58450d">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c73c413-8a88-44fd-8b90-c0069f1aaba6">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24cce4b6-7547-4c7f-97c3-c152ee88f135"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b30990ce-149b-4f02-a9ed-f5459dcdf184">
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f81fc9f-9009-47eb-9016-7fa643e10e5a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d315c413-bae4-433e-96be-f74e33da07c5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/611c43e5-b8c7-4053-a6fe-ddd8b88e2bd8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14bc6b19-179a-41f7-a1c3-a64e0a5ebf45"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/784ea5eb-2c48-46f4-a6e5-f350888bc58d"/>
    <dc:identifier>DB00052</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <rdfs:label>Somatotropin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4a619b9-23ca-4ae3-bbb0-b6ac3b40dfe5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5cc349e-7616-470c-90d6-ed5de3e01706">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc52b078-d618-48e8-9cdc-8016a2072d1e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab4a5568-e80e-407f-81c2-50ecc6a8f878"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d785bbc6-da9c-40c3-893a-6ea1e79f2bb9"/>
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9b9478f-fad9-4afb-9de3-19c992dff444"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d80b0ae1-71e0-445e-a9b0-8be9bc440835"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f459a18-8f4f-41fd-8520-2998f050a9b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>CHEBI_84293</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
    <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6339c89-f68e-469b-9746-4708fc4b88aa">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c6b272b-c8ee-467d-9d53-b32c42c6fc34">
        <rdfs:label>Hyperuricemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/89fee7bd-5373-44ba-af7e-7b1f9ae4a6b7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf355c7f-b9d2-4d59-8d9c-212a1814f27c">
        <rdfs:label>Hyperlipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19563366-8c13-46b5-9f78-5c909a213003">
        <dc:identifier>HP:0000105</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged kidney</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f8fba4a-43bb-4590-8e5e-2122b025b59d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b32688aa-f21f-42c8-9829-f50a60752d13">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32225104-c1e2-4bf5-9188-94c93defa960">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78b8777e-f1e3-4a91-bbf7-25c8fb146ce5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb0a19b9-bb09-4b38-98d0-78344051af11">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
        <rdfs:label>elevated liver iron concentration</rdfs:label>
        <dc:identifier>HP:0040134</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da0a3235-96f5-4141-a351-a7070e223e41">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa44c95f-9f64-41f7-9071-dd4849eeb337"/>
    <dc:identifier>DB01432</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e009898e-907f-42e5-bca9-9483771a1fff">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d763a605-193f-4344-9e0c-349e6953df57"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98cf90ac-e13b-47b4-9d02-27625baa8dfd"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84ac0cb1-1658-45b1-aee3-192a81a6e9af"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cholestyramine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/812a0bc8-8b23-45cc-ad98-7b36528b462c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <rdfs:label>Urea</rdfs:label>
    <dc:identifier>DB03904</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0c6942d-254f-4083-ae1b-3559a18ab6e6"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cfa9de0-8843-43bb-90a0-fff41fde5af0">
    <dc:identifier>HP:0002180</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:label>Neurodegeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c76bc7d-269b-4f21-9037-2efa7257d245">
    <rdfs:label>Potassium Citrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92e881ec-dd0c-4ac6-b0dc-4bebe944ba18">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77eb03e2-18f2-46b8-b5d7-69b27826b382"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/098380c6-768d-410d-9303-cfe7e5a5b00a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/432bee8f-0e7d-42e5-8561-672f6970c64c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88c2669c-3715-48d8-a305-97329c12ae90"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615182"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b720a29-2e63-478d-b3eb-36551c86adde"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <dc:identifier>DB09125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db435108-f8a5-4675-b4c6-0864dacf5393"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2ad8124-c5fe-4fb5-b553-e0c14a790953">
    <dc:identifier>DB01045</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/353af4e5-407a-4359-8c64-97273cbedfd3">
        <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06643d46-4220-45e3-93c0-1fcd74a3e0b1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5016a8c-be4a-4b8d-8fde-95369641c09c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d347f82-4216-431c-b3ff-0071aae5b3a9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f418c234-eaa9-43a8-aa79-c0e62971df43"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9dccea44-cb63-4158-81ab-e2b338f88f67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e70f7699-1335-475a-9eb4-9c10f45fdeae"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eece4296-487e-4702-96a3-90db79862000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Rifampicin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f89157ea-e2b7-4f43-8d15-d5fc7f5a9f3f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4edbec9f-a016-4ce2-ac3e-609e847abbca">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoalbuminemia</rdfs:label>
        <dc:identifier>HP:0003073</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2006eab-8abd-438b-89f4-193f3fecdfc1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:label>Chronic diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d3443af-b920-47a3-b402-a44e8f75892b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001019</dc:identifier>
        <rdfs:label>Exfoliative erythema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9988cdca-97f2-442f-822a-154144244fbd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/234500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77da61d3-47e7-4d94-ade9-9ef79bc99694">
    <dc:identifier>HP:0030098</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67c188c8-e092-4143-b526-5fe031888e2d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26169d8c-7cf6-4723-b5ff-0aa08605db4d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292c7e7c-3b61-4198-99dd-96c865727fb2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5cc56712-d0fc-4e26-a533-386b6b178e81">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c40167bc-5c1c-47bb-8c6f-c185304a53c8">
        <rdfs:label>No result is  added</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9baae767-331f-4f69-9c1b-ac151678bb6a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2bd597ae-f0cd-4537-ad95-80667601d343">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3657a037-edc8-4d4f-ac14-23815fcfccec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad84aef7-1d23-468e-8eba-33f0a281efff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fc0e118d-10d8-4079-826e-7e0885aa53bb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/676dabb6-f33d-4bd7-b361-5f4dff4a7dfb">
        <rdfs:label>incoordination</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002311</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f7f1e34-0d2a-4075-9ad8-2fda856d531d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50e77f40-1a6e-4d49-8f82-ead62352d26d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000789</dc:identifier>
        <rdfs:label>infertility</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82944638-774e-4c95-8945-7ea02caf8cc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f4e404d8-d13f-4f3a-bb73-a239465580d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cb8b1bf-6493-46e6-90ae-a2cd1000ed9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a16207a-5413-4fb7-93bb-3ed76f7b8d14">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:label>hypomagnesemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93843f74-5323-46a7-942a-cd7e19428d13">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc25f738-81eb-432d-84b7-bfe3f8d5ede1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
        <dc:identifier>HP:0000559</dc:identifier>
        <rdfs:label>Corneal scar</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/717fe949-c57c-4f89-b227-59cdab7a396e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9daed9d1-3162-4f0b-b1b7-9d4f6cf0318a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ae0d44c-d44a-4164-b94c-0479af74835d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c58edf6b-c9fc-44be-a9b9-4ebb25f9cc67">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000491</dc:identifier>
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80bf7385-9735-4a3b-bb50-ba6c8b9c3281">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b49c1c06-cf34-4b1f-8533-2c1b3e2db12d"/>
    <rdfs:label>Gemcabene</rdfs:label>
    <dc:identifier>DB05123</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06643d46-4220-45e3-93c0-1fcd74a3e0b1">
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:label>hyperbilirunbinemia</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15c89e7e-bdd0-4c05-8b02-9eefc473f715">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dade0e3b-6e5e-48c3-b094-96927627d31f"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a44fc3ba-9b34-45d8-b794-100c5bfdba75">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e05b3d5c-c9e9-4748-994d-d46a5a6d102c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a036fcb-9786-49c8-8011-28ace9de0bd4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5d3fc73-ae48-449d-ba03-1e57a08d64ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
        <dc:identifier>HP:0011167*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fab512fd-a2f6-46ff-825c-6ef4cfed4dec">
    <rdfs:label>Rigidity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
    <dc:identifier>HP:0002063</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f97515a4-55a2-45c1-866b-da32ac6414c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3efed567-afa5-4053-a220-da718567e0a3">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b7d6dd0-7a5f-4567-a706-bbf98e2b6345"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2893da54-71b5-4a68-ae60-16bf0284a49a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>oxidative stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ecd68c0d-50a5-4504-80fa-c10e11c772b3"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45ccfddb-925d-454a-a1a7-c49e5d929053">
    <rdfs:label>Decreased niacinamide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc98983f-2722-4f1b-9a8a-8f8c6e6b01c7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbd4e35c-7132-4fd7-bebd-c1dedb48b079"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610198"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f916675e-053b-4250-82d4-3021b18b6c2d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ebbc211-7403-4711-87f4-f8a35ba78086">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9091c4c-5ff1-4ab9-b1b5-dff2320afb0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bad8d3ea-1382-4eeb-aa6e-42525422fb54"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1065a8ae-714f-44c1-97ce-a8eed92eed7c">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32433b24-4fc2-4286-838a-9fc882355135">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b117b7c2-a2aa-49e2-bfce-56db02753d21"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98733fe3-371e-489d-b651-4dc32eb05d39">
        <rdfs:label>verruciform xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031517</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7787e63-5ae2-4ee0-9632-33a86d0118b7"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65a74880-161f-485c-8937-10a8db217bf5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e694286-d0c4-4c96-ae33-c66f84521676">
    <rdfs:label>Copper</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/820faf79-f231-4af9-ab36-10c74d4d7c9e"/>
    <dc:identifier>DB09130</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/889f8492-8f67-4070-bce2-9b6e6e1be536">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a27b7ad4-6346-4a13-8563-a0b4e7215e0c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12ca6ff3-6cd0-490b-befb-8df7d5c936a9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26c56c81-72bd-4fb7-bfb7-2eeae7c91064"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fedbb36c-5c51-4098-ab19-2d988566c337">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>constipation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
    <dc:identifier>HP:0002019</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f83f3e0-2ccb-4f1a-acd4-a91af04c5459">
    <dc:identifier>DB01219</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63033298-4941-495d-bd1e-6d79059f1454"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <rdfs:label>Dantrolene</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0694245e-3e2c-43df-87f0-6f7b0777770a">
    <dc:identifier>HP:0020062</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Hemoglobin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/526ce503-e8f8-4467-9b31-b59c7fe9de5d">
    <rdfs:label>Insulin Aspart</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <dc:identifier>DB01306</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d2a8fd1-d35e-4f19-81e4-080e3c8e0cb6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cbb198-fdf3-4ab0-a795-03ee758e96c9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ca048b8-8bc1-4a35-88a4-057343486db8">
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd6f98c4-b9a7-48f5-8bec-4cf0b233f29b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/09edf1ae-3d8b-4cf6-901f-76aafb5b1759"/>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e7d64db-8e5b-49ea-8549-e1d0e353c822"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5aeff573-e8f6-4878-942a-2e5c7fb77210"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f4170cf-9e1d-42c0-8e75-4ea0eea07009">
    <dc:identifier>DB04815</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <rdfs:label>Clioquinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba17a744-451a-4ebf-a810-01f6d892595d"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c6e2a97-60d2-4a57-8409-287dfabf097d">
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/915c84c0-e383-429e-982f-25e5d2e83669">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low dopamine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc3aae74-0aea-4e82-af83-95fc3b3978b2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56a76daa-0b84-4e2a-9d3e-62383299cc9b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/574bfe97-1e3b-47b2-8341-17ef66715cdf"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a1e09b9-9f3d-4f3e-9304-6fab9f01369d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
    <dc:identifier>HP:0000467</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>neck muscle weakness</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f4162db-c069-4f54-b835-8a6fe8e3655f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9de31126-a9f6-4e64-889c-db580ed688d2"/>
    <rdfs:label>NeuAc</rdfs:label>
    <dc:identifier>CHEBI_17012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be12a21b-cd3d-407b-9db3-2e181f813f3f"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02636921-7565-4aab-a6fb-4e3011ece367">
    <dc:identifier>HP:0011018</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>extended G1 interval</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3442f9c1-8acb-4c02-a711-77d13215941a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>skin thickening</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
    <dc:identifier>HP:0100725</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/807a858a-42a8-4e24-8f9d-00332b0e5052">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a16bf620-0e49-4a29-8145-4807c5bf25f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d8ca65bc-e4f9-4b06-b6cf-d551748d8350">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0151b46b-2605-42b8-beb5-aa27762d98f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4728774b-0d34-452d-89c1-2db0c4809bea">
        <rdfs:label>hypoproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
        <dc:identifier>MP:0005567</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdafb666-0421-4960-9a50-a329138fc3ea">
        <rdfs:label>blood coagulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
        <dc:identifier>HP:0001928</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93573316-c438-4423-9e26-53405613bb4d">
        <rdfs:label>Metabolism abnormality</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73b034b4-4892-410b-adb3-82b7d25d9ae0"/>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c65ca80-0d9a-4b21-9683-180b63de3eae">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>urinary tract infection</rdfs:label>
        <dc:identifier>HP:0000010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b08b1ae-eb58-4734-8bf9-1d696aefa1b4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f03e2c92-cb2f-4528-8c44-59a978ebb0ab">
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b78c26f-215d-4b8f-91d3-ba8afbf02148">
    <dc:identifier>MP:0003354</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
    <rdfs:label>Astrocytosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30951780-9ec3-4d78-a1a3-b7d6ef340a09"/>
    <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8772811d-70fe-4fd6-bf2d-6039d195e455">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cabb080d-a35a-4ce5-848e-85f9f95349d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2fc9369f-ff20-4f72-b0c3-051a089e2232">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74f06808-da64-41c0-b97e-83c39736281d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>abnormal liver function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7f490a0-34b8-4d7a-847c-3eb45338a0dd">
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>hepatomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f3b32c5-0947-4800-8c36-70d5aff1f64a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4419f46a-6575-4084-a74d-90b3559d8912">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b588af37-0958-4d5a-ae91-87e54c320588"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e9e9564-f122-4d1f-bac4-437c92432974">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low mean hemoglobin level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <dc:identifier>HP:0001903</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40fe9f35-ffae-4b66-9037-bda6e28c5020">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012825</dc:identifier>
    <rdfs:label>Mild attack</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e268d6cf-de29-4277-8219-eec60e8dc254">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ER-associated degradation of R8L</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3420464-ad9b-4e28-a4dd-8df97ddfa7ee">
    <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
    <dc:identifier>HP:0012378*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d6336a1-dfe9-4703-bc7a-0cb660774827">
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c041c64c-d72e-4d5c-8ec5-7d0425d63bf6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a555c19c-22b1-45e9-9214-1250a6644922"/>
        <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6df2948d-ca54-41af-a254-0d7bbc1ab0a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ece832d-4848-4be9-aecb-37b581e05405">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/560ee669-989a-418c-a7e0-882276424301"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a56674e-7899-427f-945f-ec9806c72542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45a59231-c19e-4b17-af41-83b81f4615b6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356*</dc:identifier>
    <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f22ebc28-9cf4-4246-9456-75e336f60057">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e99e3ab4-d2bf-4773-bb26-149cfb43479f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neuronal death</rdfs:label>
        <dc:identifier>HP:0002529</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35c21fc3-32af-4e18-81a7-8246924d54f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d6be053-f9a6-439a-8694-5ec575f64596">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
    <dc:identifier>HP:0003679</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9573f1b5-8cb7-4b77-95d9-5b23be9e746f">
    <rdfs:label>Interferon beta-1a</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <dc:identifier>DB00060</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51af8498-91e6-4837-aad9-014545d5d5f5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60317fa9-0764-428c-93b8-a7104e8db388">
    <dc:identifier>DB00145</dc:identifier>
    <rdfs:label>Glycine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f78ab660-5a46-4434-a37b-2d56269a8ac5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0288547c-70c1-4796-bd44-26e31c59cd0b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00deefff-503e-4edb-89e6-adc9a55adb06">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2af4dc96-c81a-464d-ab92-9d6bd9484fb8"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed0a0048-5b66-42ce-b78e-765af895749d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a83284a-6abd-444c-9fb8-15aab03bb5f1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ad553b7-b4f0-4ae6-8f4c-4a904469c502"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5f2e2e1-89de-496a-aeac-9dc2c57e65ec">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f5740f8-a3e5-47e1-8fc1-15a186c6ccde"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c13f1a-a634-484a-a495-e73572d60aed">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Voice tremor</rdfs:label>
        <dc:identifier>HP:0012477</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e13ec00-0f7a-4252-b63b-6096c31b5830"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6098715-15fe-435b-9230-1e068add7af8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Poor intelligibility</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a63878c5-9d35-4be8-9563-65278ac31fb1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f57d8e97-9ed2-498c-b990-9f5619dedbe9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77da61d3-47e7-4d94-ade9-9ef79bc99694"/>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a673bb9e-d4f1-43f0-bfca-1b286745dbe2"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ea46e5b1-2984-422b-9a5f-5cf80708f4f8"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2de997b-3d3b-4658-920a-a26cb5ec86e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/879ff66c-8b7e-4c89-8e77-2984b7a5226f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9f3a159-1628-4d16-bfef-cfd5a05ac1f3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
    <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6cb9a641-41df-420a-b228-b8c5b8be5b9e"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
    <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68339f5f-fadf-4b61-a5e3-ae20ffda4ae1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fda852e-893a-430f-ae67-596443cd3c8e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad15c432-5d07-41f0-a3ac-44920de8f80e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87219aed-169e-477d-99f2-c11eee5c3bd0"/>
    <dc:identifier>DB00190</dc:identifier>
    <rdfs:label>Carbidopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a888d64-687f-4efb-b220-c97db42c19aa"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/746fcd20-3815-4f7e-829e-2a3ab3721535"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a56e387e-07b3-4c20-824e-79e5b46a09de"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e57c0cf6-1002-4a5a-b829-6d76a819e5d4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f17e4b3f-18a0-46f8-a913-ab261660dc31">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47224550-d1c6-4785-b188-c23aaff8e46d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d9b2cbc-acb5-4410-b15b-5d00cec7d5fa"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6ccdff0-d10c-44b3-aef9-22cb19cb56b4"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f1e951b-5d8d-44e0-b501-c88e07bdab80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35fc09ca-565e-4ba6-a6eb-c36475e327fa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45f8b09e-e4ce-473c-be56-e0fd498de0e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/498fe19c-2496-410d-a02e-dbfe6ec4c887"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb4f23ec-18ca-47c1-88a0-c0aa434211d6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51adc0f7-a192-4332-b0e9-384c84a889b8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB06720</dc:identifier>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4339145d-3d73-43f5-b5f2-57b1c6da2906"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83afba56-be16-47c2-896c-548beece0241">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e840584c-ad31-4350-9d6e-9b7289bc4837"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2723d6ca-4728-4427-984b-27637743f7f6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8863db44-f1c1-418f-a022-d0fc128246ef">
        <dc:identifier>HP:0002900*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0256de13-be85-41f0-bdaa-33806b03c402"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51757d50-3a94-47eb-93ea-c354d6ea7977">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf04e886-4a72-4d1c-8cd9-8333f557a0b7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
        <rdfs:label>verrucous lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e850ca62-64ab-42c9-919a-da51c7336d38">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hoarseness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
        <dc:identifier>HP:0001609</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a81cc19-c3a8-4dc9-9071-21c71bf7aa10"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4baaade-213d-4b0a-bd19-bc6ed4d8f208">
        <rdfs:label>Skin lesion</rdfs:label>
        <dc:identifier>HP:0011122</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/29630709-da81-4f54-ac5a-865220158142"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/427b7007-e022-4d6e-b43a-26e8b08b9d06">
        <rdfs:label>Mucosal lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da78b2fe-1715-420b-bbea-404974d4782f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b54c3539-4e3b-41f2-8a76-880388f94bf6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
        <dc:identifier>HP:0000962</dc:identifier>
        <rdfs:label>hyperkeratosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd387055-df08-4c3b-8e7e-d17bcafbd9a9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3be96baf-3d4e-4055-a31e-4e49bf665790">
    <dc:identifier>DB00627</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b78ba9ae-978b-40fd-b3c8-4752f401b9d2"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9d6f189-4822-4f90-9a10-5abc59fd98f5">
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9988cdca-97f2-442f-822a-154144244fbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39229228-699f-484a-9db8-6ca9dc4b3941"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d972ffb0-c71f-4e33-b3cb-3950030d8c90"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f89157ea-e2b7-4f43-8d15-d5fc7f5a9f3f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12654155-063c-4ccf-b150-3c90220a4243"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9d24aee-dcff-445b-976c-7bc9682a2fee">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9348695a-4333-4499-8a07-c20d1317a386"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/837f9c08-eb54-407b-aa5b-6771e906135e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9988cdca-97f2-442f-822a-154144244fbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c30d1c7-1d29-4fae-a729-d3bf5baba82e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5e2341-16d1-494b-abea-5fb1e04c8936"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/409d4a75-0f3c-48a2-85b5-365dbcdcad5f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Niacin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7af5c6d6-8b71-4c07-8948-f9b53df913ca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19a77541-f8da-41ec-860b-e800e7993c48"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c186e20-61b9-4cec-84df-853e60e9dcc5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5358e7c8-0d0c-4cf3-987e-373649bf3629">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/142c0b21-24f5-4577-92c1-4abdfd7d175d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29e144ba-452f-4bbb-9a9d-3539e83537c9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/766cd1c7-b047-47ee-b485-cadebeed35c4">
    <rdfs:label>Tocilizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2eeee490-7ffc-404f-a4f9-f094dd6b6fd5"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c8b36395-2311-4543-9c24-2d30a083bbd2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/165317cd-f2df-4c04-9ab8-2c09626753c1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fd7d306-3299-4abe-b30d-29a1e1e366cc"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <dc:identifier>DB06273</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e17a954e-a7bd-45db-8665-6d121880504d">
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01e3bf7a-1ac5-4d1b-b50e-222fc8b1a452"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7e4d492-d639-4368-95ad-12c34576ee31">
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/933d065c-9a60-45fe-b5f4-3568e8a272fb">
    <rdfs:label>Asfotase alfa</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6798b31f-8ca3-46b7-afe6-d436f1a44d1d">
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b8dcd43-1406-44e3-bda1-feab52a9420e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3ef120d-1f57-431c-b2ef-3d044dd8c0fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c6017a4-ae23-4e6c-936a-b8e0b79a30a7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/000224b1-9a3d-4885-9172-cb9f80e66d6a"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8332d2bc-82ae-4f1d-a835-be7122f6f1c4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e0d631f-cc40-43c1-9c69-014e15933c87"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e7224d1-b07a-4c2c-b246-ac9c247a0f1e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
    <dc:identifier>DB09105</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8eebba85-0abf-4c4d-bb6f-d81fb1348786">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5324ae10-1c71-482a-874e-36519478b75a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001892</dc:identifier>
        <rdfs:label>Bleeding tendency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c10d77f8-b9f2-422f-8bb9-7d69466a0e30">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Vitamin K insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4eaae60f-28b8-47f7-8eb8-f697aef67c91">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bac9cd96-88ce-4d06-b6a3-ef2237197c29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5237def0-8ce4-4d74-9d7a-e27846bfccd1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ed73c07-90a7-419b-9189-0d3935841b2c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/898a50b2-6386-400d-9840-0eb26249f6df"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f009c63-578c-4df3-b45a-f4d48c3b23f7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Mannitol</rdfs:label>
    <dc:identifier>DB00742</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1f0904e-1973-499f-a19c-479b79159030">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd9465fb-80db-4868-a16e-bea596cceff6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fc18f3f-9d9e-4153-afda-cdd26557c7b3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66712bbd-7a5a-458d-8f2c-88af87f56ff2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
    <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2401622-2c19-401c-b5b5-b14f8e6e41c6"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b6bdad2-25ce-498a-b8ad-82fd18045d49">
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011042</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89628dd7-584b-428b-91f2-b3bfbcccbd07">
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30e2bad5-325e-4f77-9c03-57f5b269c6cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>high serum phenylalanine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5263151d-1282-40b5-a054-4c09e549ee12">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>neurological malfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e973034-2bbf-4789-a118-ef934aec7d70">
    <rdfs:label>Topiramate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18826038-41d2-47f3-af91-65c42632c41d"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa061eb3-8be0-47ab-af54-4d9c66ba598c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeb8aa85-fcaa-4019-bd07-99880a473534"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <dc:identifier>DB00273</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a983e713-c7e7-4b33-a0ed-a4e2832d1617">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeb8aa85-fcaa-4019-bd07-99880a473534"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f8651f1-c4d7-44bc-a1ca-cfc1ffbce608">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d10a936b-63c3-4049-a844-01c8118148b3"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f24258d-aebb-43f2-b03f-75857705574f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5098d783-5de3-4236-8888-c1141ad4054f">
        <dc:identifier>HP:0030390*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfa06d4f-8172-45e1-9b79-20df1b61d6cf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low cell autofluorescence</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e5df7476-b10e-48e3-aace-1ba659ecc63d"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
    <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ca5bb1f-355e-4bdf-a037-53ecf9a0744a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80e46fd2-164d-4d6f-99d4-2859710e119b">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e9e1817-7142-4dc6-a83e-7135c387aec1"/>
        <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84a95174-ae3c-4e59-8027-e42858917452">
    <dc:identifier>DB00603</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c6b7daf-947f-41ff-96a7-e210d31b369e"/>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a3c7b81b-3771-4903-a6e1-e406613eb99d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/936a38e9-31ba-4df7-9859-a65fc32e97dd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2df2591f-22d6-4adf-9070-f63de964fe6e"/>
    <rdfs:label>Eculizumab</rdfs:label>
    <dc:identifier>DB01257</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6368ed22-0de4-4915-9a0c-1f4325cb26be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14ecc967-b86f-406e-9359-9c95661ce961"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8aa6c9d3-a1ad-46a7-be71-563e143ac050">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a03eaca-6ce6-43e8-be44-4382a95b0120">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d72b6dce-e6ee-40ff-b55f-e6f41617c4f3">
        <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
        <dc:identifier>HP:0100502</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1779c62-5f68-482f-9ea5-a8295805dee5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025548</dc:identifier>
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0694245e-3e2c-43df-87f0-6f7b0777770a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcdff5f7-3d09-43b2-bcf5-c0fda8e28954"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/642e2f85-f3a2-4463-912d-6e5d43409b2e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df052ebb-fefe-4230-828f-ef06ba537e12"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
    <rdfs:label>Elapegademase</rdfs:label>
    <dc:identifier>DB14712</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/940a6dc5-dcba-4469-a97b-65ddb74fd4b4">
    <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
    <dc:identifier>MP:0011598</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/064f03e0-7e97-4915-84db-0117784979d4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cabb080d-a35a-4ce5-848e-85f9f95349d9"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c05f5bf-0e04-4af7-92ef-47133427161c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/037e2bf7-ff68-478d-818f-953df85c6c0e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1f4ea216-3dac-403a-b29a-630a63331881">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55c7b11e-7e91-447a-91ac-c48b842aa3e1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffc7093-b068-4349-9abf-2ba4e2e4657c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72bf2674-b1fe-4dc5-94d3-fabaac212bf5"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a52461f5-a5d9-4bed-a319-27bc0644bcf9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfd4698e-6195-4083-815e-b078f72d6fb6"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9c5301b-677f-43d7-a16b-c06ac5171cf9"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
    <dc:identifier>N05A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a877ed51-e2d8-4ddb-89ef-36451aec812d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a918b6be-0a3a-4489-aab7-f2e49257e978">
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/355ef659-8a6e-4fa6-94d2-33a923224b8d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f3a159-1628-4d16-bfef-cfd5a05ac1f3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00688</dc:identifier>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6530288-8bd8-4db1-8f74-f2e17d566567">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66f5f75d-9d5d-4d3f-882b-1127842015f7">
        <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd3ded96-9a37-4e75-9e23-4d4f8f280dfd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9aa74d78-f0db-4ae8-98a0-7ac8e400b623">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00a4b3c3-2342-4a61-afe3-301f9b823caf"/>
    <rdfs:label>Valproic Acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bd5954e-5c49-4926-b17c-32a50d9e2acb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c092f6f5-42f3-4fa4-b65b-8af7aa6b03aa">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db3985c2-b6b9-41ec-be70-fa71c2927fd1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d757734-382d-4a37-b46c-36ecac272ff7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00313</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b647fc3d-a893-402c-a07d-d245c580bb35"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0227f94a-91b7-4c4a-a06d-6576450d1d82"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12fa3b3e-1bd9-46b4-9b70-b4cd595973e5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a601478-470a-4a27-9de3-fbfaa91e99ec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a9d32c1-188a-4a9e-8a23-38a9d52ce4eb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bca57e85-c670-4ea0-a655-0a9ad0ef9801">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Neurologic abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80a81f30-6647-4c2c-b1b2-2588e2f612d9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d628142-333d-4b26-b42f-e4df4db71876">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cceea351-a6d8-43c7-9bc4-9b3ac1e7067e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88c1d2f1-dc91-49bb-9054-e53dd38dceb9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cee6aea9-20a2-4d6b-9035-944ac7c5a01d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dd2a090-bb96-44db-ba3f-3b913d517497"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00509</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1a9c460-1115-41a5-9619-f4eed48bb6bb"/>
    <rdfs:label>Dextrothyroxine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/804ca8c8-8158-4715-b0c0-06027b1ffb44">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/711a8d7b-bd7b-46c6-bf59-20090d9ce915"/>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8be1823b-bc2a-4e0b-b900-cf7f4ebd3306">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b38ca848-e39f-4e42-9223-4a58059b6941"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1607c18-ccc7-42c7-8007-08a1fa0bd03d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ea6f20e-d453-4da5-be14-73ce43509c95"/>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17b27d39-08d8-4224-af37-88e041c2a3d6"/>
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79bbeaed-e415-4c4c-94d6-5b2f87f29a56"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7a01ba0-360e-4342-8e8b-066f0154103a">
    <dc:identifier>DB02952</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3e18973-3dec-40c9-8c8e-e47915bf5531">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2705a380-8b8a-4dc9-b4fe-dc65524fca44"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b43037a-756b-430b-9b6a-22258bfd67c7"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67fe55e1-ed30-4335-a4b8-bc1a5f2c14dc">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/368219e4-6dd6-44e7-81cd-532e93e2ed32"/>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c9fef0d-ff97-433b-929e-11cb23b41136">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da712b15-99a0-490c-8947-4d6f5ce3ea3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f89504b4-0eda-4abe-9daa-aa69a92725b3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7834053-daf8-4ab2-bddd-74692e310970">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/398aa24c-ed0f-410f-9a97-7747badeacdd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8c5bdb0-d3be-4bda-b2d9-cc21f405ac64">
        <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
        <dc:identifier>HP:0011990</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/951ab410-1c39-4902-86e8-ecc12b467625"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f6b7a0c-f002-47e9-bdb4-ac04008906e8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <rdfs:label>Alprazolam</rdfs:label>
    <dc:identifier>DB00404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3541cbba-2f3e-4a37-a68f-960deb314170"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c32eda36-58c6-4afd-937f-939d33650e89">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lipid peroxidation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/531e48e3-afb3-4961-970b-1c66e0ed148e">
    <rdfs:label>Galactose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23592d79-8156-4cc6-bd21-8d04b2e0d029"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1e59d260-d1ec-4ab1-a38a-35c9b37eb739">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/951ab410-1c39-4902-86e8-ecc12b467625"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607091"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB11735</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ae63045-256b-4a87-ba37-6d19a4f0355b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a009369b-5294-4233-ba21-a4a328782e51"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e8c92ee2-306e-4e2e-8b27-60f1290624bd">
    <dc:identifier>DB01599</dc:identifier>
    <rdfs:label>Probucol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/343b0592-0136-4409-976b-fb12c09a7a5d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e8794ad-47c9-4b89-ab5f-60b5ad15907e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/caa0aee3-8ad7-43ac-ab02-7d3de0108cca"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5553b4d5-f4ff-4329-8ace-618355296ca1">
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/751ec493-2c23-4fb0-b381-c500ca077567">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7f813cd-60f4-4fcd-ad8e-3335435d1ceb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c11707fa-281d-4b61-b727-9a974aa3f4ea">
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cab13c81-05ea-4401-ba07-bc8e8ff123b3">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed7c8982-4e79-47bb-bab8-6271a19cf6f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/88e411f4-6c32-42a7-b40f-9ba0ccdaf8a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adbdaea1-7e4d-4ead-ba25-c9c225ed75b9">
        <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb29b4a4-20c6-4096-92fa-8751a272d570">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9065b729-f567-4173-8b12-09bc18444ada">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebe4632b-bfba-4ceb-9be8-4a6a7b152677"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/349200ab-cb72-46c9-9c73-475251c5694f">
    <rdfs:label>elevated CSF GHB levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22adf1d4-aa86-4526-aa4b-e474af91bd48">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed02a91a-ac25-432e-9bd0-671025939aa5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/09718863-5d84-4ca1-b8ec-16426ab01a27"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3f329ef-b815-429d-b6f9-3245bf05ff5c"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15a22976-fdcf-4672-995a-f96304e9fc45"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac4861fc-4dc5-4d44-98da-69333cf3794b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cbe905a-cc20-4747-a444-a14ba62c42b9"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e63c954-0c21-4e98-98e3-7700d4f46046">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormality of movement</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5cc9035a-e403-459e-b23f-d544ff440c0a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9f69f8d-1a59-406c-9b5b-bf9c29cc9576"/>
    <rdfs:label>Cholecalciferol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <dc:identifier>DB00169</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f70af369-5e5e-4255-9ab3-c265e6f04729">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <rdfs:label>Migalastat</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b222979a-9ae9-4b44-b848-e34908e6d1f6">
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11a6ecb9-a950-4b78-bcac-820c2de2a760"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB05018</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f43e48a8-441d-48e5-b7a8-6ceb6d18d931">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50574a06-a7ac-4cbc-9370-552d5de412b2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/253dbfb6-c4c9-4ec3-84ea-9bd5fa15c3fa"/>
        <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf9e1e66-de3d-4a43-99b3-ac9ab91e2f81"/>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
        <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
        <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11a6ecb9-a950-4b78-bcac-820c2de2a760"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fcdcba6-13b1-4e0b-8dbe-ec4fc2578638">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0f8563c-47a1-4e26-8a3e-bb2c8b06ebaf">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f59d912-bf34-4531-b294-73250e2717af"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9806df12-6581-4315-9798-b80e9f4cc4e1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ad52170-f5c2-4fb7-ab22-f0f55418d4d7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90d9b9e5-2a42-4f37-9171-bfd78f416b05"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/146e5d61-dad2-4ea9-8e4f-55c96aa8cb8e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccb6fb1e-abcb-4ff1-8195-571e0a716bf7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e74c417-e8fa-4945-ab87-a631dd43f8ab"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e433389-6e25-4c63-bf76-7d10c8897710">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6eebe778-4538-4f53-ba95-0a5d17d872f9"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48505edf-4d02-458a-93f7-eb172be26b60"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ad52170-f5c2-4fb7-ab22-f0f55418d4d7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4a026a2-bd84-4a06-a21b-f543aa4ff6f6"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63c47c83-5bbd-454a-9675-86cc2915cd32"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4248b03-28be-42d8-a0b0-0562a9fb3b01"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6b4273b-985f-4ec6-be76-57f4de7da30a"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe4fa974-dd8a-4134-a3e3-23b366d751b5"/>
    <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
    <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6391925e-ad51-46cd-a848-20d0a7eabef4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c293b4fa-2fbd-44cd-becc-703befc3524d">
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2403c76b-780f-4a6f-84ed-5d919d2817a8">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bbc4cd1c-0efd-4c2c-9e6d-9955bd6ed77a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/733e9112-b19b-4381-b2c0-0664b4b099d3"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9348695a-4333-4499-8a07-c20d1317a386"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d315c413-bae4-433e-96be-f74e33da07c5">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000117</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
    <rdfs:label>low phosphate reabsorption</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cfd8ab10-f104-4764-b156-85c299faae1d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52e12eae-0deb-4ec0-918e-eeb7c42bd721"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67c188c8-e092-4143-b526-5fe031888e2d"/>
    <dc:identifier>DB03793</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/395b00df-1952-402a-b18b-937fea46fe49"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94e6654f-e073-4892-86f2-49209e6ed11e">
    <dc:identifier>DB00061</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/632f0b83-e3d6-4a14-ad5d-d2090e92564c"/>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef81c1b8-f08c-4b74-b5a5-a74afda28064">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26c56c81-72bd-4fb7-bfb7-2eeae7c91064"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6377736d-572a-4d15-b59d-0cb88358ca1b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6ccb5a9-ccb7-405d-9f56-86e7049ee1f1"/>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/732853b1-e2e9-4d89-960b-dd1d031336d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04cbe884-9144-4f40-8265-f7b7035f8c57"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86467b77-eb53-4926-a6a4-6221833d7787"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e268d6cf-de29-4277-8219-eec60e8dc254"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0fd962f1-20a6-4ddd-a897-b9ab43695bc3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8cf47e1-c767-40bc-a2d6-6355a91f1b6e">
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
        <dc:identifier>HP:0000407</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54a4598d-0d46-419e-b6e0-43fccff7c0cf">
        <rdfs:label>Metabolic alkalosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ec2e11c-bc14-45ea-bc6b-d08f87fb1fbf">
        <rdfs:label>Mislocalization of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0a2e711-65e6-45e3-9f4c-0db76c7e2fe1">
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab8cd42a-bb4e-43a8-a37d-ff0eb497c943"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e821a064-8345-4e8f-90bb-4e8caefeea79">
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd120bcf-be2e-4d32-a9da-cfa641a905e1"/>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6c9d376-ca7b-4160-b079-e1117665c941"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5921e8dd-b336-48ee-8d19-3c04b337e2c5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df34cf3e-17f0-4ca0-b89d-26744e0f8509">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ca4bb2d-c7e8-476d-8e02-4bac084f740b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e008ae9-41e2-47b9-8d25-b63bc33a67cb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:label>White matter changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b9cc1c6c-eb1c-4c53-af6c-74161e547cf0"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84cbbab0-38aa-47c1-ba0b-75017bfc3481">
    <rdfs:label>hypochromic anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c54c9432-88b0-472e-ba09-13b7927f93b4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e487ec45-c9c9-4e0b-bd57-629b9ae73a23"/>
    <dc:identifier>DB14992</dc:identifier>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1f0904e-1973-499f-a19c-479b79159030"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3dab6d11-e3b2-4a18-9f03-f5a65289d40a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0a8e426-576b-4c36-a026-0277e11645a5"/>
    <rdfs:label>Modified Atkins diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ac605c0-bc24-415d-94a7-0ab473ca5fda">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
    <dc:identifier>(DB00328</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfa2a1c6-b1d6-4ed0-b96a-d68a63f42287"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81b444cd-d6ea-4574-865f-a8e674395146">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c09d6251-9766-45c1-8260-39a6d6033900"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/398e858f-daa9-4b8b-a643-6f2015ddc16d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d347f82-4216-431c-b3ff-0071aae5b3a9">
    <rdfs:label>pruritus</rdfs:label>
    <dc:identifier>HP:0000989</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d796314-f2c2-43ea-8a53-11d8cf94b4c0">
    <dc:identifier>HP:0003688</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46b4eff6-497a-4f94-a75d-76ef4ea1e8af">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9150a20-4d18-4603-bc3e-17d25e57fc21">
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1eb1275-9bde-496f-9681-354255c735af"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4860051-9aca-4dfd-b66c-b19d400f7b0f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7240267a-3245-4447-bdb2-7cf8aa906136"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>r LCAT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74389c8b-af35-4649-bf0b-2374e01da4d6">
    <rdfs:label>Hypophosphatasia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <dc:identifier>HP:0002148</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d267f62e-5627-49eb-accb-bec949f2141a"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c1d71b7-f130-4a7f-94b9-f76b53041963">
    <rdfs:label>High prolactin level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000870</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfb6866f-78e5-4b16-860a-0beff0e3ca0c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010472</dc:identifier>
    <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3648e6f7-b49a-4cd4-8b28-8e9cf8a0a582">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54a4598d-0d46-419e-b6e0-43fccff7c0cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cb8b1bf-6493-46e6-90ae-a2cd1000ed9c"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d742ac12-e967-49db-a7a5-9bd600760026"/>
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74fa063f-fb6f-42a0-bbb5-7e778f5e77d9">
        <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
        <dc:identifier>EC:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34f612ed-0cc4-48af-a1ef-3cd290812663">
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low quality of ife</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6a6417b-7681-4735-8461-7e87f80d6c91">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e1063c9-6fbc-41b9-b6e3-28a328089972">
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99ebc1ca-b632-45c0-a749-e45d19de525a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
        <dc:identifier>HP:0002013</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7c2a30b3-783e-487c-b021-2035706b48a7"/>
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29467f99-74c6-4b52-90fb-ee3c2970b474">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cfa9de0-8843-43bb-90a0-fff41fde5af0"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76f16336-3e70-46d5-99a7-a049e99aa3ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13b0702a-9a03-4f93-9236-44c19993e46a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ed32a57-c530-4cd7-be77-11dad8e55244">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012656</dc:identifier>
    <rdfs:label>dopamine deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d35fdc13-5137-4df1-88fc-272eb870ba06">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96d14e8f-0179-4357-a1f5-35b2862b4987"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/098380c6-768d-410d-9303-cfe7e5a5b00a">
    <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012321</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59909865-fad0-4a6d-a503-cb70bbace729">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ec27308-357e-4901-9bd2-8a648661c944"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07fbebbf-36bc-4762-9b28-18e697db7c02">
    <dc:identifier>HP:0001954</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <rdfs:label>Periodic fever</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1922631b-124f-4d43-ad8e-cb9f595442b0">
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e985ad80-53ea-4c3c-b23f-110885cf14a2">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
        <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
        <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5731132d-2694-4db2-91ee-48c77f78af09"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bba14e86-5518-43ae-beae-ad698e26dc6c"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b95ff98-159a-48d6-8034-621a8f9cc5f4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
    <dc:identifier>DB12528</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4352fb42-1424-416d-921d-4f2cfcad126d">
    <dc:identifier>HP:0002718</dc:identifier>
    <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/146e5d61-dad2-4ea9-8e4f-55c96aa8cb8e">
    <dc:identifier>HP:0001913</dc:identifier>
    <rdfs:label>Granulocytopenia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7f32594-6f10-407d-a125-956e1b038c54">
    <rdfs:label>Acidemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cfd822c-1530-456e-a857-51889d29a910">
    <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88fb3bc2-6ca9-4ebf-962b-80752ca58c9b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42126e19-a685-4f52-8a00-dfa258b6dea9">
        <rdfs:label>Reduced visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd9bcade-186a-4f1e-8511-449d27ed28c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51ceca60-8b86-4426-8a28-09e3f5cb3d98">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f77453-f7e4-42b6-a2de-002531f95d96"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4311cd6-5e43-4cc7-a184-b56c3b9ebdd6">
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8dcfb002-9a5a-4591-b954-6681fe19bc66">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42b4f744-a4a5-47aa-a56a-0f603be440c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc0800dc-9a1e-452e-922f-4f6c7c817b92">
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3da90ab7-d4ae-42a8-af90-09df23d10de8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b843cfc-8bf3-4996-8f2c-8cd1b7cff789"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4deec4ed-ff23-408b-a7d5-06e40cd197e3">
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89ca3b1d-8684-4aac-9aa3-dfde4476c8b9"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2297988d-0574-4e4c-b141-c5603ef45e69">
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8147bb4-8115-4e31-8ef1-81948ba6886d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a847fd8-af6f-49bd-b1dd-22eee15a8860"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63c47c83-5bbd-454a-9675-86cc2915cd32">
        <rdfs:label>Gait instability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002317</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88677ed4-7e05-471e-8766-5c0f0f924af8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cced741-40ed-4c9e-a8bb-bd6bc2801c9a"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bcbdab8b-2401-4eb0-ab6a-78f2e1061e2d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97d6079e-2445-4e92-9812-b6ab167a9538"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f3d8168-14b2-45cf-b7c3-84495e8c9d31"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e4bf97c-6cd2-489e-85ed-0b147e140d94">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
    <rdfs:label>Stroke-like episodes</rdfs:label>
    <dc:identifier>HP:0002401</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b4b5e5f-86b1-4059-83fa-42803da074c9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b393836a-1c5b-47ce-947c-81731ad33012"/>
    <dc:identifier>DB00994</dc:identifier>
    <rdfs:label>Neomycin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/994c0ea1-028a-4612-8b03-5760bee283a6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63874f6e-4956-42a5-b9cc-bed2eec84f24"/>
    <rdfs:label>Zonisamide</rdfs:label>
    <dc:identifier>DB00909</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e120615d-3894-4af2-b930-7637555fe748">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cf05fbf-d39b-4b28-a814-73477b20cfbd"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c26c367f-6ac9-46c6-9c07-fc2fdedc6097"/>
        <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2dd3077-07e9-46da-b33d-13754228cb32"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cad1756-2add-480e-a5d1-76b544cfc904">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Low quality of life</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/322264bc-5c26-4131-8c51-0546996934c2">
    <rdfs:label>Phenobarbital</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9af799cf-7a10-440e-aae1-f39ba618353b">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50ae3a8e-f73e-401a-95db-9b8ee75f5b16"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/daf129ca-3685-4c43-8dcb-e2d76f8b195f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e655713-0f6a-4c38-99e6-696e8c840da2">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5d3fc73-ae48-449d-ba03-1e57a08d64ce"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a9d32c1-188a-4a9e-8a23-38a9d52ce4eb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e59b2b4b-13a9-488f-aa84-7798f71dbce7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce1b744-30c9-4898-839a-1a434cbd7cc6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/918e8af3-03d2-4e47-81ce-c37e18ad2baa"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/efc78ccb-bb2c-409b-8537-766434396b4c"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/99508364-0c31-4390-8f99-ac04b2d9d7af">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7c7e434-9c5f-4956-bade-9e49c1d26522">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3dcf1117-46d5-45b2-8196-c2ce508bba2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98870c08-af20-4a81-9f29-43662e3093e0">
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87585278-a23b-41d2-9d5e-2b6fc1c404f5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6391925e-ad51-46cd-a848-20d0a7eabef4"/>
    <dc:identifier>DB13873</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/158812d6-9163-4cb8-babc-af91ed850f9a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/733e9112-b19b-4381-b2c0-0664b4b099d3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
    <rdfs:label>Fenofibric acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81a606ee-99b5-4577-a330-c5e70d7c0dd8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
    <dc:identifier>HP:0010472</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfcca95b-cf48-4c3a-b6a3-dfefa46fb10f">
    <dc:identifier>HP:0010819</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>astatic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4d1fb51-5a91-44b7-9c66-b3086e0ff041">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a52cc20b-8b83-46cf-ac3c-3be3910161a4">
    <rdfs:label>Sodium citrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8ecfe0c-d74c-4221-99ca-23ebc46b5998">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07ce0720-7309-40c7-a7ca-6dad06e43170"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/364451c5-2950-4eb5-b077-6302c13c73cd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/555b1923-13e5-4975-96fb-fc8997acb521"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
    <dc:identifier>DB09154</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/235c3d14-f899-4888-880b-8b911403b480">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d3bc500-db57-464d-900c-46ac198ecd1e">
        <rdfs:label>Low tumor response rate</rdfs:label>
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d40148d-b493-489f-ac07-13319f9dfe9a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c3f4a05-d0cd-464b-85cc-ae574006e8b4">
        <rdfs:label>phospholylation of RET</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/629b8e40-c199-4f31-8370-97720dcf3825">
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
        <rdfs:label>overall survival( premature death)</rdfs:label>
        <dc:identifier>MP:    ....</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8fe4188-e46a-4638-a565-770f503453e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4eea5a7-4516-47c0-b3cb-92c27556a251"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8eb0a165-e35c-4616-987a-db76ac6d38c3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e6adb42-3ae0-498f-a751-c1432709dadf">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46998c96-d2d7-4f6d-9288-715356954098"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ca4bb2d-c7e8-476d-8e02-4bac084f740b">
    <rdfs:label>leucine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5921e8dd-b336-48ee-8d19-3c04b337e2c5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e28f9d7-95c1-4ae3-90f2-9ba535568097">
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
    <rdfs:label>Cataract</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/447c18c4-8e70-4041-9d19-3b7df3df189b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000735</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
    <rdfs:label>Impaired social interaction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cf56b22-4066-426f-b44c-4295520d974f">
    <rdfs:label>low physical capacity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b9d3218-11d1-494c-8cf5-699a11b2c5ff">
    <rdfs:label>Cholic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09cf4420-09e3-45e6-a66b-6f631d971a92"/>
    <dc:identifier>DB02659</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52e80729-7f27-41e4-be94-030cfd63996b"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/251ea1d8-b5e7-4931-8e76-b5e99b45e458">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef6ab83a-e5bf-45b8-b489-d71200422976"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adb32338-cb3a-4cfe-9568-58365960de82">
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed9932f1-7077-488f-88e5-c56e711573c6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59929b26-9698-4576-8cf4-0204e3d0a62e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e699e85a-095b-460d-a15e-86f7d760fbee">
        <dc:identifier>MP:0003949</dc:identifier>
        <rdfs:label>dyslipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a7f0ce7-7601-409d-9259-637d04204b50">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <rdfs:label>proteinuria</rdfs:label>
        <dc:identifier>HP:0000093</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27140403-3e4f-452b-8991-8ba6564ceb82">
        <rdfs:label>low APO A level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0317fa3-267e-4291-8f8c-42144dc6eac1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal plasma lipids levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07fb4767-2333-4091-9fc3-ec2de0eb19ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b09a9c6f-5c6e-4e8e-824d-b92f8b9a6a1e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bb88cc6-b739-4bbe-9727-e86073328b75">
        <rdfs:label>low HDL-C level</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5751681-1623-4cd8-bdab-a1b77738d623">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:label>Low Apo B protein level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78ec9d55-8358-4f85-8530-d3d6f11ad382">
        <dc:identifier>MP:0003193</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28af4e36-da69-44ff-ad70-434d070e79e5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/940a6dc5-dcba-4469-a97b-65ddb74fd4b4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edfe617f-a8f4-4a9f-8f4b-3a72b68bc195">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <rdfs:label>Thalidomide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d83214c-aca4-4eae-b1fd-c2444d2d8660">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42d5ce64-949d-42b6-b35c-b671b5d5e63e"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dacff46f-6f13-4acb-9e5a-223a16a0f9e0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01041</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51af8498-91e6-4837-aad9-014545d5d5f5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6834f325-703c-41c7-b695-ad856a577238">
    <dc:identifier>DB01348</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <rdfs:label>Spirapril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c015534-ed12-4eff-abf3-2c33af2d2429"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ea6fa46-1a1d-4bd1-84ff-23c1965e1d0b">
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012212</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90dbb52d-ab49-4056-b217-b7dcb90963f7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
    <rdfs:label>neurodevelopmental delay</rdfs:label>
    <dc:identifier>HP:0012758</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49e0a818-357e-449f-b6e0-802d5dc40f4e">
    <rdfs:label>Fluoxetine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e10a640-88d0-4c6c-a1ac-a67aba20536d">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40eaff8e-b6e9-4c55-b7a0-a6607f50adb5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9105123-07e9-4e07-b2fc-234e50d57b05"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f26c4bb-2ecf-450f-80e9-3317eae67a2c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00472</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81de4237-2664-43b2-bb19-4e1f8d53e3a8">
    <rdfs:label>Ornithine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <dc:identifier>DB00129</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/500e2245-77db-4575-a2b5-3461d9a8f856"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5562c3b0-7ef4-42c1-b264-b11519506b88">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cfaf7aa8-11b8-4299-aef2-cde9ed2c0670">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b542bff6-b7d7-4b32-8c43-ad041de514b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5263151d-1282-40b5-a054-4c09e549ee12"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53bee3ea-c6dc-45b4-8b41-dd028aa9b364">
        <rdfs:label>immune dysfunctions</rdfs:label>
        <dc:identifier>HP:0002715</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a870b62f-de92-4650-aa46-60cba1542799">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8f4b7dd7-be5f-44e6-b00a-489f698f0b82">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f8a6045-1c61-4edc-bbad-200f473e1733">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result was added</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/adcc43db-78d1-4be8-9a7a-c52c74e56217">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/293d2472-edba-4311-b4f6-d553a3b29f6c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5cdc9ed-101e-4f1f-bdc8-c6881bf567ab">
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56a59fd8-c98e-4080-80d7-51012a3f4fd1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9aa366b-27d3-433c-a28d-add26e575049">
    <rdfs:label>Pamidronic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36ff4a9b-e393-4903-8107-1109d6e679d0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b81b494-d7a2-4113-b20f-29569341cd5f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/346ebbda-2226-40f6-8590-7d00cd54327f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd47623f-14f1-441b-a024-7b8e4863f811"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74389c8b-af35-4649-bf0b-2374e01da4d6"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00282</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af3f10f4-c8b6-4f11-ab93-78156a39bd49">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b8efb05-48d6-42c7-b6e6-19a4e06e1739"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/281ccf5b-fd23-43e7-9814-2f978f649bd2">
        <rdfs:label>Diabetic polyneuropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001271</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/850da02e-01c3-4126-9123-e20503c7bbe0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd558b0e-3313-4694-b581-6e225df5a3f9">
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/359b6586-0a77-4061-ba0e-6feffcca1c7c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f91dfbf8-9fa0-4da2-929c-252795e7a659"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145980"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a870b62f-de92-4650-aa46-60cba1542799"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f422f51b-c7ab-470e-9b5d-8f6bf0b7c2ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5aeff573-e8f6-4878-942a-2e5c7fb77210"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e9b6243-a513-4941-b0ce-4590448f14a2"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ca048b8-8bc1-4a35-88a4-057343486db8"/>
    <rdfs:label>Cinacalcet</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/47711a0e-d090-490a-b871-7fd000038c45"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f616bf20-feab-4dd6-bfbf-d0b33728995e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/005dcd81-868d-4b2d-b839-c7d2b43f3916">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003077*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/707499fa-4573-4a74-836f-adfbb5394520"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afd7591c-30a3-465b-b72d-dc5e3eeb42c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67314d43-b002-4d30-9db9-a1f4df5f7a7f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80196547-8f25-4103-834c-3417bd65b80b">
    <dc:identifier>DB06168</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8f92031-55a5-4d78-b7c8-4a38beedaeca"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbd222f0-ccce-4eae-8c82-460fd7d6ea66"/>
    <rdfs:label>Canakinumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31674645-e85d-4263-b6c7-9213121adb8d">
    <dc:identifier>DB01611</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/586d65ec-d6e4-492c-8198-b68f7fbec862"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a52f774-0f8a-4b4e-9be2-2c4b5fa58441">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a009369b-5294-4233-ba21-a4a328782e51"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d622c379-90c9-4d4a-b995-8ee004a3e530"/>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b801f1a5-2f90-4180-b328-c9d893483647">
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fafeb52-37e7-426d-9757-c0c97d5a9c45"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfa4096c-8afa-4652-a6bd-d500b6351f6a"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9806df12-6581-4315-9798-b80e9f4cc4e1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4544339e-f409-426d-a986-f790eea025ec">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c285734-06cc-44a8-b5c8-8b48954a15cb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>delayed growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3216900a-db33-47e9-b881-dd1154f28cc0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4420e3d-7e0a-4b9f-b9de-18624e2e056a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6eb83704-c7b9-40ba-81d0-693680fb72c3">
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:label>myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abcf5447-fdb9-4c11-9dcd-fcf27098b029"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ab33ff5-4bbf-499e-9938-2010dabde1a3">
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8be1e54e-5ca0-41f4-9738-4fe98bd965f3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3301f59-cb4e-49af-9d1f-152fce512386">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/940589a1-2620-42e2-b615-1984ec17aed9"/>
    <dc:identifier>DB00999</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67266c63-40f5-4a26-8623-2f750b81b365">
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <dc:identifier>DB08876</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5b5ee4a-212b-4371-a162-d1e4772bf29f"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0dabde4-5317-4768-9015-9f0c4b80df44">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ca25656-4b22-4de3-bc12-e7e67389ca45"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbbb9a48-e58c-464d-bc40-fc768eaea767">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9b546b2-5433-406f-95d3-69b8ca15ecaa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34e83e0-ceb4-4b5c-9243-371e8549c8f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/722cb8b3-72c6-4c38-8180-b40cbd6e6215">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d796314-f2c2-43ea-8a53-11d8cf94b4c0"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a379835-6898-4442-bbee-6a86bf2dfb08">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd135e98-0d38-4372-a5f4-7977e1f829dd"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6bcd3838-c0b3-4f2d-9497-0b8c5015a40e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81d2c616-9cc1-47b7-86ea-f6f6ab703f16"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0990430-c4f0-4a2b-b4ad-4f772ce6f66a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5d9cabe-54f4-4ccf-a4fc-abf768aa4a28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7521ae3e-353f-4882-90ab-a99fd977c96d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a5fee83-1a4e-4389-9b34-20bc42e2b173">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high glycogen levels in muscles</rdfs:label>
        <dc:identifier>HP:0009051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2533574d-e44b-42eb-9b14-0778af92c9c2">
        <dc:identifier>HP:0001395</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:label>liver fibrosis progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e142b4a-205a-4b79-82ac-d17ae470b009">
    <rdfs:label>Abnormal gait</rdfs:label>
    <dc:identifier>HP:0001288</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd893588-9c11-423c-88c3-2ea25fd6734b">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bca57e85-c670-4ea0-a655-0a9ad0ef9801"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eca560ee-56ef-4346-9626-3a08a27763a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5220722f-d237-45e5-bc61-7e3add33f1dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/971cae57-7589-47fc-b3aa-51f7f2b3f55b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d35281f-db61-45cc-ab22-7efd41029716">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6eb46921-171a-4d68-aeda-9adfd8017c3f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d9eb0d9-98ac-456f-9f58-c77063a6e12d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea2e7b38-dff9-4bfc-945a-24c3ef90312a">
    <dc:identifier>DB04076</dc:identifier>
    <rdfs:label>Hypoxanthine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d42c3f8b-434b-48e1-b439-6ada342a638b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a9f61f0-abea-4aec-bbb0-ca89c575ad01">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <dc:identifier>DB00586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08649d8f-e8f6-4976-a5f0-9336e863196e"/>
    <rdfs:label>Diclofenac</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a2e52cfb-ef71-4adb-9d5d-aa82b8799792">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e8794ad-47c9-4b89-ab5f-60b5ad15907e">
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:label>Atherosclerosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34a21c53-659a-41b1-b7af-6dbe9da3eb78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/032800a8-baf5-42a1-bef2-9241f27a58f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9b02ee2-4adc-4a3b-a1ef-082422d16b49">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
    <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
    <dc:identifier>HP:0025454*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/20961677-21c2-4689-a414-09fbb712ccb6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d73eb5c-5b9f-4a45-8a9e-0f95fa83bd2d"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd9bb9b2-6c92-4884-bd71-5b8188c49133">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bca75230-50f6-4e1f-9291-5b30c0702604">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Jaundice</rdfs:label>
        <dc:identifier>HP:0000952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75139ff9-e825-41e7-b198-51971a31d70c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypersomnia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dacbb3b-beb7-4a44-93fe-ab6a4b7fc097"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1701074-111a-4673-8f14-53e2a602d404"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8831cba7-90a9-4e13-8e17-72dfb8e0b10a"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8db23554-dd2c-4b70-a688-3d4d9f3e1084">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab515d09-5113-4ac4-89d8-c61c11e48103"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9872c26-cafe-49f5-aa9d-df813573be9d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c602469f-1555-469a-8d47-929375a2f4a9">
    <dc:identifier>DB00098</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/161775e1-2aaa-4552-b6c8-d1ca13546aa9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/875390e6-46bb-4dad-8b3e-d8f187d429d9"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8eb62dbf-b727-4207-8256-aa535b17e5d1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78bb714c-2203-4710-8d0d-a5c72a4f6f16"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d07a211e-c05a-4b1f-9484-bcb7c695adeb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001410</dc:identifier>
    <rdfs:label>Liver dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1a30608-329a-4e95-a98e-3ca48016d19e">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6bf693d-6642-4d5f-a0ab-f7db24120100"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa66503e-1406-4186-8942-7543ad5bb64e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80f44e37-a174-49b5-a926-b54ac8bf0b14">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
    <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
    <dc:identifier>HP:0001877*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69cdf794-7923-43fe-a1bd-fa7ae480a1f9">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <rdfs:label>cyclodextrins</rdfs:label>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5327574-bd6a-47c4-8390-b485dd551d74"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07ce0720-7309-40c7-a7ca-6dad06e43170">
    <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004364</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d3082d9-2b17-4119-a335-df3d4e9177bf">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a63878c5-9d35-4be8-9563-65278ac31fb1"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c87e4f5-a85a-4520-ab01-62d40addbb8d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c751e936-de2e-42db-824a-d963a9d967b5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45a59231-c19e-4b17-af41-83b81f4615b6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be82b69f-37e6-49e5-b09e-8e432f819cb0">
        <dc:identifier>HP:0002446</dc:identifier>
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e1c0082-2ef2-4071-9d24-a3a2800ffdf5">
        <rdfs:label>Oligodendrocyte loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100709</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa1569ae-bee8-436a-a2f7-8ec5fd45c833">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pyramidal neuron loss</rdfs:label>
        <dc:identifier>HP:0002062*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86d4e768-754b-4c70-93f3-1acde984ea0f">
        <rdfs:label>Hypomyelination</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
        <dc:identifier>MP:0013438</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b78c26f-215d-4b8f-91d3-ba8afbf02148"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb2390b4-acda-45e1-9055-821fe5cfa7df">
        <rdfs:label>Neuronal vacuolation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1869c8f-8c03-4d4b-b626-0862a3a6c2f3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cfd822c-1530-456e-a857-51889d29a910"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae64b0ef-d9eb-445e-9571-09fce656eade">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b0506b0-9fe8-4dea-8f94-89482f777d87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cb6b68c-3a6a-41af-b7f7-4449d4c768f6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100708</dc:identifier>
        <rdfs:label>Microgliosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99a33100-0665-4659-a644-90d604c0017b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9d4e20f-2ac4-42b6-b787-d4b4483971e6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <dc:identifier>MP:0000880</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9620f95-9da8-4aa8-8828-72bafc3eb8e0">
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b2c5d7b-3708-412c-bdf1-19a60f7ed59b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f614950e-5296-44f1-8e53-ec0fbf38fc53"/>
    <dc:identifier>DB09241</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
    <rdfs:label>Methylene blue</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d39cffad-b5f8-4d75-81d2-dc9131571284">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
    <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
    <dc:identifier>HP:0012217</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13816ab9-0bd1-438f-8b5f-bd706b9d2f8b">
    <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0469d9d0-5ebd-4db0-b8d5-adacaec2b100">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88d9e02e-34ce-41fb-abef-0b2011d4929f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/441a3d55-2ec4-468e-8a85-5a8abc7514b9"/>
        <rdfs:label>AAV-based gene therapy</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
    <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
    <rdfs:label>CYSTATHIONINURIA</rdfs:label>
    <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/934927f7-37ef-4f09-b383-ab32a3b895fb"/>
    <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/293d2472-edba-4311-b4f6-d553a3b29f6c">
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f4b7dd7-be5f-44e6-b00a-489f698f0b82"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45edb67b-b66a-49b9-a22b-7ed1250b82ef">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c40a53b5-d4f0-4f44-aea3-c7e9f94e9e67"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/981fd130-31e3-41c2-a336-769a8799f195">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <dc:identifier>HP:0000821</dc:identifier>
        <rdfs:label>subclinical hypothyroidism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1e3e087-35eb-4241-a6b2-b34ce2a7e45a"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64c08b25-0018-405a-b512-dfc20eec8bd3">
    <rdfs:label>Sargramostim</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bbc515d-21b5-4d93-b361-2ca7e5749807"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a5a4ac4-09b2-4a17-a8f0-d05d334d397c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <dc:identifier>DB00020</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9105123-07e9-4e07-b2fc-234e50d57b05">
    <dc:identifier>HP:0000817</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:label>Poor eye contact</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e42ec896-87c5-433f-b7b6-fc48876846b4">
    <rdfs:label>Progressive emphysema</rdfs:label>
    <dc:identifier>HP:0002097</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1402e13d-78a2-452d-b079-146a32615abc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>photosensitivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <dc:identifier>HP:0000992</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c6f5431-6541-4fc7-be87-6f8e629023b4">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46f5282c-b242-4eae-9b64-e0364ecc5aa8">
        <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
        <dc:identifier>HP:0000166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d47a8322-6058-4eb8-b9b9-ff741af2c9ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8243aabd-a796-46a8-913a-5632b47de19f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/374cd58b-b119-4c6c-9fc7-f3bf316e3be9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01e8e043-6dd7-4041-a174-fcd700d250d4">
    <dc:identifier>DB00502</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a9aa0c1-ad18-4981-88fb-1ca3f1930511"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <rdfs:label>Haloperidol</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/080beba2-ab42-454e-bfa2-c3e70f5f7383">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36ca9747-d45a-4836-84a5-15f1cf5b7fac">
        <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
        <dc:identifier>DB08830</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcfda2a1-4f21-4a4c-99ee-62a4b8a66a9d"/>
        <rdfs:label>Dehydroascorbic acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/441a3d55-2ec4-468e-8a85-5a8abc7514b9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6048bb24-42dc-45e9-b746-a7d09772c4ec"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f82d870-b6c8-4eb6-8588-6221b0d09dc9">
        <rdfs:label>neurotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0469d9d0-5ebd-4db0-b8d5-adacaec2b100"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e950836-613f-4389-9b58-cd8a8def2c2e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a314421-06ea-4457-b1d4-fb252c4708a0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a829df3a-e02b-4016-880e-73edaab94a60"/>
    <rdfs:label>Bortezomib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ecde138e-c458-4556-8a7d-e8e2e1f3dcb1"/>
    <dc:identifier>DB00188</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2605bf9-91f1-4522-90f1-9775e6b40751">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2893da54-71b5-4a68-ae60-16bf0284a49a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/349200ab-cb72-46c9-9c73-475251c5694f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d5d9cabe-54f4-4ccf-a4fc-abf768aa4a28"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94ac7d1b-edd3-4285-848d-32e260cac7c4">
    <dc:identifier>DB01956</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/113217a9-a8c0-4401-9e8e-2fc44e5bbce9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc97a6b9-f10b-41c2-9b67-0dd4c264fe68"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e09c443-969d-431c-8142-8918875747c9"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Taurine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/087af317-5bab-49b6-a65a-4e469a72c134"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9645bead-9a97-48bf-b7b2-8567e88c7352">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c286c14-0358-45b8-a29d-9b1de0065748"/>
    <rdfs:label>Tazobactam</rdfs:label>
    <dc:identifier>DB01606</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34c71ec5-ea13-4a7c-a538-9efab3c76a56">
    <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0045010</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c46a1ce-4ce7-4dc5-952f-e05ae6a3c64c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2893da54-71b5-4a68-ae60-16bf0284a49a"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65b7a0ee-8883-4458-b5a3-efe1e3a046f8">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b049b9f3-3846-43ca-b8e7-821c1ea01232"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b508497d-7c68-4518-ae3e-6ae9c047eedd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27a66888-45a8-4c6c-8cb7-6535e27bc483">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7e18041-3063-4055-b178-0d03a39d848b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e1fccea-7ace-4711-94e2-3b17b771c3f4">
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/830d1413-354f-4ed4-b369-5d47ab367db8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0aabcf89-2744-46db-872e-45a766e42c92">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>abnormal hepatic function tests</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7f813cd-60f4-4fcd-ad8e-3335435d1ceb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
    <rdfs:label>Isoniazid</rdfs:label>
    <dc:identifier>DB00951</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5553b4d5-f4ff-4329-8ace-618355296ca1"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55c8d768-83f6-4e0d-b52f-d2191cf03fa4">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:label>Decreased plasma carnitine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79da40d1-0326-4d01-81a2-d3c9df608ee4">
    <dc:identifier>HP:0002474*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>communicative skills abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5cd76163-ecef-4c2f-a41f-0ddb49147b8c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa734f00-55cc-40e8-ab3e-2617989dffd8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e2be0ef-1b8b-4bd3-bec6-efe7e72531f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe0c8894-a4b3-4103-ab1e-9665333c7509">
    <rdfs:label>Risperidone</rdfs:label>
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4989dd2-09f8-442d-bd98-5e1774923823"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8642364-0fd2-4cef-aff7-a8e329a3f399"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/007ae017-e492-422a-8762-e08bbe711456">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/521222ff-65ea-4484-8dd1-21f6b997cfc2">
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>secondary hyperparathyrodism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be3c9f9d-8506-40f8-8a22-315c69bfbd96">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100543</dc:identifier>
    <rdfs:label>Abnormal mental status</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f056e0c8-56f1-4865-a3f8-ecb059efd766">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2d5660e-af80-4270-b55f-43bfda4dd13b">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c5d8f9b-93db-46cd-a7a5-ebf0de7e5001"/>
        <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
        <dc:identifier>DB14476</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75c275d1-3a96-44aa-bb9d-d626b08bf414">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ptosis</rdfs:label>
    <dc:identifier>HP:0000508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69c149c7-db39-4e31-9d9f-209702c739ea">
    <rdfs:label>ochronosis</rdfs:label>
    <dc:identifier>HP:0030764</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9162b838-93eb-42a4-9d12-218f58e245ba">
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4ae71e9-0cbf-47e0-bb33-80cad344eb7d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2bdacf66-1c2d-4f8d-ae0b-615479110345">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edc9a834-9648-4cf3-a1ce-d2a15db57559"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69b8d8c1-a904-4da1-ba87-4c3a744b0df6">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/349fd930-c2e3-4c34-b1a4-550bb5731cc2"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9fe889c-fdf1-491f-91ca-84ddec2827d5"/>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a49dd2ff-df08-4eec-8816-a3becbfeb839">
    <dc:identifier>DB00067</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a5fd61d-2b31-4626-81e3-3c50f23c718e"/>
    <rdfs:label>Vasopressin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4121d27-5eaf-413f-86a9-85b93cdce3ed">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <dc:identifier>DB00788</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3dafc4fc-7345-449d-a601-663ec1be2fc6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a379835-6898-4442-bbee-6a86bf2dfb08"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc818bd5-5120-46cd-813e-7829bec6c992"/>
    <rdfs:label>Naproxen</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb4f23ec-18ca-47c1-88a0-c0aa434211d6">
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormality in bone mineral density</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/585cde36-50a0-4b32-99f2-80c71122cb7c">
    <dc:identifier>HP:0000565</dc:identifier>
    <rdfs:label>esotropia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0d1c163-6ad1-4481-b3ab-73bf9ce9720a">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72b2611-f5bf-4506-9aed-e198ea6373ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9093d3a-5a81-4574-b974-70bd07884ec1"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02d91a85-f1a8-4aed-a592-4db958ae023b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cbed3563-1acb-4926-b323-86e481547f83"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84fdc90a-f31c-4f97-bb2c-ae6b1f29f85c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b08efb7-0db6-4fa5-8c58-b9ca1f35f20c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/851626f3-e56b-4dc6-bc5a-824c296eb7cc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <dc:identifier>HP:0003111</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0978cd54-ad5a-4168-b81b-449fb2fb0415">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d0c7abe-f41f-4c39-ada2-faf6248de369"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14ecc967-b86f-406e-9359-9c95661ce961"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4163ee97-6d81-41dd-a8a1-2e91f59f329e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6db5a469-57b0-4caf-8ff8-bdfbb4aa1ee7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f4c9221-12e5-4dda-8c11-f05d32fae292"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24cce4b6-7547-4c7f-97c3-c152ee88f135"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b07b617-cca7-473d-94b0-95c56fef18c3">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eaf7b49-cec4-4671-a8c2-01f50cca3b50"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5516913f-f9e2-4452-8d2a-49742c98f9f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aabf5bbf-78dc-4ac3-aba2-abf397c8705f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98cf90ac-e13b-47b4-9d02-27625baa8dfd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5d147a9-78fb-4d49-9af2-5c06758aee6a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c9d1483-d8ed-4f5e-a562-cf9e4c209b7a">
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
        <dc:identifier>MP:00011911</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51e7a0fa-29c2-487a-9048-9bc7631c521e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00fa6db0-1891-4015-bcf1-639f4660a786">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51757d50-3a94-47eb-93ea-c354d6ea7977"/>
    <rdfs:label>Acitretin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01939bf5-3e60-4a7a-a7dc-09afc9291440"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f90b53e7-e983-4d45-a842-792db8cadf27"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb5cc76d-9352-431a-987d-81284558d654">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormal movement</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b8f23b7-33f3-4cc5-bc50-12af81602b6a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e99c7814-fd9d-4128-a814-d3fa3f68bb93">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e06729b-25fb-410e-9c28-df478e205e36"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9aeb525d-5cbc-4d21-8b3c-f679ba192353"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d85c5f4-f092-49cb-aaff-62dc35218f54">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e154a342-4670-49d9-95be-30deaf4dde98"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd357443-ea63-487c-a806-dc129f976ff4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012030</dc:identifier>
    <rdfs:label>Abnormal urinary steroid level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ac74b5b-d475-4abb-a4aa-52ad91939d4c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
    <dc:identifier>HP:0001992*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04d353a8-6a56-4b81-9645-3f55392d5bd4">
    <rdfs:label>encephalopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001298</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50d072f1-a848-4852-bf30-0b7ea50ce0d7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8828d469-f070-47a2-a705-34a46d968164"/>
    <rdfs:label>Hemin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cec103dd-0c84-4a62-b26d-d4aa207f1c0e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d7310a2-d388-4ce5-8db5-a45a6d3003ea"/>
    <dc:identifier>DB03404</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7671cc0-c0f5-4c49-9930-854f1593a6fb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/552ab966-fa7a-4806-a158-dc92a0b68c57"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cea846f-7cc8-47c4-9c84-f91f94ebed07">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <dc:identifier>HP:0002180</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce4616ca-0d17-48ea-9bce-342ef5b54f6b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor swallowing</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
    <dc:identifier>HP:0002015</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82a8cf74-43a1-4ebf-9fa6-1dd371638fd7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d23c1c1-1c0a-494e-a8fa-d31fd071d08b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89628dd7-584b-428b-91f2-b3bfbcccbd07"/>
    <dc:identifier>DB00360</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39564387-dbde-4850-b7b8-c7490016434a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/401bba3a-cc56-415d-bd79-4e3dc539d694"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cb17e77-1287-4de5-806d-6236f16f7e9b"/>
    <rdfs:label>Sapropterin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b657bb78-0219-4c49-bf84-82907b9b0330">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941b6634-daa8-4b2e-b463-2fac9f1ec100"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d067c28a-3aaa-4501-b02b-f39703394094"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5750773b-4ba7-4e6c-992c-48345bca2fd2"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c1ecc5a-60e7-4b1d-bd1e-7ccffec27c70">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total homocysteine level</rdfs:label>
    <dc:identifier>HP:0010919</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20521ca3-8b71-4800-9273-d60bd0a9445c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d654d2e2-5e5f-4c4e-8a73-c2acfed3fcf7">
        <dc:identifier>HP:0001889</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:label>Megalobalstic anaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e832841-0e59-492f-816e-243a998fcd0a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00afa006-5330-49b6-b183-b307c26e16dc">
        <dc:identifier>HP:0001897</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
        <rdfs:label>Normocytic anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39a0af19-a4b4-4675-9ef2-ba5898cf913b">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc0db0a-8b96-4200-91fe-79b4f362fe63"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/264c283b-76a5-49dd-8a37-7bc7002fef20">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36e00010-11c6-4dec-9b42-c975e84a18a8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3849a62c-4ece-47f4-8d88-7646235d289b">
        <dc:identifier>HP:0000953</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperpigmentation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86df1bf5-291a-44cd-aa3d-e7def73766a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db03851e-1043-4453-bba1-5aa51d798fee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aef592d9-99f3-4675-a5a6-0d92cace2357">
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7c91678-e965-48a2-9827-529829af25e0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93cdef08-4d7a-4cb0-a286-897d1994b6b7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4e404d8-d13f-4f3a-bb73-a239465580d9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3648e6f7-b49a-4cd4-8b28-8e9cf8a0a582"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <rdfs:label>Acetazolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76f1bc6a-cae3-4797-ab95-704a08b68123">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86595754-1d17-4ccb-ab1a-2f728ec79ce3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d64b43b-5f9e-4430-9954-dbc532ad2f1c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd80e74c-7ffe-4223-a2ca-0d9fe0d4a5a8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b856cfb-b7ad-41b9-8e2a-2f23b285ffc9"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04896202-9261-4ffb-95c0-4ecb3e39ae69"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a1ca30b-560d-4162-8d7e-4538fb28adcf"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b43037a-756b-430b-9b6a-22258bfd67c7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7a01ba0-360e-4342-8e8b-066f0154103a"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/851407e3-d4db-4029-985a-68102855d589">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Imapired muscle function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f52c18e-dac8-48c2-9bc7-51b12f52b065">
    <rdfs:label>Ketosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001946</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8ee87b0-1069-41f4-8a4f-80925f8ea65f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
    <dc:identifier>HP:0008344</dc:identifier>
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/823f18e4-2620-427e-8cc8-22d3776e2639">
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:label>lack of strenght</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/052c394c-d7db-4a67-8fe5-f72d76951352">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8035780f-ac41-4c47-a0c5-663bffd46a43">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008222</dc:identifier>
        <rdfs:label>Female infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74032cce-1978-41fc-8d14-23ba7e943c78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce1d3e64-f5dc-455a-9eac-e435f46de046"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e2ae6d8-68e2-4c34-90e4-59cd26b76927">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84cbbab0-38aa-47c1-ba0b-75017bfc3481"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66eeb284-07a0-4926-a764-9d6c8a0b1919">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5610a08d-2a7d-454c-a145-b0a9aedafea3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/217cfc1c-b052-4450-b4b0-81191f86e72f"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d6bab5b-d643-481b-bf17-c188fdaffa9a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f8ef834-32d8-4e1c-9a06-0d21005e357f"/>
    <dc:identifier>DB05271</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
    <rdfs:label>Rotigotine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79ed3ee3-3cd7-4a63-b156-fc3434d9d4b6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb29b4a4-20c6-4096-92fa-8751a272d570"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35c21fc3-32af-4e18-81a7-8246924d54f1"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60df6c0a-8b1e-4cce-866d-74c0d9acd56d">
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3314f8c-e1d5-44d2-9cb1-f282dfefb6a1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
    <dc:identifier>DB01324</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0fb8417-ab21-4e91-b48a-9b3a7725c67b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7096a802-ee4f-4c3d-be89-c8643f39253c">
    <dc:identifier>HP:0025034*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>erythroid progenitor depletion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d887c3d-7e4a-4d41-8e61-f972eb663aed">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:label>Abormal liver size</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46233dc8-3254-4bef-8b56-19b6a21ab3a0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52fa3732-71d3-453d-bcf6-faf20278fb1e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3dcf1117-46d5-45b2-8196-c2ce508bba2e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <dc:identifier>DB03766</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99508364-0c31-4390-8f99-ac04b2d9d7af"/>
    <rdfs:label>Propanoic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94de5ca5-699b-4cb3-a369-3f364953a30c">
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <dc:identifier>M02AA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56160213-e451-4bcd-a70a-cbbee9cfe450">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e187be9-f9ed-4665-924b-9a8be99f69b1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a8d1018-7fe8-48fc-aaa4-562dc01a71d8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b03bbcb-312f-41c5-b866-df2b6bcfc69f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
    <dc:identifier>HP:0001278</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>orthostatic hypotension</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a38de070-226e-4fc3-a07e-27f08b2cdaa2">
    <rdfs:label>Liver injury</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001392</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c70036fe-7c25-45fa-94c6-08d097e76905">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <rdfs:label>Green tea leaf</rdfs:label>
    <dc:identifier>DB14307</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12cf4ab2-3588-4975-8d12-615441fe2807"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/135c03f8-15ea-487e-b1b6-5df3afc94adc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bdd4bbc-78c9-4a96-aba3-711acc866796"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0c991f8-347e-4a90-af0f-a44dfe5341bb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49fe8e79-b26e-48d7-babf-19a9d9736406"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ce7ecdc-1860-4039-813e-d9049d78266f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a38de070-226e-4fc3-a07e-27f08b2cdaa2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cf87a9f-c85e-49f2-bcf2-4ed97fb30c8d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7b3f6e8-760d-4be7-b388-0b9f490cb495">
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <dc:identifier>HP:0040006*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce4616ca-0d17-48ea-9bce-342ef5b54f6b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e40adcf6-1223-4fc6-93c6-2b94a0b182b1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a73e053e-09df-49a2-a481-ec9c953791a2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cfa9de0-8843-43bb-90a0-fff41fde5af0"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14f8eec3-1b0d-47b5-ad5a-2b85e56f73e3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d057164-f944-4e6f-bb20-a3c3fff958e1">
        <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
        <dc:identifier>HP:0040210</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c27d3be-8cca-4a4c-8a99-8c2db693a4a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffbc4930-f22a-4c5f-a587-b37677f9d4c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f25e6d71-662f-4ef2-97aa-b978bb1b5204">
    <dc:identifier>HP:0030178</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
    <rdfs:label>signal abnormality of the cortex</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ca89186-4735-4364-850a-160b0317a0ed">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c05f5bf-0e04-4af7-92ef-47133427161c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4ae71e9-0cbf-47e0-bb33-80cad344eb7d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbc1bd24-11bd-42a4-84ba-0358194e7959">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003158</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
        <rdfs:label>Hyposthenuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfa2fd09-039e-4aed-9763-1a3f9ae3c667">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acab9460-0fde-408b-8a99-fb879fca2aa6"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
        <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f9f8136-8d80-4dd3-8549-021e548c6657"/>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b43108da-26d6-4767-9177-d8e886a7b5e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/268576ef-e50b-4aeb-a2d4-66ffacb57565"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/615dc5c9-5fae-447e-8b68-c69f6c650e86">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c382c638-aeaf-4e04-8b6a-2859c465a6d0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000504</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
        <rdfs:label>abnormal central vision</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/597e760a-afa0-45a3-a025-ed34894e5bc0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
        <rdfs:label>choroidal neovascularization</rdfs:label>
        <dc:identifier>HP:0011506</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec3f2a74-c5e9-453d-9bc6-f7101f213db6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/607c7782-521f-432a-815e-057051c5c1dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eb4e678-72b9-40d9-a637-2552d1757853">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:label>decreased visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e9e1817-7142-4dc6-a83e-7135c387aec1">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ca5bb1f-355e-4bdf-a037-53ecf9a0744a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72535f40-2267-494e-bb5e-9df6bf9b6489"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a91b686-e457-4da6-bde4-956b3cb0bd13">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a64e2977-806e-4624-8a35-9bac82148060">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8ee87b0-1069-41f4-8a4f-80925f8ea65f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc5f777f-3073-4478-a908-3975829971dc"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1777090-9fd2-4456-ac74-ad892bd71e78"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52f4851a-e488-4ac0-b212-9b54e22ca378"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Norleucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4955bda-a178-4bd8-a816-900d07fff87e"/>
    <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
    <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15a22976-fdcf-4672-995a-f96304e9fc45">
    <rdfs:label>DIURETICS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b2d1d9f-3e33-4a5c-8ece-a8e6d4928c73"/>
    <dc:identifier>C03</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e6261ac-2373-4628-a9f9-1d991bcce4a5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d97572a-84ce-49f0-8675-6bd870a4dfb6"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e96b6542-beb0-40df-a0b1-93a8cb07db53"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22adf1d4-aa86-4526-aa4b-e474af91bd48"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/268576ef-e50b-4aeb-a2d4-66ffacb57565">
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfa2fd09-039e-4aed-9763-1a3f9ae3c667"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bba2f1c3-8299-437e-b2d1-a855c218af67">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a07684f0-8c31-40ac-95bb-ded479d84cb4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37f84eee-02d0-41d1-995b-a83510963aa0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613027"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a036fcb-9786-49c8-8011-28ace9de0bd4">
    <dc:identifier>CHEBI_32030</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a44fc3ba-9b34-45d8-b794-100c5bfdba75"/>
    <rdfs:label>Kaliumbromid</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14fc6b81-2337-4ab4-b49c-8a61ac6c5cdb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07518080-9e30-4279-9d15-60ea2652eeea"/>
    <rdfs:label>Velmanase alfa</rdfs:label>
    <dc:identifier>DB12374</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/253dbfb6-c4c9-4ec3-84ea-9bd5fa15c3fa">
    <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11b24f79-2384-446d-8e36-67bb27c940c0">
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d05e88b-76a9-4624-ad45-7bf5a91f13cc"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea8c039c-288c-4349-9e2c-682f704d55ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06dbd340-67a1-4c77-9c2f-a3297527fbea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adfda94f-4061-4802-9398-3e903d11c1f9"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50f62047-630f-460d-9707-c2451acef4f4">
    <rdfs:label>Atrial fibrillation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005110</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11a6ecb9-a950-4b78-bcac-820c2de2a760">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f70af369-5e5e-4255-9ab3-c265e6f04729"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/232a46ac-2049-4470-a7da-00ae1775e3fb">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32225104-c1e2-4bf5-9188-94c93defa960"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82f3cf63-d872-4332-a3b3-fcef86a78bb4">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f91dfbf8-9fa0-4da2-929c-252795e7a659">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003072</dc:identifier>
    <rdfs:label>Hypercalcemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a57d3744-7ed3-43a0-bf2a-2d5fe32213cc">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/652f8740-c86a-480b-9204-4428185f15f1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e09e612d-c174-4497-b15e-0b0fa90b145b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3ae5385-416c-4e3d-88b0-6f5b828398d9">
    <dc:identifier>HP:0031377</dc:identifier>
    <rdfs:label>Abnormal cellular proliferation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16b63096-e37a-47ea-8c24-a50b53038f90"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a11e3a0-8974-480f-a06e-1eea5c084bfe">
    <rdfs:label>Growth Failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ccc4ae5-4489-44df-843b-d942ee1a1030">
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/272324ef-3f9d-407b-9e57-f01ec19da783"/>
    <rdfs:label>Sobetirome</rdfs:label>
    <dc:identifier>DB07425</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/498fe19c-2496-410d-a02e-dbfe6ec4c887">
    <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100712</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/881801cf-e67b-484e-bd79-650bbaf727e0">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5d3fc73-ae48-449d-ba03-1e57a08d64ce"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a63878c5-9d35-4be8-9563-65278ac31fb1"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d3f7f17-c9b4-46a9-940a-8e9cbd2ea8e9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/177a9bf7-d384-43b2-8669-211a8b8a86cd">
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/398e858f-daa9-4b8b-a643-6f2015ddc16d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c09d6251-9766-45c1-8260-39a6d6033900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00028</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81b444cd-d6ea-4574-865f-a8e674395146"/>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/552e6b7a-ad88-4b4a-9fed-d6bf770b90b4">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <dc:identifier>HP:0002150</dc:identifier>
    <rdfs:label>High calcium excretion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9eae8588-af20-438c-a717-7a4db8507019">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
    <dc:identifier>HP:0031429</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low bone formation biomarkers</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81cf865c-490e-42d4-a540-590710a1362e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <dc:identifier>HP:0002360*</dc:identifier>
    <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f2955f3-3fec-4ed0-9fd1-a1777bf4e342">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <dc:identifier>DB14104</dc:identifier>
    <rdfs:label>Linoleic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed5ebe35-bdca-40d9-bcd3-1b5546f5239d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f3bec90-31fa-4dc3-b408-beda869053ef">
    <rdfs:label>Ademetionine</rdfs:label>
    <dc:identifier>DB00118</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08643ee8-0221-4226-8f96-766a7ac5d717"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b50248a8-d5c7-4827-bd87-0b0b951fc885"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82746bdf-b553-44e4-9e28-9d4ec8de3641"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f3b32c5-0947-4800-8c36-70d5aff1f64a"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/816f265c-4103-4ad1-8eb8-c0d019948dbe">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f84c37d-0859-4d3c-8201-edba5abe4db4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/440be4f7-be02-4d74-a87c-c9a9ea5bda88">
        <rdfs:label>Eltrombopag</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93ad1f40-dd6c-40a3-8bcf-fc6a8fcb2278"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
        <dc:identifier>DB06210</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b39058ac-240a-4232-b101-6235b762cc6f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c386ea5-9690-4f5c-99b7-6b46b85ea77c"/>
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f64b4a99-e68e-4c83-986a-fa588c39347d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53791a5f-2f95-4f75-9bb8-f605c3fb6d25">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa6d5508-f25e-4448-9ee5-bb283d02a4df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04cbe884-9144-4f40-8265-f7b7035f8c57"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a4e44d9-c213-49ac-bc99-91e97c88a948">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9357e507-2685-4323-abc4-2f8ea55e511a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2adbc36b-7e9c-4d44-9ec5-69205a926038">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000938</dc:identifier>
        <rdfs:label>osteopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dcf5382-2d3b-4f21-8d6e-83bca3f41caa">
    <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
    <dc:identifier>HP:0011118*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd9c34d4-82df-4979-8277-7a03e6f922ea">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <dc:identifier>DB00776</dc:identifier>
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12ca6ff3-6cd0-490b-befb-8df7d5c936a9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22bc794b-9706-4d72-87ae-d61c9a4946d4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef81c1b8-f08c-4b74-b5a5-a74afda28064"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/512e3c69-989d-44b6-bbaa-cc358eea4c8d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2a97b9d-fe67-4c94-ba4c-e281ceeb9ea0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4c207e8-5349-4931-bc4d-e78d47765c7a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ece832d-4848-4be9-aecb-37b581e05405"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <dc:identifier>DB00288</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ace0012a-9719-4153-9512-61b383cfe1aa"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f779eb0-bed1-4beb-970d-53f8a8f3a7a1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31aaf23a-f20e-4d45-adb5-7795a8084ef5"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a63b314-608b-4a9a-81ca-6e9a2d708469"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/560ee669-989a-418c-a7e0-882276424301"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Amcinonide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e13bc82-b2df-4f9b-a2f6-4b3ebd4b2225"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b93592b3-6401-4449-989e-a96e370111f5">
    <dc:identifier>HP:0001019</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <rdfs:label>Erythroderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b95ff98-159a-48d6-8034-621a8f9cc5f4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62c8df7a-98c4-4720-9b77-e034f2222b0e">
    <rdfs:label>Lorazepam</rdfs:label>
    <dc:identifier>DB00186</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad0a9f1c-14f5-4891-aefd-9b37eae7c158">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb703ac5-f882-49ee-83fa-57310bb6deb4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be3c9f9d-8506-40f8-8a22-315c69bfbd96"/>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fdb2f0a-ff13-4606-980c-debf4cbb4513">
    <dc:identifier>DB09269</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9badca47-581f-4812-93c5-43b12a78d11f"/>
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e5aa00c-950c-4212-9bb7-f29781c4cee1">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbd4e35c-7132-4fd7-bebd-c1dedb48b079"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ea6fa46-1a1d-4bd1-84ff-23c1965e1d0b"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc47b9bf-4dfe-43c8-83f8-49b8b3ee2fd7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Failurre to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <dc:identifier>HP:0001508</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b61f5216-e96b-4c2a-94c4-0d6ad3445593">
    <rdfs:label>Filgrastim</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9de3fde9-72f3-4faf-8a73-f42b27f2466c">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b764ccc-b1d1-4293-880d-db167bc12900"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20c44b8d-5609-4ee3-845a-2aeb97b7b0d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af2cb7e-1ca6-4e92-b6aa-cf2bf387f1ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/158dc01e-94b5-4915-bc25-4fc8df9381fc"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00099</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b78512b2-5386-4780-8ef7-98a84ccd690c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b6b592b-f592-437e-835b-546df7618a67"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4163862-1867-4150-b387-a28325dd9c98">
    <rdfs:label>CoCarbs + HPro</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c483f3e9-f80e-4f2d-b13a-155813f480a4"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b195c3c-dde2-41ec-bdd5-1b88049d458c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a293808-e537-4339-b8a7-e6b0a8cc07ed"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24166807-4286-44e0-8a27-12811e46608e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98ce0237-9fdf-4da1-b409-49097816a51e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
    <dc:identifier>HP:0010832*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e75a6e9c-0574-4c57-ae57-801b7f2276d7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
    <rdfs:label>disability(Functional motor problems)*</rdfs:label>
    <dc:identifier>HP:0004302*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b2128ad-12d9-48cd-933c-70fee9372efc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6dba8e66-11b9-4f6a-a077-3d9c9e6ef355"/>
    <dc:identifier>DB01076</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7537b02d-43f9-4b0a-af71-28cb1ced89b3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5449bf6c-ac9b-460b-ad46-6be56a54ee11"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d0b9735-9f36-4d57-8aa0-249e0b097e81"/>
    <rdfs:label>Atorvastatin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
    <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3bbd6739-8e49-4f70-8148-00c8cb61a699"/>
    <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57288a0a-ff89-4cd1-9b94-76c337df6675">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eece4296-487e-4702-96a3-90db79862000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75976640-f032-4f57-adcc-9fe155175f3a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62a56ca3-b5e3-44bd-8529-bd5327d97229"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7309065e-d343-46e3-939c-676937d7379b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/275f104b-d049-43e2-9474-5a45ac2afee4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e142b4a-205a-4b79-82ac-d17ae470b009"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaae60f-28b8-47f7-8eb8-f697aef67c91"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc1df2dc-dccc-469d-a269-9983d47a9ad2">
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1245d36d-7a40-4e03-91e0-0b5ca11f613a"/>
    <rdfs:label>Lovastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa35a2a5-398f-431b-80f9-41cfa877caf8">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ef31913-10fa-4a67-965d-063be7362d34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4281184f-087b-472a-bf30-1aae71b3e3f1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7787e63-5ae2-4ee0-9632-33a86d0118b7"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/237cdb08-bdfd-43bf-a99a-b24570015f86"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/198f3976-2360-4600-b36e-3f6dcdcda81c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22af28e7-5a4b-4cb4-8146-6e1bb27510d6"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b4bf0e9-7120-49e0-9a3c-7313a9841df8">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e86bc7e-bf6f-4c03-af0c-22dc5a17ce81"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58b8288e-8003-44da-bc42-04b31c0cb60a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5504d59-2ffb-4895-9a64-f05596511d38"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48447ac3-e936-42ce-948d-30ea85f71516">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001735</dc:identifier>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36f359a7-baf7-4318-82b5-5a358b5d8112">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a5a138f-e485-4aeb-95da-485426b1f914"/>
    <dc:identifier>DB00988</dc:identifier>
    <rdfs:label>Dopamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04376742-921d-4b54-a05b-27053b7ca102">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fad94b52-f4f8-4a00-a296-15a092d80d6f">
        <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/816f265c-4103-4ad1-8eb8-c0d019948dbe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0da0a2a-c3da-4b7c-baa9-c21111f73cac"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c7024f-b4e2-4a79-a027-4775ba0b8f58">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
    <dc:identifier>HP:0000739</dc:identifier>
    <rdfs:label>anxiety</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2501ba3d-58e9-4f7d-a98d-c25cfaa11ee1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73b5f7ce-bf56-4a3e-94db-70937ef2ead7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b81c65c4-fd0b-4419-9225-64458b27930d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80a4f9d1-8e7d-48ff-a187-08872cbc0fa8">
    <dc:identifier>C09C</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05f0c7c7-5da3-437f-a513-b09c8ad425de"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e5aa00c-950c-4212-9bb7-f29781c4cee1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc98983f-2722-4f1b-9a8a-8f8c6e6b01c7"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76610333-ab22-4d4a-9a47-33dfa341319f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3151df42-6578-45d0-9c1c-36f19b50ea3e">
        <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa2298f8-d472-4ba0-8184-028d6a438766"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f15ef51-0b8d-4f11-b75d-243e120248b4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ca6cfb-a17d-4658-82b5-80acd9977884"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5288c6e-1fe7-4169-86b6-2e9b34e2378f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac63736f-ffa4-4c27-b534-20b30d4bbe70"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a9b32db-06a6-42a2-8d11-5a077b5df8cd">
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
        <dc:identifier>HP:0002111</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a4e94ad-2a5a-4383-90a4-f8821263b64b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fc56461-a19c-41ac-80f7-c5a690c43234"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65528f4a-6815-4fb7-80ff-102d0ec11bb2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78b8777e-f1e3-4a91-bbf7-25c8fb146ce5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/232a46ac-2049-4470-a7da-00ae1775e3fb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b32688aa-f21f-42c8-9829-f50a60752d13"/>
    <rdfs:label>Deferiprone</rdfs:label>
    <dc:identifier>DB08826</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f6e2b87-b055-4a6d-87e5-7bff7f32c2eb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Thrombosis</rdfs:label>
    <dc:identifier>HP:0001977</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c72cc30-22b0-4c43-8e22-237aec1f8571">
    <dc:identifier>DB06372</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <rdfs:label>Rilonacept</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93ca0b06-8259-411e-9116-eaf520c78120"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b768f59-b948-4d5d-9f98-b020f53adb94">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3452a816-b8a1-4aaf-9c0e-56215349bc72"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b96c8c47-7c70-4a85-a972-f0ac89c1b34e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/61ed8845-7107-4439-9ca4-1e2bd3e4febc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd5f30ab-6fa8-4041-92b4-c315e566e59f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef096d5-e80b-49a5-9c0c-7388b7c269cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6ff49118-69e2-4da5-8b1b-b03182506fb6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/242261d4-5fbb-4fba-acf3-0eb1abafa9c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf355c7f-b9d2-4d59-8d9c-212a1814f27c"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a11e3a0-8974-480f-a06e-1eea5c084bfe"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5504d59-2ffb-4895-9a64-f05596511d38">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b4bf0e9-7120-49e0-9a3c-7313a9841df8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
    <rdfs:label>Heparin</rdfs:label>
    <dc:identifier>DB01109</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5232d7dc-c5a9-4c0c-bd68-c69ef40bd1a6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f459a18-8f4f-41fd-8520-2998f050a9b6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5d558c2-8c3f-4071-8cff-03d8083baf2c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc52b078-d618-48e8-9cdc-8016a2072d1e"/>
        <dc:identifier>DB13245</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
        <rdfs:label>Thiram</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1fd33c4-e64f-46a0-95d7-315615f75f69">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal reflexes</rdfs:label>
    <dc:identifier>HP:0001347</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/391e2917-2832-4f83-b4ea-a7585f44603f">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93027a1a-0cc1-455c-adbc-2a5cbd3fbe80">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b18676ce-f7e7-481d-bf18-86060704b03e"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b4fd5198-5008-4209-a719-c92b3dd78d1f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <dc:identifier>DB14681</dc:identifier>
    <rdfs:label>Cortisone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a55c2ec-d492-4e68-8a00-282d5c7455ef">
    <rdfs:label>Benzodiazepine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
    <dc:identifier>DB12537</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63033298-4941-495d-bd1e-6d79059f1454"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2db02586-69d0-4cac-9383-2dc32396c878">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9bb6e56a-cb60-466c-8d53-6e0a2dce8d62">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b99a191e-3cbc-45cc-ba84-dd14110037e6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2373090-613d-4bda-9018-c8b5e05dae80"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phosphorus</rdfs:label>
    <dc:identifier>DB14151</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d9e84c9-e709-4c2e-9306-9d2ec108232e">
    <rdfs:label>Digoxin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54971c2c-a20c-454a-87ad-231d0bbf7efd"/>
    <dc:identifier>DB00390</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b117b7c2-a2aa-49e2-bfce-56db02753d21">
    <rdfs:label>Glycolic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1065a8ae-714f-44c1-97ce-a8eed92eed7c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <dc:identifier>DB03085</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eaa8a71c-36bb-4ca0-93f4-ff1750f45390">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Proximal tubular dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <dc:identifier>HP:0000114</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/417c943f-e56a-46b4-8c05-0552fe2c6589">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7539c8f-64e7-41b8-a059-3de380c1f773"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad84aef7-1d23-468e-8eba-33f0a281efff">
    <rdfs:label>rAAV-PPCR</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bd597ae-f0cd-4537-ad95-80667601d343"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb703ac5-f882-49ee-83fa-57310bb6deb4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62c8df7a-98c4-4720-9b77-e034f2222b0e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/898a50b2-6386-400d-9840-0eb26249f6df">
    <dc:identifier>HP:0002181</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
    <rdfs:label>Brain oedema</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c269fca-0e61-4edc-8c0e-c096f43a0992">
    <dc:identifier>A11EB</dc:identifier>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4985d387-d468-4d02-a51e-a2369b183a20"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/084b2a35-3fd9-4b13-8d21-1eefca74efc0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced ejection fraction</rdfs:label>
    <dc:identifier>HP:0012664</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b843cfc-8bf3-4996-8f2c-8cd1b7cff789">
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc0800dc-9a1e-452e-922f-4f6c7c817b92"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0052fce8-325d-4d18-9533-cc43d31391bd">
    <rdfs:label>Tocopherol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2d7caf8-7894-455c-a5e8-175402cbae8b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8200960d-25ec-4bb0-8ced-e7f931e749c6"/>
    <dc:identifier>DB11251</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb1e630e-c82a-446c-98d0-9742f12ebf8e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08767fb1-d06b-4b72-9567-e2ed89685560">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad0e6303-a2bb-4a4f-b0ae-3fd144a8dff8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e27df70a-ed41-41df-aa9f-5ed03d5e6eae">
    <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001874</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c5d8f9b-93db-46cd-a7a5-ebf0de7e5001">
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/664152f2-e136-46c8-80ca-918e0ef71967">
        <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f056e0c8-56f1-4865-a3f8-ecb059efd766"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b06d530-52ac-4f56-8556-ffbc7a7f661b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>impairment of reference</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a59aa38-3a2e-45a9-a7f5-1135bdf7be24">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2369ffd-7180-4f9f-b762-8209d4ed9202">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>working spatial memory impairment*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <dc:identifier>HP:0002354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b509f0a-268d-4322-8373-8c8e419fbc19"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1108017-6fbc-4446-90b7-1816825ca126"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea35de46-7b7e-4559-8637-ece906663b86">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a3f32f6e-6bb2-497a-b68f-7f1edc816a82"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25ca3332-a2ca-49c8-bbaa-ba28014f4072">
    <dc:identifier>HP:0012649</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
    <rdfs:label>Inflammation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8a251ef-c622-45c8-b727-a883cd907a3d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee21f419-9976-4f91-a8a2-ac1e9921e1c7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6a6417b-7681-4735-8461-7e87f80d6c91"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1e03c11-dbee-4b18-85a6-93019614afa6"/>
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71e12ac3-a3e1-40ba-9c17-b57d729ae0cd"/>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1a30608-329a-4e95-a98e-3ca48016d19e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01076743-72aa-4fb1-93d6-27f5a506deb6">
    <rdfs:label>Protein oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34ac4711-f38b-4e68-b446-fe4dfcc7ea3f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f54f0a4-e344-4a63-bb01-c1b5dc304cc2"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/563d1d27-6e9a-4451-9710-da314979f74a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <dc:identifier>DB00636</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27162c9c-a137-423d-b975-3e4ccebc48c2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d741dccb-ef8e-4039-822f-1239c1aa2a67"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ca89186-4735-4364-850a-160b0317a0ed"/>
    <rdfs:label>Clofibrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b94459d-a2e4-4c0d-ad72-91f7c4d95dde">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b975c9ae-fe71-413e-8900-69563585fb2d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee305c21-1476-42d5-a1f2-4163d7080a98"/>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d017202-c31c-41d7-a04d-67cb575925ee"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <dc:identifier>DB08809</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20322566-345d-447b-9445-35410c113b6c">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdff136b-deec-48f3-98b1-d8d31864a96e"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44eb51f6-e941-4880-add7-093018f3bf17">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d2e79ca-e9b6-43f2-8ba3-c341198c2e45">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f3d9f2f-b718-4ddc-85c9-3c753dbafc77"/>
        <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be07b39c-5bf4-4305-b1df-c33c04d9b1a9">
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low physical activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae91baa0-d336-4435-a5bc-68efac372716">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <rdfs:label>Fructose</rdfs:label>
    <dc:identifier>DB04173</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a57d3744-7ed3-43a0-bf2a-2d5fe32213cc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5b14531-b4bc-4c2e-bca1-413c28cb2f30">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d74de25c-0cbb-4c0c-9dec-7703166a1c70"/>
    <dc:identifier>DB04729</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24147933-b439-421b-a2e2-e0b9613ba864">
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>behavioral disability</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47f38364-49e5-4eba-b445-885cb2fbd576">
    <dc:identifier>B01</dc:identifier>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e61a056-329f-4930-abd4-5319d83bccb5">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12ed3540-6f2a-4667-bf98-8ad89dfb2974"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f6e2b87-b055-4a6d-87e5-7bff7f32c2eb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1af35628-5f9a-4acb-a0a9-df768cf80679">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040189*</dc:identifier>
    <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e577898-8c2f-4817-a96f-6c46e92006ae">
    <dc:identifier>DB00571</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
    <rdfs:label>Propranolol</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a089ae67-fcd9-4476-8efb-48121733cd96">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0337e63-2258-4c5e-90be-b8df63116813"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cf56b22-4066-426f-b44c-4295520d974f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e39e5a54-5503-4b4c-b006-b544032b42cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52fb8c9e-2502-4e38-b388-3cbaa416c77b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2084562-df02-451e-9374-0a1b8fa51f85">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/041fe055-beea-4bcd-9f41-ddb4a5759e9d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0766c44-6983-4c8a-baeb-b4c1102c24e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d33271b3-12b9-4428-a3ca-6bcd6b660d67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB6756</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68e0e82e-6bf0-4656-bd22-51ff30c8b671">
    <rdfs:label>High plasma uric acid levels</rdfs:label>
    <dc:identifier>HP:0002149</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/128e6dcf-7a73-432a-8817-d9a089fef270">
    <rdfs:label>Optic nerve damage</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001138</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b493c84-aed7-4465-9f46-be617658810d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c31f466-644a-4852-a96c-bdde059b5fd8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
        <dc:identifier>HP:0012029</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ccdeeb7-51f0-4c55-b588-e76c867f48bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd357443-ea63-487c-a806-dc129f976ff4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ec08122-ac5a-4d22-82e4-896c2254a8ba"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81dfa979-a0cd-4891-be60-c3863babfe74"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1f858a9-9cad-439b-98f2-89d06640a3e7">
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc4f41b5-b7a9-4a62-b5db-94cb79ceed8f">
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c89da8b5-146c-4e6a-b845-8ad12d669ab1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f466b9d-87e8-44d1-bc3c-4d3d6972f093">
    <rdfs:label>L-Glutamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3dda97d-f782-4821-9c9a-4dfb840a5740"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4374e942-ecb6-4579-9a6c-743f6b654c98"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a52d3ad-315e-432c-a82d-bc9ff58803f6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbef015d-cadf-49e5-95ee-0c537c741dbb"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <dc:identifier>B05BB01</dc:identifier>
    <rdfs:label>electrolytes</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83964963-bd6a-4d0f-8f92-252e6370601c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low 5‐MTHF level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/679c5186-b72f-400d-a626-42d37ed253cb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90cd58dd-f5a5-4aef-a380-595f451fb0a9"/>
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <dc:identifier>D07A</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f560cf5-4771-4ab9-be74-2b3250f8ab25">
    <dc:identifier>DB06777</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b493c84-aed7-4465-9f46-be617658810d"/>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4264ab45-71fb-4eb6-81a0-4fbcc6595039"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a27b7ad4-6346-4a13-8563-a0b4e7215e0c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fc9369f-ff20-4f72-b0c3-051a089e2232"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91af7cca-793b-42a4-88ce-9565c5c6d080">
    <rdfs:label>Prednisolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6eb6d4ae-26b7-4219-a02f-4404fa4875e8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33e537cd-4efd-4e52-8c28-768b06df58de"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ff2c52f-a200-436c-abec-5a077a11045d"/>
    <dc:identifier>DB00860</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65ccc832-8e12-44ef-a17b-ef82e0127c2b">
    <rdfs:label>vitamine K</rdfs:label>
    <dc:identifier>CHEBI_28384</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a569d6a-d56b-4187-b34a-e946321b53fc"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/856a13ca-1fcd-4074-aba2-92752413f2d5">
    <rdfs:label>Activated charcoal</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79484d3c-506c-4703-b75a-c1d3c7fed59e"/>
    <dc:identifier>DB09278</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88c2669c-3715-48d8-a305-97329c12ae90">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa2298f8-d472-4ba0-8184-028d6a438766">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76610333-ab22-4d4a-9a47-33dfa341319f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a5688f0-e1d5-474f-998b-f1e68ed2ae4f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012113*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
    <rdfs:label>Low cerebral creatine content</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bfb5c9de-edba-4f4c-8029-b454c6ca3f12">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/531c42e4-4f87-4b7b-b1bf-06c33406b0e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2893da54-71b5-4a68-ae60-16bf0284a49a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1072beea-4537-41c7-9fe2-b7fc68cd9939">
    <dc:identifier>DB06285</dc:identifier>
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5624438-f71a-41fb-8371-fd0510c10f7f"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7c91b202-ac00-45f3-b73b-4e1663af1de5"/>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cfe38ed-a891-41d7-834a-734a98aa40d7">
    <rdfs:label>PL-induced cytotoxicity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0afa85f-8c04-4d92-8e2a-e8e614e0a2d9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0715d925-a942-4a4b-a415-00885ed76fb7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/563d7bd7-196b-4475-b17b-41ef70e18fe6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af8aa857-5eb1-4d22-b4cc-f0f44d048014"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3808f1ed-cb72-4498-bb0f-eb7d2daeb400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7240267a-3245-4447-bdb2-7cf8aa906136">
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low HDL-C  level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b682f74a-e4a7-4084-8341-6c444be483af">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002150</dc:identifier>
    <rdfs:label>High calcium excretion in urine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8535b43-b9d0-4ccd-b650-dd078113f2c0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9dea009-b978-47be-9b56-d85435fd6202"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b72a1afd-4c11-4626-9dd6-2367418f13ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece91ad5-0a22-4b8a-983d-b4f249927020"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f483da5f-38d2-4872-a1a0-0a38227ffe81"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3ec4442-53e2-4ace-9441-8183db608d3e">
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e1b88a5-8654-4cc6-85d0-7f1b55cf8b41">
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/851407e3-d4db-4029-985a-68102855d589"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9fb5a087-ef18-44d6-8b86-cfef2423e736"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/880defd6-d6eb-49a4-9fb0-75386e5f9cb4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7a76be3e-6e9f-49bf-9e2e-307f1fd2e244"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c39453f4-faa4-47b5-b67a-6cbe413a545a">
    <dc:identifier>DB00451</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d472d553-25b6-47f8-952a-3ba08b4aae6b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45edb67b-b66a-49b9-a22b-7ed1250b82ef"/>
    <rdfs:label>Levothyroxine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6ffc6139-af38-4605-84c3-9ec77a8c93c8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6c28310-dbdf-4e25-96f3-b64f33d05b27"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f6b7a0c-f002-47e9-bdb4-ac04008906e8"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b8dcd43-1406-44e3-bda1-feab52a9420e">
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal developmental milestones</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/052b6975-e813-478f-bdda-aff73af84dde">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <dc:identifier>DB01403</dc:identifier>
    <rdfs:label>Methotrimeprazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a9aa0c1-ad18-4981-88fb-1ca3f1930511"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b72a63e-5ee5-4f0a-bcb4-82e0ffd6ed25">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6208c9e7-5b4a-4037-9fb5-f6de0612f93c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1717d2d3-3f3e-4cc1-95cd-3e899a133990"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/414f01dd-ec91-4661-887d-dca8eafcbaf2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fffa6dc1-9471-464e-bb65-ef04580507d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17fed48f-cf3c-414c-9690-7207b16cbf96"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f2a856e2-7483-4ede-b4cc-ac6f6f28f3e6"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9c1f5e1-5369-4832-a2ab-27bfd3f439f0">
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiomyopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee1a8bad-3848-46e2-8f06-629f47955b06">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <dc:identifier>DB03147</dc:identifier>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0649d754-dc46-4c54-9310-d79b79cb3eb9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1c2477b-19b4-490e-a36a-701a94d4f908">
    <dc:identifier>DB00244</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/051ee681-31c0-42aa-bdc2-1176c245466d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
        <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebb3c74d-9b6c-47ce-9c32-ef0cf6d07fa0"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cc1666d-7379-4cf5-a0f9-809ed974934a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/158dc01e-94b5-4915-bc25-4fc8df9381fc"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Mesalazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc864910-7d07-4b28-aff5-55fdd9e068c6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal microtubule assembly</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50c33221-193c-4b0a-b4da-00db87c52f2f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c346cdbd-ded6-4a78-ac65-e6ff0b8c7d28"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
    <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
    <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c002b63c-3475-4d7e-95e8-693f1a6c4d66"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8a6e0ee-a3e7-4cfa-a424-550562648550">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/416022be-ec89-49af-a54c-1be19343b3c4">
    <rdfs:label>Pioglitazone</rdfs:label>
    <dc:identifier>DB01132</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30f4a107-63df-43e0-897d-d95d44f49952"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/09718863-5d84-4ca1-b8ec-16426ab01a27">
    <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0d158f6-cbac-4b86-875b-3bb4f0717769"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
    <dc:identifier>C09CA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22adf1d4-aa86-4526-aa4b-e474af91bd48"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/888f606b-3259-44da-9b09-63c444cc650d">
    <rdfs:label>Icosapent</rdfs:label>
    <dc:identifier>DB00159</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfe3e2b6-d40b-45b0-84ff-898261dcaaeb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4248b03-28be-42d8-a0b0-0562a9fb3b01">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:label>Elevated blood homocystine</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d0abf48-ecf3-4382-bd98-f4376a907ead">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c51102f3-5469-487d-9741-3638c21d2db8"/>
    <dc:identifier>DB00143</dc:identifier>
    <rdfs:label>Glutathione</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a71b36c-d255-49cc-a7e7-0c57ac693a0f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <dc:identifier>DB00111</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2706dcde-fb0e-4ab3-bc18-49d194e5c32a"/>
    <rdfs:label>Daclizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ede613b6-93d0-4c02-b076-c73b8a14acb8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>dysarthria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <dc:identifier>HP:0001260</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f3730d5-dfba-4ea8-9738-33d3a0eeff4f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d0b9735-9f36-4d57-8aa0-249e0b097e81"/>
    <rdfs:label>Pitavastatin</rdfs:label>
    <dc:identifier>DB08860</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/894a50aa-11fa-4a87-87ac-ed646c5a3c20">
    <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
    <dc:identifier>HP:0003495</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93ad1f40-dd6c-40a3-8bcf-fc6a8fcb2278">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f84c37d-0859-4d3c-8201-edba5abe4db4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/192a46a3-df77-4acd-afc8-3108d7d79eba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90d9b9e5-2a42-4f37-9171-bfd78f416b05"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88ee7d78-44e7-4b55-98df-320dc5e1f85a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/574168e1-9b19-4f06-b1b3-93766e7a3f83"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f81fc9f-9009-47eb-9016-7fa643e10e5a">
    <rdfs:label>retarded growth</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/607c7782-521f-432a-815e-057051c5c1dd">
    <rdfs:label>Bevacizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
    <dc:identifier>DB00112</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/615dc5c9-5fae-447e-8b68-c69f6c650e86"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f82fd44-0098-4f13-bb65-a18860b9312b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low intracellular cysteine*</rdfs:label>
    <dc:identifier>HP:0010918</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d156e49-e5e2-4488-a019-aa43ba76b43c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfa2a1c6-b1d6-4ed0-b96a-d68a63f42287"/>
    <dc:identifier>DB00700)</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23a5be26-5e81-419d-8d73-28be60c0bb2a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a03eaca-6ce6-43e8-be44-4382a95b0120"/>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a58d0822-2c57-4430-98d5-6ba76ec452bc"/>
    <dc:identifier>DB00115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/043b1a0a-5213-4b17-88ca-483c55a0454f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5d3a598-a8af-4274-95b7-7b9a260650f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1206e98a-f345-4eec-8552-773c107b8be9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a65bb703-b398-41ac-a265-0e3b097e468c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c848d5e-e6f3-4790-97a7-e5282ab6925f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2116f4ad-d81f-4832-8c0b-c6145b35a998">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/784b7119-0502-43c3-b03e-e2beaa71a9a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba72f902-49c3-49b0-8268-129f6a33df8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47e387fe-71c0-40d6-9019-53871201b2c1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012217</dc:identifier>
        <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2af6872b-c150-45a3-b056-e40a3003fabb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6f4c61d-acaf-46cf-a153-16c5d4d18601">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ede70e26-c6cf-4458-9905-7e9c97edcb1b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45ccfddb-925d-454a-a1a7-c49e5d929053"/>
    <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
    <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
    <dc:identifier>EC0:0007121</dc:identifier>
  </ddiem:Evidence>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/10eec07f-db33-429a-b75f-6702152d3023">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3adc0299-e316-475e-a73b-062af1e4fdf2"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/585cde36-50a0-4b32-99f2-80c71122cb7c"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6179482c-be19-47c6-aa2f-1a9abf1aabe9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4b0dd13-19ec-455e-a7d5-1f6f54dc8382">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <rdfs:label>Abnormality of immune system physiology</rdfs:label>
    <dc:identifier>HP:0010978</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f38d2639-0ceb-458d-b83c-264ab11070c9">
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28384333-ff3b-4aaa-a13e-dda66b00bbb7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8623bcb-682c-4a58-aa93-022461b52971">
    <rdfs:label>flavanols</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36559af7-b59c-4f67-92e9-89bc98f76d31"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cf5f290-9651-4e58-88cd-a5ed71990198">
    <dc:identifier>HP:0001941</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:label>acidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63185821-a268-40bc-b2cb-da6f9e138c47">
    <dc:identifier>DB01592</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fab7ae9-b35e-4aae-9648-597101e0f21c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a58d0822-2c57-4430-98d5-6ba76ec452bc"/>
    <rdfs:label>Iron</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1fbecd4-0917-439f-8d5d-2e6f659a2fcf">
    <rdfs:label>hyperproteinemia</rdfs:label>
    <dc:identifier>HP:0002152</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f254ba62-3390-47a5-bcf5-9c880861332b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:label>Low developmental score</rdfs:label>
    <dc:identifier>HP:0012759*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99fe085b-8d45-4d84-8f94-d3b7dbcc4617">
    <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebd5e161-ffcf-4e7e-9881-42e8b637f66c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
    <dc:identifier>HP:0002500</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>White matter alteration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a65bb703-b398-41ac-a265-0e3b097e468c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <dc:identifier>DB09043</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/043b1a0a-5213-4b17-88ca-483c55a0454f"/>
    <rdfs:label>Albiglutide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c12a2ce3-138a-4b7c-8690-32a092264c0f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da019ad3-639a-47e0-88e2-61270ce47d26"/>
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ddb12537-e141-4725-a775-b39463959f59">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfa06d4f-8172-45e1-9b79-20df1b61d6cf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6509bdba-958f-4df5-ae09-70c5d944f1e3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0dabe0d1-33c0-446a-9264-fbc31b4f3a13"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef5eec5a-bde0-4ef8-9060-8daf77deeec7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>membrane fluidity alterations</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02636921-7565-4aab-a6fb-4e3011ece367"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e5e9361-80b5-4365-9882-a366a1096059">
    <rdfs:label>Limb dystonia</rdfs:label>
    <dc:identifier>HP:0001332</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9534626b-f7d1-42e4-b9ab-80176bb06f3f">
    <dc:identifier>DB00073</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c23dcc8f-73bb-40f2-8853-4dbb799ca8c9"/>
    <rdfs:label>Rituximab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c6ac36b-4bcb-455d-9a70-60ccb62490b6">
    <dc:identifier>DB00697</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63033298-4941-495d-bd1e-6d79059f1454"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
    <rdfs:label>Tizanidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb48ff8b-2c8a-4688-a9b6-d283d4a88423">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/efaeca2a-58dd-452c-a1fc-9816227af1b9"/>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <dc:identifier>DB03485</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c212d191-1f7e-45a7-85ed-de01c8a4aba8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0701b11-4762-4bc4-b620-8725b5f03a59"/>
    <dc:identifier>DB00162</dc:identifier>
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ed2fbc5-c5de-4664-baf4-29c106ae7096"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/823d662e-a1b8-4690-9524-87ba85a53702">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <dc:identifier>DB13173</dc:identifier>
    <rdfs:label>Cerliponase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36f446a0-f352-4224-b760-d4dc61b0e1bc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf7bef0b-5adb-4dee-9fd4-7742e69f4fbd">
    <rdfs:label>Geneticin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a42b0bc-9a23-45c8-bbf1-68c45cd174df"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <dc:identifier>DB04263</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91e8e6bb-6127-4f86-adf8-70aff8f1e111">
    <dc:identifier>DB09144</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b524c7c-a9fd-48e5-a03b-0e5cd9750e87"/>
    <rdfs:label>Uridine triacetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/706371de-39da-4b65-bb89-ac1d7fee73ee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/62c6c722-06b0-4641-914e-cd9ce5e70406"/>
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a94cfbd8-75ac-4d0b-95fe-cabb8d0a1480">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <dc:identifier>DB05294</dc:identifier>
    <rdfs:label>Vandetanib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f6cc0c9-b675-40d0-85f3-ee5c2e8ead56"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2e41ea6-b423-48e1-aaea-80d4a421ac1d"/>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/744dbc08-13d4-4503-a7b0-11688f9f2596">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3768645-431f-48df-9887-fb70e1ee8555">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b52c60f-2502-4167-a8ef-0b75477e0323"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ed4fd73-d918-4be3-bff1-93d84e5a6c8f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Biotin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e098e85-25de-43c3-ab5b-6d5bb6dcd9cf"/>
    <dc:identifier>DB00121</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/980090c3-ccac-4a28-82d5-39cacc0d9ee1">
    <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9100fec-5a81-4c2c-a575-c2a15b286cd8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <dc:identifier>HP:0004348</dc:identifier>
    <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4eea5a7-4516-47c0-b3cb-92c27556a251">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/235c3d14-f899-4888-880b-8b911403b480"/>
    <rdfs:label>Cabozantinib</rdfs:label>
    <dc:identifier>DB08875</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2dc28944-2bf7-4c6b-83d9-4b3f23e80434">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02bff4ab-2bbb-47c0-9094-95f83f33e532"/>
    <dc:identifier>CHEBI_26537</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
    <rdfs:label>retinoid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89493d8a-f22a-43b7-aa4f-a5c4121d91b1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4631fdf-72f8-4149-b1c3-99074d207c52"/>
    <dc:identifier>DB06756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93f53cd3-4f92-4020-835b-90d43b91495a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <rdfs:label>Glycine betaine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e32ea1f-6cc4-4bcc-bec7-3521f24bd9c5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6368ed22-0de4-4915-9a0c-1f4325cb26be"/>
    <rdfs:label>Probenecid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0978cd54-ad5a-4168-b81b-449fb2fb0415"/>
    <dc:identifier>DB01032</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39f26b8e-057e-48a6-abd1-461991706c24">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2df13e4d-7f28-40a1-86a2-1fb36533919d"/>
    <rdfs:label>Calcium</rdfs:label>
    <dc:identifier>DB01373</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67919c2e-59c1-4cf3-bbb0-bb2718753cfb">
    <rdfs:label>Lipoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/128df633-d824-41ac-b6d9-0d26434a6907"/>
    <dc:identifier>DB00166</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f22ebc28-9cf4-4246-9456-75e336f60057"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79ed3ee3-3cd7-4a63-b156-fc3434d9d4b6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00acbc92-86bc-425d-801f-1a9bfdc41bb8">
    <dc:identifier>DB01037</dc:identifier>
    <rdfs:label>Selegiline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1acb2eb-9e43-4f33-bca8-bf6d23e7ab57"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cceea351-a6d8-43c7-9bc4-9b3ac1e7067e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/478501a6-c93e-48a1-96aa-83021109e67e">
    <dc:identifier>DB02209</dc:identifier>
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18dfd05d-aa02-42a4-a254-a5677682c753"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ae0d44c-d44a-4164-b94c-0479af74835d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93843f74-5323-46a7-942a-cd7e19428d13"/>
    <rdfs:label>Infliximab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <dc:identifier>DB00065</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3fc97b8-d5c0-41e4-9631-f56c65435c67">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4b0dd13-19ec-455e-a7d5-1f6f54dc8382"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2430d674-e64b-46cd-a343-635cf878fe8e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d8475e4-3f83-4149-a06c-b9c4cbc2cd99"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9f974ee-3cc5-43b7-8fd2-01192ea58ddc"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/000224b1-9a3d-4885-9172-cb9f80e66d6a">
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:label>deteriorating pulmonary function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2c52f6c-b2a0-4125-ba78-f95ccf447d3e">
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16d48b36-3e37-4069-84dd-bab082169292"/>
    <dc:identifier>DB09539</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a5398a5-1678-4bb5-a784-8bc9b30c9685">
    <rdfs:label>AAV-GLUT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24a9bbd4-b4de-4ef8-b54c-05a6cdd67d52"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dd2a090-bb96-44db-ba3f-3b913d517497">
    <rdfs:label>Hepatomeglay</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffbc4930-f22a-4c5f-a587-b37677f9d4c1">
    <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14f8eec3-1b0d-47b5-ad5a-2b85e56f73e3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4d8293f-a0b1-4470-8873-ddf7361929fc">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b195c3c-dde2-41ec-bdd5-1b88049d458c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5bdb5842-da73-4703-abb8-76142c6dc116">
    <dc:identifier>DB00608</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec4c9975-62f3-4e05-9345-4357e607e277"/>
    <rdfs:label>Chloroquine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85888ba4-7cfb-4f6a-8953-ce89e1a18573">
    <rdfs:label>high plasma ferritin</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/032800a8-baf5-42a1-bef2-9241f27a58f7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2e52cfb-ef71-4adb-9d5d-aa82b8799792"/>
    <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a836316b-3d8c-4839-960f-6414de8ce35c">
    <rdfs:label>Citric acid</rdfs:label>
    <dc:identifier>DB04272</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226bb2c5-9400-4a3c-895f-e84a507f117e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d1455c10-5bc2-480c-8e2f-d9547a1ed20e">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9395aee-b4c9-4036-a7eb-789af8336854">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/61ed8845-7107-4439-9ca4-1e2bd3e4febc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/054fa7d1-ebf0-4362-9e1b-7571b6c58f51"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba4ed023-3be6-48f7-ba57-870873f3c8b8">
    <dc:identifier>HP:0008972*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a358c532-4289-46f6-9c2d-1d63e27fd87c">
    <rdfs:label>Baclofen</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7465158f-4a9f-43d5-abb2-b60ffd5967a5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/442bad41-442e-4752-90b8-117632f4194d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <dc:identifier>DB00181</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/664e9f7f-f05a-4541-aef2-bfc19487fe36"/>
    <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/041fe055-beea-4bcd-9f41-ddb4a5759e9d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52fb8c9e-2502-4e38-b388-3cbaa416c77b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3149512-e11d-4925-9ffc-fbfdd68a9a29">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>language impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
    <dc:identifier>HP:0002463</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2fa1614a-99ae-4bb9-b5a8-2d8f155c1201">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68e0e82e-6bf0-4656-bd22-51ff30c8b671"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c95e1990-cf9e-4afd-991f-ea0e12d81ceb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05b208a0-d210-443b-8f4e-7eb2c4746eab">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/368291aa-b3b4-49d6-b1cc-87ea33505c00">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02fe4fc6-f4f8-4194-9f78-30ea4f4dcb17"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/161775e1-2aaa-4552-b6c8-d1ca13546aa9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <rdfs:label>Ciclosporin</rdfs:label>
    <dc:identifier>DB00091</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50303f97-89b7-4016-8fd7-728e33162d84">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/875390e6-46bb-4dad-8b3e-d8f187d429d9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6be1ef24-de92-43e4-a708-5e5286c87473">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031544</dc:identifier>
    <rdfs:label>High blood malonylcarnitine level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d4e6f18-d6ce-467d-a66f-9614e0bc00ea">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Diabetes</rdfs:label>
    <dc:identifier>HP:0000819</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07557582-883b-4c32-a39a-d8c9f6675c18">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/054fa7d1-ebf0-4362-9e1b-7571b6c58f51"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d510aab-e949-4aae-abf2-8b369b0bdd83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/894a50aa-11fa-4a87-87ac-ed646c5a3c20"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e71d5737-cc02-4bfa-b1da-53f7e1effd19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50fd257c-2601-44c5-8d65-9b52678b2aa4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004345</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
        <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1717d2d3-3f3e-4cc1-95cd-3e899a133990">
    <rdfs:label>Cefoperazone</rdfs:label>
    <dc:identifier>DB01329</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b72a63e-5ee5-4f0a-bcb4-82e0ffd6ed25"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b99a191e-3cbc-45cc-ba84-dd14110037e6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2db02586-69d0-4cac-9383-2dc32396c878"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/314d89a4-d39b-4be0-98b5-a258dca150dc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7159043c-a4aa-405e-8d8d-27604f655feb"/>
    <rdfs:label>GNT0003</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b61e24aa-b008-4d25-89a2-f89a8b75534f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
    <dc:identifier>HP:0007359</dc:identifier>
    <rdfs:label>Focal seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4a88fcb-1cfc-4dfb-8803-ae050482ecda">
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/510c05df-f4ae-42f7-9262-eb808efa48e0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
    <dc:identifier>DB00855</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ece562a-6c74-4116-be0d-778144dfa6dd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/248fe1f0-7114-4e59-b746-5b84b963700b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <dc:identifier>DB12536</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be2de346-bce3-4f12-b90c-32336203e5c7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b6eff20-4285-4cf9-8a26-3348bdc137af"/>
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d9c5301b-677f-43d7-a16b-c06ac5171cf9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/037e2bf7-ff68-478d-818f-953df85c6c0e"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97447b63-c7f4-4b6f-9de4-cafc71e99268">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/09718863-5d84-4ca1-b8ec-16426ab01a27"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f636d678-b760-425d-b48c-c9cb44472451"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac4861fc-4dc5-4d44-98da-69333cf3794b"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3f329ef-b815-429d-b6f9-3245bf05ff5c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76154b12-6a67-4372-8586-0c63cd6eee92">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012051</dc:identifier>
    <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac46ddd4-fe2f-4675-bc1a-dbfbfaf00b5f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08649d8f-e8f6-4976-a5f0-9336e863196e"/>
    <rdfs:label>Ethoxzolamide</rdfs:label>
    <dc:identifier>DB00311</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7fabebf-d6ce-47aa-8479-dbf83bcb8f9b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3ae5385-416c-4e3d-88b0-6f5b828398d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3d08770-f6f6-4e27-907b-d5ec35d8e173"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85d425bc-b325-4e79-ae63-8377d9642407">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>neurologic dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ba6865f-031f-4a88-95f3-34f48667abe6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10eec07f-db33-429a-b75f-6702152d3023"/>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0cee0bca-6f4a-4bba-aecb-acc499ed79ea"/>
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89ca227d-790f-4a99-a6de-e0af90bc0dea">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3adc0299-e316-475e-a73b-062af1e4fdf2"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38a897eb-da41-46f8-a1d6-aafd59758d15"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48d96a3a-8831-469c-9956-7d9b3671fbef">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/42599921-0a2d-4ddb-be08-0ba8b116b786"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
    <dc:identifier>S01BC</dc:identifier>
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31dcf2f1-3fa6-4ea8-9dac-2955e17bfe8d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8da5c17a-d8d1-436e-ad25-5cc106dc5edc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25bddb0e-a921-46d3-8c31-d58b68da910b"/>
    <dc:identifier>DB00328</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21814c36-9226-44ef-b887-bc8d8bb294e4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00deefff-503e-4edb-89e6-adc9a55adb06"/>
    <rdfs:label>Indometacin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f9f94fe-74bd-41f6-b05c-b8f02e1970d1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7fabebf-d6ce-47aa-8479-dbf83bcb8f9b"/>
    <rdfs:label>Dexamethasone</rdfs:label>
    <dc:identifier>DB01234</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0db9dd51-2991-4753-aa56-b7b17db43f0a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cc822c0-829b-4a2c-9424-96f3a2828174">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1e8d1f2-355f-40ae-8958-479821c2bbb0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1add26b9-141a-4104-8adc-abac0a29c9b0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/118d17bd-ed81-4ff2-8e76-87501e1f6b78"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1daf8b3b-c100-4e80-918b-0e5b2fd67324"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e6adb42-3ae0-498f-a751-c1432709dadf"/>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a0c02d2-4afd-4855-91e5-73d24585be5a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c393967d-800e-4163-9926-928f4fbdb5f3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d0b9735-9f36-4d57-8aa0-249e0b097e81"/>
    <dc:identifier>DB01098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5731132d-2694-4db2-91ee-48c77f78af09">
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10b8640b-2385-4f0d-8a85-bcfff6724674">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b82cd115-6ae7-4ae4-8b23-98166a334ca1"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/212127cc-64c0-4894-b037-4db09f0db16f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a298c8c7-3eaf-4e47-9f08-3b988034ba1b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42948e3e-e4ae-4a24-804d-c153e79f4073">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e4dee7f-6a5f-4f9e-8f50-98410cd1e689"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1eb49c-1091-48b7-99d0-dfa5a89b30ed">
    <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
    <dc:identifier>HP:0012335</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85c1db22-3cd9-4ddb-be83-b70c2e12963f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/128e6dcf-7a73-432a-8817-d9a089fef270"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1404189d-35d8-4abb-bb96-5b9749df1d8a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4f08c85-d467-476e-aaa7-39d6ada4cc5f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10d3aaa7-f5da-47db-a66e-86d8716e5a70"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8dac0e7f-5f30-44b2-a5b2-50171f3ccc8f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
    <rdfs:label>Folic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0e5c43f-622a-4b86-ae94-366e1fc006f0"/>
    <dc:identifier>DB00158</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d97572a-84ce-49f0-8675-6bd870a4dfb6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Fukutin function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9d68ab0-9ba6-47cc-84ca-0daffc8e2437">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebe4632b-bfba-4ceb-9be8-4a6a7b152677"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277410"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c360d1a3-3aee-4de6-be54-82b2539bea4b">
    <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
    <dc:identifier>HP:0001980</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10267dd4-a9da-47e2-b793-33d4806fe16d">
    <dc:identifier>DB14500</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02d91a85-f1a8-4aed-a592-4db958ae023b"/>
    <rdfs:label>Potassium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79d10fcf-7b34-4223-ae82-9c4ab9aca1c1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84c636f9-7dd0-4d90-bc29-e8e7a01880e5">
    <dc:identifier>CHEBI_15724</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66b49d87-5b3a-463c-9f65-07038eabd615"/>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4daee65-d089-4c40-9d86-98f6edb7d78b">
    <dc:identifier>DB03756</dc:identifier>
    <rdfs:label>Doconexent</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88fb3bc2-6ca9-4ebf-962b-80752ca58c9b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2373090-613d-4bda-9018-c8b5e05dae80">
    <rdfs:label>Rickets</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <dc:identifier>HP:0002748</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86f669f7-a772-454c-8aae-628976d513b0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/955645a3-fb33-448a-8503-5a6790690bc5">
    <dc:identifier>HP:0002530</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Axial dystonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/242261d4-5fbb-4fba-acf3-0eb1abafa9c9">
    <rdfs:label>AAV-cG6PGH</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd5f30ab-6fa8-4041-92b4-c315e566e59f"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9dccea44-cb63-4158-81ab-e2b338f88f67">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2ad8124-c5fe-4fb5-b553-e0c14a790953"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fe7f092-65b3-44cd-9e77-ac7c05936541">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14bc6b19-179a-41f7-a1c3-a64e0a5ebf45"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c9a73d-4af7-43ff-a3dc-6711c7180453">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <dc:identifier>HP:0001943*</dc:identifier>
    <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8bbf3741-0255-4e70-9fdf-1ea75e67fec4">
    <rdfs:label>AT342</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d57900eb-9a03-41ae-a728-8684476ea8a2"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
    <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52c8972a-174a-4912-9224-dcb6a660b44c"/>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fa9770b-e0cd-4264-ba34-b46fc9d6ae0f">
    <rdfs:label>Ambroxol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
    <dc:identifier>DB06742</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d94b2e23-a6e9-44ee-8e55-c59e62d8b2ef"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/372910bb-164e-4e3a-8f5e-b6ffd26c256f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c269fca-0e61-4edc-8c0e-c096f43a0992"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a8d1018-7fe8-48fc-aaa4-562dc01a71d8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000479*</dc:identifier>
    <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd413f02-0560-405c-ba91-937102567eef">
    <rdfs:label>Pathological apoptosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6dc2a651-4860-41d2-91aa-ba124d8e412b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee182544-7dbc-4a07-92ad-36dda56595f7"/>
    <rdfs:label>Sebelipase alfa</rdfs:label>
    <dc:identifier>DB11563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/142c0b21-24f5-4577-92c1-4abdfd7d175d">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7af5c6d6-8b71-4c07-8948-f9b53df913ca"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67314d43-b002-4d30-9db9-a1f4df5f7a7f">
    <rdfs:label>Obeticholic acid</rdfs:label>
    <dc:identifier>DB05990</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f616bf20-feab-4dd6-bfbf-d0b33728995e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/398aa24c-ed0f-410f-9a97-7747badeacdd">
    <dc:identifier>DB02745</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f89504b4-0eda-4abe-9daa-aa69a92725b3"/>
    <rdfs:label>Uridine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38aaf2d6-7da9-463a-a372-b8e5f2e14b92">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
    <dc:identifier>HP:0000725</dc:identifier>
    <rdfs:label>psychotic  disorder</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bd2ea45-801b-4dbf-8c6c-0362e143cbce">
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:label>Rhabdomyolysis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abff2dbd-db35-4318-8927-374c37c0a36a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/587b44f1-9e85-42d4-b924-e95610c9b146"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9fb5a087-ef18-44d6-8b86-cfef2423e736">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3ec4442-53e2-4ace-9441-8183db608d3e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a19679d9-516e-4c7e-b339-3f2e7704058a">
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>intolerance to sunlight</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50eee7e4-80ba-44ec-a088-7afdaf8f7ef1">
    <rdfs:label>Tocofersolan</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <dc:identifier>DB11635</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58ed00ea-bb52-49f1-bb94-c2fc48dd2e5c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2739179d-0f5a-423e-9227-d26e904ad81d">
    <rdfs:label>Low 5-MTHF level</rdfs:label>
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/017e27e4-161a-46f5-abd1-56878c6b165e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012130*</dc:identifier>
    <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7e18041-3063-4055-b178-0d03a39d848b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
    <dc:identifier>DB01001</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65b7a0ee-8883-4458-b5a3-efe1e3a046f8"/>
    <rdfs:label>Salbutamol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3873c731-d400-4489-9a2e-6339ecfcffcb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a235f133-7c07-4a8c-9a71-5ecb4aff13d0"/>
    <rdfs:label>Desmopressin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <dc:identifier>DB00035</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93f95be3-220c-4871-90ef-0a44705221a7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38a897eb-da41-46f8-a1d6-aafd59758d15">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:label>Delayed motor development</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7255c96c-f940-4541-81be-887b7ac848c5">
    <dc:identifier>DB01586</dc:identifier>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c7202ab-fb63-43b3-a7d8-e0d61e917f97"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36952fb1-378b-487b-b273-ba0aa348f937"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca2a0961-88f1-4a5f-a942-7858d8380ff2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High urinary malonic acid</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <dc:identifier>HP:0012120</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20f215bf-08f6-4281-bfa1-1e96c63cb0d8">
    <rdfs:label>Metoclopramide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee35785a-9d20-44de-88cd-1e506c5936d6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <dc:identifier>DB01233</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80582869-b76d-4df1-a776-867537320c74">
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006279</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31511e7d-915c-41c0-83ee-726d7766b53a">
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea63a6e8-0536-46ba-9b4e-bf1cecd64d09"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/090d79eb-30c3-4772-ab9e-7135a36ade71">
    <dc:identifier>DB12273</dc:identifier>
    <rdfs:label>Ecopipam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0907f41c-ea8f-4ea1-a2df-a34ec8b92c08"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7666698-507f-4c8f-a50e-aa4dc0edc6f9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a5a138f-e485-4aeb-95da-485426b1f914"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
    <dc:identifier>DB0084</dc:identifier>
  </ddiem:Drug>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
    <dc:identifier>ECO:0005242</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
  </ddiem:Evidence>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ccc5b64-b760-4248-bfbc-3776a057812f">
    <dc:identifier>DB09395</dc:identifier>
    <rdfs:label>Sodium acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8f4768d-250b-4b26-8c09-b616aa002769"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e99309dc-104e-4b55-98c7-30d72bbf637b">
    <dc:identifier>DB11981</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a1224a3-d2f0-4029-a543-982fef3444a6"/>
    <rdfs:label>Elamipretide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f97515a4-55a2-45c1-866b-da32ac6414c0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8b36679-e0c6-4ab5-ab5c-37f448fed306">
    <dc:identifier>HP:0002344</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b09a9c6f-5c6e-4e8e-824d-b92f8b9a6a1e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed9932f1-7077-488f-88e5-c56e711573c6"/>
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba72f902-49c3-49b0-8268-129f6a33df8f">
    <rdfs:label>rhPBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2116f4ad-d81f-4832-8c0b-c6145b35a998"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
    <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f7b6912e-ad76-4301-810d-da036d13bcd2"/>
    <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f3d9f2f-b718-4ddc-85c9-3c753dbafc77">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44eb51f6-e941-4880-add7-093018f3bf17"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeaab8fc-3b02-4755-a22b-3054adf8a8bd"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f98c52a8-6744-45f4-ba3b-fa4a77ae17cf">
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77eb03e2-18f2-46b8-b5d7-69b27826b382">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypocitraturia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
    <dc:identifier>HP:0012405</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06a6ecad-7999-4afe-8314-af9183ea67e9">
    <dc:identifier>DB08834</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3a73903-edc5-450d-a7d5-cb9a2dec5e54"/>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8bcbbfbd-b5d7-46d2-80e2-2350a69fe2d8">
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d5691ad-6043-4189-8ad9-d5b805ebdb15"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21f713ca-379b-44d8-a0e2-fb63172ee7d3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
    <rdfs:label>Agalsidase beta</rdfs:label>
    <dc:identifier>DB00103</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5af25f86-a5fd-47e9-b9ec-3b96c7d41bfd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1f0904e-1973-499f-a19c-479b79159030"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4452984d-16b8-4eb7-9d64-42183c7158b2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bfb5cdf-c8bb-44fe-95ac-5a5160feed12"/>
    <rdfs:label>Metreleptin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <dc:identifier>DB09046</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9d33ce6-8238-4e76-9408-d1171f898933">
    <dc:identifier>HP:0040087</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:label>Abnormal serum folate</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97d6079e-2445-4e92-9812-b6ab167a9538">
    <dc:identifier>A11EA</dc:identifier>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2297988d-0574-4e4c-b141-c5603ef45e69"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f29b7ef2-cc96-4b6e-af96-eebed375bf70">
    <rdfs:label>Soybean oil</rdfs:label>
    <dc:identifier>DB09422</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0366fc5-0da1-4974-999b-fa2f57b827ed"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f1c458c-6136-4db6-bb89-386a2f7e165f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003434</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/639ffb7b-4623-4abb-ad56-9abd7b6f14ae">
    <rdfs:label>Milrinone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a5a138f-e485-4aeb-95da-485426b1f914"/>
    <dc:identifier>DB00235</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7609e6-d4dd-4c7a-8d2d-88e256ea7d9d">
    <rdfs:label>Low total RBC folate level</rdfs:label>
    <dc:identifier>HP:0040087</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaa32e72-3a07-4ab1-b1bf-748377e6c894">
    <rdfs:label>mitochondrial dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003287</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6ccdff0-d10c-44b3-aef9-22cb19cb56b4">
    <rdfs:label>growth faliure</rdfs:label>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f1e951b-5d8d-44e0-b501-c88e07bdab80">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>avascular osteonecrosis</rdfs:label>
    <dc:identifier>HP:0010885</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80fd8f70-e883-471c-be59-5995be8c2ea5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <rdfs:label>Chloral hydrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27d4411b-2432-415a-8335-31864d36ab64"/>
    <dc:identifier>DB01563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ebfd6c0-7021-4f1e-9551-5d829deab670">
    <dc:identifier>HP:0003343</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
    <rdfs:label>GSH deficiency</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f26c4bb-2ecf-450f-80e9-3317eae67a2c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49e0a818-357e-449f-b6e0-802d5dc40f4e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cff52bb-109d-4202-ad41-4639a7f0a666">
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Metabolic Decompensation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c54d4c63-8c0f-452b-a709-577a3ded5099">
    <rdfs:label>Amphetamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63033298-4941-495d-bd1e-6d79059f1454"/>
    <dc:identifier>DB00182</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c053f7c-469e-4da1-bc7b-b0575a9ab4d5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040006*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdb4131b-1dd5-4595-ba36-40050f9f83a7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c70a3abd-5312-427d-8e62-8bd81fdadb11">
    <dc:identifier>DB06775</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <rdfs:label>Carglumic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ae63045-256b-4a87-ba37-6d19a4f0355b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a52f774-0f8a-4b4e-9be2-2c4b5fa58441"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0be33f4b-4770-4d4c-86fc-2de2dc547382">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e68be91-439b-46e2-83cc-570ee8c8d44c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/469b68cf-6426-48ac-92f8-2a07eac7b6e9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bae94f1a-b0dc-4ca8-b56e-c9bd0a0126dc"/>
    <rdfs:label>Chlorpropamide</rdfs:label>
    <dc:identifier>DB00672</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7df10b9e-9e90-4f5d-885a-2b7a5db33ddb">
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d66d1830-071a-43b7-9d28-777d0f910509"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9612a008-5079-4800-9d46-29ad81a08d72">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d29cae5-5d01-48ad-8f15-6b9a8f6dddc8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cd9719d-234c-4379-a999-8f6bc6c0628f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <dc:identifier>DB08909</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9b546b2-5433-406f-95d3-69b8ca15ecaa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0dabde4-5317-4768-9015-9f0c4b80df44"/>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <dc:identifier>DB04844</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aab254cd-7f8b-4735-999a-fb17122b9ff6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce5488ff-160c-45a3-8ac3-dca5ddaac27e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c112d76-342c-4614-90b0-873f962104d8">
        <rdfs:label>concommitant low vit D level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100512*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca5e5b44-4674-4bda-bbb4-97d8524e7828">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1f2325a-e230-47d1-bc3d-7b1c53edaff8">
        <rdfs:label>Clonazepam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d3082d9-2b17-4119-a335-df3d4e9177bf"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63874f6e-4956-42a5-b9cc-bed2eec84f24"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a9d32c1-188a-4a9e-8a23-38a9d52ce4eb"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81730b0a-97d2-4613-a8f5-9e141533f9b1"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5f2e2e1-89de-496a-aeac-9dc2c57e65ec"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/881801cf-e67b-484e-bd79-650bbaf727e0"/>
        <dc:identifier>DB01068</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b49db01b-44a6-4be3-bae3-65a848ff5afc"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/994c0ea1-028a-4612-8b03-5760bee283a6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bac9cd96-88ce-4d06-b6a3-ef2237197c29">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57288a0a-ff89-4cd1-9b94-76c337df6675"/>
    <rdfs:label>Phylloquinone</rdfs:label>
    <dc:identifier>DB01022</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8eebba85-0abf-4c4d-bb6f-d81fb1348786"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab515d09-5113-4ac4-89d8-c61c11e48103">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd9bb9b2-6c92-4884-bd71-5b8188c49133"/>
    <dc:identifier>DB14098</dc:identifier>
    <rdfs:label>Cobalamin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b542bff6-b7d7-4b32-8c43-ad041de514b0">
    <rdfs:label>Inositol</rdfs:label>
    <dc:identifier>DB13178</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5562c3b0-7ef4-42c1-b264-b11519506b88"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1991909-2133-40ff-baf0-5694ab5089b7">
    <rdfs:label>Protoporphyrin</rdfs:label>
    <dc:identifier>DB02285</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc900168-313a-4318-8fee-2251a3eaeb6c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64c11458-3768-4faf-918c-747b8036fb2d">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a040b17e-741e-4853-b890-0624562bba5f"/>
    <dc:identifier>S01EC</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ab76d29-5daf-4c9d-8158-ace75a6665cc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45ffa80d-e72b-4cff-9819-261c5c8f539a"/>
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b113e6b-547b-461a-8f9b-e3c4c1e43655">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/251ea1d8-b5e7-4931-8e76-b5e99b45e458"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1217d62-45aa-4b30-9972-5b442deec3ed"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1164811-a5af-4e90-bf6f-2e18380dcb53"/>
    <rdfs:label>Nicotinamide</rdfs:label>
    <dc:identifier>DB02701</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d73dc357-63cd-4469-841c-fbd1c69776b5">
    <rdfs:label>dysphagia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
    <dc:identifier>HP:0002015</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e750d45-6c01-4f13-8cb3-a9a86992702c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e6ae98a-aa7c-4f38-af58-d573865c4183"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b4fd5198-5008-4209-a719-c92b3dd78d1f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/391e2917-2832-4f83-b4ea-a7585f44603f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e352df34-8cc2-42c0-bed2-7ab151c80097">
    <rdfs:label>Myoclonic seizures</rdfs:label>
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
    <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLUTATHIONURIA</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bf0262fb-06fd-4f3b-a478-e7801796a6f9"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da712b15-99a0-490c-8947-4d6f5ce3ea3f">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67fe55e1-ed30-4335-a4b8-bc1a5f2c14dc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96c96015-ffd4-494e-be70-11e9e1534755">
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low endurance</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67c3e8cf-e01e-4ba6-b75d-dbf44b5d4782">
    <dc:identifier>L04</dc:identifier>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a040b17e-741e-4853-b890-0624562bba5f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/837f9c08-eb54-407b-aa5b-6771e906135e">
    <rdfs:label>High total plasma cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be64c2e0-4daa-422e-a2bb-aad63e41066a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a20fa06-94ef-4ae1-b240-f58f6f69a2af"/>
    <dc:identifier>DB00419</dc:identifier>
    <rdfs:label>Miglustat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b768f59-b948-4d5d-9f98-b020f53adb94"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c014bcb-8f71-4c40-9786-7998a2cc54dd">
    <dc:identifier>DB11135</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <rdfs:label>Selenium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfb5c9de-edba-4f4c-8029-b454c6ca3f12"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a1eb0df-f35f-4870-8f1f-e792ce8bf12b">
    <dc:identifier>A11E</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17fe3292-5533-411b-9434-c750d9c94f3b"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af8aa857-5eb1-4d22-b4cc-f0f44d048014">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <dc:identifier>DB13257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0afa85f-8c04-4d92-8e2a-e8e614e0a2d9"/>
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b982aafa-c84c-4ca2-a528-61b0ff1dc933">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003128</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:label>lactic acidosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3683f47-e2a3-45d3-b9d4-d74e61678cf3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
    <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b621a7e9-531d-42c5-a3d7-0a170640ad51"/>
    <dc:identifier>DB14502</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e187be9-f9ed-4665-924b-9a8be99f69b1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94de5ca5-699b-4cb3-a369-3f364953a30c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1960b9-56ea-4f15-b05e-12485d99e70f">
    <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
    <dc:identifier>HP:0025460</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2607e65a-d8bd-4185-bdad-86f84da24069">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>Abnormal cardiac function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8eb62dbf-b727-4207-8256-aa535b17e5d1">
    <dc:identifier>HP:0012410</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c42a41e3-20a0-4f12-a74b-7640708c319c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d80b0ae1-71e0-445e-a9b0-8be9bc440835">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86aa09d2-e9ee-42b8-a49a-92289115fc5d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fe7f092-65b3-44cd-9e77-ac7c05936541"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/007ae017-e492-422a-8762-e08bbe711456"/>
    <rdfs:label>Vitamin D</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08767fb1-d06b-4b72-9567-e2ed89685560"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aab254cd-7f8b-4735-999a-fb17122b9ff6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82af25dc-9e92-46fd-b9d5-ebc351e5082c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a4e44d9-c213-49ac-bc99-91e97c88a948"/>
    <dc:identifier>DB11094</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/841a465e-4a72-4fff-b69e-904c2ca94b71">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60af4e1b-676a-47c6-8f3e-29f26c623579"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c46a1ce-4ce7-4dc5-952f-e05ae6a3c64c"/>
    <dc:identifier>DB00126</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95a63ba6-b1a2-4c2f-a473-74dbaf3ed615"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/722cb8b3-72c6-4c38-8180-b40cbd6e6215"/>
    <rdfs:label>Ascorbic acid</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8fcb9d1-1478-45f1-af01-204d681995e2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78177983-6b3a-47df-a93f-8ce746584ad1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e07fa432-8e13-435d-8387-20bca48b43b9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e2e0528-5514-4b70-89de-e64810973ffc"/>
    <rdfs:label>GNeo-IDUA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b98d9f8a-6ca3-445d-a102-9d7e007ed405">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <dc:identifier>DB06667</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb8f02d6-112e-41d7-a616-2aab2b922ef9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5cc56712-d0fc-4e26-a533-386b6b178e81"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dacff46f-6f13-4acb-9e5a-223a16a0f9e0">
    <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aabf5bbf-78dc-4ac3-aba2-abf397c8705f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <dc:identifier>DB00973</dc:identifier>
    <rdfs:label>Ezetimibe</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b07b617-cca7-473d-94b0-95c56fef18c3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66b79f3b-24a6-4d69-86cf-9cbffe404fdf">
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95ea52fd-6704-4bf7-8bec-3f98f3949a04"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27342a5b-0788-4ef7-a85d-a17d549a12ed">
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001958</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df6cfa3e-7bf9-4659-b68a-625b56ef6e5f">
    <rdfs:label>low bone mineral density</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004349</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75630b3e-d051-4958-8a71-3c04792e4e95">
    <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/698c9ed4-8026-44b2-aced-327e32728a58">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87867f47-be92-4112-9ef5-567709890e4a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <rdfs:label>Curcumin</rdfs:label>
    <dc:identifier>DB11672</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75d23047-719f-4c0e-b9d7-7de7873dd6be">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02d91a85-f1a8-4aed-a592-4db958ae023b"/>
    <rdfs:label>Spironolactone</rdfs:label>
    <dc:identifier>DB00421</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a1aa8e4-da90-49d9-a722-963e150b34e6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiac hypertrophy</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c3dd4e7-cf58-4178-a0e3-8b869a154ea6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca2de4aa-d0b5-4e08-b0da-7b1fee71c95a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0151b46b-2605-42b8-beb5-aa27762d98f7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <rdfs:label>Mannose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/807a858a-42a8-4e24-8f9d-00332b0e5052"/>
    <dc:identifier>DB12907</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21b77679-726e-4bea-a5a9-182ec825941a">
    <dc:identifier>HP:0008281</dc:identifier>
    <rdfs:label>Acute hyperammonemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12043873-f5de-41e3-8158-cbae595205b6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8243aabd-a796-46a8-913a-5632b47de19f">
    <dc:identifier>DB00926</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c6f5431-6541-4fc7-be87-6f8e629023b4"/>
    <rdfs:label>Etretinate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1595ea90-87f2-43a1-baf6-2abd120f870d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003326</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <rdfs:label>Myalgia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4420e3d-7e0a-4b9f-b9de-18624e2e056a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4544339e-f409-426d-a986-f790eea025ec"/>
    <rdfs:label>high protein diet</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebb3c74d-9b6c-47ce-9c32-ef0cf6d07fa0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1c2477b-19b4-490e-a36a-701a94d4f908"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d070b7d-873d-4444-9345-73a5011c5cfa">
    <rdfs:label>Increased muscle fatiguability</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <dc:identifier>HP:0003750</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30be2429-5d3a-4d52-a7e4-749744734b33">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74865371-e741-4202-896a-47e9ac7b15e8"/>
    <dc:identifier>DB00808</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
    <rdfs:label>Indapamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b01b4ed6-394f-4804-b402-6583cd1906ea">
    <dc:identifier>DB00090</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da65354e-867b-428e-a1d7-c7e273f6d838"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f15ef51-0b8d-4f11-b75d-243e120248b4"/>
    <rdfs:label>Laronidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fcfda2a1-4f21-4a4c-99ee-62a4b8a66a9d">
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/080beba2-ab42-454e-bfa2-c3e70f5f7383"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f57e3278-23dc-49cc-9be9-2003b3065f46">
        <rdfs:label>Sulfide toxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d75d6234-be92-44be-baa9-6d6abb5d8245">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
    <rdfs:label>neutropenia</rdfs:label>
    <dc:identifier>HP:0001875</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8a53c9e-b713-4539-bc8d-f817556927aa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c2e02e2-0d01-4bd5-85e1-3f789147df7c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2612d739-bc2b-4fe4-8d9e-4007a2be443e">
    <dc:identifier>DB00936</dc:identifier>
    <rdfs:label>Salicylic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0c6942d-254f-4083-ae1b-3559a18ab6e6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebefa275-fdb8-434b-8b1b-502cf1d696c6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <rdfs:label>Vatiquinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9d68ab0-9ba6-47cc-84ca-0daffc8e2437"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9065b729-f567-4173-8b12-09bc18444ada"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fdf73bc8-1fbe-4fe2-a56a-f41e7e8d2373"/>
    <dc:identifier>DB11917</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa6d5508-f25e-4448-9ee5-bb283d02a4df">
    <dc:identifier>DB11098</dc:identifier>
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f64b4a99-e68e-4c83-986a-fa588c39347d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e06729b-25fb-410e-9c28-df478e205e36">
    <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c9c9f4c-ae97-41d0-983d-e12b53dec8cf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
    <dc:identifier>DB00494</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/541ba10c-1973-41b8-aaf2-c6a0fc53f59d"/>
    <rdfs:label>Entacapone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce1d3e64-f5dc-455a-9eac-e435f46de046">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/052c394c-d7db-4a67-8fe5-f72d76951352"/>
    <rdfs:label>Progesterone</rdfs:label>
    <dc:identifier>DB00396</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b29adae0-975a-4518-b83c-26366a94ff3a">
    <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76e4d810-1838-48ea-a1ba-5f3c8b68241a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c6f41a3e-1a5d-4b47-8e7a-cee169457383"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9b9478f-fad9-4afb-9de3-19c992dff444">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5cc349e-7616-470c-90d6-ed5de3e01706"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fdffce3-029b-48ea-a6ca-e2c3b0b319d2">
    <dc:identifier>MP:0001845</dc:identifier>
    <rdfs:label>inflammation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5153516d-ef1c-4d39-9e30-791e9e8a1f9b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca210f46-51de-4c40-b89c-f5fe2b46d00b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd135e98-0d38-4372-a5f4-7977e1f829dd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98dc6599-2f07-4248-bbba-ced05b7fedf4">
        <rdfs:label>joint swelling</rdfs:label>
        <dc:identifier>HP:0001386</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f009c63-578c-4df3-b45a-f4d48c3b23f7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5237def0-8ce4-4d74-9d7a-e27846bfccd1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7a244c9-85d3-4775-a122-0cc3d958833b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <dc:identifier>HP:0012446</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>depletion of cerebral folate</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06eeebd3-9001-40f2-8602-80838be02074">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a54c00d-3085-47e2-bcdf-461bae7da7a3"/>
    <rdfs:label>Dihydrexidine</rdfs:label>
    <dc:identifier>DB12890</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c78ae9d8-e383-443a-8a6e-99990b009351">
    <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/215399cf-5e8a-4238-a6d4-b862ea27bb64">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83e19865-0c93-4606-addf-eb7584a90e52">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be783e1f-b84a-4e4e-89e2-410f36e3fca3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e6de0ad-a31d-4629-a581-5c4fef738289">
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/135c03f8-15ea-487e-b1b6-5df3afc94adc"/>
    <dc:identifier>DB15146</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f807f2e3-c815-42a6-a226-c6dd9de66d3a"/>
    <rdfs:label>Adrabetadex</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1e9917b-f90f-4ab8-9a45-bf9ad4bb5ff3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07f2fb21-125d-49b8-a949-daa6d2103bec"/>
    <rdfs:label>β-galactosidase:RTB lectin fusion</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/adfa4d60-4ffe-4f9a-a290-ce35ec163f64">
    <dc:identifier>DB11133</dc:identifier>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8772811d-70fe-4fd6-bf2d-6039d195e455"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/064f03e0-7e97-4915-84db-0117784979d4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59741b49-9b15-44e6-aa11-0d82be562599">
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0009830*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/692c5701-0747-48d1-9a55-ef571fdb71e5">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0d158f6-cbac-4b86-875b-3bb4f0717769"/>
    <dc:identifier>B01A</dc:identifier>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a74456da-fe9f-4e1f-94fb-f15dee407a78">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acute decompensation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
    <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12c0507f-1785-4286-ab2b-416ac738428f"/>
    <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56c98cfe-15b4-47fe-a8a9-bf0174aa0cef">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Delayed Develoment</rdfs:label>
    <dc:identifier>HP:0001263</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cc1666d-7379-4cf5-a0f9-809ed974934a">
    <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neutropenia with IBD</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/901d7225-0288-4090-9d8f-a32dd6060542">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
    <dc:identifier>HP:0003800</dc:identifier>
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f3f75f0-00a9-4109-a5b9-797f1daa2268">
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a9180ef-750c-436d-bd52-289367f4f9df"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77a39deb-1e88-456c-b97b-df93c6069114">
    <rdfs:label>Metformin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58596a5a-ea70-478c-ba85-d957ec3a3955"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <dc:identifier>DB00331</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b222a6ca-91b5-4ede-9796-362df96ea8d0">
    <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4d77e1a-b5ff-4f7a-b02b-df263e81e680">
    <dc:identifier>DB01609</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19ac1883-1b39-4035-9add-c3f7fff0a47c"/>
    <rdfs:label>Deferasirox</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8aae9e1c-eb01-4b3c-ae0a-e1b2722a1f07">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc5f777f-3073-4478-a908-3975829971dc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High α-ketoisocaproate level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e2be0ef-1b8b-4bd3-bec6-efe7e72531f0">
    <rdfs:label>Serine</rdfs:label>
    <dc:identifier>DB00133</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5cd76163-ecef-4c2f-a41f-0ddb49147b8c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03112008-ad31-43c8-9c1f-e41753e7f9bd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64d16ac4-414f-4291-9983-8bea3fa3c9fa"/>
    <dc:identifier>DB09115</dc:identifier>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f081ba46-25ed-40e1-bfd3-1928106d6894">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2319cda4-5430-4482-8246-df01173a3e26">
    <dc:identifier>DB00679</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27d4411b-2432-415a-8335-31864d36ab64"/>
    <rdfs:label>Thioridazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28ed736c-c558-478c-9833-119f898ae5a3">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001738</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
    <rdfs:label>pancreatic dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab83ec28-3662-40bd-80e3-0f5e885452c3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9ad5d78-174c-4673-8fcc-eabe5b0cbcb3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7521ae3e-353f-4882-90ab-a99fd977c96d">
    <rdfs:label>Sirolimus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0990430-c4f0-4a2b-b4ad-4f772ce6f66a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2605bf9-91f1-4522-90f1-9775e6b40751"/>
    <dc:identifier>DB00877</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fc5660d-a3bb-43fa-b9fb-5c0f55719f6f">
    <rdfs:label>NA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8535b43-b9d0-4ccd-b650-dd078113f2c0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ede70e26-c6cf-4458-9905-7e9c97edcb1b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2af6872b-c150-45a3-b056-e40a3003fabb"/>
    <dc:identifier>DB14933</dc:identifier>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/adb0e266-ae9b-4a83-8bb6-0f39b90a6e63">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55e84ed1-3526-4fb7-bd79-f93ad0e32b3d"/>
    <dc:identifier>DB14573</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15d32543-c054-45a6-b4b8-6243a94c7985">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003808</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
    <rdfs:label>Abnormal muscle tone</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28f27c16-ad9e-4c95-acc5-82803591bb98">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae10a49a-e401-4b12-befd-ba3efb8ab1a4"/>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <dc:identifier>DB01323</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88e411f4-6c32-42a7-b40f-9ba0ccdaf8a4">
    <dc:identifier>DB12839</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
    <rdfs:label>Pegvaliase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cab13c81-05ea-4401-ba07-bc8e8ff123b3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5220722f-d237-45e5-bc61-7e3add33f1dc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd893588-9c11-423c-88c3-2ea25fd6734b"/>
    <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b98cb1bd-e13d-4943-a683-07b9f8fe5e89">
    <dc:identifier>C03D</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eae1669b-4d6d-4200-bcd9-8bbb97589fb7"/>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f531ee1-aa02-434f-bea4-4534870d6666">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003648</dc:identifier>
    <rdfs:label>high Lactic acid</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d08a57fa-d6a4-4bf9-ad14-dd91722a514e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6dde8c3b-c8bb-4b4b-9bd3-808d19414f63"/>
    <rdfs:label>Arginine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d62832f7-ff10-42bc-bacd-bf9055437f64">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07557582-883b-4c32-a39a-d8c9f6675c18"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d1455c10-5bc2-480c-8e2f-d9547a1ed20e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
    <rdfs:label>Brexanolone</rdfs:label>
    <dc:identifier>DB11859</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f418c234-eaa9-43a8-aa79-c0e62971df43">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
    <dc:identifier>HP:0012202</dc:identifier>
    <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a51cd54-d4de-428f-9d34-01eb7978c3eb">
    <dc:identifier>HP:0001507*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d8184f04-7a03-44f9-b48e-d6f2e660aba7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d957489f-49ed-4cd1-95ca-83aa0036fcbe"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4860051-9aca-4dfd-b66c-b19d400f7b0f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46b4eff6-497a-4f94-a75d-76ef4ea1e8af"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74693e17-2e86-4fbd-926e-40c317324fc5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63033298-4941-495d-bd1e-6d79059f1454"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cf9d3c6-2dd4-438b-8e9e-4cf5f48ac7f0"/>
    <rdfs:label>Trihexyphenidyl</rdfs:label>
    <dc:identifier>DB00376</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1712752-1ecf-4679-8d10-1ef9c9ff1116">
    <dc:identifier>HP:004017</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
    <rdfs:label>Low serum testosterone levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0c9dd11-58cb-4eeb-b570-652b8892260a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
    <rdfs:label>Corneal Oedema</rdfs:label>
    <dc:identifier>HP:0012040</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c0c29a5-d6ff-4ef7-b722-bf0bd46dd68f">
    <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca1dffca-34e9-4000-9f15-74525f77b278">
    <dc:identifier>DB00034</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ec1194c-82f6-46f3-9a23-54b91fd453ab"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/319c3092-2761-4215-a373-f7bf3254e0cb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>waxy scaling plaques</rdfs:label>
    <dc:identifier>HP:0040189*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f8be94d-7341-4cd9-af72-abf8e3654070">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
    <dc:identifier>HP:0000144</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cbcc2ca6-a2ff-4b80-8acb-7529bd4b02f8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0f22cd2-5370-4a7f-98fe-dd7c396e52ae"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
    <dc:identifier>DB00053</dc:identifier>
    <rdfs:label>Imiglucerase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2e8d9ad-c7cd-41f1-97fe-a587578edf64">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e59feb3d-9853-4d90-9c7f-0de3d7b5ef70">
    <dc:identifier>DB00437</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a8af3df-c396-4e48-8a8e-67ccba092fdf"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fa1614a-99ae-4bb9-b5a8-2d8f155c1201"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e473bf18-1503-442c-bac3-c9bce77e48c0"/>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e55fb50-596a-44e2-b1fa-3629af243374"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f55346f4-47df-44ce-8e86-0b70de4388f8">
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>psychomotor retardation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e779ce96-f611-454c-837d-d9ef04678868">
    <dc:identifier>DB00051</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
    <rdfs:label>Adalimumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1e83365-c6a7-46d0-87c1-20b83cf76f35"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61a9f4ae-2510-41c0-8ea0-5bb10f59e6e4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>retinal dystrophy</rdfs:label>
    <dc:identifier>HP:0000556</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84d65beb-7e5c-4be9-998d-0544ce0bd97d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4abb85d4-8517-4861-b5eb-c510673a09b2"/>
    <rdfs:label>Gene therapy *</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8da35c72-ebb6-4c4f-aecb-1268144503b1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eabd970c-5968-40b6-9ae7-9bc36993741e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0e5c43f-622a-4b86-ae94-366e1fc006f0"/>
    <dc:identifier>DB00016</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e84b6790-1d51-4d82-b40d-07b22a078bc2">
    <dc:identifier>HP:0002917</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
    <rdfs:label>Hypomagnesemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93988ec6-fe69-4659-8d11-6f7cb60e8668">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6dba8e66-11b9-4f6a-a077-3d9c9e6ef355"/>
    <dc:identifier>DB06281</dc:identifier>
    <rdfs:label>Torcetrapib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/241d27c9-31a7-4ec8-89fc-0a0d6bf2bb0b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low hb level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <dc:identifier>HP:0001903</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6ee1bf4-036f-439e-b962-321e8070e31c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3a4fd3f-446b-433c-ac0c-4948b5a15017"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a0815c4-74dd-4612-acb5-be4dc9db6b37">
    <dc:identifier>(DB00440</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97e50583-8e2d-4518-b6df-b37a607d3ccb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0938fc4-e89e-4d12-b360-f85199fbe522">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b1749704-e514-40a5-8405-c327fa585043"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04c62eab-e203-4576-8abe-9b8e4b3c0c93">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80ede094-f9ce-4ca0-88a3-03ee16b395c5"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1777090-9fd2-4456-ac74-ad892bd71e78">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a91b686-e457-4da6-bde4-956b3cb0bd13"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20d99d82-7194-489d-b4e4-5fd6e535d195">
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a214faaf-a48e-477c-bfcb-57fd1090dceb"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60bec5bb-5f9f-40fc-8950-7112b4cd07a2">
    <rdfs:label>failure to thrive</rdfs:label>
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb672bfe-486d-4d47-a0db-1f7e8833d506">
    <dc:identifier>DB00119</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4cad84f6-5727-4e0c-a632-d1d70bf0520a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76f1bc6a-cae3-4797-ab95-704a08b68123"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59a3413e-ef0c-4516-b195-f9dd5dfc77f4"/>
    <rdfs:label>Pyruvic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1101fad2-de67-4287-a1a6-87e05c6a105a">
    <dc:identifier>DB00213</dc:identifier>
    <rdfs:label>Pantoprazole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f093a514-f850-4bfc-9fb4-2e31711f9432"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5602421-c834-4dd0-97f7-da39f6fda9d8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a83cb2bf-4a87-4b49-b99a-666f702e941a"/>
    <dc:identifier>DB01783</dc:identifier>
    <rdfs:label>Pantothenic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e16e09e1-822b-4448-9a49-b3dcfb615a8a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30333ecf-19dc-4f7e-9e6f-c30ad83ed703"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ac605c0-bc24-415d-94a7-0ab473ca5fda"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d156e49-e5e2-4488-a019-aa43ba76b43c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7802d54-4387-454b-8d96-31b4d742bde8">
    <rdfs:label>Inflammatory myopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
    <dc:identifier>HP:0009071</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e19c4292-fbae-420c-9b4c-fc636d83e437">
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19a6b821-b9a9-4f8a-8e06-1509ccc82a1a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed4d99a5-84be-44cb-bb19-45fed773d2b4"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e327836-ca42-41c4-a564-b7cc593af2e3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04a21a12-cabf-4b37-895b-26e5378dc3a6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2e93818-38e4-434a-983d-3424d9cd4852">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2088ad03-dc77-462e-b1eb-8e5b1168771a"/>
    <dc:identifier>DB00147</dc:identifier>
    <rdfs:label>Pyridoxal</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa4056a7-b466-4750-8ab3-027608a21b64">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6e77669-7cc8-480e-8698-de8aec6298ef"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad15c432-5d07-41f0-a3ac-44920de8f80e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4f08c85-d467-476e-aaa7-39d6ada4cc5f">
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85c1db22-3cd9-4ddb-be83-b70c2e12963f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55c7b11e-7e91-447a-91ac-c48b842aa3e1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Generalized convulsion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e5362ec-213e-45f5-bfab-8519b0b3feb3">
    <rdfs:label>Flumazenil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
    <dc:identifier>DB01205</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d9d5b87a-b9b0-4dde-afb5-6e5a7e48d31a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9da4e1a7-5897-4556-bfb4-558d015e4a41">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91c1e748-9af2-4125-9063-9a8be4052fe2"/>
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e70f7699-1335-475a-9eb4-9c10f45fdeae">
    <rdfs:label>high serum alkaline phosphatase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003155</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29bb72bd-49a7-4435-a0ef-39fdc4fff088">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>Behavioural Disability</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06dbd340-67a1-4c77-9c2f-a3297527fbea">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11b24f79-2384-446d-8e36-67bb27c940c0"/>
    <dc:identifier>CHEBI_32362</dc:identifier>
    <rdfs:label>enanthate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/408bc3f8-dd8b-4e65-8ffc-1d562ee37e8b">
    <rdfs:label>Bezafibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7537b02d-43f9-4b0a-af71-28cb1ced89b3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a092306-f6e7-44bc-912f-30a89b810fb5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52c1c685-cd16-4a71-9da4-dcb3e392dc6f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <dc:identifier>DB01393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c541570-804f-4247-83f6-65d374d75cb9"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/caa0aee3-8ad7-43ac-ab02-7d3de0108cca">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e8c92ee2-306e-4e2e-8b27-60f1290624bd"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8edb283d-cb61-4cc7-a980-ce95fe25ffaa">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low IQ score</rdfs:label>
    <dc:identifier>HP:0001249</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43e2b74f-109b-4bab-bfe2-6559307b6751">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a404b486-ca51-45c1-97db-df6a5b6f9035"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e563117-f217-4b1d-a00d-f8a097422e14">
    <dc:identifier>DB00136</dc:identifier>
    <rdfs:label>Calcitriol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a337cf09-e90a-447a-aac8-05af35ec220f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abbc1ecc-505b-4989-a291-00ffa20eaf83">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:label>Decreased lung function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70e73ca8-5250-4ca8-88e0-5751ff6b97d0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <dc:identifier>DB08883</dc:identifier>
    <rdfs:label>Perampanel</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a47d96b8-0115-4c4f-9098-90b50b0c3685"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0337e63-2258-4c5e-90be-b8df63116813">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e577898-8c2f-4817-a96f-6c46e92006ae"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78bb714c-2203-4710-8d0d-a5c72a4f6f16">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c602469f-1555-469a-8d47-929375a2f4a9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1537f38d-ce08-48e6-9f60-e120f876a4eb">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8341c50-7a1d-44d6-8a83-24f5ba5030db"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c245617-8921-4787-af7f-cf2bf1df18a3">
    <rdfs:label>Status epilepticus</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66dcdf86-c8e0-405b-a7a2-62a46393911d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>decrease muscle strenght</rdfs:label>
    <dc:identifier>HP:0001324</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee81409c-03a9-45ee-99b3-0676a5d49ed9">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <dc:identifier>HP:0003141</dc:identifier>
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdb22dfc-c107-41c8-ba10-b47356ee5e76">
    <rdfs:label>Impaired fine motor skillls</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/189b1414-7512-4e1e-98b8-431f269bbaa0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <rdfs:label>Ursadiol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cbb890f-5b9c-4d2e-a695-b0aa843f57b0"/>
    <dc:identifier>DB14555</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3ef120d-1f57-431c-b2ef-3d044dd8c0fe">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:label>failure-to-thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b81b494-d7a2-4113-b20f-29569341cd5f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9aa366b-27d3-433c-a28d-add26e575049"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91f5c738-56ff-4e27-bf4f-68ceeb365ded">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b621a7e9-531d-42c5-a3d7-0a170640ad51"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
    <dc:identifier>DB09449</dc:identifier>
    <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/158dc01e-94b5-4915-bc25-4fc8df9381fc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b61f5216-e96b-4c2a-94c4-0d6ad3445593"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5610a08d-2a7d-454c-a145-b0a9aedafea3">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <dc:identifier>CHEBI_2786</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e2ae6d8-68e2-4c34-90e4-59cd26b76927"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c04333d-ae39-4c50-ae57-40031f358602">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45806735-3dd0-43f7-a90d-0d67432867f2"/>
    <rdfs:label>AAV-treated βgal</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/879ff66c-8b7e-4c89-8e77-2984b7a5226f">
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f57d8e97-9ed2-498c-b990-9f5619dedbe9"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3d11d14-06d0-4295-bbff-6cb26700e247">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/603bdac3-9a43-436f-9059-106cafeca75c"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c7433c6-3914-4ef5-833a-73f3e83df80f"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f79713ba-41ef-4fe0-882f-5460223e535b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85c68e43-8ab5-497c-b8b3-da3bf47c591e"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e885d4d3-7218-4056-b724-1abc4e85617a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7568c4f2-502d-41b9-bc60-ffa1b2930da5"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50574a06-a7ac-4cbc-9370-552d5de412b2">
    <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/043ab169-0ca0-4911-a450-305bed85c438">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/421d9d6d-4568-4d49-997e-447cb5fef2c0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab8fde9e-4e62-47c2-a44e-6b057698086d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36bc30a3-7eb3-41de-8c92-4ed94f3a63a0"/>
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42b4f744-a4a5-47aa-a56a-0f603be440c1">
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4311cd6-5e43-4cc7-a184-b56c3b9ebdd6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cef66e9e-7615-4e21-b164-1b65d4df6179">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e821a064-8345-4e8f-90bb-4e8caefeea79"/>
    <rdfs:label>hepcidin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f4c9221-12e5-4dda-8c11-f05d32fae292">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4163ee97-6d81-41dd-a8a1-2e91f59f329e"/>
    <rdfs:label>Complex Carbohydrates</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0da0a2a-c3da-4b7c-baa9-c21111f73cac">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04376742-921d-4b54-a05b-27053b7ca102"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d59c870-703a-4d84-a24f-d6ab22e21966">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49bae8d4-b801-47e6-a7ff-5f611b86ea9f">
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24b9801a-35ce-4ddc-8e3d-2e47c1036c27"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30263682-21fe-41a9-923d-e802ee38b83e">
    <rdfs:label>Ad-hBUGT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9f1e57d-7787-464a-b3f3-8a2615fbf412"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/500d465d-2243-4db0-bba8-a2dfef071299">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6397fcfc-b3bc-4752-a2d9-38bf6431c786">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012446</dc:identifier>
    <rdfs:label>Abnormal CSF folate level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/510db69f-7841-4f13-a3a9-463a01a58791">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/545acae2-21b4-490f-bb7a-0ef0a52c3c04"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ea6f20e-d453-4da5-be14-73ce43509c95">
    <rdfs:label>High VLDL triglycerides</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7c6ecd2-7c11-49a7-ab14-c62a2040b8b0">
    <rdfs:label>Chlorpromazine</rdfs:label>
    <dc:identifier>DB00477</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/648e01d6-f688-495e-8ba9-e786bcbbf5ec"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c798239-a637-438f-bf34-853c76310a40">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b37a75a6-1d24-4853-9cf5-d2b30b9e1c47">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <dc:identifier>HP:0004305</dc:identifier>
    <rdfs:label>involuntary movements</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1d7c965-9325-4f91-b315-97513188f98c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3997a458-ab76-46b7-a691-24d25d762a9b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bba14e86-5518-43ae-beae-ad698e26dc6c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1922631b-124f-4d43-ad8e-cb9f595442b0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/382f05d2-061e-44f7-ab45-dde12da5b8ec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/47bc38e5-2fbc-4c92-972f-bc0b22ba7ca7"/>
    <rdfs:label>Prokinetic agents</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db03851e-1043-4453-bba1-5aa51d798fee">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <dc:identifier>DB03614</dc:identifier>
    <rdfs:label>Methylcobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20521ca3-8b71-4800-9273-d60bd0a9445c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37f84eee-02d0-41d1-995b-a83510963aa0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bba2f1c3-8299-437e-b2d1-a855c218af67"/>
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfbb0cec-20eb-4e2a-9385-22c8d805d89c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Parkinsonism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8332d2bc-82ae-4f1d-a835-be7122f6f1c4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased physical function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12ed3540-6f2a-4667-bf98-8ad89dfb2974">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47f38364-49e5-4eba-b445-885cb2fbd576"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6dda16a3-1b83-48d3-8c50-2760565b0dfc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3b83eaf-1ad8-4692-b0bc-207c4fc2c7fa"/>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68234d1f-7a90-48ea-90f4-3583726b6c8f">
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Congestive heart failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1380804-882c-4dd5-8910-ffd37904d0a9">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
    <dc:identifier>N06AB</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5dfa105d-8fa4-4aa9-b7cd-248a75351662"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c853963-4544-453b-8727-608930aee968">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33654628-ce75-496e-808c-70afd7e22902"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b0506b0-9fe8-4dea-8f94-89482f777d87">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c751e936-de2e-42db-824a-d963a9d967b5"/>
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0437f0d-a1c0-4667-a9fd-13991c3a9dfa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/692c5701-0747-48d1-9a55-ef571fdb71e5"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e98ceca6-0760-4ad7-8b0c-53b853cf936b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ee5f69d-d1b6-46fb-928a-1b56ace61fda"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d9eb0d9-98ac-456f-9f58-c77063a6e12d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased muscle mass</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ffc7093-b068-4349-9abf-2ba4e2e4657c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Complex partial seizure</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c22b2787-e320-4af5-aafd-03f5b0d74d89">
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/107ee0cb-2dea-4a05-bf04-7bdf40f332c8"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7e991f1-f03c-4081-a48d-7c0f30185c40">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5721f4c2-c513-477d-9cee-28e130aacf05"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9aeb525d-5cbc-4d21-8b3c-f679ba192353">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b8f23b7-33f3-4cc5-bc50-12af81602b6a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edc9a834-9648-4cf3-a1ce-d2a15db57559">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9162b838-93eb-42a4-9d12-218f58e245ba"/>
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
  </ddiem:Drug>
</rdf:RDF>
